0001651944-22-000054.txt : 20221103 0001651944-22-000054.hdr.sgml : 20221103 20221103164657 ACCESSION NUMBER: 0001651944-22-000054 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DermTech, Inc. CENTRAL INDEX KEY: 0001651944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 842870849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38118 FILM NUMBER: 221358751 BUSINESS ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-450-4222 MAIL ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Constellation Alpha Capital Corp. DATE OF NAME CHANGE: 20150827 10-Q 1 dmtk-20220930.htm 10-Q dmtk-20220930
000165194412-312022Q3falseP2YP2Y0.50.250.25fourten years, six months00016519442022-01-012022-09-3000016519442022-10-28xbrli:shares00016519442022-09-30iso4217:USD00016519442021-12-31iso4217:USDxbrli:shares0001651944dmtk:AssayMember2022-07-012022-09-300001651944dmtk:AssayMember2021-07-012021-09-300001651944dmtk:AssayMember2022-01-012022-09-300001651944dmtk:AssayMember2021-01-012021-09-300001651944dmtk:ContractualActivitiesMember2022-07-012022-09-300001651944dmtk:ContractualActivitiesMember2021-07-012021-09-300001651944dmtk:ContractualActivitiesMember2022-01-012022-09-300001651944dmtk:ContractualActivitiesMember2021-01-012021-09-3000016519442022-07-012022-09-3000016519442021-07-012021-09-3000016519442021-01-012021-09-300001651944us-gaap:CommonStockMember2021-12-310001651944us-gaap:AdditionalPaidInCapitalMember2021-12-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001651944us-gaap:RetainedEarningsMember2021-12-310001651944us-gaap:CommonStockMember2022-01-012022-03-310001651944us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016519442022-01-012022-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310001651944us-gaap:RetainedEarningsMember2022-01-012022-03-310001651944us-gaap:CommonStockMember2022-03-310001651944us-gaap:AdditionalPaidInCapitalMember2022-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310001651944us-gaap:RetainedEarningsMember2022-03-3100016519442022-03-310001651944us-gaap:CommonStockMember2022-04-012022-06-3000016519442022-04-012022-06-300001651944us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-04-012022-06-300001651944us-gaap:RetainedEarningsMember2022-04-012022-06-300001651944us-gaap:CommonStockMember2022-06-300001651944us-gaap:AdditionalPaidInCapitalMember2022-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300001651944us-gaap:RetainedEarningsMember2022-06-3000016519442022-06-300001651944us-gaap:CommonStockMember2022-07-012022-09-300001651944us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-07-012022-09-300001651944us-gaap:RetainedEarningsMember2022-07-012022-09-300001651944us-gaap:CommonStockMember2022-09-300001651944us-gaap:AdditionalPaidInCapitalMember2022-09-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300001651944us-gaap:RetainedEarningsMember2022-09-300001651944us-gaap:CommonStockMember2020-12-310001651944us-gaap:AdditionalPaidInCapitalMember2020-12-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001651944us-gaap:RetainedEarningsMember2020-12-3100016519442020-12-310001651944us-gaap:CommonStockMember2021-03-310001651944us-gaap:CommonStockMember2021-01-012021-03-310001651944us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100016519442021-01-012021-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-03-310001651944us-gaap:RetainedEarningsMember2021-01-012021-03-310001651944us-gaap:AdditionalPaidInCapitalMember2021-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310001651944us-gaap:RetainedEarningsMember2021-03-3100016519442021-03-310001651944us-gaap:CommonStockMember2021-04-012021-06-300001651944us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000016519442021-04-012021-06-300001651944dmtk:AtTheMarketOfferingMemberus-gaap:CommonStockMember2021-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-04-012021-06-300001651944us-gaap:RetainedEarningsMember2021-04-012021-06-300001651944us-gaap:CommonStockMember2021-06-300001651944us-gaap:AdditionalPaidInCapitalMember2021-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-06-300001651944us-gaap:RetainedEarningsMember2021-06-3000016519442021-06-300001651944us-gaap:CommonStockMember2021-07-012021-09-300001651944us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-07-012021-09-300001651944us-gaap:RetainedEarningsMember2021-07-012021-09-300001651944us-gaap:CommonStockMember2021-09-300001651944us-gaap:AdditionalPaidInCapitalMember2021-09-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-300001651944us-gaap:RetainedEarningsMember2021-09-3000016519442021-09-300001651944dmtk:PublicFollowOnOfferingMember2022-01-012022-09-300001651944dmtk:PublicFollowOnOfferingMember2021-01-012021-09-300001651944dmtk:AtTheMarketOfferingMember2022-01-012022-09-300001651944dmtk:AtTheMarketOfferingMember2021-01-012021-09-300001651944srt:MinimumMember2022-01-012022-09-300001651944srt:MaximumMember2022-01-012022-09-300001651944dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember2022-07-012022-09-300001651944dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember2021-07-012021-09-300001651944dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember2022-01-012022-09-300001651944dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember2021-01-012021-09-300001651944dmtk:AssetsHeldUnderFinanceLeasesMember2022-09-300001651944dmtk:AssetsHeldUnderFinanceLeasesMember2021-12-310001651944dmtk:AssetsHeldUnderFinanceLeasesMember2022-01-012022-09-300001651944dmtk:AssetsHeldUnderFinanceLeasesMember2021-01-012021-12-31dmtk:revenueStream0001651944dmtk:ContractRevenueAdhesivePatchKitsMember2022-07-012022-09-300001651944dmtk:ContractRevenueAdhesivePatchKitsMember2021-07-012021-09-300001651944dmtk:ContractRevenueAdhesivePatchKitsMember2022-01-012022-09-300001651944dmtk:ContractRevenueAdhesivePatchKitsMember2021-01-012021-09-300001651944dmtk:ContractRevenueRNAExtractionsMember2022-07-012022-09-300001651944dmtk:ContractRevenueRNAExtractionsMember2021-07-012021-09-300001651944dmtk:ContractRevenueRNAExtractionsMember2022-01-012022-09-300001651944dmtk:ContractRevenueRNAExtractionsMember2021-01-012021-09-300001651944dmtk:ContractRevenueProjectManagementFeesMember2022-07-012022-09-300001651944dmtk:ContractRevenueProjectManagementFeesMember2021-07-012021-09-300001651944dmtk:ContractRevenueProjectManagementFeesMember2022-01-012022-09-300001651944dmtk:ContractRevenueProjectManagementFeesMember2021-01-012021-09-300001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberdmtk:AssayRevenuePayorAMember2022-07-012022-09-30xbrli:pure0001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberdmtk:AssayRevenuePayorAMember2021-07-012021-09-300001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberdmtk:AssayRevenuePayorAMember2022-01-012022-09-300001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberdmtk:AssayRevenuePayorAMember2021-01-012021-09-300001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberdmtk:AssayRevenuePayorAMember2022-01-012022-09-300001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberdmtk:AssayRevenuePayorAMember2021-01-012021-12-310001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberdmtk:AssayRevenuePayorBMember2022-01-012022-09-300001651944us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberdmtk:AssayRevenuePayorBMember2021-01-012021-12-3100016519442022-09-302022-09-300001651944srt:MinimumMember2022-09-300001651944srt:MaximumMember2022-09-300001651944dmtk:AssayMember2022-09-300001651944dmtk:AssayMember2021-12-310001651944dmtk:ContractualActivitiesMember2022-09-300001651944dmtk:ContractualActivitiesMember2021-12-310001651944us-gaap:WarrantMember2022-01-012022-09-300001651944us-gaap:WarrantMember2022-07-012022-09-300001651944dmtk:StockOptionsAndRestrictedStockUnitsMember2022-07-012022-09-300001651944dmtk:StockOptionsAndRestrictedStockUnitsMember2022-01-012022-09-300001651944us-gaap:WarrantMember2021-07-012021-09-300001651944us-gaap:WarrantMember2021-01-012021-09-300001651944dmtk:StockOptionsAndRestrictedStockUnitsMember2021-01-012021-09-300001651944dmtk:StockOptionsAndRestrictedStockUnitsMember2021-07-012021-09-300001651944us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001651944us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2022-07-012022-09-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2021-07-012021-09-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2022-01-012022-09-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2021-01-012021-09-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMembersrt:MinimumMember2022-01-012022-09-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMembersrt:MaximumMember2022-01-012022-09-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMembersrt:MinimumMember2021-01-012021-09-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMembersrt:MaximumMember2021-01-012021-09-300001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-12-310001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-03-310001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-06-300001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-07-012022-09-300001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-09-300001651944us-gaap:FairValueInputsLevel1Memberdmtk:RestrictedCashMember2022-09-300001651944us-gaap:FairValueInputsLevel1Memberdmtk:RestrictedCashMember2021-12-3100016519442019-08-292019-08-290001651944us-gaap:CorporateDebtSecuritiesMember2022-09-300001651944us-gaap:MunicipalNotesMember2022-09-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember2022-09-300001651944us-gaap:CorporateDebtSecuritiesMember2021-12-310001651944us-gaap:MunicipalNotesMember2021-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember2021-12-310001651944dmtk:CowenLimitedLiabilityCompanyMember2020-11-102020-11-100001651944dmtk:CowenLimitedLiabilityCompanyMember2020-11-102020-12-310001651944dmtk:CowenLimitedLiabilityCompanyMember2022-01-012022-09-300001651944dmtk:CowenLimitedLiabilityCompanyMember2021-01-012021-12-310001651944dmtk:CowenLimitedLiabilityCompanyMember2022-08-082022-08-0800016519442021-01-062021-01-0600016519442021-01-112021-01-1100016519442021-01-110001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2017-06-232017-06-230001651944dmtk:PublicSpecialPurposeAcquisitionCompaniesWarrantsMember2017-06-232017-06-230001651944dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember2017-06-232017-06-230001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMemberus-gaap:CommonStockMember2022-09-300001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2021-09-300001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2021-01-012021-09-300001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2021-12-310001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2022-09-300001651944dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember2021-12-310001651944dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember2022-09-300001651944dmtk:PlacementAgentWarrantsMember2015-01-012016-12-310001651944dmtk:PlacementAgentWarrantsMember2016-12-310001651944dmtk:PlacementAgentWarrantsMemberus-gaap:CommonStockMember2016-12-310001651944dmtk:PlacementAgentWarrantsMember2016-01-012018-12-310001651944dmtk:PlacementAgentWarrantsMember2018-12-310001651944dmtk:PlacementAgentWarrantsMemberus-gaap:CommonStockMember2018-12-310001651944dmtk:PlacementAgentWarrantsMemberdmtk:TwoThousandEighteenConvertibleBridgeNotesMember2021-01-012021-03-310001651944dmtk:PlacementAgentWarrantsMemberdmtk:TwoThousandEighteenConvertibleBridgeNotesMember2020-12-310001651944dmtk:PlacementAgentWarrantsMemberdmtk:TwoThousandEighteenConvertibleBridgeNotesMemberus-gaap:CommonStockMember2020-12-310001651944dmtk:PlacementAgentWarrantsMember2022-09-300001651944dmtk:PlacementAgentWarrantsMember2021-12-310001651944dmtk:ManagementWarrantsMember2022-09-300001651944dmtk:ManagementWarrantsMemberus-gaap:CommonStockMember2022-09-300001651944dmtk:ManagementWarrantsMemberus-gaap:CommonStockMember2022-01-012022-09-300001651944dmtk:ManagementWarrantsMember2021-12-310001651944us-gaap:CostOfSalesMember2022-07-012022-09-300001651944us-gaap:CostOfSalesMember2021-07-012021-09-300001651944us-gaap:CostOfSalesMember2022-01-012022-09-300001651944us-gaap:CostOfSalesMember2021-01-012021-09-300001651944us-gaap:SellingAndMarketingExpenseMember2022-07-012022-09-300001651944us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300001651944us-gaap:SellingAndMarketingExpenseMember2022-01-012022-09-300001651944us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001651944dmtk:TwoThousandTwentyEquityIncentivePlanMembersrt:MinimumMemberdmtk:IncentiveAndNonQualifiedStockOptionsMember2022-01-012022-09-300001651944dmtk:IncentiveStockOptionsMemberdmtk:TwoThousandTwentyEquityIncentivePlanMembersrt:MinimumMember2022-01-012022-09-300001651944dmtk:TwoThousandTwentyEquityIncentivePlanMembersrt:MaximumMember2022-01-012022-09-300001651944dmtk:TwoThousandTwentyEquityIncentivePlanMember2022-09-300001651944dmtk:TwoThousandTwentyEquityIncentivePlanMembersrt:MaximumMember2022-09-300001651944dmtk:TwoThousandTwentyEquityIncentivePlanMember2022-01-012022-09-300001651944dmtk:A2022InducementEquityIncentivePlanMember2022-03-310001651944dmtk:A2022InducementEquityIncentivePlanMember2022-09-012022-09-300001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMembersrt:MaximumMember2022-09-300001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-09-300001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-01-012022-09-3000016519442022-09-012022-09-01dmtk:period0001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-02-282021-02-280001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-08-312021-08-310001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-12-310001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-01-010001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-02-280001651944dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-08-310001651944dmtk:WarrantsToPurchaseCommonStockMember2022-09-300001651944dmtk:WarrantsToPurchaseCommonStockMember2021-12-310001651944dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember2022-09-300001651944dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember2021-12-310001651944us-gaap:EmployeeStockOptionMember2022-09-300001651944us-gaap:EmployeeStockOptionMember2021-12-310001651944us-gaap:RestrictedStockUnitsRSUMember2022-09-300001651944us-gaap:RestrictedStockUnitsRSUMember2021-12-310001651944dmtk:AuthorizedForFutureEquityGrantsMember2022-09-300001651944dmtk:AuthorizedForFutureEquityGrantsMember2021-12-310001651944dmtk:AuthorizedForFutureESPPPurchasesMember2022-09-300001651944dmtk:AuthorizedForFutureESPPPurchasesMember2021-12-310001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2022-01-012022-09-30dmtk:Warrant0001651944us-gaap:InterestIncomeMember2022-07-012022-09-300001651944us-gaap:InterestIncomeMember2021-07-012021-09-300001651944us-gaap:InterestIncomeMember2022-01-012022-09-300001651944us-gaap:InterestIncomeMember2021-01-012021-09-300001651944dmtk:KilroyRealtyLPMember2021-07-012021-07-01utr:sqftiso4217:USDutr:sqft0001651944dmtk:KilroyRealtyLPMember2021-07-01dmtk:phase0001651944dmtk:KilroyRealtyLPMember2022-09-300001651944dmtk:KilroyRealtyLPMember2021-12-310001651944dmtk:KilroyRealtyLPMember2022-03-310001651944dmtk:FirstAmendmentMemberdmtk:KilroyRealtyLPMember2022-04-012022-04-300001651944dmtk:FirstAmendmentMemberdmtk:KilroyRealtyLPMember2022-04-300001651944dmtk:SecondAmendmentMemberdmtk:KilroyRealtyLPMember2022-04-222022-04-220001651944dmtk:SecondAmendmentMemberdmtk:KilroyRealtyLPMember2022-04-300001651944dmtk:KilroyRealtyLPMember2022-04-222022-04-220001651944dmtk:KilroyRealtyLPMember2022-04-300001651944dmtk:KilroyRealtyLPMember2022-04-012022-04-300001651944us-gaap:DemandDepositsMemberdmtk:KilroyRealtyLPMemberus-gaap:LetterOfCreditMember2022-09-300001651944us-gaap:DemandDepositsMemberdmtk:KilroyRealtyLPMemberus-gaap:LetterOfCreditMember2022-04-012022-04-300001651944us-gaap:DemandDepositsMemberdmtk:KilroyRealtyLPMemberus-gaap:LetterOfCreditMember2022-04-300001651944us-gaap:StandbyLettersOfCreditMemberus-gaap:DemandDepositsMemberdmtk:KilroyRealtyLPMember2022-09-3000016519442021-01-010001651944dmtk:SpouseOfChiefCommercialOfficerMemberdmtk:EVERSANALifeScienceServicesLLCMember2022-07-012022-09-300001651944dmtk:SpouseOfChiefCommercialOfficerMemberdmtk:EVERSANALifeScienceServicesLLCMember2021-07-012021-09-300001651944dmtk:SpouseOfChiefCommercialOfficerMemberdmtk:EVERSANALifeScienceServicesLLCMember2022-01-012022-09-300001651944dmtk:SpouseOfChiefCommercialOfficerMemberdmtk:EVERSANALifeScienceServicesLLCMember2021-01-012021-09-300001651944dmtk:SpouseOfChiefCommercialOfficerMemberdmtk:EVERSANALifeScienceServicesLLCMember2022-09-300001651944dmtk:SpouseOfChiefCommercialOfficerMemberdmtk:EVERSANALifeScienceServicesLLCMember2021-12-310001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMembersrt:MaximumMember2019-10-012019-10-010001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2020-05-112020-05-110001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2021-01-020001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2020-11-112020-11-110001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2021-02-262021-02-260001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2021-07-012021-09-300001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2022-07-012022-09-300001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2022-01-012022-09-300001651944dmtk:DermTechOperationsIncMemberdmtk:BrotherOfChiefExecutiveOfficerMember2021-01-012021-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________________
FORM 10-Q
________________________
Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to            
Commission File Number: 001-38118
________________________
DERMTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
________________________
Delaware84-2870849
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
11099 N. Torrey Pines Road, Suite 100
La Jolla, CA
92037
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (858) 450-4222
________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per shareDMTK
The Nasdaq Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filero
Non-accelerated fileroSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of October 28, 2022, the registrant had 30,214,705 shares of common stock, $0.0001 par value per share, outstanding.


Table of Contents
Page
Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021
i

PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
DERMTECH, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
(Unaudited)
September 30, 2022December 31, 2021
Assets
Current assets:
Cash and cash equivalents$95,492 $176,882 
Short-term marketable securities53,636 48,449 
Accounts receivable6,101 3,847 
Inventory1,391 480 
Prepaid expenses and other current assets4,212 3,166 
Total current assets160,832 232,824 
Property and equipment, net4,943 4,549 
Operating lease right-of-use assets24,644 7,744 
Restricted cash3,477 3,025 
Other assets167 167 
Total assets$194,063 $248,309 
Liabilities and Stockholders’ Equity  
Current liabilities:  
Accounts payable$2,997 $2,880 
Accrued compensation8,321 5,120 
Accrued liabilities3,539 1,227 
Short-term deferred revenue417 1,380 
Current portion of operating lease liabilities1,588 1,453 
Current portion of finance lease obligations124 121 
Total current liabilities16,986 12,181 
Warrant liability20 146 
Long-term finance lease obligations, less current portion77 136 
Operating lease liabilities, long-term21,992 6,148 
Total liabilities39,075 18,611 
Stockholders’ equity:  
Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 30,213,206 and 29,772,922 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
3 3 
Additional paid-in capital450,904 436,183 
Accumulated other comprehensive loss(1,095)(124)
Accumulated deficit(294,824)(206,364)
Total stockholders’ equity154,988 229,698 
Total liabilities and stockholders’ equity$194,063 $248,309 
See accompanying notes to unaudited condensed consolidated financial statements.
1

DERMTECH, INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenues:
Assay revenue$3,433 $2,954 $11,098 $8,054 
Contract revenue140 76 426 619 
Total revenues3,573 3,030 11,524 8,673 
Cost of revenues:    
Cost of assay revenue3,644 2,875 10,410 7,450 
Cost of contract revenue50 23 111 74 
Total cost of revenues3,694 2,898 10,521 7,524 
Gross (loss) profit(121)132 1,003 1,149 
Operating expenses:    
Sales and marketing14,632 9,826 45,076 24,245 
Research and development5,702 4,426 18,955 10,271 
General and administrative8,806 6,199 26,258 17,672 
Total operating expenses29,140 20,451 90,289 52,188 
Loss from operations(29,261)(20,319)(89,286)(51,039)
Other income/(expense):    
Interest income, net485 38 700 107 
Change in fair value of warrant liability4 169 126 (1,350)
Total other income/(expense)489 207 826 (1,243)
Net loss$(28,772)$(20,112)$(88,460)$(52,282)
Weighted average shares outstanding used in computing net loss per share, basic and diluted30,096,261 29,639,802 29,969,435 28,599,375 
Net loss per share of common stock outstanding, basic and diluted$(0.96)$(0.68)$(2.95)$(1.83)
See accompanying notes to unaudited condensed consolidated financial statements.
2

DERMTECH, INC.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net loss$(28,772)$(20,112)$(88,460)$(52,282)
Unrealized net loss on available-for-sale
    marketable securities
(230)(10)(971)(7)
Comprehensive loss$(29,002)$(20,122)$(89,431)$(52,289)
See accompanying notes to unaudited condensed consolidated financial statements.
3

DERMTECH, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share and per share data)
(Unaudited)
Common stockAdditional
paid-in
capital
Accumulated
other
comprehensive
loss
Accumulated
deficit
Total
stockholders’
equity
SharesAmount
Balance, December 31, 202129,772,922 $3 $436,183 $(124)$(206,364)$229,698 
Issuance of common stock from option exercises and RSU releases109,275 — 40 — — 40 
Issuance of common stock from warrant exercises11,101 — 12 — — 12 
Issuance of common stock from Employee Stock Purchase Plan47,339 — 515 — — 515 
Unrealized net loss on available-for-sale marketable securities— — — (570)— (570)
Stock-based compensation— — 3,894 — — 3,894 
Net loss— — — — (30,108)(30,108)
Balance, March 31, 202229,940,637 $3 $440,644 $(694)$(236,472)$203,481 
Issuance of common stock from RSU releases88,591 — — — —  
Issuance of common stock from warrant exercises9,219 — 10 — — 10 
Unrealized net loss on available-for-sale marketable securities— — — (171)— (171)
Stock-based compensation— — 4,837 — — 4,837 
Net loss— — — — (29,580)(29,580)
Balance, June 30, 202230,038,447 $3 $445,491 $(865)$(266,052)$178,577 
Issuance of common stock from RSU releases74,010 — — — —  
Issuance of common stock from Employee Stock Purchase Plan100,749 — 477 — — 477 
Unrealized net loss on available-for-sale marketable securities— — — (230)— (230)
Stock-based compensation— — 4,936 — — 4,936 
Net loss— — — — (28,772)(28,772)
Balance, September 30, 202230,213,206 $3 $450,904 $(1,095)$(294,824)$154,988 
See accompanying notes to unaudited condensed consolidated financial statements.
4

DERMTECH, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share and per share data)
(Unaudited)
Common stockAdditional
paid-in
capital
Accumulated
other
comprehensive
income/(loss)
Accumulated
deficit
Total
stockholders’
equity
SharesAmount
Balance, December 31, 202020,740,413 $2 $189,868 $(1)$(128,029)$61,840 
Issuance of common stock at $29.50 per share, net of $9.1 million in issuance costs
4,872,881 1 134,581 — — 134,582 
Issuance of common stock from option exercises and RSU releases176,673 — 408 — — 408 
Issuance of common stock from warrant exercises3,089,325 — 72,081 — — 72,081 
Issuance of common stock from Employee Stock Purchase Plan39,960 — 392 — — 392 
Unrealized net gain on available-for-sale marketable securities— — — 9 — 9 
Stock-based compensation— — 2,172 — — 2,172 
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder— — 411 — — 411 
Net loss— — — — (15,068)(15,068)
Balance, March 31, 202128,919,252 $3 $399,913 $8 $(143,097)$256,827 
Issuance of common stock from option exercises and RSU releases157,277 — 188 — — 188 
Issuance of common stock at a weighted average price of $46.33 through at-the market offering, net of $0.7 million in issuance costs
530,551 — 23,836 — — 23,836 
Issuance of common stock from warrant exercises314 — 5 — — 5 
Unrealized net loss on available-for-sale marketable securities— — — (6)— (6)
Stock-based compensation— — 3,538 — — 3,538 
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder— — 23 — — 23 
Net loss— — — — (17,102)(17,102)
Balance, June 30, 202129,607,394 $3 $427,503 $2 $(160,199)$267,309 
Issuance of common stock from option exercises and RSU releases76,768 — 81 — — 81 
Issuance of common stock from warrant exercises14,881 — 343 — — 343 
Issuance of common stock from Employee Stock Purchase Plan18,155 — 574 — — 574 
Unrealized net loss on available-for-sale marketable securities— — — (10)— (10)
Stock-based compensation— — 3,736 — — 3,736 
Net loss— — — — (20,112)(20,112)
Balance, September 30, 202129,717,198 $3 $432,237 $(8)$(180,311)$251,921 
See accompanying notes to unaudited condensed consolidated financial statements.
5

DERMTECH, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
Nine Months Ended September 30,
20222021
Cash flows from operating activities:  
Net loss$(88,460)$(52,282)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation1,187 654 
Change in fair value of warrant liability(126)1,350 
Amortization of operating lease right-of-use assets1,788 909 
Stock-based compensation13,667 9,446 
Amortization of premiums, net of accretion of discounts on marketable securities328 463 
Loss on disposal of equipment350 13 
Changes in operating assets and liabilities:  
Accounts receivable(2,254)(1,339)
Inventory(911)(320)
Prepaid expenses and other current assets(1,046)(104)
Operating lease liabilities(2,709)(1,130)
Accounts payable, accrued liabilities and deferred revenue955 1,525 
Accrued compensation3,201 1,389 
Net cash used in operating activities(74,030)(39,426)
Cash flows from investing activities:  
Purchases of marketable securities(26,420)(25,150)
Sales of marketable securities 350 
Maturities of marketable securities19,934 18,475 
Purchases of property and equipment(1,372)(1,664)
Net cash used in investing activities(7,858)(7,989)
Cash flows from financing activities:  
Proceeds from issuance of common stock in connection with public follow-on offering, net 134,582 
Proceeds from issuance of common stock in connection with at-the-market offering, net 23,836 
Proceeds from exercise of common stock warrants22 70,271 
Proceeds from RSU releases (par value only) and the exercise of stock options40 677 
Proceeds from contributions to the employee stock purchase plan992 966 
Principal repayments of finance lease obligations(104)(80)
Net cash provided by financing activities950 230,252 
Net (decrease)/increase in cash, cash equivalents and restricted cash(80,938)182,837 
Cash, cash equivalents and restricted cash, beginning of period179,907 24,248 
Cash, cash equivalents and restricted cash, end of period$98,969 $207,085 
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents$95,492 $204,061 
Restricted cash3,477 3,024 
Total cash, cash equivalents and restricted cash$98,969 $207,085 
Supplemental cash flow information:  
Cash paid for interest on finance lease obligations$10 $13 
Supplemental disclosure of noncash investing and financing activities:  
Purchases of property and equipment recorded in accounts payable$511 $462 
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder$ $434 
Cashless exercise of common stock warrants$ $2,158 
Right-of-use assets obtained in exchange for lease obligations$18,688 $9,071 
Property and equipment acquired under finance leases$48 $105 
Change in net unrealized losses on available-for-sale marketable securities$(971)$(7)
See accompanying notes to unaudited condensed consolidated financial statements.
6

DERMTECH, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
1.    The Company and a Summary of its Significant Accounting Policies
(a)    Nature of Operations
On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock.
The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including genomic tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) to collect biological information for commercial applications in the medical diagnostic field.
The ongoing COVID-19 pandemic has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company implemented additional safety measures in accordance with Centers for Disease Control and Prevention, Occupational Safety and Health Administration and other guidance within its CLIA laboratory operations. Additionally, and during this time, the Company transitioned administrative functions to predominantly remote work. The pandemic reduced patient access to clinician offices for in-person testing and reduced access by the Company's sales force for in-office sales calls, which negatively impacted the volume of billable samples. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical, and long-lasting and may again in the future, adversely affect the Company's operating results.
(b)    Basis of Presentation
The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission (“SEC”), Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.
The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of September 30, 2022, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
7

(c)    Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.
(d)    Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that have in the past and may, at times, exceed this insured limit.
Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.
(e)    Property and Equipment, Net
Property and equipment, net is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to eleven years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $0.4 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $21,000 and $17,000 for the three months ended September 30, 2022 and 2021, respectively. The Company recorded depreciation expense of $1.2 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases of $0.1 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively.
Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the condensed consolidated statements of operations. Gross assets recorded under finance leases were $0.4 million as of September 30, 2022 and December 31, 2021. Accumulated amortization associated with finance leases was $0.1 million as of September 30, 2022 and December 31, 2021. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the condensed consolidated statements of operations in the period realized. Loss of disposal on equipment was $0.1 million for the three months ended September 30, 2022 and $8,000 for the three months ended September 30, 2021. Loss on disposal of equipment was $0.4 million and $13,000 for the nine months ended September 30, 2022 and 2021, respectively. The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the three or nine months ended September 30, 2022 and 2021.
(f)    Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of September 30, 2022, the Company maintained $64.6 million in a sweep account, which maintains cash balances throughout various interest-bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $0.3 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of September 30, 2022. The Company has not experienced any losses in such accounts.
8

(g)    Revenue Recognition
The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.
Assay Revenue
The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLAplus (now referred to as the DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLAplus), which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT where a collection kit would be sent to the patient’s home. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.
The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.5 million and $0.5 million of revenue reported for the three and nine months ended September 30, 2022, respectively, and an additional $18,000 and $0.1 million of revenue reported for the three and nine months ended September 30, 2021, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.
Contract Revenue
Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing genomic services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of services may include sample collection using the Smart Sticker, assay development for research partners, patient segmentation and stratification, extraction, isolation, expression, amplification and detection of RNA, DNA, protein and microbiome, including data analysis and reporting.
9

(a) Disaggregation of Revenue
The following table presents the Company’s revenues disaggregated by revenue source during the three and nine months ended September 30, 2022 and 2021 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Assay Revenue
DermTech Melanoma Test$3,433 $2,954 $11,098 $8,054 
Contract Revenue
Adhesive patch kits22 14 126 329 
RNA extractions94 19 204 158 
Project management fees24 43 96 132 
Total revenues$3,573 $3,030 $11,524 $8,673 
The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors that represent 10% or more of the respective amounts for the periods shown:
Total RevenuesAccounts Receivable
Three Months Ended September 30,Nine Months Ended September 30,As of September 30, 2022As of December 31, 2021
2022202120222021
Assay Revenue
Payor A46 %36 %41 %35 %20 %23 %
Payor B****15 %15 %
*Less than 10%
There were no other third-party payors or pharmaceutical customers that individually accounted for more than 10% of the Company’s total revenue or accounts receivable for the periods shown in the table above.
(b) Deferred Revenue and Remaining Performance Obligations
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.
In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.
The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of September 30, 2022 and December 31, 2021 was $0.4 million and $1.4 million, respectively. As of September 30, 2022 we reclassified $0.9 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services.
Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of September 30, 2022, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was immaterial. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two to three years.
10

(h)    Accounts Receivable
Assay Accounts Receivable
Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivables are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $5.9 million and $3.6 million of gross assay accounts receivable as of September 30, 2022 and December 31, 2021, respectively.
Contract Accounts Receivable
Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of September 30, 2022, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company recorded $0.2 million and $0.2 million of contract accounts receivable as of September 30, 2022 and December 31, 2021, respectively.
(i)    Net Loss Per Share
Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the three and nine months ended September 30, 2022 and 2021, the outstanding common stock warrants, stock options, and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the three and nine months ended September 30, 2022 excludes the effect of anti-dilutive equity instruments including 714,261 shares of common stock issuable upon the exercise of outstanding common stock warrants and 5,024,323 shares of common stock issuable upon the exercise of stock options and release of RSUs. Diluted net loss per share of common stock for the three and nine months ended September 30, 2021 excludes the effect of anti-dilutive equity instruments including 734,581 shares of common stock then issuable upon the exercise of outstanding warrants and 2,564,059 shares of common stock then issuable upon the exercise of stock options and release of RSUs.
11

(j)    Fair Value Measurements
The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2022 (in thousands):
September 30, 2022
Level 1Level 2Level 3Total
Assets:    
Cash equivalents$30,529 $ $ $30,529 
Restricted cash3,477   3,477 
Marketable securities, available for sale:
Corporate debt securities 14,938  14,938 
Municipal debt securities 2,320  2,320 
U.S. government debt securities 36,378  36,378 
Total marketable securities, available for sale 53,636  53,636 
Total assets measured at fair value on a recurring basis$34,006 $53,636 $ $87,642 
Liabilities:
Warrant liability$ $ $20 $20 
Total liabilities measured at fair value on a recurring basis$ $ $20 $20 
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 (in thousands):
December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents$16,380 $ $ $16,380 
Restricted cash3,025   3,025 
Marketable securities, available for sale:
Corporate debt 15,352  15,352 
Municipal debt securities 7,412  7,412 
U.S. government debt securities 25,685  25,685 
Total marketable securities, available for sale 48,449  48,449 
Total assets measured at fair value on a recurring basis$19,405 $48,449 $ $67,854 
Liabilities:
Warrant liability$ $ $146 $146 
Total liabilities measured at fair value on a recurring basis$ $ $146 $146 
12

The Company’s marketable debt securities are classified as available-for-sale securities based on management’s intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.
The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.
The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Assumed risk-free interest rate4.22%0.53%
2.37% - 4.22%
0.46% - 0.64%
Assumed volatility118.13%89.77%
92.77% - 118.13%
85.85% - 89.77%
Expected term1.92 years2.92 years
1.92 - 2.42 years
2.92 - 3.42 years
Expected dividend yield
The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):
Balance as of December 31, 2021$146 
Change in fair value of warrant liability(17)
Balance as of March 31, 2022129 
Change in fair value of warrant liability(105)
Balance as of June 30, 2022$24 
Change in fair value of warrant liability(4)
Balance as of September 30, 2022$20 
As of September 30, 2022 and December 31, 2021, the Company maintains letters of credit of $3.5 million and $3.0 million, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.
The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.
(k)    Accounting Pronouncements Issued But Not Yet Effective
In June 2022, the Financial Accounting Standards Board issued ASU No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.
The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.
13

2.    Balance Sheet Details
Short-Term Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of September 30, 2022 were as follows (in thousands):
September 30, 2022
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$15,259 $ $(321)$14,938 
Municipal debt securities2,339  (19)2,320 
U.S. government debt securities37,133 3 (758)36,378 
Total short-term marketable securities, available-for-sale$54,731 $3 $(1,098)$53,636 
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2021 were as follows (in thousands):
December 31, 2021
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$15,385 $ $(33)$15,352 
Municipal debt securities7,417  (5)7,412 
U.S. government debt securities25,771 1 (87)25,685 
Total short-term marketable securities, available-for-sale$48,573 $1 $(125)$48,449 
As of September 30, 2022, the estimated market value of debt securities with contractual maturities of less than twelve months was $38.3 million; the remaining debt securities that the Company held at that date had an estimated market value of $15.3 million and contractual maturities of up to 21 months. As of December 31, 2021, the estimated market value of debt securities with contractual maturities of less than twelve months was $21.2 million; the remaining debt securities that the Company held at that date had an estimated market value of $27.2 million and contractual maturities of up to 23 months.
The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. It was determined that no credit losses existed as of September 30, 2022 or December 31, 2021, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. Gross realized gains and losses on the Company’s debt securities for the three and nine months ended September 30, 2022 and 2021 were not significant.
14

Prepaid Expenses and Property and Equipment, Net
Condensed consolidated balance sheet details are as follows (in thousands):
September 30,
2022
December 31,
2021
Prepaid expenses and other current assets:
Prepaid insurance$1,547 $1,801 
Prepaid trade shows693 440 
Prepaid software fees1,038 551 
Prepaid employee compensation291 238 
Other current assets643 136 
Total prepaid expenses and other current assets$4,212 $3,166 
Property and equipment, gross:
Laboratory equipment$4,744 $4,805 
Computer equipment356 171 
Furniture and fixtures807 124 
Leasehold improvements1,009 1,074 
Construction-in-progress585  
Total property and equipment, gross7,501 6,174 
Less accumulated depreciation(2,558)(1,625)
Total property and equipment, net$4,943 $4,549 
Accrued Compensation and Accrued Liabilities
Condensed consolidated balance sheet details are as follows (in thousands):
September 30,
2022
December 31,
2021
Accrued compensation:
Accrued paid time off$1,790 $1,245 
Accrued wages, bonus and other6,531 3,875 
Total accrued compensation$8,321 $5,120 
Accrued liabilities:
Accrued consulting services$1,173 $775 
Customer refund liability926  
Other accrued expenses1,440 452 
Total accrued liabilities$3,539 $1,227 
3.    Stockholders’ Equity
(a)    Classes of Stock
The Company’s amended and restated certificate of incorporation authorizes it to issue 50,000,000 shares of common stock and 5,000,000 shares of preferred stock. Both classes of stock have a par value of $0.0001 per share.
15

(b)    At-The-Market Offering

On November 10, 2020, the Company entered into a sales agreement (the “November 2020 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2020, the Company issued an aggregate of 951,792 shares of common stock pursuant to the November 2020 Sales Agreement at a weighted average purchase price of $20.97 resulting in aggregate gross proceeds of approximately $20.0 million, reduced by $0.9 million in issuance costs, resulting in net proceeds to the Company of approximately $19.1 million. For the nine months ended September 30, 2022, the Company did not issue any shares pursuant to the November 2020 Sales Agreement. For the year ended December 31, 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the November 2020 Sales Agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million.

On August 8, 2022, the Company entered into a second sales agreement (the “August 2022 Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million under a second at-the-market offering program. For the nine months ended September 30, 2022, the Company did not issue any shares pursuant to the August 2022 Sales Agreement.
(c)    2021 Underwritten Public Offering
On January 6, 2021, the Company entered into an underwriting agreement with Cowen and William Blair & Company, L.L.C. as representatives of the several underwriters (the "Underwriters"). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company. On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company received aggregate gross proceeds of approximately $143.7 million, and net proceeds of approximately $134.6 million, after deducting underwriting discounts and commissions and other offering expenses.
(d)    Warrants
SPAC Warrants
The Company previously issued a total of 14,936,250 SPAC warrants (the "SPAC Warrants") to purchase common stock in public and private placement offerings which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 warrants (the "Public SPAC Warrants") and as part of the private placement offering, the Company issued 561,250 warrants (the "Private SPAC Warrants"). The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.
The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.
Between January 1, 2021 and September 30, 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds.
Outstanding SPAC Warrants totaled 2,815,853 as of September 30, 2022 and December 31, 2021. Private SPAC Warrants that were still owned by the original holder totaled 80,350 as of September 30, 2022 and December 31, 2021.
16

Placement Agent Warrants
In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling of common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled 10,039 as of September 30, 2022 and December 31, 2021.
Management Warrants
Warrants to purchase shares of DermTech Operations' common stock were issued to executive officers of DermTech Operations in lieu of issuing certain stock options (the “Management Warrants”). The Management Warrants were assumed by the Company in connection with the Business Combination. The Management Warrants have a ten-year life and are exercisable shares of the Company's common stock at $1.08 per share. For the nine months ended September 30, 2022, the Company issued 20,320 shares of common stock pursuant to the exercise of Management Warrants. The Management Warrants vested monthly over a four-year period. Outstanding Management Warrants totaled zero and 20,320 as of September 30, 2022 and December 31, 2021, respectively.
(e)    Stock-Based Compensation
Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 ESPP, and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of revenue$353 $299 $986 $709 
Sales and marketing1,294 1,098 3,822 2,580 
Research and development1,074 644 2,899 1,473 
General and administrative2,215 1,695 5,960 4,684 
Total stock-based compensation$4,936 $3,736 $13,667 $9,446 
The total compensation cost related to non-vested awards not yet recognized as of September 30, 2022 was $49.1 million, which is expected to be recognized over a weighted average term of 2.28 years.
Equity Incentive Plans
In May 2020, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which replaced our Amended and Restated 2010 Stock Plan and provides for the granting of incentive and non-qualified stock options, restricted stock and stock-based awards to employees, directors and consultants providing services to the Company. Under the 2020 Plan, incentive and non-qualified stock options may be granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of the Company’s capital stock, the exercise price may not be less than 110% of the fair market value of the Company’s common stock on the date of grant and the term of the option may not be longer than five years.
The 2020 Plan authorizes the Company to issue up to 1,900,000 shares of the Company’s common stock pursuant to awards granted under the 2020 Plan, plus the number of shares underlying any stock option and other stock-based awards previously granted under the 2010 Plan that are forfeited, canceled, or terminated (other than by exercise) on or after May 26, 2020; provided that no more than 1,400,000 shares may be added to the 2020 Plan pursuant to such forfeitures, cancellations and terminations. In addition, the number of shares available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year beginning in fiscal year 2021 and ending on the second day of fiscal year 2025, by an amount equal to the smaller of (i) 3.5% of the number of shares of common stock outstanding on such date and (ii) an amount determined by the administrator of the 2020 Plan. The 2020 Plan will expire on April 12, 2030 or an earlier date approved by a vote of the Company’s stockholders or board of
17

directors. The contractual term of options granted under the 2020 Plan is not more than ten years. Vesting provisions vary based on the specific terms of the individual option awards.
In March 2022, the Company’s board of directors adopted the 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), pursuant to which the Company reserved 950,000 shares of its common stock (subject to customary adjustments in the event of a change in capital structure of the Company) for the issuance of equity awards under the Inducement Plan. In September 2022, the Company amended and restated the Inducement Plan to reserve an additional 1,000,000 shares of its common stock. The Inducement Plan and its amendment were approved by the Company’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan may be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.
As of September 30, 2022, 1,002,843 shares remained available for future grant under our equity incentive plans.
Employee Stock Purchase Plan
In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (as amended, the "2020 ESPP"), which allows for full-time and certain part-time employees of the Company to purchase shares of common stock at a discount to fair market value. The 2020 ESPP authorizes the Company to issue up to 400,000 shares of the Company’s common stock. In addition, the number of shares available for issuance under the 2020 ESPP will automatically increase on the first day of each of the Company’s fiscal years beginning in 2021 and ending on the first day of 2030, in an amount equal to the lesser of (i) 300,000 shares, (ii) 1% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the board of directors of the Company, subject to adjustment upon changes in capitalization of the Company.
The 2020 ESPP permits our eligible employees to purchase discounted shares of our common stock at semi-annual intervals through periodic payroll deductions. Shares are purchased at a price equal to 85% of the lower of: (i) the fair market value of the Company’s common stock on the first business day of an offering period or (ii) the fair market value of the Company’s common stock on the last business day of an offering period. A new offering period commences every year on approximately March 1 and September 1. At the end of each offering period, the accumulated contributions are used to purchase shares of the Company’s common stock. The last business day of each purchase period is referred to as the purchase date. Purchase dates are every six months on February 28 or February 29 and August 31.

In August 2022, the Company’s board of directors approved an amendment to the 2020 ESPP. Effective September 1, 2022, each offering period is twenty-four months and consists of four six-month purchase periods during which payroll deductions of the participants are accumulated under the 2020 ESPP. Prior to September 1, 2022, each offering period was six months.
On February 28, 2021 and August 31, 2021, the Company issued 39,960 and 18,155 shares of its common stock, respectively, pursuant to scheduled purchases under the 2020 ESPP. As of December 31, 2021, 549,289 shares of common stock were reserved for future issuance under the 2020 ESPP. On January 1, 2022, an additional 297,729 shares of common stock became available under the 2020 ESPP pursuant to an automatic annual increase. On February 28, 2022 and August 31, 2022, the Company issued 47,339 and 100,749 shares of its common stock, respectively, pursuant to scheduled purchases under the 2020 ESPP. As of September 30, 2022, 698,930 shares of common stock remained available for future grants under the 2020 ESPP.
18

Common Stock Reserved for Future Issuance
Common stock reserved for future issuance consists of the following as of September 30, 2022 and December 31, 2021 (in thousands):
September 30,
2022
December 31,
2021
Warrants to purchase common stock10 31 
SPAC Warrants to purchase common stock*704 704 
Stock options issued and outstanding1,732 1,721 
RSUs issued and outstanding3,292 983 
Authorized for future equity grants1,003 603 
Authorized for future ESPP purchases699 549 
Total common stock reserved for future issuance7,440 4,591 
*Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.
4.    Leases, Commitments and Contingencies
Adoption of ASC 842
In the third quarter of 2021, the Company adopted ASU 2016-02, and ASC Topic 842, Leases (“ASC 842”) using the modified retrospective approach with an effective date of January 1, 2021.
Finance Leases
The Company leases certain laboratory equipment from various third parties, through equipment finance leases (previously referred to as “capital leases”). These leases either include a bargain purchase option or the terms of the leases are at least 75 percent of the useful lives of the assets and are therefore classified as finance leases. These leases are capitalized in property and equipment, net on the accompanying condensed consolidated balance sheets. Initial asset values and finance lease obligations are based on the present value of future minimum lease payments. Gross assets recorded under finance leases were $0.4 million and $0.4 million as of September 30, 2022 and December 31, 2021, respectively. Accumulated amortization associated with finance leases was $0.1 million and $0.1 million as of September 30, 2022 and December 31, 2021, respectively. Total finance lease interest expense was approximately $3,000 and $5,000 for the three months ended September 30, 2022 and 2021, respectively, and $10,000 and $13,000 for the nine months ended September 30, 2022 and 2021, respectively, and is included within interest income, net on the condensed consolidated statements of operations. Long-term finance lease obligations are as follows (in thousands):
September 30, 2022December 31, 2021
Gross finance lease obligations$215 $274 
Less imputed interest(14)(17)
Present value of net minimum lease payments201 257 
Less current portion of finance lease obligations(124)(121)
Total long-term finance lease obligations$77 $136 
19

Operating Leases
Del Mar Heights Lease
On July 1, 2021, the Company entered into an Office Lease (the “Del Mar Lease”) with Kilroy Realty, L.P. (the “Landlord”), with respect to an aggregate of 95,997 rentable square feet consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130 (the “Entire Premises”). The Entire Premises covered by the Del Mar Lease will serve as the Company’s new principal office.
The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease. The Company has the option to extend the term of the Del Mar Lease for two additional five-year periods, subject to the terms of the Del Mar Lease.
As the Landlord tenders possession of each portion of the Entire Premises for which the applicable improvements required by the Del Mar Lease are substantially complete, the Company will be obligated to make monthly payments of base rent with respect to such portion of the Entire Premises as set forth on Schedule 1 to the Del Mar Lease. In the event the Company exercises its option to extend the Del Mar Lease term, the Del Mar Lease provides for monthly rent payments during the additional five-year periods at the then-current market rent as determined in accordance with the Del Mar Lease. In addition to rent, the Del Mar Lease requires the Company to pay additional rent amounts for taxes, insurance, maintenance and other expenses.
During year ended December 31, 2021, the Company took initial possession of the first phase of its corporate headquarters, and the Company capitalized a ROU asset and related lease liability of $5.7 million associated with the first phase. During the three months ended March 31, 2022, the lease for the second phase of the Company’s corporate headquarters commenced and the Company capitalized a ROU asset and related lease liability of $15.8 million. The extension option periods were not considered in the determination of the ROU asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options.
Del Mar Lease Amendments
During April 2022, the Company amended the Del Mar Lease through the execution of the First Amendment to Office Lease (the "First Amendment") and the Second Amendment to Office Lease (the "Second Amendment") (collectively, the "Del Mar Lease Amendments"). Pursuant to the First Amendment to the Del Mar Lease, the Company elected to utilize a one-time increase in an additional improvement allowance of $25.00 per rentable square foot, which increased the tenant improvement allowance by $2.4 million to $14.4 million, provided under the Del Mar Lease to make certain improvements to the Entire Premises. As a result, the Company will pay an increased monthly base rent to the Landlord, in order to repay costs relating to the additional design and construction. Pursuant to the Second Amendment, the Company elected to expand the Entire Premises to include 14,085 rentable square feet comprising the executive parking level (the “Expansion Premises”), which increased the tenant improvement allowance by $2.1 million to $16.5 million. The Landlord will tender possession of the Expansion Premises following substantial completion of improvements, pursuant to an agreed upon work letter and will run contemporaneously with the term of the Existing Premises. The Company intends to use the additional space for general office and laboratory use. As the Landlord tenders possession of the Expansion Premises, the Company will be obligated to pay the Landlord increased monthly installments of base rent for the Expansion Premises. Upon inclusion of the Expansion Premises, the Company will lease approximately 110,082 rentable square feet rentable square feet from the Landlord.
20

The Del Mar Lease Amendments were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. The Company evaluated the Del Mar Lease Amendments under ASC 842 and concluded that the Del Mar Lease Amendments would be accounted for as a single contract with the Del Mar Lease because the additional lease payments related to the tenant improvement allowance due to the Del Mar Lease Amendments were not commensurate with ROU asset granted to the Company. Accordingly, the Company remeasured the lease liability using the additional monthly rent payments and the incremental borrowing rate at the effective date of the modification of 6.50%. The remeasurement for the modification resulted in an increase to the lease liability and the ROU asset of approximately $1.2 million.
The extension option periods were not considered in the determination of the ROU asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options. Pending execution of the Landlord's obligations to prepare leased spaces for occupancy, the Company expects the operating leases for the additional office and laboratory space to commence on various dates in the year ending December 31, 2022. The Company has an estimated future lease payment obligation of approximately $54.0 million related to corporate office facilities that were in the process of being constructed as of September 30, 2022. The lease liabilities and the corresponding ROU assets associated with these lease obligations will be recorded upon the commencement date of the operating leases using the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.
In connection with the original lease agreement, in lieu of a cash security deposit, the Company’s bank issued a letter of credit on its behalf, which is secured by a deposit, of $3.0 million and is included in restricted cash on the condensed consolidated balance sheet based on the term of the underlying lease. In April 2022, pursuant to the Second Amendment, the Company’s bank increased the letter of credit on its behalf by $0.5 million, totaling $3.5 million. As of September 30, 2022, none of the standby letter of credit amount has been used.
Torrey Pines Lease
In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the Torrey Lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations. As part of the fifth amendment, the Company was entitled to a tenant improvement allowance for certain costs incurred while performing these improvements in the amount of $0.3 million, which amount may be increased by up to $0.1 million at the Company’s election and subject to a corresponding increase in rent. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs.
The lease term for all leased space has an expiration date of April 30, 2023, and an option to extend the lease term on all leased space for one additional three-year term, which the Company is not reasonably certain that it will exercise. As such, the Company did not include this option in the determination of the total lease term. On January 1, 2021, in conjunction with the adoption of the guidance in ASU 2016-02, the Company recognized a ROU asset and corresponding lease liability for its facility lease as the present value of lease payments not yet paid at January 1, 2021. The ROU asset and corresponding lease liability was estimated assuming the remaining lease term of 28 months at January 1, 2021, and an estimated discount rate of 4.04%, which was the Company’s incremental borrowing rate at the date of adopting ASC 842. The Company recorded a lease liability of $3.1 million and a ROU asset of $2.8 million, which is net of $0.3 million of the Company’s previously capitalized tenant improvement allowance and deferred rent, upon adoption.
21

The components of lease expense for the three and nine months ended September 30, 2022 was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Operating lease cost
Operating lease cost$1,056 $379 $2,724 $1,023 
Variable lease costs (1)
188 171 680 486 
Total operating lease cost$1,244 $550 $3,404 $1,509 
Finance lease cost  
Amortization of leased assets$21 $17 $62 $53 
Interest on lease liabilities3 5 10 13 
Total finance lease cost$24 $22 $72 $66 
(1) Variable lease costs are primarily related to common area maintenance charges and property taxes.
Other information related to leases was as shown in the table below.
Nine Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3,621 $1,516 
Operating cash flows from finance leases$10 $13 
Financing cash flows from finance leases$104 $80 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$18,688 $9,071 
Finance leases$48 $105 
Weighted average remaining lease term in years:
Operating leases10.019.33
Finance leases2.372.67
Weighted average discount rate:
Operating leases6.44 %5.78 %
Finance leases5.81 %5.76 %
The Company’s future minimum lease payments under operating and financing leases at September 30, 2022 are as follows (in thousands):
20222023202420252026ThereafterTotal
Operating lease obligations, including interest$791 $2,948 $2,774 $2,853 $2,934 $20,612 $32,912 
Finance lease obligations, including interest25 133 19 19 15 4 215 
Total future minimum lease payments$816 $3,081 $2,793 $2,872 $2,949 $20,616 $33,127 
Amounts presented in the table above exclude non-cancelable future minimum lease payments for operating leases that have not commenced as of September 30, 2022.
Legal Proceedings
From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.
22

5.    Related Party Transactions
During 2021 and 2022, the Company engaged EVERSANA Life Science Services, LLC (“EVERSANA”) to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s Chief Commercial Offer, is an employee of EVERSANA. The Company incurred $1.1 million and $0.9 million in costs for the three months ended September 30, 2022 and 2021, respectively, and $2.8 million and $1.8 million for the nine months ended September 30, 2022 and 2021, respectively. Amount due to EVERSANA were $0.7 million and $0.6 million as of September 30, 2022 and December 31, 2021, respectively.
On October 1, 2019, the Company entered into a consulting agreement with Michael Dobak pursuant to which the Company will compensate Michael Dobak, in an amount not to exceed $100,000, for certain public relations and marketing services. On July 28, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to modify the terms of Michael Dobak’s compensation. The amended consulting agreement compensated Michael Dobak $15,000 per month from May 11, 2020 through September 30, 2021 and also granted him a restricted stock unit award that fully vested in a single installment on August 31, 2020 and represented the contingent right to receive 5,000 shares of common stock on January 2, 2021. On November 11, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to extend the term through December 31, 2021 with a continued monthly payment of $15,000. On February 26, 2021, the Company and Michael Dobak agreed to extend his agreement through April 30, 2021 with a revised monthly payment of $20,000. Michael Dobak is the brother of Dr. John Dobak, the Company’s Chief Executive Officer. The Company incurred zero costs for the three months ended September 30, 2022 and 2021, respectively, and zero and $0.1 million for the nine months ended September 30, 2022 and 2021.
There were no other related party transactions identified during the nine months ended September 30, 2022 and 2021.
6.    Subsequent Events
The Company considered subsequent events through November 3, 2022, the date the condensed consolidated financial statements were available to be issued.
23

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following Discussion and Analysis of Financial Condition and Results of Operations of DermTech, Inc. (together with its subsidiaries, “DermTech,” “we,” “us,” “our” or the “Company”) should be read in conjunction with the condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited condensed consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December 31, 2021, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 10, 2022.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report, including the following Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are intended to be covered by the “safe harbor” created by those sections. All statements, other than statements of historical facts, contained in this report, including statements regarding DermTech’s or its management’s intentions, beliefs, expectations and strategies for the future, are forward looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “potential,” “could,” “would,” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements are made as of the date of this report, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that could cause actual results to differ materially are more fully described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC. We assume no obligation to update any of the forward-looking statements after the date of this report or to conform these forward-looking statements to actual results.
Overview
We are a molecular diagnostic company developing and marketing novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases. Our technology provides a more accurate alternative to surgical biopsy, minimizing patient discomfort, scarring, and risk of infection, while maximizing convenience. Our scalable genomics assays are used to non-invasively collect a tissue sample for analysis.
We are initially commercializing tests that will address unmet needs in the diagnostic pathway of pigmented skin lesions, such as moles or dark colored skin spots. The DMT facilitates the clinical assessment of pigmented skin lesions for melanoma. We initially marketed this test directly to a concentrated group of dermatologists and are currently expanding marketing efforts to a broader group of clinicians and to a small group of primary care providers. The application of our Smart Sticker to collect samples non-invasively may allow us to eventually market the DMT to primary care physicians more broadly, beyond integrated primary care networks, and expand our efforts through telemedicine channels. We process our tests in our high complexity molecular laboratory that is certified under CLIA, College of American Pathologists accredited and New York licensed. We also provide laboratory services to several pharmaceutical companies that access our technology on a contract basis for their clinical trials or other studies to advance new drugs.
Events, Trends and Uncertainties

The DMT without the additional test for the presence of telomerase reverse transcriptase gene driver mutations (“TERT”) (formerly known as PLAplus) became eligible for Medicare reimbursement on February 10, 2020. Each reference to the DMT in this paragraph refers only to the DMT without the add-on test for TERT. In late October 2019, the American Medical Association provided us with a PLA Code. Pricing of $760 for the PLA Code was published on December 24, 2019 as part of the Clinical Laboratory Fee Schedule for 2020. The final Local Coverage Determination, or LCD, expanded the coverage proposal in the draft LCD from one to two tests per date of service and it allows clinicians to order the DMT if they have sufficient skill and experience to decide whether a pigmented lesion should be biopsied. Our local Medicare Administrative Contractor, Noridian, has issued its own Local Coverage Decision, or Noridian’s LCD, announcing coverage of the DMT. Even though the effective date of Noridian’s LCD was June 7, 2020, Noridian began reimbursing us for the DMT as of February 10, 2020. With Medicare coverage granted, we have the opportunity to approach commercial payors, and as a result, we believe that the DMT may generate significant revenues in 2022 and 2023. No LCD currently covers the optional add-on test for TERT available to those ordering the DMT.
24

Despite the grant of Medicare coverage for the DMT (without the add-on test for TERT), uncertainty surrounds commercial payor reimbursement, including governmental and commercial payors, of any test incorporating new technology, including tests developed using our technologies. Because each payor generally determines for its own enrollees or insured patients whether to cover or otherwise establish a policy to reimburse our tests, seeking payor approvals is a time-consuming and costly process. We cannot be certain that coverage for our current tests and our planned future tests will be provided in the future by additional commercial payors or that existing policy decisions or reimbursement levels will remain in place or be fulfilled under existing terms and provisions. If we cannot obtain or maintain coverage and reimbursement from private and governmental payors such as Medicare and Medicaid for our current tests, or new tests or test enhancements that we may develop in the future, our ability to generate revenues could be limited. This may have a material adverse effect on our business, financial condition, results of operation, and cash flows.
Impacts of COVID-19 and Current Inflationary Environment

The ongoing COVID-19 pandemic has affected many segments of the global economy, including the cancer screening and diagnostics industry. The pandemic and related precautionary measures have significantly impacted, and may continue to impact, our workforce, supply chain, and operating results including our sample volumes, revenues, margins, and cash utilization, among other measures. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical, and long-lasting and may vary from location to location. Our business was negatively impacted by the pandemic but has in large part recovered. Future outbreaks of COVID-19 and its variants could diminish patients’ and our sales representatives’ access to healthcare provider offices. Pandemic-related supply chain disruptions, whether caused by restrictions or slowdowns in shipping or logistics, increases in demand for certain goods used in our operations, or otherwise, could impact our operations.

Global supply chain disruptions and the higher inflationary environment have resulted in higher prices, which could impact our liquidity, business, financial condition and results of operations.
Contract Revenue
Contract revenues with pharmaceutical companies relate to ongoing clinical trial contracts and new contracts. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress which can be difficult to forecast due to variability of patient enrollment, drug safety and efficacy and other factors. Many of our historical contracts with third parties were structured to contain milestone billing payments, which typically are advance payments on work yet to be performed. These advanced payments are structured to help fund operations and are included in deferred revenue as the work has not yet been performed. These advance payments will remain in deferred revenue until we process the laboratory portion of the contracts allowing us to recognize the revenue.
Optional Add-on Test for TERT (formerly known as PLAplus)
During the second quarter of 2021, we announced the launch of the optional add-on test for TERT (then known as PLAplus) available to those ordering the DMT, which delivers objective and actionable information to guide clinical management decisions for skin lesions that may be melanoma. This add-on test combines TERT promoter DNA driver mutation analyses as a reflex test to the DMT’s standard RNA gene expression test. TERT is individually associated with histopathologic features of aggressiveness and poor survival in melanoma. The combined tests elevate the sensitivity from 91% to 97% and maintain a negative predictive value of >99%, resulting in a less than 1% probability of missing melanoma. By combining RNA gene expression and DNA mutation analyses, the DMT provides a highly accurate non-invasive genomic test for enhanced early melanoma detection.
25

Financial Overview
Revenue
We generate revenue through laboratory services that are billed to Medicare, private medical insurance companies and to pharmaceutical companies who order our laboratory services, which can include sample collection kits, assay development, patient segmentation and stratification, genomic analysis, data analysis and reporting. Our revenue is generated from two revenue streams: assay revenue and contract revenue. Assay revenue can be highly variable as it is based on payments received by government and private insurance payors that are and are not under contract and can vary based on patient insurance coverage, deductibles and co-pays. As much of our assay revenue is driven by the samples that are sent by physicians to our central lab for testing, a key performance measure for us is samples that are received and processed by our central lab successfully, also known as billable samples. Our laboratory services are ordered by customers on projects that may span over several years, which makes our contract revenue highly variable. Segments of these contracts may be increased, delayed or eliminated based on the success of each customers’ clinical trials or other factors.
Operating Expenses
Sales and Marketing Expenses
Sales and marketing expenses are primarily related to our specialty field sales force, market research, reimbursement efforts, conference attendance, public relations, advertising, and general marketing.
Research and Development Expenses
Our research and development ("R&D") expenses consist primarily of salaries and fringe benefits, clinical trials, consulting costs, facilities costs, laboratory costs, equipment expense, and depreciation. We also conduct clinical trials to validate the performance characteristics of our tests and to show medical cost benefit in support of our reimbursement efforts.
General and Administrative Expenses
Our general and administrative expenses consist of senior management compensation, consulting, legal, billing and collections, human resources, information technology, accounting, insurance, and general business expenses.
Financing Activities
2020 At-The-Market Offering
On November 10, 2020, the Company entered into a sales agreement with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the sales agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million. For the nine months ended September 30, 2022, the Company did not issue any shares pursuant to the November 2020 Sales Agreement.
2021 Underwritten Public Offering
On January 6, 2021, the Company, entered into an underwriting agreement with Cowen and William Blair & Company, L.L.C. as representatives of the several underwriters (the “Underwriters”). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company.
On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company’s aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $143.7 million.
2022 At-The-Market Offering
On August 8, 2022, the Company entered into a sales agreement with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million. The Company did not issue or sell any shares of common stock pursuant to the sales agreement in the third quarter of 2022.
26

Results of Operations
Three Months Ended September 30, 2022 and September 30, 2021
Assay Revenue
Assay revenues grew $0.5 million, or 16%, to $3.4 million for the three months ended September 30, 2022 compared to $3.0 million for the three months ended September 30, 2021. Billable samples increased to approximately 18,080 for the three months ended September 30, 2022 compared to approximately 11,720 for the three months ended September 30, 2021. Sample volume is dependent on two major factors: the number of clinicians who order an assay in any given quarter and the number of assays ordered by each clinician during the period. The number of ordering clinicians and the utilization per clinician can vary based on a number of factors including patients presenting with skin cancer conditions, clinician reimbursement, office workflow, market awareness and clinician education.
Contract Revenue
Contract revenues with pharmaceutical companies increased $64,000, or 84%, to $140,000 for the three months ended September 30, 2022, compared to $76,000 for the three months ended September 30, 2021. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress, which can be difficult to forecast due to variability of patient enrollment, drug safety and efficacy and other factors.
Cost of Revenue
Cost of revenues increased $0.8 million, or 27%, to $3.7 million for the three months ended September 30, 2022 compared to $2.9 million for the three months ended September 30, 2021. The increase was largely attributable to a higher billable sample volume in 2022, and higher overhead costs, partially offset by streamlined laboratory processes. As of September 30, 2022, a large portion of the costs of revenue are fixed, and these costs include the CLIA facility, quality assurance, management and supervision and equipment calibration and depreciation. The variable cost of revenue expenses incurred primarily relate to compensation-related costs for our laboratory scientists and technicians, laboratory supplies, shipping costs and Smart Sticker collection kits. We remain committed to continuing the automation of our laboratory processes in order to become more cost efficient and productive.
Operating Expenses
Sales and Marketing
Sales and marketing expenses increased $4.8 million, or 49%, to $14.6 million for the three months ended September 30, 2022 compared to $9.8 million for the three months ended September 30, 2021. The increase was primarily attributable to higher compensation-related costs from the expansion of the commercial team, increased spending on marketing and payor infrastructure and activities, and travel expenses.
Research and Development
R&D expenses increased $1.3 million, or 29%, to $5.7 million for the three months ended September 30, 2022 compared to $4.4 million for the three months ended September 30, 2021. The increase was due to higher compensation costs of expanding the R&D team, including the addition of some senior leadership and increased travel and overhead costs.
General and Administrative
General and administrative expenses increased $2.6 million, or 42%, to $8.8 million for the three months ended September 30, 2022 compared to $6.2 million for the three months ended September 30, 2021. The increase was primarily due to higher payroll-related costs and stock-based compensation as we continue to add infrastructure such as human resources, billing, information technology and legal resources, and higher consulting expenses, and overhead.
Interest Income, net
Interest income, net of $0.5 million and $38,000 for the three months ended September 30, 2022 and 2021, respectively, consists primarily of interest earned on our short-term marketable securities.
27

Change in Fair Value of Warrant Liability
Change in fair value of warrant liability for the three months ended September 30, 2022 was a gain of $4,000 compared to a gain of $0.2 million for the three months ended September 30, 2021. The change in fair value of warrant liability is calculated by adjusting the value of the outstanding Private SPAC Warrants held by original holders to the current market value at each reporting period.
Nine Months Ended September 30, 2022 and September 30, 2021
Assay Revenue
Assay revenues increased $3.0 million, or 38%, to $11.1 million for the nine months ended September 30, 2022 compared to $8.1 million for the nine months ended September 30, 2021. Billable samples increased to approximately 50,770 for the nine months ended September 30, 2022 compared to approximately 32,840 for the nine months ended September 30, 2021. The increase in assay revenue was primarily due to higher billable sample volume.
Contract Revenue
Contract revenues with pharmaceutical companies decreased $0.2 million, or 31%, to $0.4 million for the nine months ended September 30, 2022, compared to $0.6 million for the nine months ended September 30, 2021. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress, which can change due to variability of patient enrollment, drug safety and efficacy and other factors.
Cost of Revenue
Cost of revenues increased $3.0 million, or 40%, to $10.5 million for the nine months ended September 30, 2022 compared to $7.5 million for the nine months ended September 30, 2021. The increase was largely attributable to a higher billable sample volume in 2022, and overhead costs, partially offset by streamlined laboratory processes. As of September 30, 2022, a large portion of the costs of revenue are fixed, and these costs include the CLIA facility, quality assurance, management and supervision and equipment calibration and depreciation. The variable cost of revenue expenses incurred primarily relate to compensation-related costs for our laboratory scientists and technicians, laboratory supplies, shipping costs, equipment maintenance, and utilities. We remain committed to continuing the automation of our laboratory processes in order to become more cost efficient and productive.
Operating Expenses
Sales and Marketing
Sales and marketing expenses increased $20.8 million, or 86%, to $45.1 million for the nine months ended September 30, 2022 compared to $24.2 million for the nine months ended September 30, 2021. The increase was primarily attributable to higher compensation-related costs from the expansion of the commercial team, increased spending on marketing and payor infrastructure and activities, and additional software, conference and travel expenses.
Research and Development
R&D expenses increased $8.7 million, or 85%, to $19.0 million for the nine months ended September 30, 2022 compared to $10.3 million for the nine months ended September 30, 2021 The increase was due to higher compensation costs of expanding the R&D team, including the addition of some senior leadership, increased clinical trial costs and increased spending on laboratory supplies to support new product development.
General and Administrative
General and administrative expenses increased $8.6 million, or 49%, to $26.3 million for the nine months ended September 30, 2022 compared to $17.7 million for the nine months ended September 30, 2021. The increase was primarily due to higher payroll-related costs and stock-based compensation as we continue to add additional infrastructure such as human resources, billing, information technology and legal resources, and higher consulting expenses, insurance and overhead costs.
28

Interest Income, net
Interest income, net of $0.7 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively, consists primarily of interest earned on our short-term marketable securities.
Change in Fair Value of Warrant Liability
Change in fair value of warrant liability for the nine months ended September 30, 2022 was a gain of $0.1 million compared to a loss of $1.4 million for the nine months ended September 30, 2021. The change in fair value of warrant liability is calculated by adjusting the value of the outstanding Private SPAC Warrants held by original holders to the current market value at each reporting period.
Liquidity and Capital Resources
We have never been profitable and have historically incurred substantial net losses, including net losses of $36.5 million for the twelve months ended December 31, 2020, $78.3 million for the twelve months ended December 31, 2021 and $88.5 million for the nine months ended September 30, 2022. As of September 30, 2022, our accumulated deficit was $294.8 million. For the nine months ended September 30, 2022, we had negative operating cash flow of $74.0 million. At the end of 2020 and throughout 2021, we raised approximately $44.5 million in gross proceeds facilitated through our at-the-market offering. In addition, we completed the 2021 Underwritten Public Offering in January 2021, which raised a total of $143.7 million in gross proceeds. We have historically financed operations through private placement and public equity offerings.
We expect our losses to continue as a result of costs relating to ongoing R&D expenses, general and administrative expenses and sales and marketing costs for existing and planned products. These losses have had, and will continue to have, an adverse effect on our working capital. Because of the numerous risks and uncertainties associated with our commercialization and development efforts, we are unable to predict when we will become profitable, and we may never become profitable. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations and cash flows.
As of September 30, 2022, our cash and cash equivalents totaled approximately $95.5 million and short-term marketable securities totaled approximately $53.6 million. Based on our current business operations, we believe our current cash, cash equivalents and short-term marketable securities will be sufficient to meet our anticipated cash requirements for at least the next 12 months. While we believe we have enough capital to fund anticipated operating costs for at least the next 12 months, we expect to incur significant additional operating losses over at least the next several years. We anticipate that we will raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements in order to support our planned operations and to continue developing and commercializing genomic tests. We may also consider raising additional capital in the future to expand our business, to pursue strategic investments or to take advantage of financing opportunities. Our present and future funding requirements will depend on many factors, including:
our revenue growth rate and ability to generate cash flows from operating activities;
the willingness of clinicians and their patients to use our telemedicine option for the DMT and the duration and extent of the effects of the ongoing COVID-19 pandemic in reducing patient access to clinician offices for in-person testing and access by our sales force for in-office sales calls;
the duration and extent of the effects of the ongoing COVID-19 pandemic on our pharmaceutical customers’ clinical trials;
our sales and marketing and R&D activities;
effects of competing technological and market developments;
costs of and potential delays in product development;
changes in regulatory oversight applicable to our tests; and
timing of and costs related to future international expansion.
There can be no assurances as to the availability of additional financing or the terms upon which additional financing may be available to us. If we are unable to obtain sufficient funding at acceptable terms, we may be forced to significantly curtail our operations, and the lack of sufficient funding may have a material adverse impact on our ability to continue as a going concern.
29

Cash Flow Analysis
Nine Months Ended September 30, 2022
Net cash used in operating activities for the nine months ended September 30, 2022 totaled $74.0 million, primarily driven by the $88.5 million net loss offset partially by non-cash related items, including $13.7 million in stock-based compensation, $1.8 million in amortization of operating lease ROU assets, $1.2 million in depreciation and $0.3 million in amortization of premiums, net of accretion of discounts on marketable securities. In addition, we had a net cash outflow of $2.8 million through net changes in working capital balances driven primarily by cash outflows of $2.3 million due to increase in accounts receivable, $1.0 million through the increase of prepaid expenses and other current assets and $2.7 million through the decrease of operating lease liabilities, partially offset by cash inflows of $3.2 million from the increase in accrued compensation.
Net cash used in investing activities for the nine months ended September 30, 2022 totaled $7.9 million, which related to the outflow from the purchase of $26.4 million of marketable securities and $1.4 million from the purchase of equipment offset by the inflow from the maturity of marketable securities of $19.9 million. Additional laboratory equipment investment will be needed to install complex automation systems and other genomic testing equipment needed to expand testing capacity.
Net cash provided by financing activities for the nine months ended September 30, 2022 totaled $1.0 million, which was driven primarily by $1.0 million in proceeds from contributions to the employee stock purchase plan.
Off-Balance Sheet Arrangements
As of September 30, 2022, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Critical Accounting Policies and Significant Judgments and Estimates
Critical accounting policies, significant judgments, and estimates are those that we believe are most important for the portrayal of the Company’s financial condition and results, and that require management’s most subjective and complex judgments. Judgments and uncertainties regarding the application of these policies may result in materially different amounts being reported under various conditions or using different assumptions. There have been no material changes to the critical accounting estimates previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and disclosed in Note 1(g) of the condensed consolidated financial statements herein.
Recent Accounting Pronouncements
See Item 1 of Part I, Note 1(k) of the condensed consolidated financial statements herein.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Our cash, cash equivalents, and short-term marketable securities are subject to economic risk which could affect our results of operations, financial condition and cash flows. We manage our exposure to this market risk through our regular operating and financing activities.
Interest Rate Risk
The primary objective of our investment activities is capital preservation to fund operations, while at the same time maximizing investment income without significantly increasing investment risk. To achieve these objectives, our investment policy allows for a portfolio of cash equivalents and investments in a variety of securities, including money market funds, U.S. government debt and corporate debt securities. Due to the short-term and conservative nature of our investments, we do not believe that we have a material exposure to interest rate risk. A 100 basis point change in interest rates would not have a significant impact on the total value of our portfolio.
30

Item 4. Controls and Procedures.
Disclosure controls and procedures enable us to record, process, summarize and report information required to be included in our Exchange Act filings within the required time period. Our disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed by us in the periodic reports filed with the Securities and Exchange Commission is accumulated and communicated to our management, including our principal executive, financial and accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q, as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act. Based upon that evaluation, our principal executive officer and our principal financial officer concluded that, as of December 31, 2021, the Company’s disclosure controls and procedures were not effective, due to the material weakness in our internal control over financial reporting discussed in Part I, Item 9A—Controls and Procedures in our Annual Report on Form 10-K for the year ended December 31, 2021.
Material Weakness in Internal Control Over Financial Reporting
A material weakness in internal control over financial reporting is a deficiency, or combination of deficiencies such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As the Company could not conclude that controls over the completeness, existence and accuracy of assay revenue and accounts receivable were designed and operating effectively as of December 31, 2021, the Company identified a material weakness in its controls over the financial reporting related to our assay revenue and accounts receivable process. Management identified the need to enhance our risk assessment process, enhance communications with our third-party service organization, and reassess the assay revenue and accounts receivable process to ensure appropriate design and operating effectiveness of controls.
Plan of Remediation of Material Weakness
To remediate these material weaknesses in our internal control over financial reporting related to assay revenue and accounts receivable described in Part I, Item 9A—Controls and Procedures in our Annual Report on Form 10-K for the year ended December 31, 2021, we plan to implement or improve documentation of alternative internal control procedures to verify the completeness and accuracy of customer contracts received and the delivery of test results. The material weakness cannot be considered remediated until the controls operate for a sufficient period and management has concluded, through testing, that our internal controls are operating effectively.
Other than the changes made in remediating the material weakness described above, there has been no change in the Company’s internal control over financial reporting that occurred during the quarter ended September 30, 2022 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
After giving full consideration to the material weakness referenced above, and the additional analyses and other procedures that we performed to ensure that our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q were prepared in accordance with U.S. GAAP, our management has concluded that our condensed consolidated financial statements present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.
31

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
We are not currently a party to any material legal proceedings.
Item 1A. Risk Factors.
There have not been any material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.
Item 6. Exhibits.
The following documents are filed as part of this Form 10-Q.
Exhibit
No.
DescriptionFiled
Herewith
FormIncorporated
by Reference
File No.
Date Filed
10.1S-3333-2666508/8/2022
10.2*S-8333-2674699/16/2022
10.3*X
31.1X
31.2X
32.1**X
101.INSInline XBRL Instance DocumentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104
The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 has been formatted in Inline XBRL.
X
*Management contract or compensatory plan or arrangement
** This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing.
32

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DermTech, Inc.
Date: November 3, 2022
By:/s/ John Dobak
John Dobak, M.D.
Chief Executive Officer
(Principal Executive Officer)
Date: November 3, 2022
By:/s/ Kevin Sun
Kevin Sun
Chief Financial Officer
(Principal Financial and Accounting Officer)
33
EX-10.3 2 ex103dermtech-amendedandre.htm EX-10.3 Document
Exhibit 10.3
DermTech, Inc.

AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN

(As amended August 9, 2022)

The following constitute the provisions of the 2020 Employee Stock Purchase Plan (the "Plan") of DermTech, Inc. (the "Company").

1.Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company. It is the intention of the Company to have the Plan qualify as an "Employee Stock Purchase Plan" under Section 423 of the Code. The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a manner consistent with the requirements of that section of the Code.

2.Definitions.

(a)"Board" shall mean the Board of Directors of the Company, or a committee of the Board of Directors named by the Board to administer the Plan.

(b)"Code" shall mean the Internal Revenue Code of 1986, as amended, including any successor statute, regulation and guidance thereto.

(c)"Common Stock" shall mean the common stock, $0.0001 par value per share, of the Company.

(d)"Company" shall mean DermTech, Inc., a Delaware corporation.

(e)"Compensation" shall mean the regular rate of salary or wages received by the Employee from the Company or a Designated Subsidiary that is taxable income for federal income tax purposes, including payments for overtime and shift premium, incentive compensation, incentive payments, bonuses and commissions, but excluding relocation, expense reimbursements, tuition or other reimbursements, other non-cash W-2 compensation (i.e. disqualifying dispositions, equity grants, equity exercises or settlements), or compensation received from the Company or a Designated Subsidiary. For purposes of determining a participant’s Compensation, any election by such participant to reduce his or her regular cash remuneration under Sections 125 (i.e. pre-tax cafeteria plan contributions) or 401(k) (i.e. pre-tax retirement contributions) of the Code (or in foreign jurisdictions, equivalent salary deductions) shall be treated as if the participant did not make such election and as if such reductions were not made. In other words ESPP Contributions are calculated on pre-tax Compensation but are withheld on a post-tax basis. Pre-tax contributions, including but not limited to those under Section 125 and 401(k), are withheld first, and ESPP Contributions are withheld only if the remaining post-tax Compensation can satisfy the elected ESPP Contribution percentage.

(f)"Continuous Status as an Employee" shall mean the absence of any interruption or termination of service as an Employee. Continuous Status as an Employee shall not be considered interrupted in the case of a leave of absence agreed to in writing by the Company, provided that such leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or statute.

(g)"Contributions" shall mean all amounts credited to the account of a participant pursuant to the Plan.




(h)"Designated Subsidiaries" shall mean the Subsidiaries which have been designated by the Board from time to time in its sole discretion as eligible to participate in the Plan.

(i)"Employee" shall mean any person who is employed by the Company or one of its Designated Subsidiaries for tax purposes and who is customarily employed for at least twenty (20) hours per week and more than five (5) months in a calendar year by the Company or one of its Designated Subsidiaries.

(j)"Exercise Date" shall mean the last business day of each Offering Period or Purchase Period of the Plan.

(k)Exercise Price” shall mean with respect to an Offering Period, an amount equal to 85% of the fair market value (as defined in Paragraph 7(b)) of a share of Common Stock on the Offering Date or on the Exercise Date, whichever is lower.

(l)"Offering Date" shall mean the first business day of each Offering Period of the Plan.

(m)"Offering Period" shall me an each twenty-four (24) month period commencing on each September 1 and March 1 to occur during the term of the Plan (or other such period or periods as determined by the Board in accordance with this Plan) with respect to which the right to purchase Common Stock may be granted under the Plan.

(n)"Plan" shall mean this DermTech, Inc. Employee Stock Purchase Plan.

(o)Purchase Period” shall mean one or more periods within an Offering Period during which contributions may be made toward the purchase of Common Stock under the Plan, as determined by the Board. The Board shall have the power to change the duration of Purchase Periods.

(p)"Subsidiary" shall mean a corporation, domestic or foreign, of which not less than 50% of the voting shares are held by the Company or a Subsidiary, whether or not such corporation now exists or is hereafter organized or acquired by the Company or a Subsidiary.

3.Eligibility.

(a)Any person who has been continuously employed as an Employee for 1 month as of the Offering Date of a given Offering Period shall be eligible to participate in such Offering Period under the Plan and further, subject to the requirements of Paragraph 5(a) and the limitations imposed by Section 423(b) of the Code. All Employees granted options under the Plan with respect to any Offering Period will have the same rights and privileges except for any differences that may be permitted pursuant to Section 423 of the Code.

(b)Any provisions of the Plan to the contrary notwithstanding, no Employee shall be granted an option under the Plan if, immediately after the grant, such Employee (or any other person whose stock would be attributed to such Employee pursuant to Section 424(d) of the Code) would own stock and/or hold outstanding options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any Subsidiary of the Company.

(c)Any provisions of the Plan to the contrary notwithstanding, no Employee shall be granted an option to purchase Common Stock under the Plan with a fair market value as defined in Paragraph 7(b)



(determined at the time such option is granted) in excess of the following limit, which shall be applied in accordance with Section 423(b)(8) of the Code:

(i)In the case of Common Stock purchased during an Offering Period that commenced in the current calendar year, the limit shall be equal to (A) $25,000 minus (B) the Offering Date fair market value of the Common Stock that the Employee previously purchased in the current calendar year under this Plan and all other employee stock purchase plans (described in Section 423 of the Code) of the Company or any parent or Subsidiary of the Company;

(ii)In the case of Common Stock purchased during an Offering Period that commenced in the immediately preceding calendar year, the limit shall be equal to (A) $50,000 minus (B) the Offering Date fair market value of the Common Stock that the Employee previously purchased under this Plan and all other employee stock purchase plans (described in Section 423 of the Code) of the Company or any parent or Subsidiary of the Company in the current calendar year and in the immediately preceding calendar year;

(iii)In the case of Common Stock purchased during an Offering Period that commenced two calendar years prior, the limit shall be equal to (A) $75,000 minus (B) the Offering Date fair market value of the Common Stock that the Employee previously purchased under this Plan and all other employee stock purchase plans (described in Section 423 of the Code) of the Company or any parent or Subsidiary of the Company in the current calendar year and in the two immediately preceding calendar years.

(d)An Employee shall not be permitted to purchase more than 2,500 shares of Common Stock on an Exercise Date. The Board may, in its sole discretion, set a new maximum number of shares that may be purchased by any participant on an Exercise Date. If a lower limit is set under this Paragraph 3(d), the Board shall notify participants of such limit prior to the commencement of the next Purchase Period for which it is to be effective.

(e)If the number of shares to be purchased on an Exercise Date by all Employees participating in this Plan exceeds the number of shares then available for issuance under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably practicable and as the Board shall determine to be equitable. In such event, the Company shall give written notice of such reduction of the number of shares to be purchased under a participant’s option to each participant affected.

(f)Any payroll deductions accumulated in an Employee’s account which are not used to purchase Common Stock due to the limitations in this Paragraph 3 shall be returned to the participant as soon as practicable after the end of the applicable Purchase Period, without interest (except to the extent required due to local legal requirements outside the United States).

(g)If a participant is precluded by the limitations of this Paragraph 3 from purchasing additional Common Stock under the Plan, then his or her employee contributions may be automatically discontinued by the Company and shall automatically resume at the beginning of the earliest Purchase Period that will end in the next calendar year (if he or she then is an eligible Employee), provided that when the Company automatically resumes such payroll deductions, the Company must apply the rate in effect immediately prior to such suspension.




(h)Any option granted under the Plan shall be deemed to be modified to the extent necessary to satisfy this Paragraph 3.

4.Offering Periods.

(a)The Plan shall be implemented by a series of Offering Periods, with a new Offering Period commencing on September 1 and March 1 of each year or the first business day thereafter (or at such other time or times as may be determined by the Board). Each Offering Period shall consist of four (4) six-month Purchase Periods commencing on each September 1 and March 1 to occur during the Offering Period or the first business day thereafter and ending February 28 (or the 29th if February has 29 days) and August 31 of each year (or commencing and ending at other such time or times as may be determined by the Board), during which payroll deductions of the participants are accumulated under this Plan. The Board shall have the power to change the Offering Dates, the Exercise Dates, and the duration of Offering Periods (provided that an Offering Period will in no event be longer than twenty-seven (27) months) or Purchase Periods without stockholder approval if such change is announced prior to the relevant Offering Period or prior to such other time period as specified by the Board. The initial Offering Period shall commence on September 1, 2020.

(b)If the fair market value of a share of Common Stock on any Exercise Date that occurs during an Offering Period is less than the fair market value of a share of Common Stock on the Offering Date of the applicable Offering Period, then such Offering Period shall automatically terminate immediately after the purchase of shares of Common Stock on such Exercise Date and a new subsequent Offering Period shall commence on the September 1 or March 1 next following such Exercise Date (or the first business day thereafter or such other time as may be determined by the Board) (an “Automatic Reset”).

5.Participation.

(a)An eligible Employee may become a participant in the Plan by completing an Enrollment Form provided by the Company and filing it with the Company or its designee at least seven (7) days prior to the applicable Offering Date, unless a later time for filing the Enrollment Form is set by the Board for all eligible Employees with respect to a given Offering Period and provided, however, that upon the termination of an Offering Period as a result of an Automatic Reset, each participant in such Offering Period shall automatically participate in the immediately following Offering Period on the same terms on which the participant participated in the terminated Offering Period pursuant to the participant’s existing Enrollment Form (as may be subsequently modified or revoked in accordance with the Plan). The Enrollment Form and its submission may be electronic as directed by the Company. The Enrollment Form shall set forth the percentage of the participant's Compensation (which shall be not less than one percent (1%) and not more than fifteen percent (15%), in increments not less than one percent (1%), to be paid as Contributions pursuant to the Plan.

(b)Payroll deductions shall commence with the first payroll or as soon as practicable following the Offering Date, unless a later time is set by the Board with respect to a given Offering Period, and shall end on the last payroll paid on or prior to the Exercise Date of the Offering Period to which the Enrollment Form is applicable, unless sooner terminated as provided in Paragraph 10.

6.Method of Payment of Contributions.

(a)Each participant shall elect to have payroll deductions made on each payroll during the Offering Period in an amount not less than one percent (1%) and not more than fifteen percent (15%), in increments not less than one percent (1%), of such participant's Compensation on each such payroll (or such other percentage as the Board may establish from time to time before an Offering Date). All payroll



deductions made by a participant shall be credited to his or her account under the Plan. A participant may not make any additional payments into such account.

(b)A participant may discontinue his or her participation in the Plan as provided in Paragraph 10, or, on one occasion only during the Purchase Period, may decrease, but may not increase, the rate of his or her Contributions during the Offering Period by completing and filing with the Company a new Enrollment Form authorizing a change in the deduction rate. The change in rate shall be effective as of the beginning of the next payroll period or as soon as practicable following the date of filing of the new Enrollment Form, if the Enrollment Form is submitted at least seven (7) days prior to such date, and, if not, as of the beginning of the next succeeding payroll period. A reduction of the payroll deduction percentage to zero shall be treated as participant’s withdrawal from such Offering Period and the Plan, effective as of the day after the next Purchase Date following the filing date of such request with the Company.

(c)Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and Paragraph 3, a participant’s payroll deductions may be suspended at any time during any Offering Period.

7.Grant of Option.

(a)On the Offering Date of each Offering Period, each eligible Employee participating in such Offering Period shall be granted an option to purchase on each Exercise Date of such Offering Period a number of shares of the Common Stock determined by dividing such Employee's Contributions accumulated prior to such Exercise Date and retained in the participant's account as of the Exercise Date by the applicable Exercise Price; provided however, that such purchase shall be subject to the limitations set forth in Paragraphs 3 and 12. The fair market value of a share of the Common Stock shall be determined as provided in Paragraph 7(b).

(b)The fair market value of the Common Stock on a given date shall be (i) if the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly reported for the Common Stock, the closing or last sale price of the Common Stock for such date (or, in the event that the Common Stock is not traded on such date, on the immediately preceding trading date), on the composite tape or other comparable reporting system; or (ii) if the Common Stock is not listed on a national securities exchange and such price is not regularly reported, the mean between the bid and asked prices per share of the Common Stock at the close of trading in the over-the-counter market.

8.Exercise of Option. Unless a participant withdraws from the Plan as provided in Paragraph 10, his or her option for the purchase of shares will be exercised automatically on each Exercise Date, and the maximum number of full shares subject to the option will be purchased for him or her at the applicable Exercise Price with the accumulated Contributions in his or her account. If a fractional number of shares results, then such number shall be rounded down to the next whole number and any unapplied cash shall be carried forward to the next Exercise Date, unless the participant requests a cash payment. The shares purchased upon exercise of an option hereunder shall be deemed to be transferred to the participant on the Exercise Date. During a participant's lifetime, a participant's option to purchase shares hereunder is exercisable only by him or her.

9.Delivery. Upon the written request of a participant, certificates representing the shares purchased upon exercise of an option will be issued as promptly as practicable after the applicable Exercise Date to participants who wish to hold their shares in certificate form, except that the Board may determine that such shares shall be held for each participant's benefit by a broker designated by the Board. Any payroll deductions accumulated in a participant’s account which are not sufficient to purchase a full



Share shall be retained in the participant’s account for the subsequent Offering Period, subject to earlier withdrawal by the participant as provided in Paragraph 10 below. Any other amounts left over in a participant’s account after an Exercise Date shall be returned to the participant.

10.Withdrawal; Termination of Employment.

(a)A participant may withdraw all but not less than all the Contributions credited to his or her account under the Plan at any time prior to an Exercise Date by giving written notice, or electronic submission of withdrawal, to the Company or its designee no later than 3 business days prior to each Exercise Date. All of the participant's Contributions credited to his or her account will be paid to him or her promptly after receipt of his or her notice of withdrawal and his or her option for the current period will be automatically terminated, and no further Contributions for the purchase of shares will be made during the Offering Period.

(b)Upon termination of the participant's Continuous Status as an Employee prior to an Exercise Date for any reason, including retirement or death, the Contributions credited to his or her account will be returned to him or her or, in the case of his or her death, to the person or persons entitled thereto under Paragraph 14, and his or her option will be automatically terminated.

(c)In the event an Employee fails to remain in Continuous Status as an Employee for at least 20 hours per week during the Offering Period in which the Employee is a participant, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to his or her account will be returned to him or her and his or her option terminated.

(d)A participant's withdrawal from an Offering Period will not have any effect upon his or her eligibility to participate in a succeeding offering or in any similar plan which may hereafter be adopted by the Company.

11.Interest. No interest shall accrue on the Contributions of a participant in the Plan.

12.Stock.

(a)The maximum number of shares of Common Stock which shall be made available for sale under the Plan shall be 400,000 shares, plus an annual increase on the first day of each of the Company’s fiscal years beginning in 2021 and ending on the first day of 2030, equal to the lesser of (i) 300,000 shares, (ii) one percent (1%) of the shares of Common Stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the Board, subject to adjustment upon changes in capitalization of the Company as provided in Paragraph 18. If the total number of shares which would otherwise be subject to options granted pursuant to Paragraph 7(a) on the Offering Date of an Offering Period exceeds the number of shares then available under the Plan (after deduction of all shares for which options have been exercised), the Company shall make a pro rata allocation of the shares remaining available for option grants in as uniform a manner as shall be practicable and as it shall determine to be equitable. Any amounts remaining in an Employee's account not applied to the purchase of shares pursuant to this Paragraph 12 shall be refunded on or promptly after the Exercise Date. In such event, the Company shall give written notice of such reduction of the number of shares subject to the option to each Employee affected thereby and shall similarly reduce the rate of Contributions, if necessary.

(b)The participant will have no interest or voting right in shares covered by his or her option until such option has been exercised.




13.Administration. The Board shall supervise and administer the Plan and shall have full power to adopt, amend and rescind any rules deemed desirable and appropriate for the administration of the Plan and not inconsistent with the Plan, to construe and interpret the Plan, to correct any defect or supply any omission or reconcile any inconsistency or ambiguity in the Plan and to make all other determinations necessary or advisable for the administration of the Plan, including without limitation, adopting subplans applicable to particular Designated Subsidiaries or locations, which subplans may be designed to be outside the scope of Section 423 of the Code.

14.Designation of Beneficiary.

(a)A participant may designate a beneficiary who is to receive any shares and cash, if any, from the participant's account under the Plan in the event of such participant's death subsequent to the end of the Purchase Period but prior to delivery to him or her of such shares and cash. In addition, a participant may designate a beneficiary who is to receive any cash from the participant's account under the Plan in the event of such participant's death prior to each Exercise Date of the Offering Period. If a participant is married and the designated beneficiary is not the spouse, spousal consent shall be required for such designation to be effective. Beneficiary designations shall be made either in writing or by electronic delivery as directed by the Company.

(b)Such designation of beneficiary may be changed by the participant (and his or her spouse, if any) at any time by submission of the required notice, which may be electronic. In the event of the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such participant's death, the Company shall deliver such shares and/or cash to the executor or administrator of the estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and/or cash to the spouse or to any one or more dependents or relatives of the participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

15.Transferability. Neither Contributions credited to a participant's account nor any rights with regard to the exercise of an option or to receive shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Paragraph 14) by the participant. Any such attempt at assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw funds in accordance with Paragraph 10.

16.Use of Funds. All Contributions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions.

17.Reports. Individual accounts will be maintained for each participant in the Plan. Statements of account will be provided to participating Employees promptly following the Exercise Date, which statements will set forth the amounts of Contributions, the per share purchase price, the number of shares purchased and the remaining cash balance, if any.




18.Adjustments upon Changes in Capitalization. Subject to any required action by the stockholders of the Company, the number of shares of Common Stock covered by unexercised options under the Plan, the number of shares of Common Stock which have been authorized for issuance under the Plan but are not yet subject to options under Paragraph 12(a) and the number of shares of Common Stock subject to annual increase under Paragraph 12(a) (collectively, the "Reserves"), the maximum number of shares of Common Stock that may be purchased by a participant in an Offering Period set forth in Paragraph 3 as well as the price per share of Common Stock covered by each unexercised option under the Plan, shall be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock. Such adjustment shall be made by the Board, whose determination in that respect shall be final, binding and conclusive.

In the event of the proposed dissolution or liquidation of the Company, an Offering Period then in progress will terminate immediately prior to the consummation of such proposed action, unless otherwise provided by the Board. In the event of a proposed sale of all or substantially all of the assets of the Company, or the merger, consolidation or other capital reorganization of the Company with or into another corporation, each option outstanding under the Plan shall be assumed or an equivalent option shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation, unless the Board determines, in the exercise of its sole discretion and in lieu of such assumption or substitution, to shorten the Offering Period then in progress by setting a new Exercise Date (the "New Exercise Date"). If the Board shortens the Offering Period then in progress in lieu of assumption or substitution in the event of a merger or sale of assets, the Board shall notify each participant in writing, at least ten days prior to the New Exercise Date, that the Exercise Date for his or her option has been changed to the New Exercise Date and that his or her option will be exercised automatically on the New Exercise Date, unless prior to such date he or she has withdrawn from the Offering Period as provided in Paragraph 10. For purposes of this paragraph, an option granted under the Plan shall be deemed to be assumed if, following the sale of assets, merger or other reorganization, the option confers the right to purchase, for each share of Common Stock subject to the option immediately prior to the sale of assets, merger or other reorganization, the consideration (whether stock, cash or other securities or property) received in the sale of assets, merger or other reorganization by holders of Common Stock for each share of Common Stock held on the effective date of such transaction (and if such holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if such consideration received in such transaction was not solely common stock of the successor corporation or its parent (as defined in Section 424(e) of the Code), the Board may, with the consent of the successor corporation, provide for the consideration to be received upon exercise of the option to be solely common stock of the successor corporation or its parent equal in fair market value to the per share consideration received by holders of Common Stock in the sale of assets, merger or other reorganization.

The Board may, if it so determines in the exercise of its sole discretion, also make provision for adjusting the Reserves, as well as the price per share of Common Stock covered by each outstanding option, in the event that the Company effects one or more reorganizations, recapitalizations, rights offerings or other increases or reductions of shares of its outstanding Common Stock, and in the event of the Company being consolidated with or merged into any other corporation.




19.Amendment or Termination.

(a)The Board may at any time terminate or amend the Plan. Except as provided in Paragraph 18, no such termination may affect options previously granted, nor may an amendment make any change in any option theretofore granted which adversely affects the rights of any participant provided that an Offering Period may be terminated by the Board on an Exercise Date or by the Board’s setting a new Exercise Date with respect to an Offering Period then in progress if the Board determines that termination of the Offering Period is in the best interests of the Company and the stockholders or if continuation of the Offering Period would cause the Company to incur adverse accounting charges in the generally-accepted accounting rules applicable to the Plan. In addition, to the extent necessary to comply with Section 423 of the Code (or any successor rule or provision or any applicable law or regulation), the Company shall obtain stockholder approval in such a manner and to such a degree as so required.

(b)Without stockholder consent and without regard to whether any participant rights may be considered to have been adversely affected, the Board shall be entitled to change the Offering Periods, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a participant in order to adjust for delays or mistakes in the Company’s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each participant properly correspond with amounts withheld from the participant’s Compensation, and establish such other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan.

20.Notices. All notices or other communications by a participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.

21.Conditions upon Issuance of Shares. Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.

As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law.

22.Information Regarding Disqualifying Dispositions. By electing to participate in the Plan, each participant agrees to provide any information about any transfer of shares of Common Stock acquired under the Plan that occurs within two years after the first business day of the Offering Period in which such shares were acquired as may be requested by the Company or any Subsidiaries in order to assist it in complying with the tax laws.

23.Right to Terminate Employment. Nothing in the Plan or in any agreement entered into pursuant to the Plan shall confer upon any Employee the right to continue in the employment of the Company or any Subsidiary, or affect any right which the Company or any Subsidiary may have to terminate the employment of such Employee.




24.Rights as a Stockholder. Neither the granting of an option nor a deduction from payroll shall constitute an Employee the owner of shares covered by an option. No Employee shall have any right as a stockholder unless and until an option has been exercised, and the shares underlying the option have been registered in the Company's share register.

25.Term of Plan. The Plan became effective upon its approval on May 26, 2020 and shall continue in effect through the tenth anniversary of such date, unless sooner terminated under Paragraph 19.

26.Applicable Law. This Plan shall be governed in accordance with the laws of the State of Delaware, applied without giving effect to any conflict-of-law principles.

EX-31.1 3 dmtk-20220930xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John Dobak, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 of DermTech, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 3, 2022
By:/s/ John Dobak
John Dobak
Chief Executive Officer
(principal executive officer)

EX-31.2 4 dmtk-20220930xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kevin Sun, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 of DermTech, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 3, 2022
By:/s/ Kevin Sun
Kevin Sun
Chief Financial Officer
(principal financial and accounting officer)

EX-32.1 5 dmtk-20220930xex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 of DermTech, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies in his capacity as the specified officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: November 3, 2022
By:/s/ John Dobak
John Dobak
Chief Executive Officer
(principal executive officer)
Date: November 3, 2022
By:/s/ Kevin Sun
Kevin Sun
Chief Financial Officer
(principal financial and accounting officer)
This certification accompanies the Quarterly Report on Form 10-Q to which it relates and shall not be deemed filed with the Securities and Exchange Commission or incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 6 dmtk-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - The Company and a Summary of its Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Leases, Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Leases, Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Balance Sheet Details - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Leases, Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Leases, Commitments and Contingencies - Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Leases, Commitments and Contingencies - Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 dmtk-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 dmtk-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 dmtk-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Michael Dobak Brother Of Chief Executive Officer [Member] Brother of chief executive officer. Marketable securities, available for sale: Investments, Fair Value Disclosure [Abstract] Total Lessee, Operating Lease, Liability, to be Paid Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Related Party Transactions [Abstract] Related Party Transactions [Abstract] Restricted Cash Restricted Cash [Member] Restricted Cash. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Computer equipment Computer Equipment Gross Computer equipment gross. Debt Instrument Debt Instrument [Axis] Present value of net minimum lease payments Finance Lease, Liability Gross assets Total property and equipment, gross Gross assets Property, Plant and Equipment, Gross Related party transaction, other Related Party Transaction, Expenses from Transactions with Related Party Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Accrued consulting services Accrued Consulting Services Current Accrued consulting services, current. Prepaid expenses and other current assets: Prepaid Expense and Other Assets, Current [Abstract] Authorized for future ESPP purchases Authorized For Future E S P P Purchases [Member] Authorized for future ESPP purchases. Financial Instruments Financial Instruments [Domain] 2026 Finance Lease, Liability, to be Paid, Year Four Statistical Measurement Statistical Measurement [Domain] Estimated discount rate Lessee, Operating Lease, Discount Rate Depreciation Depreciation expense Depreciation Number of six month purchase periods Number Of Six Month Purchase Periods Number Of Six Month Purchase Periods Weighted-average discount rate for operating leases (in percent) Operating Lease, Weighted Average Discount Rate, Percent Assets Recorded under Finance Leases Assets Held Under Finance Leases [Member] Assets held under finance leases. Sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Total future minimum lease payments due in 2026 Operating And Finance Lease Liability Payments Due Year Four Operating and capital lease liability payments due year four. Additional paid-in capital Additional Paid in Capital, Common Stock Total future minimum lease payments due thereafter Operating And Finance Lease Liability Payments Due Thereafter Operating and capital lease liability payments due thereafter. 2025 Finance Lease, Liability, to be Paid, Year Three Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Schedule of Warrant Liability Valuation Method Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Anti-dilutive equity instruments excluded from diluted net loss per share of common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2022 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Operating lease obligations, including interest Lessee, Operating Lease, Liability, to be Paid [Abstract] Accounts receivable gross Accounts Receivable, before Allowance for Credit Loss, Current Prepaid insurance Prepaid Insurance Equity Component Equity Component [Domain] Total assets measured at fair value on a recurring basis Assets, Fair Value Disclosure Amortization of Laboratory Equipment Acquired under Finance Leases Amortization Of Laboratory Equipment Acquired Under Finance Leases [Member] Amortization of laboratory equipment acquired under finance leases. Principal repayments of finance lease obligations Repayments of Debt and Lease Obligation Amortization of leased assets Finance Lease, Right-of-Use Asset, Amortization Related Party Related Party [Domain] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Plan Name Plan Name [Axis] Investment Holdings [Line Items] Investment Holdings [Line Items] Standby Letter of Credit Standby Letters of Credit [Member] Total marketable securities, available for sale Estimated Market Value Debt Securities, Available-for-Sale Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Plan Name Plan Name [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of Long Term Finance Lease Obligations Schedule Of Long Term Finance Lease Obligations Table [Table Text Block] Schedule of long term finance lease obligations. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Issuance price per share (in usd per share) Shares Issued, Price Per Share Authorized for future equity grants Authorized For Future Equity Grants [Member] Authorized for future equity grants. Award Type Award Type [Axis] Warrants issued to purchase common stock (in shares) Class Of Warrant Or Right, Warrants Or Rights Issued To Purchase Common Stock Class of warrant or rights issued to purchase common stock. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Tenant improvement allowance Tenant Improvement Allowance Tenant improvement allowance. Current portion of operating lease liabilities Operating Lease, Liability, Current Schedule of Short-Term Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Related Party Transaction Related Party Transaction [Domain] Liability Class Liability Class [Axis] Total liabilities Liabilities Weighted-average remaining lease term of operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Warrants vesting period Warrants Vesting Period Warrants vesting period. Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of stock, net of issuance costs Issuance of preferred stock, total offering amount Stock Issued During Period, Value, New Issues Cashless exercise of common stock warrants Cashless Exercise Of Common Stock Warrants Cashless exercise of common stock warrants. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Accumulated other comprehensive income/(loss) AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Document Type Document Type Gross proceeds from issuance of common stock Gross Proceeds From Issuance Of Common Stock Gross proceeds from issuance of common stock. Useful life of the assets Property, Plant and Equipment, Useful Life Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Assets: Assets, Fair Value Disclosure [Abstract] Cost of revenues: Cost of Revenue [Abstract] Finance lease obligations, including interest Finance Lease, Liability, to be Paid [Abstract] Product and Service Product and Service [Domain] Entity Shell Company Entity Shell Company Thereafter Finance Lease Liability Payments Due After Year Four Finance lease liability payments due after year four. Decrease in issuance costs Increase (Decrease) In Stock Issuance Costs Increase decrease in stock issuance costs. 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Financial Instrument Financial Instrument [Axis] Proceeds from exercise of common stock warrants Total proceeds from exercise of public warrants Proceeds from Warrant Exercises U.S. government debt securities US Government Agencies Short-Term Debt Securities [Member] Public SPAC Warrants Public Special Purpose Acquisition Companies Warrants [Member] Public special purpose acquisition companies warrants. Total Revenues Revenue Benchmark [Member] Document Period End Date Document Period End Date Furniture and fixtures Furniture and Fixtures, Gross Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Total assets Assets Income Statement Location Income Statement Location [Axis] Antidilutive Securities Antidilutive Securities [Axis] Shares, issued (in shares) Shares, Issued Schedule of Accrued Compensation and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Accrued compensation Total accrued compensation Employee-related Liabilities, Current Variable lease costs Variable Lease, Cost Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Proceeds from RSU releases (par value only) and the exercise of stock options Proceeds From Release Of RSUs And Stock Options Exercised Proceeds From Release Of RSUs And Stock Options Exercised Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Long-term finance lease obligations, less current portion Total long-term finance lease obligations Finance Lease, Liability, Noncurrent Kilroy Realty, L.P Kilroy Realty L P [Member] Kilroy Realty, L.P. Accrued compensation: Employee-related Liabilities, Current [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Operating lease liabilities Increase to operating lease liability Increase (Decrease) in Operating Lease Liability Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type Award Type [Domain] Total number exercised of public warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Weighted average term expected to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Accounts Receivable Receivable [Policy Text Block] Proceeds from contributions to the employee stock purchase plan Proceeds from Stock Plans Warrant Liability Warrant Liability [Member] Warrant liability. Duration of offering period (in months) Duration Of Offering Period Duration Of Offering Period Gross (loss) profit Gross Profit Total revenues Revenue from Contract with Customer, Including Assessed Tax Entity Registrant Name Entity Registrant Name Issuance of stock, net of issuance costs shares (in shares) Issuance of common stock, net of issuance costs shares (in shares) Stock Issued During Period, Shares, New Issues Percentage of useful lives of assets Percentage Of Useful Lives Of Assets Percentage of useful lives of assets. Area of building (in square feet) Area Of Building Area of building. Common shares issued upon exercise of warrants (in shares) Common Shares Issued Upon Exercise Of Warrants Common shares issued upon exercise of warrants. Subsequent Events Subsequent Events [Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Entity Address, City or Town Entity Address, City or Town Increase to operating right-of-use asset Increase (Decrease) In Operating Lease, Right-Of-Use-Asset Increase (Decrease) In Operating Lease, Right-Of-Use-Asset Tenant improvements Tenant Improvements Shares purchased by underwriters (in shares) Stock Purchased By Underwriters Pursuant To Option Granted Stock purchased by underwriters pursuant to option granted. Sweep account Deposits, Money Market Deposits Operating expenses: Operating Expenses [Abstract] Common stock outstanding percentage Common Stock Outstanding Percentage Common stock outstanding percentage. Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in the measurement of lease liabilities. Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers Schedule of Product Information [Table Text Block] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value per share (in usd per share) Common stock, par value per share (in usd per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Trading Symbol Trading Symbol Entity File Number Entity File Number Warranty liability Warranty, Rights and Obligations, Fair Value Option [Member] Incentive Stock Options Incentive Stock Options [Member] Incentive stock options. Municipal debt securities Municipal Notes [Member] Research and development Research and Development Expense Leasehold improvements Leasehold Improvements, Gross Fair Value by Liability Class Fair Value by Liability Class [Domain] Project management fees Contract Revenue Project Management Fees [Member] Contract revenue project management fees. Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Maturities of marketable securities Proceeds From Maturity Of Marketable Securities Proceeds From Maturity Of Marketable Securities RSUs issued and outstanding Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Schedule of Future Minimum Lease Payments Under Operating and Financing Leases Schedule Of Future Minimum Rental Payments For Operating And Capital Leases Table [Table Text Block] Schedule of future minimum rental payments for operating and capital leases. Use of Estimates Use of Estimates, Policy [Policy Text Block] Customer refund liability Customer Refund Liability, Current The Company and a Summary of its Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Total future minimum lease payments due in 2025 Operating And Finance Lease Liability Payments Due Year Three Operating and capital lease liability payments due year three. Concentration risk, percentage Concentration Risk, Percentage Subsequent Events [Abstract] Subsequent Events [Abstract] Additional common stock reserved (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Assumed volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Accounts payable, accrued liabilities and deferred revenue Increase (Decrease) in Accounts Payable and Accrued Liabilities Lease Amendments [Axis] Lease Amendments [Axis] Lease Amendments Due to related party Due to Related Parties Credit Facility Credit Facility [Domain] Exercise price of warrant (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Cash paid for interest on finance lease obligations Interest Paid, Excluding Capitalized Interest, Operating Activities Net loss per share of common stock outstanding, basic (in usd per share) Earnings Per Share, Basic Number of improvement phases Number Of Improvement Phases Number Of Improvement Phases Number of days granted to underwriters option to purchase Underwriters Grant Period Option Underwriters grant period option. 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three SPAC Warrants Special Purpose Acquisition Companies Warrants [Member] Special purpose acquisition companies warrants. Construction-in-progress Construction in Progress, Gross Concentration Risk Type Concentration Risk Type [Domain] Counterparty Name Counterparty Name [Domain] Sales and marketing Selling and Marketing Expense Public Follow-on Offering Public Follow On Offering [Member] Public follow on offering. Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Right-of-use assets obtained in exchange for finance lease obligations Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Entity Interactive Data Current Entity Interactive Data Current EVERSANA EVERSANA Life Science Services LLC [Member] EVERSANA Life Science Services, LLC. Sale of stock, number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Operating lease cost Operating Lease Cost [Abstract] Operating lease cost. Payor B Assay Revenue Payor B [Member] Assay Revenue Payor B. Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Summary of Changes in Fair Value of Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Second Amendment Second Amendment [Member] Second Amendment Accumulated deficit Retained Earnings [Member] Prepaid software fees Prepaid Software Fees Prepaid software fees. Insured amount by FDIC Cash, FDIC Insured Amount Common stock Common stock Common Stock [Member] Components of Lease Expense Lease, Cost [Table Text Block] Options remain available for issuance pursuant to future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Revenue Recognition Revenue [Policy Text Block] Statement [Table] Statement [Table] Renewal term Lessee, Operating Lease, Renewal Term Document Quarterly Report Document Quarterly Report Letter of Credit Letter of Credit [Member] Current assets: Assets, Current [Abstract] Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent Statistical Measurement Statistical Measurement [Axis] Accounting Policies The Company And Summary Of Its Significant Accounting Policies [Table] The company and summary of its significant accounting policies. Related Party Transaction Related Party Transaction [Axis] Estimated market value of remaining debt securities with contractual maturities of up to 23 months Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 21 Months Estimated market value of remaining debt securities with contractual maturities of up to 21 months. Accumulated deficit Retained Earnings (Accumulated Deficit) Cash equivalents Cash Equivalents, at Carrying Value Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Purchases of marketable securities Payments to Acquire Marketable Securities Equity Components Equity Components [Axis] Fair Value, Recurring Fair Value, Recurring [Member] Total future minimum lease payments due in 2022 Operating And Finance Lease Liability Payments Remainder Of Fiscal Year Operating and capital lease liability payments remainder of fiscal year. Related Party Transactions Related Party Transactions Disclosure [Text Block] Interest income, net Interest Income (Expense), Nonoperating, Net Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Total future minimum lease payments due in 2023 Operating And Finance Lease Liability Payments Due Next Twelve Months Operating and capital lease liability payments due next twelve months. Financing cash flows from finance leases Finance Lease, Principal Payments Warrants expiration period Warrants and Rights Outstanding, Term Increase (decrease) to restricted cash and cash equivalents Restricted Cash and Cash Equivalents, Increase (Decrease) Restricted Cash and Cash Equivalents, Increase (Decrease) Estimated market value of debt securities with contractual maturities of less than 12 months Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months Estimated market value of debt securities with contractual maturities of less than 12 months. Total other income/(expense) Nonoperating Income (Expense) Prepaid trade shows Prepaid Trade Shows Current Prepaid trade shows, current. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Number of shares issued for each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Product Information [Line Items] Product Information [Line Items] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Cowen and Company LLC Cowen Limited Liability Company [Member] Cowen Limited Liability Company. Loss from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Accounting Pronouncements Issued But Not Yet Effective New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Payor A Assay Revenue Payor A [Member] Assay Revenue Payor A. Total liabilities measured at fair value on a recurring basis Liabilities, Fair Value Disclosure Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Related party certain marketing cost Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Preferred stock, par value per share (in usd per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Additional paid-in capital Additional Paid-in Capital [Member] Balance Sheet Location Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Restricted cash Restricted cash Restricted Cash, Noncurrent Weighted average shares outstanding used in computing net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Assumed volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Total future minimum lease payments Lessee, Operating and Finance Lease, Liability, To Be Paid [Abstract] Lessee, Operating and Finance Lease, Liability, To Be Paid Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Total operating lease cost Operating Lease Costs Operating lease cost. Accounts Receivable Accounts Receivable [Member] Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 30,213,206 and 29,772,922 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Debt Instrument, Name Debt Instrument, Name [Domain] Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Warrant liability Warrant Liability Fair Value Disclosure Warrant liability fair value disclosure. Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total future minimum lease payments due in 2024 Operating And Finance Lease Liability Payments Due Year Two Operating and capital lease liability payments due year two. Issuance of common stock from warrant exercises Adjustments to Additional Paid in Capital, Warrant Issued Current liabilities: Liabilities, Current [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Operating And Capital Lease Liability Payments Due Operating And Finance Lease Liability Payments Due Operating and capital lease liability payments due. Short-term deferred revenue Short term deferred revenue Contract with Customer, Liability, Current Interest on lease liabilities Operating cash flows from finance leases Finance Lease, Interest Expense Purchases of property and equipment recorded in accounts payable Capital Expenditures Incurred but Not yet Paid Warrant liability Warrants and Rights Outstanding Income Statement Location Income Statement Location [Domain] Current portion of finance lease obligations Less current portion of finance lease obligations Finance Lease, Liability, Current Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Remaining lease term Lessee, Operating Lease, Remaining Lease Term Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Private SPAC Warrants Private Special Purpose Acquisition Companies Warrants [Member] Private special purpose acquisition companies warrants. Investment Holdings [Table] Investment Holdings [Table] Issuance of common stock from Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Impairment losses Impairment of Long-Lived Assets to be Disposed of Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Accrued compensation Increase (Decrease) in Employee Related Liabilities 2023 Finance Lease, Liability, to be Paid, Year One Options granted, exercise price expressed as a percentage of fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Issuance of common stock from Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name Counterparty Name [Axis] The Company and Summary of its Significant Accounting Policies [Line Items] The Company And Summary Of Its Significant Accounting Policies [Line Items] The company and summary of its significant accounting policies. Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 2024 Finance Lease, Liability, to be Paid, Year Two Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Lease Amendments [Domain] Lease Amendments [Domain] Lease Amendments [Domain] Operating cash flows from operating leases Operating Lease, Payments 2022 Inducement Equity Incentive Plan 2022 Inducement Equity Incentive Plan [Member] 2022 Inducement Equity Incentive Plan Change in fair value of warrant liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Stock options issued and outstanding Share-Based Payment Arrangement, Option [Member] Sales and marketing Selling and Marketing Expense [Member] Assumed volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses Gross Proceeds From Offering Before Deducting Underwriting Discounts And Commissions And Other Offering Expenses Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses. Balance Sheet Location Balance Sheet Location [Axis] Public offering price (in usd per share) Sale of Stock, Price Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Statement of Comprehensive Income [Abstract] Class of Warrant or Right Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Issuance of common stock from option exercises and RSU releases Stock Issued During Period, Value, Stock Options Exercised And RSU Release Stock issued during period value stock options exercised and RSU release. Credit losses Credit Losses Credit Losses Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Placement Agent Warrants Placement Agent Warrants [Member] Placement agent warrants. Total current assets Assets, Current 2018 Convertible Bridge Notes Two Thousand Eighteen Convertible Bridge Notes [Member] Two thousand eighteen convertible bridge notes. Entity Small Business Entity Small Business Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Incentive and Non-qualified Stock Options Incentive And Non Qualified Stock Options [Member] Incentive and non-qualified stock options. Measurement Frequency Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Revenues: Revenues [Abstract] Warrants to purchase common stock Warrants To Purchase Common Stock [Member] Warrants to purchase common stock. Restricted cash Restricted Cash Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Compensation cost related to non-vested awards not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Interest Income, Net Interest Income [Member] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Expansion premise (in square feet) Rentable And Usable Square Feet Rentable And Usable Square Feet Class of Stock [Line Items] Class of Stock [Line Items] Operating lease, liability Operating Lease, Liability Amortization of premiums, net of accretion of discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Gross finance lease obligations Gross finance lease obligations Finance Lease, Liability, to be Paid Adhesive patch kits Contract Revenue Adhesive Patch Kits [Member] Contract revenue, adhesive patch kits. Cash held in excess of FDIC limit Cash, Uninsured Amount Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Finance lease cost Finance Lease Costs [Abstract] Finance lease cost. Inventory Inventory, Net Accounts payable Accounts Payable, Current Change in net unrealized losses on available-for-sale marketable securities Change In Unrealized Gain (Loss) On Available For Sale Marketable Securities Change in unrealized gain loss on available-for-sale marketable securities. Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Schedule Of Product Information [Table] Schedule of Product Information [Table] Schedule of Prepaid Expenses and PP&E Schedule Of Prepaid Expenses And Property And Equipment Table [Table Text Block] Schedule of prepaid expenses and PP&E. Nature of Operations Nature of Operations [Text Block] Common Stock Warrants Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Weighted average shares outstanding used in computing net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Management Warrants Management Warrants [Member] Management warrants. Tenant improvement allowance per rentable square foot (in usd per square foot) Tenant Improvement Allowance Per Rentable Square Foot Tenant improvement allowance per rentable square foot. 2020 Equity Incentive Plan Two Thousand Twenty Equity Incentive Plan [Member] Two thousand twenty equity incentive plan. Number of renewal terms Lessee, Operating Lease, Number Of Renewal Terms Lessee, Operating Lease, Number Of Renewal Terms Accrued liabilities: Accrued Liabilities, Current [Abstract] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Total stock-based compensation Share-Based Payment Arrangement, Expense Supplemental disclosure of noncash investing and financing activities: Noncash Investing and Financing Items [Abstract] Security Exchange Name Security Exchange Name Class of Warrant or Right Class of Warrant or Right [Domain] Loss on disposal of equipment Gain (Loss) on Disposition of Assets Increase in improvement allowance per rentable square foot (in usd per square foot) Increase In Tenant Improvement Allowance Per Rentable Square Foot Increase In Tenant Improvement Allowance Per Rentable Square Foot Letters of credit Letters of Credit Outstanding, Amount Stock Options and RSUs Stock Options And Restricted Stock Units [Member] Stock options and restricted stock units. General and administrative General and Administrative Expense [Member] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Common stock available for issuance (in shares) Total common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Cover [Abstract] Property and equipment, gross: Property, Plant and Equipment, Gross [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Accumulated amortization Accumulated amortization Depreciation, Depletion and Amortization, Nonproduction Reclassification of deferred revenue Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract Weighted-average discount rate for finance leases (in percent) Finance Lease, Weighted Average Discount Rate, Percent Assumed risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Total liabilities and stockholders’ equity Liabilities and Equity Increase (decrease) in revenue Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue Related Party Related Party [Axis] Accrued paid time off Accrued Vacation, Current Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] 2020 Employee Stock Purchase Plan Two Thousand Twenty Employee Stock Purchase Plan [Member] Two thousand twenty employee stock purchase plan. Level 2 Fair Value, Inputs, Level 2 [Member] Demand Deposits Demand Deposits [Member] Current Fiscal Year End Date Current Fiscal Year End Date Short-term marketable securities Marketable Securities, Current Reconciliation of cash, cash equivalents and restricted cash, end of period: Restricted Cash and Cash Equivalents [Abstract] Net loss per share of common stock outstanding, diluted (in usd per share) Earnings Per Share, Diluted Sale of Stock Sale of Stock [Domain] Conversion ratio of reverse stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Assay revenue DermTech Melanoma Test Assay [Member] Assay. Gain (loss) on disposition of property plant equipment Gain (Loss) on Disposition of Property Plant Equipment Summary of Common Stock Reserved for Future Issuance Schedule of Stock by Class [Table Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Contract revenue Contractual Activities [Member] Contract activities. Change in fair value of warrant liability Change in fair value of warrant liability Fair Value Adjustment of Warrants Concentration Risk Type Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Assumed risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum First Amendment First Amendment [Member] First Amendment 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Customer Concentration Risk Customer Concentration Risk [Member] Remaining performance obligation, estimated revenue expected to be recognized Revenue, Remaining Performance Obligation, Amount Contractual term of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Corporate debt securities Corporate Debt Securities [Member] Other income/(expense): Nonoperating Income (Expense) [Abstract] Term of the option Equity Incentive Plan Option Term Equity incentive plan option term. Assumed risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Total cost of revenues Cost of Revenue Accrued wages, bonus and other Accrued Bonus And Deferred Compensation Current Accrued bonus and deferred compensation, current. Product and Service Product and Service [Axis] Weighted-average remaining lease term of finance leases (in years) Finance Lease, Weighted Average Remaining Lease Term SPAC Warrants to purchase common stock* Special Purpose Acquisition Company Warrants To Purchase Common Stock [Member] SPAC warrants to purchase common stock. Prepaid employee compensation Prepaid Employee Compensation Prepaid employee compensation. Credit Facility Credit Facility [Axis] Unrealized net loss on available-for-sale marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Entity Tax Identification Number Entity Tax Identification Number Common stock initially reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Weighted average purchase price per share (in usd per share) Weighted Average Purchase Price Per Share In Offering Weighted average purchase price per share in offering. Total finance lease cost Finance Lease Cost Finance lease cost. Reclassification of warrant liability due to Private SPAC Warrants not held by original holder Reclassification of warrant liability due to Private SPAC Warrants not held by original holder Reclassification Of Warrant Liability Due To Private SPAC Warrants Not Held By Original Holder Reclassification of warrant liability due to private SPAC warrants not held by original holder. Issuance of common stock from option exercises and RSU releases (in shares) Stock Issued During Period, Shares, Stock Options Exercised And RSU Release Stock issued during period shares stock options exercised and RSU release. Schedule of Revenues Disaggregated by Revenue Source Disaggregation of Revenue [Table Text Block] Number of revenue streams (in number of streams) Number Of Revenue Streams Number of revenue streams. DermTech Operations Derm Tech Operations Inc [Member] DermTech Operations, Inc. Leana Wood Spouse Of Chief Commercial Officer [Member] Spouse of chief commercial officer. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net (decrease)/increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Percentage of price at shares purchased Percentage Of Price At Shares Purchased Percentage of price at shares purchased Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Property and equipment acquired under finance leases Noncash or Part Noncash Acquisition, Fixed Assets Acquired Measurement Frequency Measurement Frequency [Axis] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other accrued expenses Other Accrued Liabilities, Current Incremental borrowing rate Operating Lease, Incremental Borrowing Rate At Effective Date Operating Lease, Incremental Borrowing Rate At Effective Date City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Leases, Commitments and Contingencies Commitments Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock Sale of Stock [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Issuance of common stock from warrant exercises (in shares) Adjustments to Additional Paid in Capital, Warrant Issued, Shares Adjustments to Additional Paid in Capital, Warrant Issued, Shares Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Number of warrants entitle holder to purchase one share Number Of Warrants Entitle Holder To Purchase One Share Number of warrants entitle holder to purchase one share. RNA extractions Contract Revenue R N A Extractions [Member] Contract revenue, RNA extractions. Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Increase in tenant improvement allowance Increase In Tenant Improvement Allowance Increase in tenant improvement allowance. Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Laboratory equipment Machinery and Equipment, Gross Research and development Research and Development Expense [Member] Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] At-The Market Offering At The Market Offering [Member] At the market offering. Right-of-use assets obtained in exchange for lease obligations Right-of-use assets obtained in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of revenue Cost of Sales [Member] EX-101.PRE 10 dmtk-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
9 Months Ended
Sep. 30, 2022
Oct. 28, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-38118  
Entity Registrant Name DERMTECH, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-2870849  
Entity Address, Address Line One 11099 N. Torrey Pines Road  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town La Jolla  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92037  
City Area Code 858  
Local Phone Number 450-4222  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol DMTK  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   30,214,705
Entity Central Index Key 0001651944  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 95,492 $ 176,882
Short-term marketable securities 53,636 48,449
Accounts receivable 6,101 3,847
Inventory 1,391 480
Prepaid expenses and other current assets 4,212 3,166
Total current assets 160,832 232,824
Property and equipment, net 4,943 4,549
Operating lease right-of-use assets 24,644 7,744
Restricted cash 3,477 3,025
Other assets 167 167
Total assets 194,063 248,309
Current liabilities:    
Accounts payable 2,997 2,880
Accrued compensation 8,321 5,120
Accrued liabilities 3,539 1,227
Short-term deferred revenue 417 1,380
Current portion of operating lease liabilities 1,588 1,453
Current portion of finance lease obligations 124 121
Total current liabilities 16,986 12,181
Warrant liability 20 146
Long-term finance lease obligations, less current portion 77 136
Operating lease liabilities, long-term 21,992 6,148
Total liabilities 39,075 18,611
Stockholders’ equity:    
Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 30,213,206 and 29,772,922 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 3 3
Additional paid-in capital 450,904 436,183
Accumulated other comprehensive loss (1,095) (124)
Accumulated deficit (294,824) (206,364)
Total stockholders’ equity 154,988 229,698
Total liabilities and stockholders’ equity $ 194,063 $ 248,309
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common stock, par value per share (in usd per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 30,213,206 29,772,922
Common stock, shares outstanding (in shares) 30,213,206 29,772,922
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Total revenues $ 3,573 $ 3,030 $ 11,524 $ 8,673
Cost of revenues:        
Total cost of revenues 3,694 2,898 10,521 7,524
Gross (loss) profit (121) 132 1,003 1,149
Operating expenses:        
Sales and marketing 14,632 9,826 45,076 24,245
Research and development 5,702 4,426 18,955 10,271
General and administrative 8,806 6,199 26,258 17,672
Total operating expenses 29,140 20,451 90,289 52,188
Loss from operations (29,261) (20,319) (89,286) (51,039)
Other income/(expense):        
Interest income, net 485 38 700 107
Change in fair value of warrant liability 4 169 126 (1,350)
Total other income/(expense) 489 207 826 (1,243)
Net loss $ (28,772) $ (20,112) $ (88,460) $ (52,282)
Weighted average shares outstanding used in computing net loss per share, basic (in shares) 30,096,261 29,639,802 29,969,435 28,599,375
Weighted average shares outstanding used in computing net loss per share, diluted (in shares) 30,096,261 29,639,802 29,969,435 28,599,375
Net loss per share of common stock outstanding, basic (in usd per share) $ (0.96) $ (0.68) $ (2.95) $ (1.83)
Net loss per share of common stock outstanding, diluted (in usd per share) $ (0.96) $ (0.68) $ (2.95) $ (1.83)
Assay revenue        
Revenues:        
Total revenues $ 3,433 $ 2,954 $ 11,098 $ 8,054
Cost of revenues:        
Total cost of revenues 3,644 2,875 10,410 7,450
Contract revenue        
Revenues:        
Total revenues 140 76 426 619
Cost of revenues:        
Total cost of revenues $ 50 $ 23 $ 111 $ 74
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net loss $ (28,772) $ (20,112) $ (88,460) $ (52,282)
Unrealized net loss on available-for-sale marketable securities (230) (10) (971) (7)
Comprehensive loss $ (29,002) $ (20,122) $ (89,431) $ (52,289)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income/(loss)
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2020   20,740,413      
Beginning balance at Dec. 31, 2020 $ 61,840 $ 2 $ 189,868 $ (1) $ (128,029)
Issuance of stock, net of issuance costs shares (in shares)   4,872,881      
Issuance of stock, net of issuance costs 134,582 $ 1 134,581    
Issuance of common stock from option exercises and RSU releases (in shares)   176,673      
Issuance of common stock from option exercises and RSU releases 408   408    
Issuance of common stock from warrant exercises (in shares)   3,089,325      
Issuance of common stock from warrant exercises 72,081   72,081    
Issuance of common stock from Employee Stock Purchase Plan (in shares)   39,960      
Issuance of common stock from Employee Stock Purchase Plan 392   392    
Unrealized net loss on available-for-sale marketable securities 9     9  
Stock-based compensation 2,172   2,172    
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder 411   411    
Net loss (15,068)       (15,068)
Ending balance (in shares) at Mar. 31, 2021   28,919,252      
Ending balance at Mar. 31, 2021 256,827 $ 3 399,913 8 (143,097)
Beginning balance (in shares) at Dec. 31, 2020   20,740,413      
Beginning balance at Dec. 31, 2020 61,840 $ 2 189,868 (1) (128,029)
Unrealized net loss on available-for-sale marketable securities (7)        
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder 434        
Net loss (52,282)        
Ending balance (in shares) at Sep. 30, 2021   29,717,198      
Ending balance at Sep. 30, 2021 251,921 $ 3 432,237 (8) (180,311)
Beginning balance (in shares) at Dec. 31, 2020   20,740,413      
Beginning balance at Dec. 31, 2020 61,840 $ 2 189,868 (1) (128,029)
Ending balance (in shares) at Dec. 31, 2021   29,772,922      
Ending balance at Dec. 31, 2021 229,698 $ 3 436,183 (124) (206,364)
Beginning balance (in shares) at Mar. 31, 2021   28,919,252      
Beginning balance at Mar. 31, 2021 256,827 $ 3 399,913 8 (143,097)
Issuance of stock, net of issuance costs shares (in shares)   530,551      
Issuance of stock, net of issuance costs 23,836   23,836    
Issuance of common stock from option exercises and RSU releases (in shares)   157,277      
Issuance of common stock from option exercises and RSU releases 188   188    
Issuance of common stock from warrant exercises (in shares)   314      
Issuance of common stock from warrant exercises 5   5    
Unrealized net loss on available-for-sale marketable securities (6)     (6)  
Stock-based compensation 3,538   3,538    
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder 23        
Net loss (17,102)       (17,102)
Ending balance (in shares) at Jun. 30, 2021   29,607,394      
Ending balance at Jun. 30, 2021 267,309 $ 3 427,503 2 (160,199)
Issuance of common stock from option exercises and RSU releases (in shares)   76,768      
Issuance of common stock from option exercises and RSU releases 81   81    
Issuance of common stock from warrant exercises (in shares)   14,881      
Issuance of common stock from warrant exercises 343   343    
Issuance of common stock from Employee Stock Purchase Plan (in shares)   18,155      
Issuance of common stock from Employee Stock Purchase Plan 574   574    
Unrealized net loss on available-for-sale marketable securities (10)     (10)  
Stock-based compensation 3,736   3,736    
Net loss (20,112)       (20,112)
Ending balance (in shares) at Sep. 30, 2021   29,717,198      
Ending balance at Sep. 30, 2021 251,921 $ 3 432,237 (8) (180,311)
Beginning balance (in shares) at Dec. 31, 2021   29,772,922      
Beginning balance at Dec. 31, 2021 229,698 $ 3 436,183 (124) (206,364)
Issuance of common stock from option exercises and RSU releases (in shares)   109,275      
Issuance of common stock from option exercises and RSU releases 40   40    
Issuance of common stock from warrant exercises (in shares)   11,101      
Issuance of common stock from warrant exercises 12   12    
Issuance of common stock from Employee Stock Purchase Plan (in shares)   47,339      
Issuance of common stock from Employee Stock Purchase Plan 515   515    
Unrealized net loss on available-for-sale marketable securities (570)     (570)  
Stock-based compensation 3,894   3,894    
Net loss (30,108)       (30,108)
Ending balance (in shares) at Mar. 31, 2022   29,940,637      
Ending balance at Mar. 31, 2022 203,481 $ 3 440,644 (694) (236,472)
Beginning balance (in shares) at Dec. 31, 2021   29,772,922      
Beginning balance at Dec. 31, 2021 229,698 $ 3 436,183 (124) (206,364)
Unrealized net loss on available-for-sale marketable securities (971)        
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder 0        
Net loss (88,460)        
Ending balance (in shares) at Sep. 30, 2022   30,213,206      
Ending balance at Sep. 30, 2022 154,988 $ 3 450,904 (1,095) (294,824)
Beginning balance (in shares) at Mar. 31, 2022   29,940,637      
Beginning balance at Mar. 31, 2022 203,481 $ 3 440,644 (694) (236,472)
Issuance of common stock from option exercises and RSU releases (in shares)   88,591      
Issuance of common stock from option exercises and RSU releases 0        
Issuance of common stock from warrant exercises (in shares)   9,219      
Issuance of common stock from warrant exercises 10   10    
Unrealized net loss on available-for-sale marketable securities (171)     (171)  
Stock-based compensation 4,837   4,837    
Net loss (29,580)       (29,580)
Ending balance (in shares) at Jun. 30, 2022   30,038,447      
Ending balance at Jun. 30, 2022 178,577 $ 3 445,491 (865) (266,052)
Issuance of common stock from option exercises and RSU releases (in shares)   74,010      
Issuance of common stock from option exercises and RSU releases 0        
Issuance of common stock from Employee Stock Purchase Plan (in shares)   100,749      
Issuance of common stock from Employee Stock Purchase Plan 477   477    
Unrealized net loss on available-for-sale marketable securities (230)     (230)  
Stock-based compensation 4,936   4,936    
Net loss (28,772)       (28,772)
Ending balance (in shares) at Sep. 30, 2022   30,213,206      
Ending balance at Sep. 30, 2022 $ 154,988 $ 3 $ 450,904 $ (1,095) $ (294,824)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Stockholders’ Equity (Parenthetical) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Issuance costs $ 0.7  
Common stock    
Issuance price per share (in usd per share)   $ 29.50
Issuance costs   $ 9.1
Common stock | At-The Market Offering    
Issuance price per share (in usd per share) $ 46.33  
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Cash flows from operating activities:            
Net loss       $ (88,460) $ (52,282)  
Adjustments to reconcile net loss to net cash used in operating activities:            
Depreciation $ 400 $ 300   1,187 654  
Change in fair value of warrant liability (4) (169)   (126) 1,350  
Amortization of operating lease right-of-use assets       1,788 909  
Stock-based compensation       13,667 9,446  
Amortization of premiums, net of accretion of discounts on marketable securities       328 463  
Loss on disposal of equipment       350 13  
Changes in operating assets and liabilities:            
Accounts receivable       (2,254) (1,339)  
Inventory       (911) (320)  
Prepaid expenses and other current assets       (1,046) (104)  
Operating lease liabilities       (2,709) (1,130)  
Accounts payable, accrued liabilities and deferred revenue       955 1,525  
Accrued compensation       3,201 1,389  
Net cash used in operating activities       (74,030) (39,426)  
Cash flows from investing activities:            
Purchases of marketable securities       (26,420) (25,150)  
Sales of marketable securities       0 350  
Maturities of marketable securities       19,934 18,475  
Purchases of property and equipment       (1,372) (1,664)  
Net cash used in investing activities       (7,858) (7,989)  
Cash flows from financing activities:            
Proceeds from exercise of common stock warrants       22 70,271  
Proceeds from RSU releases (par value only) and the exercise of stock options       40 677  
Proceeds from contributions to the employee stock purchase plan       992 966  
Principal repayments of finance lease obligations       (104) (80)  
Net cash provided by financing activities       950 230,252  
Net (decrease)/increase in cash, cash equivalents and restricted cash       (80,938) 182,837  
Cash, cash equivalents and restricted cash, beginning of period     $ 24,248 179,907 24,248 $ 24,248
Cash, cash equivalents and restricted cash, end of period 98,969 207,085   98,969 207,085 179,907
Reconciliation of cash, cash equivalents and restricted cash, end of period:            
Cash and cash equivalents 95,492 204,061   95,492 204,061 $ 176,882
Restricted cash 3,477 3,024   3,477 3,024  
Total cash, cash equivalents and restricted cash $ 98,969 $ 207,085   98,969 207,085  
Supplemental cash flow information:            
Cash paid for interest on finance lease obligations       10 13  
Supplemental disclosure of noncash investing and financing activities:            
Purchases of property and equipment recorded in accounts payable       511 462  
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder     $ 411 0 434  
Cashless exercise of common stock warrants       0 2,158  
Right-of-use assets obtained in exchange for lease obligations       18,688 9,071  
Property and equipment acquired under finance leases       48 105  
Change in net unrealized losses on available-for-sale marketable securities       (971) (7)  
Public Follow-on Offering            
Cash flows from financing activities:            
Proceeds from issuance of common stock       0 134,582  
At-The Market Offering            
Cash flows from financing activities:            
Proceeds from issuance of common stock       $ 0 $ 23,836  
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
The Company and a Summary of its Significant Accounting Policies The Company and a Summary of its Significant Accounting Policies
(a)    Nature of Operations
On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock.
The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including genomic tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) to collect biological information for commercial applications in the medical diagnostic field.
The ongoing COVID-19 pandemic has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company implemented additional safety measures in accordance with Centers for Disease Control and Prevention, Occupational Safety and Health Administration and other guidance within its CLIA laboratory operations. Additionally, and during this time, the Company transitioned administrative functions to predominantly remote work. The pandemic reduced patient access to clinician offices for in-person testing and reduced access by the Company's sales force for in-office sales calls, which negatively impacted the volume of billable samples. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical, and long-lasting and may again in the future, adversely affect the Company's operating results.
(b)    Basis of Presentation
The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission (“SEC”), Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.
The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of September 30, 2022, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
(c)    Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.
(d)    Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that have in the past and may, at times, exceed this insured limit.
Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.
(e)    Property and Equipment, Net
Property and equipment, net is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to eleven years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $0.4 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $21,000 and $17,000 for the three months ended September 30, 2022 and 2021, respectively. The Company recorded depreciation expense of $1.2 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases of $0.1 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively.
Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the condensed consolidated statements of operations. Gross assets recorded under finance leases were $0.4 million as of September 30, 2022 and December 31, 2021. Accumulated amortization associated with finance leases was $0.1 million as of September 30, 2022 and December 31, 2021. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the condensed consolidated statements of operations in the period realized. Loss of disposal on equipment was $0.1 million for the three months ended September 30, 2022 and $8,000 for the three months ended September 30, 2021. Loss on disposal of equipment was $0.4 million and $13,000 for the nine months ended September 30, 2022 and 2021, respectively. The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the three or nine months ended September 30, 2022 and 2021.
(f)    Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of September 30, 2022, the Company maintained $64.6 million in a sweep account, which maintains cash balances throughout various interest-bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $0.3 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of September 30, 2022. The Company has not experienced any losses in such accounts.
(g)    Revenue Recognition
The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.
Assay Revenue
The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLAplus (now referred to as the DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLAplus), which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT where a collection kit would be sent to the patient’s home. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.
The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.5 million and $0.5 million of revenue reported for the three and nine months ended September 30, 2022, respectively, and an additional $18,000 and $0.1 million of revenue reported for the three and nine months ended September 30, 2021, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.
Contract Revenue
Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing genomic services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of services may include sample collection using the Smart Sticker, assay development for research partners, patient segmentation and stratification, extraction, isolation, expression, amplification and detection of RNA, DNA, protein and microbiome, including data analysis and reporting.
(a) Disaggregation of Revenue
The following table presents the Company’s revenues disaggregated by revenue source during the three and nine months ended September 30, 2022 and 2021 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Assay Revenue
DermTech Melanoma Test$3,433 $2,954 $11,098 $8,054 
Contract Revenue
Adhesive patch kits22 14 126 329 
RNA extractions94 19 204 158 
Project management fees24 43 96 132 
Total revenues$3,573 $3,030 $11,524 $8,673 
The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors that represent 10% or more of the respective amounts for the periods shown:
Total RevenuesAccounts Receivable
Three Months Ended September 30,Nine Months Ended September 30,As of September 30, 2022As of December 31, 2021
2022202120222021
Assay Revenue
Payor A46 %36 %41 %35 %20 %23 %
Payor B****15 %15 %
*Less than 10%
There were no other third-party payors or pharmaceutical customers that individually accounted for more than 10% of the Company’s total revenue or accounts receivable for the periods shown in the table above.
(b) Deferred Revenue and Remaining Performance Obligations
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.
In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.
The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of September 30, 2022 and December 31, 2021 was $0.4 million and $1.4 million, respectively. As of September 30, 2022 we reclassified $0.9 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services.
Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of September 30, 2022, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was immaterial. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two to three years.
(h)    Accounts Receivable
Assay Accounts Receivable
Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivables are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $5.9 million and $3.6 million of gross assay accounts receivable as of September 30, 2022 and December 31, 2021, respectively.
Contract Accounts Receivable
Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of September 30, 2022, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company recorded $0.2 million and $0.2 million of contract accounts receivable as of September 30, 2022 and December 31, 2021, respectively.
(i)    Net Loss Per Share
Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the three and nine months ended September 30, 2022 and 2021, the outstanding common stock warrants, stock options, and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the three and nine months ended September 30, 2022 excludes the effect of anti-dilutive equity instruments including 714,261 shares of common stock issuable upon the exercise of outstanding common stock warrants and 5,024,323 shares of common stock issuable upon the exercise of stock options and release of RSUs. Diluted net loss per share of common stock for the three and nine months ended September 30, 2021 excludes the effect of anti-dilutive equity instruments including 734,581 shares of common stock then issuable upon the exercise of outstanding warrants and 2,564,059 shares of common stock then issuable upon the exercise of stock options and release of RSUs.
(j)    Fair Value Measurements
The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2022 (in thousands):
September 30, 2022
Level 1Level 2Level 3Total
Assets:    
Cash equivalents$30,529 $— $— $30,529 
Restricted cash3,477 — — 3,477 
Marketable securities, available for sale:
Corporate debt securities— 14,938 — 14,938 
Municipal debt securities— 2,320 — 2,320 
U.S. government debt securities— 36,378 — 36,378 
Total marketable securities, available for sale— 53,636 — 53,636 
Total assets measured at fair value on a recurring basis$34,006 $53,636 $— $87,642 
Liabilities:
Warrant liability$— $— $20 $20 
Total liabilities measured at fair value on a recurring basis$— $— $20 $20 
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 (in thousands):
December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents$16,380 $— $— $16,380 
Restricted cash3,025 — — 3,025 
Marketable securities, available for sale:
Corporate debt— 15,352 — 15,352 
Municipal debt securities— 7,412 — 7,412 
U.S. government debt securities— 25,685 — 25,685 
Total marketable securities, available for sale— 48,449 — 48,449 
Total assets measured at fair value on a recurring basis$19,405 $48,449 $— $67,854 
Liabilities:
Warrant liability$— $— $146 $146 
Total liabilities measured at fair value on a recurring basis$— $— $146 $146 
The Company’s marketable debt securities are classified as available-for-sale securities based on management’s intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.
The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.
The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Assumed risk-free interest rate4.22%0.53%
2.37% - 4.22%
0.46% - 0.64%
Assumed volatility118.13%89.77%
92.77% - 118.13%
85.85% - 89.77%
Expected term1.92 years2.92 years
1.92 - 2.42 years
2.92 - 3.42 years
Expected dividend yield
The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):
Balance as of December 31, 2021$146 
Change in fair value of warrant liability(17)
Balance as of March 31, 2022129 
Change in fair value of warrant liability(105)
Balance as of June 30, 2022$24 
Change in fair value of warrant liability(4)
Balance as of September 30, 2022$20 
As of September 30, 2022 and December 31, 2021, the Company maintains letters of credit of $3.5 million and $3.0 million, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.
The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.
(k)    Accounting Pronouncements Issued But Not Yet Effective
In June 2022, the Financial Accounting Standards Board issued ASU No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.
The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Details Balance Sheet Details
Short-Term Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of September 30, 2022 were as follows (in thousands):
September 30, 2022
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$15,259 $— $(321)$14,938 
Municipal debt securities2,339 — (19)2,320 
U.S. government debt securities37,133 (758)36,378 
Total short-term marketable securities, available-for-sale$54,731 $$(1,098)$53,636 
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2021 were as follows (in thousands):
December 31, 2021
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$15,385 $— $(33)$15,352 
Municipal debt securities7,417 — (5)7,412 
U.S. government debt securities25,771 (87)25,685 
Total short-term marketable securities, available-for-sale$48,573 $$(125)$48,449 
As of September 30, 2022, the estimated market value of debt securities with contractual maturities of less than twelve months was $38.3 million; the remaining debt securities that the Company held at that date had an estimated market value of $15.3 million and contractual maturities of up to 21 months. As of December 31, 2021, the estimated market value of debt securities with contractual maturities of less than twelve months was $21.2 million; the remaining debt securities that the Company held at that date had an estimated market value of $27.2 million and contractual maturities of up to 23 months.
The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. It was determined that no credit losses existed as of September 30, 2022 or December 31, 2021, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. Gross realized gains and losses on the Company’s debt securities for the three and nine months ended September 30, 2022 and 2021 were not significant.
Prepaid Expenses and Property and Equipment, Net
Condensed consolidated balance sheet details are as follows (in thousands):
September 30,
2022
December 31,
2021
Prepaid expenses and other current assets:
Prepaid insurance$1,547 $1,801 
Prepaid trade shows693 440 
Prepaid software fees1,038 551 
Prepaid employee compensation291 238 
Other current assets643 136 
Total prepaid expenses and other current assets$4,212 $3,166 
Property and equipment, gross:
Laboratory equipment$4,744 $4,805 
Computer equipment356 171 
Furniture and fixtures807 124 
Leasehold improvements1,009 1,074 
Construction-in-progress585 — 
Total property and equipment, gross7,501 6,174 
Less accumulated depreciation(2,558)(1,625)
Total property and equipment, net$4,943 $4,549 
Accrued Compensation and Accrued Liabilities
Condensed consolidated balance sheet details are as follows (in thousands):
September 30,
2022
December 31,
2021
Accrued compensation:
Accrued paid time off$1,790 $1,245 
Accrued wages, bonus and other6,531 3,875 
Total accrued compensation$8,321 $5,120 
Accrued liabilities:
Accrued consulting services$1,173 $775 
Customer refund liability926 — 
Other accrued expenses1,440 452 
Total accrued liabilities$3,539 $1,227 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
(a)    Classes of Stock
The Company’s amended and restated certificate of incorporation authorizes it to issue 50,000,000 shares of common stock and 5,000,000 shares of preferred stock. Both classes of stock have a par value of $0.0001 per share.
(b)    At-The-Market Offering

On November 10, 2020, the Company entered into a sales agreement (the “November 2020 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2020, the Company issued an aggregate of 951,792 shares of common stock pursuant to the November 2020 Sales Agreement at a weighted average purchase price of $20.97 resulting in aggregate gross proceeds of approximately $20.0 million, reduced by $0.9 million in issuance costs, resulting in net proceeds to the Company of approximately $19.1 million. For the nine months ended September 30, 2022, the Company did not issue any shares pursuant to the November 2020 Sales Agreement. For the year ended December 31, 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the November 2020 Sales Agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million.

On August 8, 2022, the Company entered into a second sales agreement (the “August 2022 Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million under a second at-the-market offering program. For the nine months ended September 30, 2022, the Company did not issue any shares pursuant to the August 2022 Sales Agreement.
(c)    2021 Underwritten Public Offering
On January 6, 2021, the Company entered into an underwriting agreement with Cowen and William Blair & Company, L.L.C. as representatives of the several underwriters (the "Underwriters"). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company. On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company received aggregate gross proceeds of approximately $143.7 million, and net proceeds of approximately $134.6 million, after deducting underwriting discounts and commissions and other offering expenses.
(d)    Warrants
SPAC Warrants
The Company previously issued a total of 14,936,250 SPAC warrants (the "SPAC Warrants") to purchase common stock in public and private placement offerings which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 warrants (the "Public SPAC Warrants") and as part of the private placement offering, the Company issued 561,250 warrants (the "Private SPAC Warrants"). The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.
The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.
Between January 1, 2021 and September 30, 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds.
Outstanding SPAC Warrants totaled 2,815,853 as of September 30, 2022 and December 31, 2021. Private SPAC Warrants that were still owned by the original holder totaled 80,350 as of September 30, 2022 and December 31, 2021.
Placement Agent Warrants
In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling of common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled 10,039 as of September 30, 2022 and December 31, 2021.
Management Warrants
Warrants to purchase shares of DermTech Operations' common stock were issued to executive officers of DermTech Operations in lieu of issuing certain stock options (the “Management Warrants”). The Management Warrants were assumed by the Company in connection with the Business Combination. The Management Warrants have a ten-year life and are exercisable shares of the Company's common stock at $1.08 per share. For the nine months ended September 30, 2022, the Company issued 20,320 shares of common stock pursuant to the exercise of Management Warrants. The Management Warrants vested monthly over a four-year period. Outstanding Management Warrants totaled zero and 20,320 as of September 30, 2022 and December 31, 2021, respectively.
(e)    Stock-Based Compensation
Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 ESPP, and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of revenue$353 $299 $986 $709 
Sales and marketing1,294 1,098 3,822 2,580 
Research and development1,074 644 2,899 1,473 
General and administrative2,215 1,695 5,960 4,684 
Total stock-based compensation$4,936 $3,736 $13,667 $9,446 
The total compensation cost related to non-vested awards not yet recognized as of September 30, 2022 was $49.1 million, which is expected to be recognized over a weighted average term of 2.28 years.
Equity Incentive Plans
In May 2020, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which replaced our Amended and Restated 2010 Stock Plan and provides for the granting of incentive and non-qualified stock options, restricted stock and stock-based awards to employees, directors and consultants providing services to the Company. Under the 2020 Plan, incentive and non-qualified stock options may be granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of the Company’s capital stock, the exercise price may not be less than 110% of the fair market value of the Company’s common stock on the date of grant and the term of the option may not be longer than five years.
The 2020 Plan authorizes the Company to issue up to 1,900,000 shares of the Company’s common stock pursuant to awards granted under the 2020 Plan, plus the number of shares underlying any stock option and other stock-based awards previously granted under the 2010 Plan that are forfeited, canceled, or terminated (other than by exercise) on or after May 26, 2020; provided that no more than 1,400,000 shares may be added to the 2020 Plan pursuant to such forfeitures, cancellations and terminations. In addition, the number of shares available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year beginning in fiscal year 2021 and ending on the second day of fiscal year 2025, by an amount equal to the smaller of (i) 3.5% of the number of shares of common stock outstanding on such date and (ii) an amount determined by the administrator of the 2020 Plan. The 2020 Plan will expire on April 12, 2030 or an earlier date approved by a vote of the Company’s stockholders or board of
directors. The contractual term of options granted under the 2020 Plan is not more than ten years. Vesting provisions vary based on the specific terms of the individual option awards.
In March 2022, the Company’s board of directors adopted the 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), pursuant to which the Company reserved 950,000 shares of its common stock (subject to customary adjustments in the event of a change in capital structure of the Company) for the issuance of equity awards under the Inducement Plan. In September 2022, the Company amended and restated the Inducement Plan to reserve an additional 1,000,000 shares of its common stock. The Inducement Plan and its amendment were approved by the Company’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan may be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.
As of September 30, 2022, 1,002,843 shares remained available for future grant under our equity incentive plans.
Employee Stock Purchase Plan
In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (as amended, the "2020 ESPP"), which allows for full-time and certain part-time employees of the Company to purchase shares of common stock at a discount to fair market value. The 2020 ESPP authorizes the Company to issue up to 400,000 shares of the Company’s common stock. In addition, the number of shares available for issuance under the 2020 ESPP will automatically increase on the first day of each of the Company’s fiscal years beginning in 2021 and ending on the first day of 2030, in an amount equal to the lesser of (i) 300,000 shares, (ii) 1% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the board of directors of the Company, subject to adjustment upon changes in capitalization of the Company.
The 2020 ESPP permits our eligible employees to purchase discounted shares of our common stock at semi-annual intervals through periodic payroll deductions. Shares are purchased at a price equal to 85% of the lower of: (i) the fair market value of the Company’s common stock on the first business day of an offering period or (ii) the fair market value of the Company’s common stock on the last business day of an offering period. A new offering period commences every year on approximately March 1 and September 1. At the end of each offering period, the accumulated contributions are used to purchase shares of the Company’s common stock. The last business day of each purchase period is referred to as the purchase date. Purchase dates are every six months on February 28 or February 29 and August 31.

In August 2022, the Company’s board of directors approved an amendment to the 2020 ESPP. Effective September 1, 2022, each offering period is twenty-four months and consists of four six-month purchase periods during which payroll deductions of the participants are accumulated under the 2020 ESPP. Prior to September 1, 2022, each offering period was six months.
On February 28, 2021 and August 31, 2021, the Company issued 39,960 and 18,155 shares of its common stock, respectively, pursuant to scheduled purchases under the 2020 ESPP. As of December 31, 2021, 549,289 shares of common stock were reserved for future issuance under the 2020 ESPP. On January 1, 2022, an additional 297,729 shares of common stock became available under the 2020 ESPP pursuant to an automatic annual increase. On February 28, 2022 and August 31, 2022, the Company issued 47,339 and 100,749 shares of its common stock, respectively, pursuant to scheduled purchases under the 2020 ESPP. As of September 30, 2022, 698,930 shares of common stock remained available for future grants under the 2020 ESPP.
Common Stock Reserved for Future Issuance
Common stock reserved for future issuance consists of the following as of September 30, 2022 and December 31, 2021 (in thousands):
September 30,
2022
December 31,
2021
Warrants to purchase common stock10 31 
SPAC Warrants to purchase common stock*704 704 
Stock options issued and outstanding1,732 1,721 
RSUs issued and outstanding3,292 983 
Authorized for future equity grants1,003 603 
Authorized for future ESPP purchases699 549 
Total common stock reserved for future issuance7,440 4,591 
*Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases, Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Leases, Commitments and Contingencies Leases, Commitments and Contingencies
Adoption of ASC 842
In the third quarter of 2021, the Company adopted ASU 2016-02, and ASC Topic 842, Leases (“ASC 842”) using the modified retrospective approach with an effective date of January 1, 2021.
Finance Leases
The Company leases certain laboratory equipment from various third parties, through equipment finance leases (previously referred to as “capital leases”). These leases either include a bargain purchase option or the terms of the leases are at least 75 percent of the useful lives of the assets and are therefore classified as finance leases. These leases are capitalized in property and equipment, net on the accompanying condensed consolidated balance sheets. Initial asset values and finance lease obligations are based on the present value of future minimum lease payments. Gross assets recorded under finance leases were $0.4 million and $0.4 million as of September 30, 2022 and December 31, 2021, respectively. Accumulated amortization associated with finance leases was $0.1 million and $0.1 million as of September 30, 2022 and December 31, 2021, respectively. Total finance lease interest expense was approximately $3,000 and $5,000 for the three months ended September 30, 2022 and 2021, respectively, and $10,000 and $13,000 for the nine months ended September 30, 2022 and 2021, respectively, and is included within interest income, net on the condensed consolidated statements of operations. Long-term finance lease obligations are as follows (in thousands):
September 30, 2022December 31, 2021
Gross finance lease obligations$215 $274 
Less imputed interest(14)(17)
Present value of net minimum lease payments201 257 
Less current portion of finance lease obligations(124)(121)
Total long-term finance lease obligations$77 $136 
Operating Leases
Del Mar Heights Lease
On July 1, 2021, the Company entered into an Office Lease (the “Del Mar Lease”) with Kilroy Realty, L.P. (the “Landlord”), with respect to an aggregate of 95,997 rentable square feet consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130 (the “Entire Premises”). The Entire Premises covered by the Del Mar Lease will serve as the Company’s new principal office.
The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease. The Company has the option to extend the term of the Del Mar Lease for two additional five-year periods, subject to the terms of the Del Mar Lease.
As the Landlord tenders possession of each portion of the Entire Premises for which the applicable improvements required by the Del Mar Lease are substantially complete, the Company will be obligated to make monthly payments of base rent with respect to such portion of the Entire Premises as set forth on Schedule 1 to the Del Mar Lease. In the event the Company exercises its option to extend the Del Mar Lease term, the Del Mar Lease provides for monthly rent payments during the additional five-year periods at the then-current market rent as determined in accordance with the Del Mar Lease. In addition to rent, the Del Mar Lease requires the Company to pay additional rent amounts for taxes, insurance, maintenance and other expenses.
During year ended December 31, 2021, the Company took initial possession of the first phase of its corporate headquarters, and the Company capitalized a ROU asset and related lease liability of $5.7 million associated with the first phase. During the three months ended March 31, 2022, the lease for the second phase of the Company’s corporate headquarters commenced and the Company capitalized a ROU asset and related lease liability of $15.8 million. The extension option periods were not considered in the determination of the ROU asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options.
Del Mar Lease Amendments
During April 2022, the Company amended the Del Mar Lease through the execution of the First Amendment to Office Lease (the "First Amendment") and the Second Amendment to Office Lease (the "Second Amendment") (collectively, the "Del Mar Lease Amendments"). Pursuant to the First Amendment to the Del Mar Lease, the Company elected to utilize a one-time increase in an additional improvement allowance of $25.00 per rentable square foot, which increased the tenant improvement allowance by $2.4 million to $14.4 million, provided under the Del Mar Lease to make certain improvements to the Entire Premises. As a result, the Company will pay an increased monthly base rent to the Landlord, in order to repay costs relating to the additional design and construction. Pursuant to the Second Amendment, the Company elected to expand the Entire Premises to include 14,085 rentable square feet comprising the executive parking level (the “Expansion Premises”), which increased the tenant improvement allowance by $2.1 million to $16.5 million. The Landlord will tender possession of the Expansion Premises following substantial completion of improvements, pursuant to an agreed upon work letter and will run contemporaneously with the term of the Existing Premises. The Company intends to use the additional space for general office and laboratory use. As the Landlord tenders possession of the Expansion Premises, the Company will be obligated to pay the Landlord increased monthly installments of base rent for the Expansion Premises. Upon inclusion of the Expansion Premises, the Company will lease approximately 110,082 rentable square feet rentable square feet from the Landlord.
The Del Mar Lease Amendments were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. The Company evaluated the Del Mar Lease Amendments under ASC 842 and concluded that the Del Mar Lease Amendments would be accounted for as a single contract with the Del Mar Lease because the additional lease payments related to the tenant improvement allowance due to the Del Mar Lease Amendments were not commensurate with ROU asset granted to the Company. Accordingly, the Company remeasured the lease liability using the additional monthly rent payments and the incremental borrowing rate at the effective date of the modification of 6.50%. The remeasurement for the modification resulted in an increase to the lease liability and the ROU asset of approximately $1.2 million.
The extension option periods were not considered in the determination of the ROU asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options. Pending execution of the Landlord's obligations to prepare leased spaces for occupancy, the Company expects the operating leases for the additional office and laboratory space to commence on various dates in the year ending December 31, 2022. The Company has an estimated future lease payment obligation of approximately $54.0 million related to corporate office facilities that were in the process of being constructed as of September 30, 2022. The lease liabilities and the corresponding ROU assets associated with these lease obligations will be recorded upon the commencement date of the operating leases using the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.
In connection with the original lease agreement, in lieu of a cash security deposit, the Company’s bank issued a letter of credit on its behalf, which is secured by a deposit, of $3.0 million and is included in restricted cash on the condensed consolidated balance sheet based on the term of the underlying lease. In April 2022, pursuant to the Second Amendment, the Company’s bank increased the letter of credit on its behalf by $0.5 million, totaling $3.5 million. As of September 30, 2022, none of the standby letter of credit amount has been used.
Torrey Pines Lease
In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the Torrey Lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations. As part of the fifth amendment, the Company was entitled to a tenant improvement allowance for certain costs incurred while performing these improvements in the amount of $0.3 million, which amount may be increased by up to $0.1 million at the Company’s election and subject to a corresponding increase in rent. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs.
The lease term for all leased space has an expiration date of April 30, 2023, and an option to extend the lease term on all leased space for one additional three-year term, which the Company is not reasonably certain that it will exercise. As such, the Company did not include this option in the determination of the total lease term. On January 1, 2021, in conjunction with the adoption of the guidance in ASU 2016-02, the Company recognized a ROU asset and corresponding lease liability for its facility lease as the present value of lease payments not yet paid at January 1, 2021. The ROU asset and corresponding lease liability was estimated assuming the remaining lease term of 28 months at January 1, 2021, and an estimated discount rate of 4.04%, which was the Company’s incremental borrowing rate at the date of adopting ASC 842. The Company recorded a lease liability of $3.1 million and a ROU asset of $2.8 million, which is net of $0.3 million of the Company’s previously capitalized tenant improvement allowance and deferred rent, upon adoption.
The components of lease expense for the three and nine months ended September 30, 2022 was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Operating lease cost
Operating lease cost$1,056 $379 $2,724 $1,023 
Variable lease costs (1)
188 171 680 486 
Total operating lease cost$1,244 $550 $3,404 $1,509 
Finance lease cost  
Amortization of leased assets$21 $17 $62 $53 
Interest on lease liabilities10 13 
Total finance lease cost$24 $22 $72 $66 
(1) Variable lease costs are primarily related to common area maintenance charges and property taxes.
Other information related to leases was as shown in the table below.
Nine Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3,621 $1,516 
Operating cash flows from finance leases$10 $13 
Financing cash flows from finance leases$104 $80 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$18,688 $9,071 
Finance leases$48 $105 
Weighted average remaining lease term in years:
Operating leases10.019.33
Finance leases2.372.67
Weighted average discount rate:
Operating leases6.44 %5.78 %
Finance leases5.81 %5.76 %
The Company’s future minimum lease payments under operating and financing leases at September 30, 2022 are as follows (in thousands):
20222023202420252026ThereafterTotal
Operating lease obligations, including interest$791 $2,948 $2,774 $2,853 $2,934 $20,612 $32,912 
Finance lease obligations, including interest25 133 19 19 15 215 
Total future minimum lease payments$816 $3,081 $2,793 $2,872 $2,949 $20,616 $33,127 
Amounts presented in the table above exclude non-cancelable future minimum lease payments for operating leases that have not commenced as of September 30, 2022.
Legal Proceedings
From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
During 2021 and 2022, the Company engaged EVERSANA Life Science Services, LLC (“EVERSANA”) to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s Chief Commercial Offer, is an employee of EVERSANA. The Company incurred $1.1 million and $0.9 million in costs for the three months ended September 30, 2022 and 2021, respectively, and $2.8 million and $1.8 million for the nine months ended September 30, 2022 and 2021, respectively. Amount due to EVERSANA were $0.7 million and $0.6 million as of September 30, 2022 and December 31, 2021, respectively.
On October 1, 2019, the Company entered into a consulting agreement with Michael Dobak pursuant to which the Company will compensate Michael Dobak, in an amount not to exceed $100,000, for certain public relations and marketing services. On July 28, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to modify the terms of Michael Dobak’s compensation. The amended consulting agreement compensated Michael Dobak $15,000 per month from May 11, 2020 through September 30, 2021 and also granted him a restricted stock unit award that fully vested in a single installment on August 31, 2020 and represented the contingent right to receive 5,000 shares of common stock on January 2, 2021. On November 11, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to extend the term through December 31, 2021 with a continued monthly payment of $15,000. On February 26, 2021, the Company and Michael Dobak agreed to extend his agreement through April 30, 2021 with a revised monthly payment of $20,000. Michael Dobak is the brother of Dr. John Dobak, the Company’s Chief Executive Officer. The Company incurred zero costs for the three months ended September 30, 2022 and 2021, respectively, and zero and $0.1 million for the nine months ended September 30, 2022 and 2021.
There were no other related party transactions identified during the nine months ended September 30, 2022 and 2021.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events .    Subsequent EventsThe Company considered subsequent events through November 3, 2022, the date the condensed consolidated financial statements were available to be issued
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Nature of Operations Nature of Operations
On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock.
The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including genomic tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) to collect biological information for commercial applications in the medical diagnostic field.
The ongoing COVID-19 pandemic has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company implemented additional safety measures in accordance with Centers for Disease Control and Prevention, Occupational Safety and Health Administration and other guidance within its CLIA laboratory operations. Additionally, and during this time, the Company transitioned administrative functions to predominantly remote work. The pandemic reduced patient access to clinician offices for in-person testing and reduced access by the Company's sales force for in-office sales calls, which negatively impacted the volume of billable samples. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical, and long-lasting and may again in the future, adversely affect the Company's operating results.
Basis of Presentation Basis of Presentation
The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission (“SEC”), Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.
The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of September 30, 2022, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Use of Estimates Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.
Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that have in the past and may, at times, exceed this insured limit.
Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.
Property and Equipment, Net Property and Equipment, Net Property and equipment, net is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to eleven years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $0.4 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $21,000 and $17,000 for the three months ended September 30, 2022 and 2021, respectively. The Company recorded depreciation expense of $1.2 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases of $0.1 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively. Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the condensed consolidated statements of operations. Gross assets recorded under finance leases were $0.4 million as of September 30, 2022 and December 31, 2021. Accumulated amortization associated with finance leases was $0.1 million as of September 30, 2022 and December 31, 2021. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the condensed consolidated statements of operations in the period realized. Loss of disposal on equipment was $0.1 million for the three months ended September 30, 2022 and $8,000 for the three months ended September 30, 2021. Loss on disposal of equipment was $0.4 million and $13,000 for the nine months ended September 30, 2022 and 2021, respectively. The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable.
Concentration of Credit Risk Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of September 30, 2022, the Company maintained $64.6 million in a sweep account, which maintains cash balances throughout various interest-bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution.
Revenue Recognition Revenue Recognition
The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.
Assay Revenue
The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLAplus (now referred to as the DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLAplus), which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT where a collection kit would be sent to the patient’s home. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.
The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.5 million and $0.5 million of revenue reported for the three and nine months ended September 30, 2022, respectively, and an additional $18,000 and $0.1 million of revenue reported for the three and nine months ended September 30, 2021, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.
Contract Revenue
Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing genomic services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of services may include sample collection using the Smart Sticker, assay development for research partners, patient segmentation and stratification, extraction, isolation, expression, amplification and detection of RNA, DNA, protein and microbiome, including data analysis and reporting.
Deferred Revenue and Remaining Performance Obligations
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.
In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.
The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of September 30, 2022 and December 31, 2021 was $0.4 million and $1.4 million, respectively. As of September 30, 2022 we reclassified $0.9 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services.
Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period.
Accounts Receivable Accounts Receivable
Assay Accounts Receivable
Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivables are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $5.9 million and $3.6 million of gross assay accounts receivable as of September 30, 2022 and December 31, 2021, respectively.
Contract Accounts Receivable
Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of September 30, 2022, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.
Net Loss Per Share Net Loss Per Share Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the three and nine months ended September 30, 2022 and 2021, the outstanding common stock warrants, stock options, and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the three and nine months ended September 30, 2022 excludes the effect of anti-dilutive equity instruments including 714,261 shares of common stock issuable upon the exercise of outstanding common stock warrants and 5,024,323 shares of common stock issuable upon the exercise of stock options and release of RSUs. Diluted net loss per share of common stock for the three and nine months ended September 30, 2021 excludes the effect of anti-dilutive equity instruments including 734,581 shares of common stock then issuable upon the exercise of outstanding warrants and 2,564,059 shares of common stock then issuable upon the exercise of stock options and release of RSUs.
Fair Value Measurements Fair Value MeasurementsThe Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The Company’s marketable debt securities are classified as available-for-sale securities based on management’s intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.
The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.
As of September 30, 2022 and December 31, 2021, the Company maintains letters of credit of $3.5 million and $3.0 million, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.
The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.
Accounting Pronouncements Issued But Not Yet Effective Accounting Pronouncements Issued But Not Yet Effective
In June 2022, the Financial Accounting Standards Board issued ASU No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.
The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Revenues Disaggregated by Revenue Source
The following table presents the Company’s revenues disaggregated by revenue source during the three and nine months ended September 30, 2022 and 2021 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Assay Revenue
DermTech Melanoma Test$3,433 $2,954 $11,098 $8,054 
Contract Revenue
Adhesive patch kits22 14 126 329 
RNA extractions94 19 204 158 
Project management fees24 43 96 132 
Total revenues$3,573 $3,030 $11,524 $8,673 
Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers
The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors that represent 10% or more of the respective amounts for the periods shown:
Total RevenuesAccounts Receivable
Three Months Ended September 30,Nine Months Ended September 30,As of September 30, 2022As of December 31, 2021
2022202120222021
Assay Revenue
Payor A46 %36 %41 %35 %20 %23 %
Payor B****15 %15 %
*Less than 10%
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2022 (in thousands):
September 30, 2022
Level 1Level 2Level 3Total
Assets:    
Cash equivalents$30,529 $— $— $30,529 
Restricted cash3,477 — — 3,477 
Marketable securities, available for sale:
Corporate debt securities— 14,938 — 14,938 
Municipal debt securities— 2,320 — 2,320 
U.S. government debt securities— 36,378 — 36,378 
Total marketable securities, available for sale— 53,636 — 53,636 
Total assets measured at fair value on a recurring basis$34,006 $53,636 $— $87,642 
Liabilities:
Warrant liability$— $— $20 $20 
Total liabilities measured at fair value on a recurring basis$— $— $20 $20 
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 (in thousands):
December 31, 2021
Level 1Level 2Level 3Total
Assets:
Cash equivalents$16,380 $— $— $16,380 
Restricted cash3,025 — — 3,025 
Marketable securities, available for sale:
Corporate debt— 15,352 — 15,352 
Municipal debt securities— 7,412 — 7,412 
U.S. government debt securities— 25,685 — 25,685 
Total marketable securities, available for sale— 48,449 — 48,449 
Total assets measured at fair value on a recurring basis$19,405 $48,449 $— $67,854 
Liabilities:
Warrant liability$— $— $146 $146 
Total liabilities measured at fair value on a recurring basis$— $— $146 $146 
Schedule of Warrant Liability Valuation Method
The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Assumed risk-free interest rate4.22%0.53%
2.37% - 4.22%
0.46% - 0.64%
Assumed volatility118.13%89.77%
92.77% - 118.13%
85.85% - 89.77%
Expected term1.92 years2.92 years
1.92 - 2.42 years
2.92 - 3.42 years
Expected dividend yield
Summary of Changes in Fair Value of Level 3 Liabilities
The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):
Balance as of December 31, 2021$146 
Change in fair value of warrant liability(17)
Balance as of March 31, 2022129 
Change in fair value of warrant liability(105)
Balance as of June 30, 2022$24 
Change in fair value of warrant liability(4)
Balance as of September 30, 2022$20 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details (Tables)
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Short-Term Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of September 30, 2022 were as follows (in thousands):
September 30, 2022
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$15,259 $— $(321)$14,938 
Municipal debt securities2,339 — (19)2,320 
U.S. government debt securities37,133 (758)36,378 
Total short-term marketable securities, available-for-sale$54,731 $$(1,098)$53,636 
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2021 were as follows (in thousands):
December 31, 2021
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$15,385 $— $(33)$15,352 
Municipal debt securities7,417 — (5)7,412 
U.S. government debt securities25,771 (87)25,685 
Total short-term marketable securities, available-for-sale$48,573 $$(125)$48,449 
Schedule of Prepaid Expenses and PP&E
Condensed consolidated balance sheet details are as follows (in thousands):
September 30,
2022
December 31,
2021
Prepaid expenses and other current assets:
Prepaid insurance$1,547 $1,801 
Prepaid trade shows693 440 
Prepaid software fees1,038 551 
Prepaid employee compensation291 238 
Other current assets643 136 
Total prepaid expenses and other current assets$4,212 $3,166 
Property and equipment, gross:
Laboratory equipment$4,744 $4,805 
Computer equipment356 171 
Furniture and fixtures807 124 
Leasehold improvements1,009 1,074 
Construction-in-progress585 — 
Total property and equipment, gross7,501 6,174 
Less accumulated depreciation(2,558)(1,625)
Total property and equipment, net$4,943 $4,549 
Schedule of Accrued Compensation and Accrued Liabilities
Condensed consolidated balance sheet details are as follows (in thousands):
September 30,
2022
December 31,
2021
Accrued compensation:
Accrued paid time off$1,790 $1,245 
Accrued wages, bonus and other6,531 3,875 
Total accrued compensation$8,321 $5,120 
Accrued liabilities:
Accrued consulting services$1,173 $775 
Customer refund liability926 — 
Other accrued expenses1,440 452 
Total accrued liabilities$3,539 $1,227 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award
Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 ESPP, and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of revenue$353 $299 $986 $709 
Sales and marketing1,294 1,098 3,822 2,580 
Research and development1,074 644 2,899 1,473 
General and administrative2,215 1,695 5,960 4,684 
Total stock-based compensation$4,936 $3,736 $13,667 $9,446 
Summary of Common Stock Reserved for Future Issuance
Common stock reserved for future issuance consists of the following as of September 30, 2022 and December 31, 2021 (in thousands):
September 30,
2022
December 31,
2021
Warrants to purchase common stock10 31 
SPAC Warrants to purchase common stock*704 704 
Stock options issued and outstanding1,732 1,721 
RSUs issued and outstanding3,292 983 
Authorized for future equity grants1,003 603 
Authorized for future ESPP purchases699 549 
Total common stock reserved for future issuance7,440 4,591 
*Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases, Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Long Term Finance Lease Obligations Long-term finance lease obligations are as follows (in thousands):
September 30, 2022December 31, 2021
Gross finance lease obligations$215 $274 
Less imputed interest(14)(17)
Present value of net minimum lease payments201 257 
Less current portion of finance lease obligations(124)(121)
Total long-term finance lease obligations$77 $136 
Components of Lease Expense
The components of lease expense for the three and nine months ended September 30, 2022 was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Operating lease cost
Operating lease cost$1,056 $379 $2,724 $1,023 
Variable lease costs (1)
188 171 680 486 
Total operating lease cost$1,244 $550 $3,404 $1,509 
Finance lease cost  
Amortization of leased assets$21 $17 $62 $53 
Interest on lease liabilities10 13 
Total finance lease cost$24 $22 $72 $66 
(1) Variable lease costs are primarily related to common area maintenance charges and property taxes.
Other information related to leases was as shown in the table below.
Nine Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3,621 $1,516 
Operating cash flows from finance leases$10 $13 
Financing cash flows from finance leases$104 $80 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$18,688 $9,071 
Finance leases$48 $105 
Weighted average remaining lease term in years:
Operating leases10.019.33
Finance leases2.372.67
Weighted average discount rate:
Operating leases6.44 %5.78 %
Finance leases5.81 %5.76 %
Schedule of Future Minimum Lease Payments Under Operating and Financing Leases
The Company’s future minimum lease payments under operating and financing leases at September 30, 2022 are as follows (in thousands):
20222023202420252026ThereafterTotal
Operating lease obligations, including interest$791 $2,948 $2,774 $2,853 $2,934 $20,612 $32,912 
Finance lease obligations, including interest25 133 19 19 15 215 
Total future minimum lease payments$816 $3,081 $2,793 $2,872 $2,949 $20,616 $33,127 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Aug. 29, 2019
Sep. 30, 2022
USD ($)
shares
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
shares
Sep. 30, 2022
USD ($)
revenueStream
shares
Sep. 30, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
The Company and Summary of its Significant Accounting Policies [Line Items]                
Conversion ratio of reverse stock split   0.5            
Depreciation expense     $ 400,000   $ 300,000 $ 1,187,000 $ 654,000  
Gross assets $ 7,501,000   7,501,000     7,501,000   $ 6,174,000
Accumulated amortization       $ 100,000   100,000    
Gain (loss) on disposition of property plant equipment     (100,000)   (8,000) (400,000) (13,000)  
Impairment losses     0   0 0 0  
Sweep account 64,600,000   64,600,000     64,600,000    
Insured amount by FDIC 250,000   250,000     250,000    
Cash held in excess of FDIC limit 300,000   300,000     $ 300,000    
Number of revenue streams (in number of streams) | revenueStream           2    
Increase (decrease) in revenue     (500,000)   $ 18,000 $ (500,000) $ 100,000  
Short term deferred revenue 417,000   417,000     417,000   1,380,000
Reclassification of deferred revenue 900,000              
Remaining performance obligation, estimated revenue expected to be recognized 0   0     0    
Accounts receivable 6,101,000   6,101,000     6,101,000   3,847,000
Level 1 | Restricted Cash                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Letters of credit 3,500,000   $ 3,500,000     $ 3,500,000   3,000,000
Common Stock Warrants                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Anti-dilutive equity instruments excluded from diluted net loss per share of common stock | shares     714,261   734,581 714,261 734,581  
Stock Options and RSUs                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Anti-dilutive equity instruments excluded from diluted net loss per share of common stock | shares     5,024,323   2,564,059 5,024,323 2,564,059  
Assay revenue                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Accounts receivable gross 5,900,000   $ 5,900,000     $ 5,900,000   3,600,000
Contract revenue                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Accounts receivable $ 200,000   $ 200,000     $ 200,000   200,000
Minimum                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Useful life of the assets           2 years    
Revenue, remaining performance obligation, expected timing of satisfaction, period 2 years   2 years     2 years    
Maximum                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Useful life of the assets           11 years    
Revenue, remaining performance obligation, expected timing of satisfaction, period 3 years   3 years     3 years    
Amortization of Laboratory Equipment Acquired under Finance Leases                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Depreciation expense     $ 21,000   $ 17,000 $ 100,000 $ 100,000  
Assets Recorded under Finance Leases                
The Company and Summary of its Significant Accounting Policies [Line Items]                
Gross assets $ 400,000   $ 400,000     400,000   400,000
Accumulated amortization           $ 100,000   $ 100,000
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation Of Revenue [Line Items]        
Total revenues $ 3,573 $ 3,030 $ 11,524 $ 8,673
DermTech Melanoma Test        
Disaggregation Of Revenue [Line Items]        
Total revenues 3,433 2,954 11,098 8,054
Adhesive patch kits        
Disaggregation Of Revenue [Line Items]        
Total revenues 22 14 126 329
RNA extractions        
Disaggregation Of Revenue [Line Items]        
Total revenues 94 19 204 158
Project management fees        
Disaggregation Of Revenue [Line Items]        
Total revenues $ 24 $ 43 $ 96 $ 132
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) - Customer Concentration Risk
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Total Revenues | Payor A          
Product Information [Line Items]          
Concentration risk, percentage 46.00% 36.00% 41.00% 35.00%  
Accounts Receivable | Payor A          
Product Information [Line Items]          
Concentration risk, percentage     20.00%   23.00%
Accounts Receivable | Payor B          
Product Information [Line Items]          
Concentration risk, percentage     15.00%   15.00%
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Assets:    
Restricted cash $ 3,477 $ 3,025
Marketable securities, available for sale:    
Total marketable securities, available for sale 53,636 48,449
Fair Value, Recurring    
Assets:    
Cash equivalents 30,529 16,380
Restricted cash 3,477 3,025
Marketable securities, available for sale:    
Total marketable securities, available for sale 53,636 48,449
Total assets measured at fair value on a recurring basis 87,642 67,854
Liabilities:    
Warrant liability 20 146
Total liabilities measured at fair value on a recurring basis 20 146
Fair Value, Recurring | Level 1    
Assets:    
Cash equivalents 30,529 16,380
Restricted cash 3,477 3,025
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Total assets measured at fair value on a recurring basis 34,006 19,405
Liabilities:    
Warrant liability 0 0
Total liabilities measured at fair value on a recurring basis 0 0
Fair Value, Recurring | Level 2    
Assets:    
Cash equivalents 0 0
Restricted cash 0 0
Marketable securities, available for sale:    
Total marketable securities, available for sale 53,636 48,449
Total assets measured at fair value on a recurring basis 53,636 48,449
Liabilities:    
Warrant liability 0 0
Total liabilities measured at fair value on a recurring basis 0 0
Fair Value, Recurring | Level 3    
Assets:    
Cash equivalents 0 0
Restricted cash 0 0
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Total assets measured at fair value on a recurring basis 0 0
Liabilities:    
Warrant liability 20 146
Total liabilities measured at fair value on a recurring basis 20 146
Corporate debt securities    
Marketable securities, available for sale:    
Total marketable securities, available for sale 14,938 15,352
Corporate debt securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Total marketable securities, available for sale 14,938 15,352
Corporate debt securities | Fair Value, Recurring | Level 1    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Corporate debt securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Total marketable securities, available for sale 14,938 15,352
Corporate debt securities | Fair Value, Recurring | Level 3    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Municipal debt securities    
Marketable securities, available for sale:    
Total marketable securities, available for sale 2,320 7,412
Municipal debt securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Total marketable securities, available for sale 2,320 7,412
Municipal debt securities | Fair Value, Recurring | Level 1    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Municipal debt securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Total marketable securities, available for sale 2,320 7,412
Municipal debt securities | Fair Value, Recurring | Level 3    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
U.S. government debt securities    
Marketable securities, available for sale:    
Total marketable securities, available for sale 36,378 25,685
U.S. government debt securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Total marketable securities, available for sale 36,378 25,685
U.S. government debt securities | Fair Value, Recurring | Level 1    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
U.S. government debt securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Total marketable securities, available for sale 36,378 25,685
U.S. government debt securities | Fair Value, Recurring | Level 3    
Marketable securities, available for sale:    
Total marketable securities, available for sale $ 0 $ 0
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details) - Warranty liability
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Assumed risk-free interest rate 4.22% 0.53%    
Assumed risk-free interest rate, minimum     2.37% 0.46%
Assumed risk-free interest rate, maximum     4.22% 0.64%
Assumed volatility 118.13% 89.77%    
Assumed volatility, minimum     92.77% 85.85%
Assumed volatility, maximum     118.13% 89.77%
Expected term 1 year 11 months 1 day 2 years 11 months 1 day    
Expected dividend yield 0.00% 0.00% 0.00% 0.00%
Minimum        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Expected term     1 year 11 months 1 day 2 years 11 months 1 day
Maximum        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Expected term     2 years 5 months 1 day 3 years 5 months 1 day
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) - Level 3 - Warrant Liability - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Beginning balance $ 24 $ 129 $ 146
Change in fair value of warrant liability (4) (105) (17)
Ending balance $ 20 $ 24 $ 129
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Investment Holdings [Line Items]    
Amortized Cost $ 54,731 $ 48,573
Gross Unrealized Gains 3 1
Gross Unrealized Losses (1,098) (125)
Estimated Market Value 53,636 48,449
Corporate debt securities    
Investment Holdings [Line Items]    
Amortized Cost 15,259 15,385
Gross Unrealized Gains 0 0
Gross Unrealized Losses (321) (33)
Estimated Market Value 14,938 15,352
Municipal debt securities    
Investment Holdings [Line Items]    
Amortized Cost 2,339 7,417
Gross Unrealized Gains 0 0
Gross Unrealized Losses (19) (5)
Estimated Market Value 2,320 7,412
U.S. government debt securities    
Investment Holdings [Line Items]    
Amortized Cost 37,133 25,771
Gross Unrealized Gains 3 1
Gross Unrealized Losses (758) (87)
Estimated Market Value $ 36,378 $ 25,685
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details - Additional Information (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Estimated market value of debt securities with contractual maturities of less than 12 months $ 38,300,000 $ 21,200,000
Estimated market value of remaining debt securities with contractual maturities of up to 23 months 15,300,000 27,200,000
Credit losses $ 0 $ 0
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Prepaid expenses and other current assets:    
Prepaid insurance $ 1,547 $ 1,801
Prepaid trade shows 693 440
Prepaid software fees 1,038 551
Prepaid employee compensation 291 238
Other current assets 643 136
Total prepaid expenses and other current assets 4,212 3,166
Property and equipment, gross:    
Laboratory equipment 4,744 4,805
Computer equipment 356 171
Furniture and fixtures 807 124
Leasehold improvements 1,009 1,074
Construction-in-progress 585 0
Total property and equipment, gross 7,501 6,174
Less accumulated depreciation (2,558) (1,625)
Total property and equipment, net $ 4,943 $ 4,549
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Accrued compensation:    
Accrued paid time off $ 1,790 $ 1,245
Accrued wages, bonus and other 6,531 3,875
Total accrued compensation 8,321 5,120
Accrued liabilities:    
Accrued consulting services 1,173 775
Customer refund liability 926 0
Other accrued expenses 1,440 452
Total accrued liabilities $ 3,539 $ 1,227
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended 36 Months Ended
Sep. 01, 2022
period
Aug. 08, 2022
USD ($)
Aug. 31, 2021
shares
Feb. 28, 2021
shares
Jan. 11, 2021
USD ($)
$ / shares
shares
Jan. 06, 2021
shares
Nov. 10, 2020
USD ($)
Jun. 23, 2017
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
shares
Sep. 30, 2022
USD ($)
Warrant
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2016
$ / shares
shares
Dec. 31, 2018
$ / shares
shares
Aug. 31, 2022
shares
Mar. 31, 2022
shares
Feb. 28, 2022
shares
Jan. 01, 2022
shares
Class of Stock [Line Items]                                          
Common stock, shares authorized (in shares)                 50,000,000       50,000,000   50,000,000            
Preferred stock, shares authorized (in shares)                 5,000,000       5,000,000                
Common stock, par value per share (in usd per share) | $ / shares                 $ 0.0001       $ 0.0001   $ 0.0001            
Preferred stock, par value per share (in usd per share) | $ / shares                 $ 0.0001       $ 0.0001                
Issuance of preferred stock, total offering amount | $                     $ 23,836 $ 134,582                  
Issuance of common stock, net of issuance costs shares (in shares)           4,237,288                              
Proceeds from issuance of common stock | $         $ 134,600                                
Shares purchased by underwriters (in shares)         635,593 635,593                              
Number of days granted to underwriters option to purchase           30 days                              
Sale of stock, number of shares issued in transaction (in shares)         4,872,881                                
Public offering price (in usd per share) | $ / shares         $ 29.50                                
Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses | $         $ 143,700                                
Warrants expiration period                 5 years       5 years                
Total proceeds from exercise of public warrants | $                         $ 22 $ 70,271              
Compensation cost related to non-vested awards not yet recognized | $                 $ 49,100       $ 49,100                
Weighted average term expected to be recognized                         2 years 3 months 10 days                
Duration of offering period (in months) 24 months                                        
Number of six month purchase periods | period 4                                        
Common stock available for issuance (in shares)                 7,440       7,440   4,591            
Common stock, shares issued (in shares)                 30,213,206       30,213,206   29,772,922            
2020 Equity Incentive Plan                                          
Class of Stock [Line Items]                                          
Common stock, shares authorized (in shares)                 1,900,000       1,900,000                
Common stock outstanding percentage                         3.50%                
Contractual term of options granted                         10 years                
Options remain available for issuance pursuant to future grants (in shares)                 1,002,843       1,002,843                
2020 Employee Stock Purchase Plan                                          
Class of Stock [Line Items]                                          
Issuance of common stock, net of issuance costs shares (in shares)     18,155 39,960                                  
Shares, issued (in shares)                 300,000       300,000                
Common stock outstanding percentage                         1.00%                
Options remain available for issuance pursuant to future grants (in shares)                 698,930       698,930               297,729
Percentage of price at shares purchased                         85.00%                
Common stock available for issuance (in shares)                             549,289            
Common stock, shares issued (in shares)                                   100,749   47,339  
2022 Inducement Equity Incentive Plan                                          
Class of Stock [Line Items]                                          
Common stock initially reserved for issuance (in shares)                                     950,000    
Additional common stock reserved (in shares)                 1,000,000                        
SPAC Warrants                                          
Class of Stock [Line Items]                                          
Warrants issued to purchase common stock (in shares)               14,936,250                          
Number of warrants entitle holder to purchase one share | Warrant                         4                
Total number exercised of public warrants (in shares)                           12,120,397              
Common shares issued upon exercise of warrants (in shares)                           3,030,092              
Total proceeds from exercise of public warrants | $                           $ 69,700              
Warrants outstanding (in shares)                 2,815,853       2,815,853   2,815,853            
Public SPAC Warrants                                          
Class of Stock [Line Items]                                          
Warrants issued to purchase common stock (in shares)               14,375,000                          
Private SPAC Warrants                                          
Class of Stock [Line Items]                                          
Warrants issued to purchase common stock (in shares)               561,250                          
Warrants outstanding (in shares)                 80,350       80,350   80,350            
Placement Agent Warrants                                          
Class of Stock [Line Items]                                          
Warrants issued to purchase common stock (in shares)                               168,522 72,658        
Warrants expiration period                               7 years 7 years        
Warrants outstanding (in shares)                 10,039       10,039   10,039            
Placement Agent Warrants | 2018 Convertible Bridge Notes                                          
Class of Stock [Line Items]                                          
Warrants issued to purchase common stock (in shares)                       15,724                  
Warrants expiration period                   7 years                      
Management Warrants                                          
Class of Stock [Line Items]                                          
Warrants expiration period                 10 years       10 years                
Warrants outstanding (in shares)                 0       0   20,320            
Cowen and Company LLC                                          
Class of Stock [Line Items]                                          
Issuance of preferred stock, total offering amount | $   $ 75,000         $ 50,000                            
Issuance of common stock, net of issuance costs shares (in shares)                   951,792     0   530,551            
Weighted average purchase price per share (in usd per share) | $ / shares                   $ 20.97         $ 46.33            
Gross proceeds from issuance of common stock | $                   $ 20,000         $ 24,600            
Decrease in issuance costs | $                   900         700            
Proceeds from issuance of common stock | $                   $ 19,100         $ 23,800            
Common stock                                          
Class of Stock [Line Items]                                          
Issuance of preferred stock, total offering amount | $                       $ 1                  
Issuance of common stock, net of issuance costs shares (in shares)                     530,551 4,872,881                  
Number of shares issued for each warrant (in shares)                 0.25       0.25                
Common stock | SPAC Warrants                                          
Class of Stock [Line Items]                                          
Exercise price of warrant (in usd per share) | $ / shares                 $ 23.00       $ 23.00                
Number of shares issued for each warrant (in shares)                 0.25       0.25                
Common stock | Placement Agent Warrants                                          
Class of Stock [Line Items]                                          
Exercise price of warrant (in usd per share) | $ / shares                               $ 8.68 $ 9.54        
Number of shares issued for each warrant (in shares)                               1 1        
Common stock | Placement Agent Warrants | 2018 Convertible Bridge Notes                                          
Class of Stock [Line Items]                                          
Exercise price of warrant (in usd per share) | $ / shares                   $ 9.54                      
Number of shares issued for each warrant (in shares)                   1                      
Common stock | Management Warrants                                          
Class of Stock [Line Items]                                          
Exercise price of warrant (in usd per share) | $ / shares                 $ 1.08       $ 1.08                
Number of shares issued for each warrant (in shares)                 20,320       20,320                
Warrants vesting period                         4 years                
Minimum | 2020 Equity Incentive Plan | Incentive Stock Options                                          
Class of Stock [Line Items]                                          
Options granted, exercise price expressed as a percentage of fair market value                         110.00%                
Minimum | 2020 Equity Incentive Plan | Incentive and Non-qualified Stock Options                                          
Class of Stock [Line Items]                                          
Options granted, exercise price expressed as a percentage of fair market value                         100.00%                
Maximum | 2020 Equity Incentive Plan                                          
Class of Stock [Line Items]                                          
Term of the option                         5 years                
Shares, issued (in shares)                 1,400,000       1,400,000                
Maximum | 2020 Employee Stock Purchase Plan                                          
Class of Stock [Line Items]                                          
Common stock available for issuance (in shares)                 400,000       400,000                
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity - Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation $ 4,936 $ 3,736 $ 13,667 $ 9,446
Cost of revenue        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation 353 299 986 709
Sales and marketing        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation 1,294 1,098 3,822 2,580
Research and development        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation 1,074 644 2,899 1,473
General and administrative        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation $ 2,215 $ 1,695 $ 5,960 $ 4,684
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)
9 Months Ended
Sep. 30, 2022
Warrant
shares
Dec. 31, 2021
shares
Class of Stock [Line Items]    
Total common stock reserved for future issuance 7,440 4,591
SPAC Warrants    
Class of Stock [Line Items]    
Number of warrants entitle holder to purchase one share | Warrant 4  
Warrants to purchase common stock    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 10 31
SPAC Warrants to purchase common stock*    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 704 704
Stock options issued and outstanding    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 1,732 1,721
RSUs issued and outstanding    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 3,292 983
Authorized for future equity grants    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 1,003 603
Authorized for future ESPP purchases    
Class of Stock [Line Items]    
Total common stock reserved for future issuance 699 549
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases, Commitments and Contingencies - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 22, 2022
USD ($)
ft²
Jul. 01, 2021
USD ($)
ft²
$ / ft²
Apr. 30, 2022
USD ($)
$ / ft²
Sep. 30, 2022
USD ($)
period
phase
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
period
phase
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Jan. 01, 2021
USD ($)
Commitments And Contingencies [Line Items]                    
Percentage of useful lives of assets             75.00%      
Gross assets       $ 7,501,000     $ 7,501,000   $ 6,174,000  
Accumulated amortization         $ 100,000   100,000      
Interest on lease liabilities       $ 3,000   $ 5,000 $ 10,000 $ 13,000    
Number of improvement phases | phase       4     4      
Number of renewal terms | period       1     1      
Renewal term       3 years     3 years      
Operating lease right-of-use assets       $ 24,644,000     $ 24,644,000   7,744,000 $ 2,800,000
Operating lease, liability                   3,100,000
Increase to operating lease liability             (2,709,000) (1,130,000)    
Total       32,912,000     32,912,000      
Tenant improvement allowance       $ 300,000     300,000     $ 300,000
Remaining lease term                   28 months
Estimated discount rate                   4.04%
Maximum                    
Commitments And Contingencies [Line Items]                    
Increase in tenant improvement allowance             $ 100,000      
Kilroy Realty, L.P                    
Commitments And Contingencies [Line Items]                    
Area of building (in square feet) | ft² 110,082 95,997                
Tenant improvement allowance per rentable square foot (in usd per square foot) | $ / ft²   125.00                
Tenant improvements   $ 12,000,000                
Number of renewal terms | period       2     2      
Renewal term       5 years     5 years      
Operating lease right-of-use assets         15,800,000       5,700,000  
Operating lease, liability         $ 15,800,000       5,700,000  
Incremental borrowing rate     6.50%              
Increase to operating lease liability     $ 1,200,000              
Increase to operating right-of-use asset     1,200,000              
Total       $ 54,000,000     $ 54,000,000      
Remaining lease term       10 years 6 months     10 years 6 months      
Kilroy Realty, L.P | First Amendment                    
Commitments And Contingencies [Line Items]                    
Tenant improvements     $ 14,400,000              
Increase in improvement allowance per rentable square foot (in usd per square foot) | $ / ft²     25.00              
Increase in tenant improvement allowance     $ 2,400,000              
Kilroy Realty, L.P | Second Amendment                    
Commitments And Contingencies [Line Items]                    
Tenant improvements     16,500,000              
Increase in tenant improvement allowance $ 2,100,000                  
Expansion premise (in square feet) | ft² 14,085                  
Kilroy Realty, L.P | Letter of Credit | Demand Deposits                    
Commitments And Contingencies [Line Items]                    
Restricted cash and cash equivalents     3,500,000 $ 3,000,000     $ 3,000,000      
Increase (decrease) to restricted cash and cash equivalents     $ 500,000              
Kilroy Realty, L.P | Standby Letter of Credit | Demand Deposits                    
Commitments And Contingencies [Line Items]                    
Restricted cash and cash equivalents       0     0      
Interest Income, Net                    
Commitments And Contingencies [Line Items]                    
Interest on lease liabilities       3,000   $ 5,000 10,000 $ 13,000    
Assets Recorded under Finance Leases                    
Commitments And Contingencies [Line Items]                    
Gross assets       $ 400,000     400,000   400,000  
Accumulated amortization             $ 100,000   $ 100,000  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]    
Gross finance lease obligations $ 215 $ 274
Less imputed interest (14) (17)
Present value of net minimum lease payments 201 257
Less current portion of finance lease obligations (124) (121)
Total long-term finance lease obligations $ 77 $ 136
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases, Commitments and Contingencies - Components of Lease Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating lease cost        
Operating lease cost $ 1,056 $ 379 $ 2,724 $ 1,023
Variable lease costs 188 171 680 486
Total operating lease cost 1,244 550 3,404 1,509
Finance lease cost        
Amortization of leased assets 21 17 62 53
Interest on lease liabilities 3 5 10 13
Total finance lease cost 24 22 72 66
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows from operating leases     3,621 1,516
Operating cash flows from finance leases $ 3 $ 5 10 13
Financing cash flows from finance leases     104 80
Right-of-use assets obtained in exchange for operating lease obligations     18,688 9,071
Right-of-use assets obtained in exchange for finance lease obligations     $ 48 $ 105
Weighted-average remaining lease term of operating leases (in years) 10 years 3 days 9 years 3 months 29 days 10 years 3 days 9 years 3 months 29 days
Weighted-average remaining lease term of finance leases (in years) 2 years 4 months 13 days 2 years 8 months 1 day 2 years 4 months 13 days 2 years 8 months 1 day
Weighted-average discount rate for operating leases (in percent) 6.44% 5.78% 6.44% 5.78%
Weighted-average discount rate for finance leases (in percent) 5.81% 5.76% 5.81% 5.76%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases, Commitments and Contingencies - Future Minimum Payments (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Operating lease obligations, including interest    
2022 $ 791  
2023 2,948  
2024 2,774  
2025 2,853  
2026 2,934  
Thereafter 20,612  
Total 32,912  
Finance lease obligations, including interest    
2022 25  
2023 133  
2024 19  
2025 19  
2026 15  
Thereafter 4  
Gross finance lease obligations 215 $ 274
Total future minimum lease payments    
Total future minimum lease payments due in 2022 816  
Total future minimum lease payments due in 2023 3,081  
Total future minimum lease payments due in 2024 2,793  
Total future minimum lease payments due in 2025 2,872  
Total future minimum lease payments due in 2026 2,949  
Total future minimum lease payments due thereafter 20,616  
Operating And Capital Lease Liability Payments Due $ 33,127  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Feb. 26, 2021
Nov. 11, 2020
May 11, 2020
Oct. 01, 2019
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Jan. 02, 2021
Related Party Transaction [Line Items]                    
Common stock, shares issued (in shares)         30,213,206   30,213,206   29,772,922  
Related party transaction, other             $ 0 $ 0    
EVERSANA | Leana Wood                    
Related Party Transaction [Line Items]                    
Related party certain marketing cost         $ 1,100,000 $ 900,000 2,800,000 1,800,000    
Due to related party         700,000   700,000   $ 600,000  
DermTech Operations | Michael Dobak                    
Related Party Transaction [Line Items]                    
Related party certain marketing cost $ 20,000 $ 15,000 $ 15,000   $ 0 $ 0 $ 0 $ 100,000    
Common stock, shares issued (in shares)                   5,000
DermTech Operations | Michael Dobak | Maximum                    
Related Party Transaction [Line Items]                    
Related party certain marketing cost       $ 100,000            
XML 48 dmtk-20220930_htm.xml IDEA: XBRL DOCUMENT 0001651944 2022-01-01 2022-09-30 0001651944 2022-10-28 0001651944 2022-09-30 0001651944 2021-12-31 0001651944 dmtk:AssayMember 2022-07-01 2022-09-30 0001651944 dmtk:AssayMember 2021-07-01 2021-09-30 0001651944 dmtk:AssayMember 2022-01-01 2022-09-30 0001651944 dmtk:AssayMember 2021-01-01 2021-09-30 0001651944 dmtk:ContractualActivitiesMember 2022-07-01 2022-09-30 0001651944 dmtk:ContractualActivitiesMember 2021-07-01 2021-09-30 0001651944 dmtk:ContractualActivitiesMember 2022-01-01 2022-09-30 0001651944 dmtk:ContractualActivitiesMember 2021-01-01 2021-09-30 0001651944 2022-07-01 2022-09-30 0001651944 2021-07-01 2021-09-30 0001651944 2021-01-01 2021-09-30 0001651944 us-gaap:CommonStockMember 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001651944 us-gaap:RetainedEarningsMember 2021-12-31 0001651944 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001651944 2022-01-01 2022-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0001651944 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001651944 us-gaap:CommonStockMember 2022-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-31 0001651944 us-gaap:RetainedEarningsMember 2022-03-31 0001651944 2022-03-31 0001651944 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001651944 2022-04-01 2022-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-04-01 2022-06-30 0001651944 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001651944 us-gaap:CommonStockMember 2022-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-06-30 0001651944 us-gaap:RetainedEarningsMember 2022-06-30 0001651944 2022-06-30 0001651944 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-07-01 2022-09-30 0001651944 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001651944 us-gaap:CommonStockMember 2022-09-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-30 0001651944 us-gaap:RetainedEarningsMember 2022-09-30 0001651944 us-gaap:CommonStockMember 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0001651944 us-gaap:RetainedEarningsMember 2020-12-31 0001651944 2020-12-31 0001651944 us-gaap:CommonStockMember 2021-03-31 0001651944 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001651944 2021-01-01 2021-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-03-31 0001651944 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-03-31 0001651944 us-gaap:RetainedEarningsMember 2021-03-31 0001651944 2021-03-31 0001651944 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001651944 2021-04-01 2021-06-30 0001651944 us-gaap:CommonStockMember dmtk:AtTheMarketOfferingMember 2021-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-04-01 2021-06-30 0001651944 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001651944 us-gaap:CommonStockMember 2021-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-06-30 0001651944 us-gaap:RetainedEarningsMember 2021-06-30 0001651944 2021-06-30 0001651944 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-07-01 2021-09-30 0001651944 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001651944 us-gaap:CommonStockMember 2021-09-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-30 0001651944 us-gaap:RetainedEarningsMember 2021-09-30 0001651944 2021-09-30 0001651944 dmtk:PublicFollowOnOfferingMember 2022-01-01 2022-09-30 0001651944 dmtk:PublicFollowOnOfferingMember 2021-01-01 2021-09-30 0001651944 dmtk:AtTheMarketOfferingMember 2022-01-01 2022-09-30 0001651944 dmtk:AtTheMarketOfferingMember 2021-01-01 2021-09-30 0001651944 srt:MinimumMember 2022-01-01 2022-09-30 0001651944 srt:MaximumMember 2022-01-01 2022-09-30 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2022-07-01 2022-09-30 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2021-07-01 2021-09-30 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2022-01-01 2022-09-30 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2021-01-01 2021-09-30 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2022-09-30 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2021-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2022-01-01 2022-09-30 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2022-07-01 2022-09-30 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2021-07-01 2021-09-30 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2022-01-01 2022-09-30 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2021-01-01 2021-09-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2022-07-01 2022-09-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2021-07-01 2021-09-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2022-01-01 2022-09-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2021-01-01 2021-09-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2022-07-01 2022-09-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2021-07-01 2021-09-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2022-01-01 2022-09-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2021-01-01 2021-09-30 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 2022-09-30 2022-09-30 0001651944 srt:MinimumMember 2022-09-30 0001651944 srt:MaximumMember 2022-09-30 0001651944 dmtk:AssayMember 2022-09-30 0001651944 dmtk:AssayMember 2021-12-31 0001651944 dmtk:ContractualActivitiesMember 2022-09-30 0001651944 dmtk:ContractualActivitiesMember 2021-12-31 0001651944 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001651944 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2022-07-01 2022-09-30 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001651944 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001651944 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2021-07-01 2021-09-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-09-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-07-01 2022-09-30 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2021-07-01 2021-09-30 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-01-01 2022-09-30 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2021-01-01 2021-09-30 0001651944 srt:MinimumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-01-01 2022-09-30 0001651944 srt:MaximumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-01-01 2022-09-30 0001651944 srt:MinimumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2021-01-01 2021-09-30 0001651944 srt:MaximumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2021-01-01 2021-09-30 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2022-01-01 2022-03-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2022-03-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2022-04-01 2022-06-30 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2022-06-30 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2022-07-01 2022-09-30 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2022-09-30 0001651944 dmtk:RestrictedCashMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001651944 dmtk:RestrictedCashMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001651944 2019-08-29 2019-08-29 0001651944 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:MunicipalNotesMember 2022-09-30 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-09-30 0001651944 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2020-11-10 2020-11-10 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2020-11-10 2020-12-31 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2022-01-01 2022-09-30 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2021-01-01 2021-12-31 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2022-08-08 2022-08-08 0001651944 2021-01-06 2021-01-06 0001651944 2021-01-11 2021-01-11 0001651944 2021-01-11 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PublicSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember us-gaap:CommonStockMember 2022-09-30 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-09-30 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-01-01 2021-09-30 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2022-09-30 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2022-09-30 0001651944 dmtk:PlacementAgentWarrantsMember 2015-01-01 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-01-01 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-01-01 2021-03-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember us-gaap:CommonStockMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2022-09-30 0001651944 dmtk:PlacementAgentWarrantsMember 2021-12-31 0001651944 dmtk:ManagementWarrantsMember 2022-09-30 0001651944 dmtk:ManagementWarrantsMember us-gaap:CommonStockMember 2022-09-30 0001651944 dmtk:ManagementWarrantsMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001651944 dmtk:ManagementWarrantsMember 2021-12-31 0001651944 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0001651944 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0001651944 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0001651944 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-09-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2021-07-01 2021-09-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-09-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001651944 srt:MinimumMember dmtk:IncentiveAndNonQualifiedStockOptionsMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2022-01-01 2022-09-30 0001651944 srt:MinimumMember dmtk:IncentiveStockOptionsMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2022-01-01 2022-09-30 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2022-01-01 2022-09-30 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2022-09-30 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2022-09-30 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2022-01-01 2022-09-30 0001651944 dmtk:A2022InducementEquityIncentivePlanMember 2022-03-31 0001651944 dmtk:A2022InducementEquityIncentivePlanMember 2022-09-01 2022-09-30 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-09-30 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-09-30 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-01-01 2022-09-30 0001651944 2022-09-01 2022-09-01 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-02-28 2021-02-28 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-08-31 2021-08-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-01-01 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-02-28 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-08-31 0001651944 dmtk:WarrantsToPurchaseCommonStockMember 2022-09-30 0001651944 dmtk:WarrantsToPurchaseCommonStockMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember 2022-09-30 0001651944 dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember 2021-12-31 0001651944 us-gaap:EmployeeStockOptionMember 2022-09-30 0001651944 us-gaap:EmployeeStockOptionMember 2021-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001651944 dmtk:AuthorizedForFutureEquityGrantsMember 2022-09-30 0001651944 dmtk:AuthorizedForFutureEquityGrantsMember 2021-12-31 0001651944 dmtk:AuthorizedForFutureESPPPurchasesMember 2022-09-30 0001651944 dmtk:AuthorizedForFutureESPPPurchasesMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2022-01-01 2022-09-30 0001651944 us-gaap:InterestIncomeMember 2022-07-01 2022-09-30 0001651944 us-gaap:InterestIncomeMember 2021-07-01 2021-09-30 0001651944 us-gaap:InterestIncomeMember 2022-01-01 2022-09-30 0001651944 us-gaap:InterestIncomeMember 2021-01-01 2021-09-30 0001651944 dmtk:KilroyRealtyLPMember 2021-07-01 2021-07-01 0001651944 dmtk:KilroyRealtyLPMember 2021-07-01 0001651944 dmtk:KilroyRealtyLPMember 2022-09-30 0001651944 dmtk:KilroyRealtyLPMember 2021-12-31 0001651944 dmtk:KilroyRealtyLPMember 2022-03-31 0001651944 dmtk:FirstAmendmentMember dmtk:KilroyRealtyLPMember 2022-04-01 2022-04-30 0001651944 dmtk:FirstAmendmentMember dmtk:KilroyRealtyLPMember 2022-04-30 0001651944 dmtk:SecondAmendmentMember dmtk:KilroyRealtyLPMember 2022-04-22 2022-04-22 0001651944 dmtk:SecondAmendmentMember dmtk:KilroyRealtyLPMember 2022-04-30 0001651944 dmtk:KilroyRealtyLPMember 2022-04-22 2022-04-22 0001651944 dmtk:KilroyRealtyLPMember 2022-04-30 0001651944 dmtk:KilroyRealtyLPMember 2022-04-01 2022-04-30 0001651944 dmtk:KilroyRealtyLPMember us-gaap:LetterOfCreditMember us-gaap:DemandDepositsMember 2022-09-30 0001651944 dmtk:KilroyRealtyLPMember us-gaap:LetterOfCreditMember us-gaap:DemandDepositsMember 2022-04-01 2022-04-30 0001651944 dmtk:KilroyRealtyLPMember us-gaap:LetterOfCreditMember us-gaap:DemandDepositsMember 2022-04-30 0001651944 dmtk:KilroyRealtyLPMember us-gaap:StandbyLettersOfCreditMember us-gaap:DemandDepositsMember 2022-09-30 0001651944 2021-01-01 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2022-07-01 2022-09-30 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2021-07-01 2021-09-30 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2022-01-01 2022-09-30 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2021-01-01 2021-09-30 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2022-09-30 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2021-12-31 0001651944 srt:MaximumMember dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2019-10-01 2019-10-01 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-05-11 2020-05-11 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-01-02 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-11-11 2020-11-11 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-02-26 2021-02-26 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2022-07-01 2022-09-30 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2022-01-01 2022-09-30 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares dmtk:revenueStream pure dmtk:period dmtk:Warrant utr:sqft iso4217:USD utr:sqft dmtk:phase 0001651944 --12-31 2022 Q3 false P2Y P2Y 0.5 0.25 0.25 4 P10Y6M 10-Q true 2022-09-30 false 001-38118 DERMTECH, INC. DE 84-2870849 11099 N. Torrey Pines Road Suite 100 La Jolla CA 92037 858 450-4222 Common Stock, par value $0.0001 per share DMTK NASDAQ Yes Yes Large Accelerated Filer true false false 30214705 95492000 176882000 53636000 48449000 6101000 3847000 1391000 480000 4212000 3166000 160832000 232824000 4943000 4549000 24644000 7744000 3477000 3025000 167000 167000 194063000 248309000 2997000 2880000 8321000 5120000 3539000 1227000 417000 1380000 1588000 1453000 124000 121000 16986000 12181000 20000 146000 77000 136000 21992000 6148000 39075000 18611000 0.0001 0.0001 50000000 50000000 30213206 30213206 29772922 29772922 3000 3000 450904000 436183000 -1095000 -124000 -294824000 -206364000 154988000 229698000 194063000 248309000 3433000 2954000 11098000 8054000 140000 76000 426000 619000 3573000 3030000 11524000 8673000 3644000 2875000 10410000 7450000 50000 23000 111000 74000 3694000 2898000 10521000 7524000 -121000 132000 1003000 1149000 14632000 9826000 45076000 24245000 5702000 4426000 18955000 10271000 8806000 6199000 26258000 17672000 29140000 20451000 90289000 52188000 -29261000 -20319000 -89286000 -51039000 485000 38000 700000 107000 -4000 -169000 -126000 1350000 489000 207000 826000 -1243000 -28772000 -20112000 -88460000 -52282000 30096261 30096261 29639802 29639802 29969435 29969435 28599375 28599375 -0.96 -0.96 -0.68 -0.68 -2.95 -2.95 -1.83 -1.83 -28772000 -20112000 -88460000 -52282000 -230000 -10000 -971000 -7000 -29002000 -20122000 -89431000 -52289000 29772922 3000 436183000 -124000 -206364000 229698000 109275 40000 40000 11101 12000 12000 47339 515000 515000 -570000 -570000 3894000 3894000 -30108000 -30108000 29940637 3000 440644000 -694000 -236472000 203481000 88591 0 9219 10000 10000 -171000 -171000 4837000 4837000 -29580000 -29580000 30038447 3000 445491000 -865000 -266052000 178577000 74010 0 100749 477000 477000 -230000 -230000 4936000 4936000 -28772000 -28772000 30213206 3000 450904000 -1095000 -294824000 154988000 20740413 2000 189868000 -1000 -128029000 61840000 29.50 9100000 4872881 1000 134581000 134582000 176673 408000 408000 3089325 72081000 72081000 39960 392000 392000 9000 9000 2172000 2172000 411000 411000 -15068000 -15068000 28919252 3000 399913000 8000 -143097000 256827000 157277 188000 188000 46.33 700000 530551 23836000 23836000 314 5000 5000 -6000 -6000 3538000 3538000 23000 23000 -17102000 -17102000 29607394 3000 427503000 2000 -160199000 267309000 76768 81000 81000 14881 343000 343000 18155 574000 574000 -10000 -10000 3736000 3736000 -20112000 -20112000 29717198 3000 432237000 -8000 -180311000 251921000 -88460000 -52282000 1187000 654000 -126000 1350000 1788000 909000 13667000 9446000 -328000 -463000 -350000 -13000 2254000 1339000 911000 320000 1046000 104000 -2709000 -1130000 955000 1525000 3201000 1389000 -74030000 -39426000 26420000 25150000 0 350000 19934000 18475000 1372000 1664000 -7858000 -7989000 0 134582000 0 23836000 22000 70271000 40000 677000 992000 966000 104000 80000 950000 230252000 -80938000 182837000 179907000 24248000 98969000 207085000 95492000 204061000 3477000 3024000 98969000 207085000 10000 13000 511000 462000 0 434000 0 2158000 18688000 9071000 48000 105000 -971000 -7000 The Company and a Summary of its Significant Accounting Policies<div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)    Nature of Operations </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including genomic tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) to collect biological information for commercial applications in the medical diagnostic field.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company implemented additional safety measures in accordance with Centers for Disease Control and Prevention, Occupational Safety and Health Administration and other guidance within its CLIA laboratory operations. Additionally, and during this time, the Company transitioned administrative functions to predominantly remote work. The pandemic reduced patient access to clinician offices for in-person testing and reduced access by the Company's sales force for in-office sales calls, which negatively impacted the volume of billable samples. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical, and long-lasting and may again in the future, adversely affect the Company's operating results. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)    Basis of Presentation</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission (“SEC”), Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of September 30, 2022, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)    Use of Estimates </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)    Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that have in the past and may, at times, exceed this insured limit. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)    Property and Equipment, Net </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmMTFlZWIyN2NmNTQ5M2Y4MWIyYWRkYTg3NzMyNzZmL3NlYzpmZjExZWViMjdjZjU0OTNmODFiMmFkZGE4NzczMjc2Zl8zNy9mcmFnOjc1NGI1NTZiMWEzZjQxNTE5MDE4M2NiMzFmYWI1OTlhL3RleHRyZWdpb246NzU0YjU1NmIxYTNmNDE1MTkwMTgzY2IzMWZhYjU5OWFfNzgxMg_e99acb6c-4822-4119-b4b7-56e6737666b3">two</span> to eleven years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $0.4 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $21,000 and $17,000 for the three months ended September 30, 2022 and 2021, respectively. The Company recorded depreciation expense of $1.2 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases of $0.1 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the condensed consolidated statements of operations. Gross assets recorded under finance leases were $0.4 million as of September 30, 2022 and December 31, 2021. Accumulated amortization associated with finance leases was $0.1 million as of September 30, 2022 and December 31, 2021. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the condensed consolidated statements of operations in the period realized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of disposal on equipment was $0.1 million for the three months ended September 30, 2022 and $8,000 for the three months ended September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Loss on disposal of equipment was $0.4 million and $13,000 for the nine months ended September 30, 2022 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the three or nine months ended September 30, 2022 and 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)    Concentration of Credit Risk </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of September 30, 2022, the Company maintained $64.6 million in a sweep account, which maintains cash balances throughout various interest-bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $0.3 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of September 30, 2022. The Company has not experienced any losses in such accounts. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)    Revenue Recognition </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assay Revenue </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (now referred to as the DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT where a collection kit would be sent to the patient’s home. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.5 million and $0.5 million of revenue reported for the three and nine months ended September 30, 2022, respectively, and an additional $18,000 and $0.1 million of revenue reported for the three and nine months ended September 30, 2021, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing genomic services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of services may include sample collection using the Smart Sticker, assay development for research partners, patient segmentation and stratification, extraction, isolation, expression, amplification and detection of RNA, DNA, protein and microbiome, including data analysis and reporting.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a) Disaggregation of Revenue </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source during the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assay Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DermTech Melanoma Test</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adhesive patch kits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNA extractions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Project management fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,524 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors that represent 10% or more of the respective amounts for the periods shown:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assay Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor B</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4pt">Less than 10%</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other third-party payors or pharmaceutical customers that individually accounted for more than 10% of the Company’s total revenue or accounts receivable for the periods shown in the table above.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b) Deferred Revenue and Remaining Performance Obligations</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of September 30, 2022 and December 31, 2021 was $0.4 million and $1.4 million, respectively. As of September 30, 2022 we reclassified $0.9 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of September 30, 2022, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immaterial</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmMTFlZWIyN2NmNTQ5M2Y4MWIyYWRkYTg3NzMyNzZmL3NlYzpmZjExZWViMjdjZjU0OTNmODFiMmFkZGE4NzczMjc2Zl8zNy9mcmFnOjc1NGI1NTZiMWEzZjQxNTE5MDE4M2NiMzFmYWI1OTlhL3RleHRyZWdpb246NzU0YjU1NmIxYTNmNDE1MTkwMTgzY2IzMWZhYjU5OWFfMTc0NjI_23f34434-7834-4ccf-868f-0c0b738cbb2f">two</span> to three years.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(h)    Accounts Receivable </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assay Accounts Receivable </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivables are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $5.9 million and $3.6 million of gross assay accounts receivable as of September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Accounts Receivable </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of September 30, 2022, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company recorded $0.2 million and $0.2 million of contract accounts receivable as of September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i)    Net Loss Per Share </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the three and nine months ended September 30, 2022 and 2021, the outstanding common stock warrants, stock options, and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022 excludes the effect of anti-dilutive equity instruments including 714,261 shares of common stock issuable upon the exercise of outstanding common stock warrants and 5,024,323 shares of common stock issuable upon the exercise of stock options and release of RSUs. Diluted net loss per share of common stock for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021 excludes the effect of anti-dilutive equity instruments including 734,581 shares of common stock then issuable upon the exercise of outstanding warrants and 2,564,059 shares of common stock then issuable upon the exercise of stock options and release of RSUs.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(j)    Fair Value Measurements</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2022 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s marketable debt securities are classified as available-for-sale securities based on management’s intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37% - 4.22%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46% - 0.64%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.77%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.77% - 118.13%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.85% - 89.77%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92 - 2.42 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 - 3.42 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company maintains letters of credit of $3.5 million and $3.0 million, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(k)    Accounting Pronouncements Issued But Not Yet Effective </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.</span></div> Nature of Operations <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including genomic tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) to collect biological information for commercial applications in the medical diagnostic field.</span></div>The ongoing COVID-19 pandemic has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company implemented additional safety measures in accordance with Centers for Disease Control and Prevention, Occupational Safety and Health Administration and other guidance within its CLIA laboratory operations. Additionally, and during this time, the Company transitioned administrative functions to predominantly remote work. The pandemic reduced patient access to clinician offices for in-person testing and reduced access by the Company's sales force for in-office sales calls, which negatively impacted the volume of billable samples. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical, and long-lasting and may again in the future, adversely affect the Company's operating results. Basis of Presentation<div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission (“SEC”), Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of September 30, 2022, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</span></div> Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates. Cash, Cash Equivalents and Restricted Cash<div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that have in the past and may, at times, exceed this insured limit. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.</span></div> Property and Equipment, Net Property and equipment, net is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmMTFlZWIyN2NmNTQ5M2Y4MWIyYWRkYTg3NzMyNzZmL3NlYzpmZjExZWViMjdjZjU0OTNmODFiMmFkZGE4NzczMjc2Zl8zNy9mcmFnOjc1NGI1NTZiMWEzZjQxNTE5MDE4M2NiMzFmYWI1OTlhL3RleHRyZWdpb246NzU0YjU1NmIxYTNmNDE1MTkwMTgzY2IzMWZhYjU5OWFfNzgxMg_e99acb6c-4822-4119-b4b7-56e6737666b3">two</span> to eleven years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $0.4 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $21,000 and $17,000 for the three months ended September 30, 2022 and 2021, respectively. The Company recorded depreciation expense of $1.2 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively, which includes amortization of laboratory equipment acquired under finance leases of $0.1 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the condensed consolidated statements of operations. Gross assets recorded under finance leases were $0.4 million as of September 30, 2022 and December 31, 2021. Accumulated amortization associated with finance leases was $0.1 million as of September 30, 2022 and December 31, 2021. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the condensed consolidated statements of operations in the period realized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of disposal on equipment was $0.1 million for the three months ended September 30, 2022 and $8,000 for the three months ended September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Loss on disposal of equipment was $0.4 million and $13,000 for the nine months ended September 30, 2022 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. </span>The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. P11Y 400000 300000 21000 17000 1200000 700000 100000 100000 400000 400000 100000 100000 -100000 -8000 -400000 -13000 0 0 0 0 Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of September 30, 2022, the Company maintained $64.6 million in a sweep account, which maintains cash balances throughout various interest-bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. 64600000 250000 300000 Revenue Recognition <div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assay Revenue </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (now referred to as the DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT where a collection kit would be sent to the patient’s home. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.5 million and $0.5 million of revenue reported for the three and nine months ended September 30, 2022, respectively, and an additional $18,000 and $0.1 million of revenue reported for the three and nine months ended September 30, 2021, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing genomic services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of services may include sample collection using the Smart Sticker, assay development for research partners, patient segmentation and stratification, extraction, isolation, expression, amplification and detection of RNA, DNA, protein and microbiome, including data analysis and reporting.</span></div>Deferred Revenue and Remaining Performance Obligations<div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of September 30, 2022 and December 31, 2021 was $0.4 million and $1.4 million, respectively. As of September 30, 2022 we reclassified $0.9 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services. </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span> less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. 2 -500000 -500000 18000 100000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source during the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assay Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DermTech Melanoma Test</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adhesive patch kits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNA extractions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Project management fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,524 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3433000 2954000 11098000 8054000 22000 14000 126000 329000 94000 19000 204000 158000 24000 43000 96000 132000 3573000 3030000 11524000 8673000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors that represent 10% or more of the respective amounts for the periods shown:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assay Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor B</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4pt">Less than 10%</span></div> 0.46 0.36 0.41 0.35 0.20 0.23 0.15 0.15 400000 1400000 900000 0 P3Y Accounts Receivable <div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assay Accounts Receivable </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivables are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $5.9 million and $3.6 million of gross assay accounts receivable as of September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Accounts Receivable </span></div>Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of September 30, 2022, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. 5900000 3600000 200000 200000 Net Loss Per Share <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the three and nine months ended September 30, 2022 and 2021, the outstanding common stock warrants, stock options, and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022 excludes the effect of anti-dilutive equity instruments including 714,261 shares of common stock issuable upon the exercise of outstanding common stock warrants and 5,024,323 shares of common stock issuable upon the exercise of stock options and release of RSUs. Diluted net loss per share of common stock for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021 excludes the effect of anti-dilutive equity instruments including 734,581 shares of common stock then issuable upon the exercise of outstanding warrants and 2,564,059 shares of common stock then issuable upon the exercise of stock options and release of RSUs.</span> 714261 714261 5024323 5024323 734581 734581 2564059 2564059 Fair Value MeasurementsThe Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.<div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s marketable debt securities are classified as available-for-sale securities based on management’s intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company maintains letters of credit of $3.5 million and $3.0 million, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.</span></div> <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2022 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30529000 0 0 30529000 3477000 0 0 3477000 0 14938000 0 14938000 0 2320000 0 2320000 0 36378000 0 36378000 0 53636000 0 53636000 34006000 53636000 0 87642000 0 0 20000 20000 0 0 20000 20000 16380000 0 0 16380000 3025000 0 0 3025000 0 15352000 0 15352000 0 7412000 0 7412000 0 25685000 0 25685000 0 48449000 0 48449000 19405000 48449000 0 67854000 0 0 146000 146000 0 0 146000 146000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37% - 4.22%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46% - 0.64%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.77%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.77% - 118.13%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.85% - 89.77%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92 - 2.42 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 - 3.42 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div> 0.0422 0.0053 0.0237 0.0422 0.0046 0.0064 1.1813 0.8977 0.9277 1.1813 0.8585 0.8977 P1Y11M1D P2Y11M1D P1Y11M1D P2Y5M1D P2Y11M1D P3Y5M1D 0 0 0 0 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 146000 -17000 129000 -105000 24000 -4000 20000 3500000 3000000 Accounting Pronouncements Issued But Not Yet Effective <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.</span></div> Balance Sheet Details<div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Marketable Securities</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of September 30, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2021 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the estimated market value of debt securities with contractual maturities of less than twelve months was $38.3 million; the remaining debt securities that the Company held at that date had an estimated market value of $15.3 million and contractual maturities of up to 21 months. As of December 31, 2021, the estimated market value of debt securities with contractual maturities of less than twelve months was $21.2 million; the remaining debt securities that the Company held at that date had an estimated market value of $27.2 million and contractual maturities of up to 23 months.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. It was determined that no credit losses existed as of September 30, 2022 or December 31, 2021, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. Gross realized gains and losses on the Company’s debt securities for the three and nine months ended September 30, 2022 and 2021 were not significant.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Expenses and Property and Equipment, Net </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid trade shows</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,174 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,943 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,549 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Compensation and Accrued Liabilities </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued paid time off</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued wages, bonus and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued compensation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,321 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued consulting services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer refund liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of September 30, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,636 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2021 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15259000 0 321000 14938000 2339000 0 19000 2320000 37133000 3000 758000 36378000 54731000 3000 1098000 53636000 15385000 0 33000 15352000 7417000 0 5000 7412000 25771000 1000 87000 25685000 48573000 1000 125000 48449000 38300000 15300000 21200000 27200000 0 0 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid trade shows</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,174 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,943 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,549 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1547000 1801000 693000 440000 1038000 551000 291000 238000 643000 136000 4212000 3166000 4744000 4805000 356000 171000 807000 124000 1009000 1074000 585000 0 7501000 6174000 2558000 1625000 4943000 4549000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued paid time off</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued wages, bonus and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued compensation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,321 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued consulting services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer refund liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1790000 1245000 6531000 3875000 8321000 5120000 1173000 775000 926000 0 1440000 452000 3539000 1227000 Stockholders’ Equity<div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)    Classes of Stock </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s amended and restated certificate of incorporation authorizes it to issue 50,000,000 shares of common stock and 5,000,000 shares of preferred stock. Both classes of stock have a par value of $0.0001 per share. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)    At-The-Market Offering</span></div><div style="padding-left:27pt;text-indent:-27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 10, 2020, the Company entered into a sales agreement (the “November 2020 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2020, the Company issued an aggregate of 951,792 shares of common stock pursuant to the November 2020 Sales Agreement at a weighted average purchase price of $20.97 resulting in aggregate gross proceeds of approximately $20.0 million, reduced by $0.9 million in issuance costs, resulting in net proceeds to the Company of approximately $19.1 million. For the nine months ended September 30, 2022, the Company did not issue any shares pursuant to the November 2020 Sales Agreement. For the year ended December 31, 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the November 2020 Sales Agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 8, 2022, the Company entered into a second sales agreement (the “August 2022 Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million under a second at-the-market offering program. For the nine months ended September 30, 2022, the Company did not issue any shares pursuant to the August 2022 Sales Agreement. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)    2021 Underwritten Public Offering </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2021, the Company entered into an underwriting agreement with Cowen and William Blair &amp; Company, L.L.C. as representatives of the several underwriters (the "Underwriters"). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company. On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company received aggregate gross proceeds of approximately $143.7 million, and net proceeds of approximately $134.6 million, after deducting underwriting discounts and commissions and other offering expenses.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)    Warrants </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPAC Warrants </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously issued a total of 14,936,250 SPAC warrants (the "SPAC Warrants") to purchase common stock in public and private placement offerings which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 warrants (the "Public SPAC Warrants") and as part of the private placement offering, the Company issued 561,250 warrants (the "Private SPAC Warrants"). The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January 1, 2021 and September 30, 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding SPAC Warrants totaled 2,815,853 as of September 30, 2022 and December 31, 2021. Private SPAC Warrants that were still owned by the original holder totaled 80,350 as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Placement Agent Warrants</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling of common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled 10,039 as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Warrants</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of DermTech Operations' common stock were issued to executive officers of DermTech Operations in lieu of issuing certain stock options (the “Management Warrants”). The Management Warrants were assumed by the Company in connection with the Business Combination. The Management Warrants have a ten-year life and are exercisable shares of the Company's common stock at $1.08 per share. For the nine months ended September 30, 2022, the Company issued 20,320 shares of common stock pursuant to the exercise of Management Warrants. The Management Warrants vested monthly over a four-year period. Outstanding Management Warrants totaled zero and 20,320 as of September 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)    Stock-Based Compensation </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 ESPP, and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"/><td style="width:41.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,936 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,736 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total compensation cost related to non-vested awards not yet recognized as of September 30, 2022 was $49.1 million, which is expected to be recognized over a weighted average term of 2.28 years. </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which replaced our Amended and Restated 2010 Stock Plan and provides for the granting of incentive and non-qualified stock options, restricted stock and stock-based awards to employees, directors and consultants providing services to the Company. Under the 2020 Plan, incentive and non-qualified stock options may be granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of the Company’s capital stock, the exercise price may not be less than 110% of the fair market value of the Company’s common stock on the date of grant and the term of the option may not be longer than five years.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan authorizes the Company to issue up to 1,900,000 shares of the Company’s common stock pursuant to awards granted under the 2020 Plan, plus the number of shares underlying any stock option and other stock-based awards previously granted under the 2010 Plan that are forfeited, canceled, or terminated (other than by exercise) on or after May 26, 2020; provided that no more than 1,400,000 shares may be added to the 2020 Plan pursuant to such forfeitures, cancellations and terminations. In addition, the number of shares available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year beginning in fiscal year 2021 and ending on the second day of fiscal year 2025, by an amount equal to the smaller of (i) 3.5% of the number of shares of common stock outstanding on such date and (ii) an amount determined by the administrator of the 2020 Plan. The 2020 Plan will expire on April 12, 2030 or an earlier date approved by a vote of the Company’s stockholders or board of </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors. The contractual term of options granted under the 2020 Plan is not more than ten years. Vesting provisions vary based on the specific terms of the individual option awards.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company’s board of directors adopted the 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), pursuant to which the Company reserved 950,000 shares of its common stock (subject to customary adjustments in the event of a change in capital structure of the Company) for the issuance of equity awards under the Inducement Plan. In September 2022, the Company amended and restated the Inducement Plan to reserve an additional 1,000,000 shares of its common stock. The Inducement Plan and its amendment were approved by the Company’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan may be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, 1,002,843 shares remained available for future grant under our equity incentive plans.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (as amended, the "2020 ESPP"), which allows for full-time and certain part-time employees of the Company to purchase shares of common stock at a discount to fair market value. The 2020 ESPP authorizes the Company to issue up to 400,000 shares of the Company’s common stock. In addition, the number of shares available for issuance under the 2020 ESPP will automatically increase on the first day of each of the Company’s fiscal years beginning in 2021 and ending on the first day of 2030, in an amount equal to the lesser of (i) 300,000 shares, (ii) 1% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the board of directors of the Company, subject to adjustment upon changes in capitalization of the Company.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 ESPP permits our eligible employees to purchase discounted shares of our common stock at semi-annual intervals through periodic payroll deductions. Shares are purchased at a price equal to 85% of the lower of: (i) the fair market value of the Company’s common stock on the first business day of an offering period or (ii) the fair market value of the Company’s common stock on the last business day of an offering period. A new offering period commences every year on approximately March 1 and September 1. At the end of each offering period, the accumulated contributions are used to purchase shares of the Company’s common stock. The last business day of each purchase period is referred to as the purchase date. Purchase dates are every six months on February 28 or February 29 and August 31.</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company’s board of directors approved an amendment to the 2020 ESPP. Effective September 1, 2022, each offering period is twenty-four months and consists of four six-month purchase periods during which payroll deductions of the participants are accumulated under the 2020 ESPP. Prior to September 1, 2022, each offering period was six months.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2021 and August 31, 2021, the Company issued 39,960 and 18,155 shares of its common stock, respectively, pursuant to scheduled purchases under the 2020 ESPP. As of December 31, 2021, 549,289 shares of common stock were reserved for future issuance under the 2020 ESPP. On January 1, 2022, an additional 297,729 shares of common stock became available under the 2020 ESPP pursuant to an automatic annual increase. On February 28, 2022 and August 31, 2022, the Company issued 47,339 and 100,749 shares of its common stock, respectively, pursuant to scheduled purchases under the 2020 ESPP. As of September 30, 2022, 698,930 shares of common stock remained available for future grants under the 2020 ESPP.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Reserved for Future Issuance </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance consists of the following as of September 30, 2022 and December 31, 2021 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPAC Warrants to purchase common stock*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized for future equity grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized for future ESPP purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,591 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.</span></div> 50000000 5000000 0.0001 0.0001 50000000 951792 20.97 20000000 -900000 19100000 0 530551 46.33 24600000 -700000 23800000 75000000 0 4237288 635593 P30D 4872881 635593 29.50 143700000 134600000 14936250 14375000 561250 P5Y 23.00 12120397 3030092 69700000 2815853 2815853 80350 80350 168522 P7Y 1 8.68 72658 P7Y 1 9.54 15724 P7Y 1 9.54 10039 10039 P10Y 1.08 20320 P4Y 0 20320 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 ESPP, and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"/><td style="width:41.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,936 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,736 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 353000 299000 986000 709000 1294000 1098000 3822000 2580000 1074000 644000 2899000 1473000 2215000 1695000 5960000 4684000 4936000 3736000 13667000 9446000 49100000 P2Y3M10D 1 1.10 P5Y 1900000 1400000 0.035 P10Y 950000 1000000 1002843 400000 300000 0.01 0.85 P24M 4 39960 18155 549289 297729 47339 100749 698930 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance consists of the following as of September 30, 2022 and December 31, 2021 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPAC Warrants to purchase common stock*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized for future equity grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized for future ESPP purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,591 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.</span></div> 10 31 704 704 1732 1721 3292 983 1003 603 699 549 7440 4591 4 Leases, Commitments and Contingencies <div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Adoption of ASC 842</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021, the Company adopted ASU 2016-02, and ASC Topic 842, Leases (“ASC 842”) using the modified retrospective approach with an effective date of January 1, 2021.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance Leases</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain laboratory equipment from various third parties, through equipment finance leases (previously referred to as “capital leases”). These leases either include a bargain purchase option or the terms of the leases are at least 75 percent of the useful lives of the assets and are therefore classified as finance leases. These leases are capitalized in property and equipment, net on the accompanying condensed consolidated balance sheets. Initial asset values and finance lease obligations are based on the present value of future minimum lease payments. Gross assets recorded under finance leases were $0.4 million and $0.4 million as of September 30, 2022 and December 31, 2021, respectively. Accumulated amortization associated with finance leases was $0.1 million and $0.1 million as of September 30, 2022 and December 31, 2021, respectively. Total finance lease interest expense was approximately $3,000 and $5,000 for the three months ended September 30, 2022 and 2021, respectively, and $10,000 and $13,000 for the nine months ended September 30, 2022 and 2021, respectively, and is included within interest income, net on the condensed consolidated statements of operations. Long-term finance lease obligations are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:69.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross finance lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of net minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term finance lease obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Del Mar Heights Lease </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company entered into an Office Lease (the “Del Mar Lease”) with Kilroy Realty, L.P. (the “Landlord”), with respect to an aggregate of 95,997 rentable square feet consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130 (the “Entire Premises”). The Entire Premises covered by the Del Mar Lease will serve as the Company’s new principal office.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease. The Company has the option to extend the term of the Del Mar Lease for two additional five-year periods, subject to the terms of the Del Mar Lease.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Landlord tenders possession of each portion of the Entire Premises for which the applicable improvements required by the Del Mar Lease are substantially complete, the Company will be obligated to make monthly payments of base rent with respect to such portion of the Entire Premises as set forth on Schedule 1 to the Del Mar Lease. In the event the Company exercises its option to extend the Del Mar Lease term, the Del Mar Lease provides for monthly rent payments during the additional five-year periods at the then-current market rent as determined in accordance with the Del Mar Lease. In addition to rent, the Del Mar Lease requires the Company to pay additional rent amounts for taxes, insurance, maintenance and other expenses.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During year ended December 31, 2021, the Company took initial possession of the first phase of its corporate headquarters, and the Company capitalized a ROU asset and related lease liability of $5.7 million associated with the first phase. During the three months ended March 31, 2022, the lease for the second phase of the Company’s corporate headquarters commenced and the Company capitalized a ROU asset and related lease liability of $15.8 million. The extension option periods were not considered in the determination of the ROU asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options. </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Del Mar Lease Amendments</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April 2022, the Company amended the Del Mar Lease through the execution of the First Amendment to Office Lease (the "First Amendment") and the Second Amendment to Office Lease (the "Second Amendment") (collectively, the "Del Mar Lease Amendments"). Pursuant to the First Amendment to the Del Mar Lease, the Company elected to utilize a one-time increase in an additional improvement allowance of $25.00 per rentable square foot, which increased the tenant improvement allowance by $2.4 million to $14.4 million, provided under the Del Mar Lease to make certain improvements to the Entire Premises. As a result, the Company will pay an increased monthly base rent to the Landlord, in order to repay costs relating to the additional design and construction. Pursuant to the Second Amendment, the Company elected to expand the Entire Premises to include 14,085 rentable square feet comprising the executive parking level (the “Expansion Premises”), which increased the tenant improvement allowance by $2.1 million to $16.5 million. The Landlord will tender possession of the Expansion Premises following substantial completion of improvements, pursuant to an agreed upon work letter and will run contemporaneously with the term of the Existing Premises. The Company intends to use the additional space for general office and laboratory use. As the Landlord tenders possession of the Expansion Premises, the Company will be obligated to pay the Landlord increased monthly installments of base rent for the Expansion Premises. Upon inclusion of the Expansion Premises, the Company will lease approximately 110,082 rentable square feet rentable square feet from the Landlord. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Del Mar Lease Amendments were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. The Company evaluated the Del Mar Lease Amendments under ASC 842 and concluded that the Del Mar Lease Amendments would be accounted for as a single contract with the Del Mar Lease because the additional lease payments related to the tenant improvement allowance due to the Del Mar Lease Amendments were not commensurate with ROU asset granted to the Company. Accordingly, the Company remeasured the lease liability using the additional monthly rent payments and the incremental borrowing rate at the effective date of the modification of 6.50%. The remeasurement for the modification resulted in an increase to the lease liability and the ROU asset of approximately $1.2 million. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extension option periods were not considered in the determination of the ROU asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options. Pending execution of the Landlord's obligations to prepare leased spaces for occupancy, the Company expects the operating leases for the additional office and laboratory space to commence on various dates in the year ending December 31, 2022. The Company has an estimated future lease payment obligation of approximately $54.0 million related to corporate office facilities that were in the process of being constructed as of September 30, 2022. The lease liabilities and the corresponding ROU assets associated with these lease obligations will be recorded upon the commencement date of the operating leases using the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the original lease agreement, in lieu of a cash security deposit, the Company’s bank issued a letter of credit on its behalf, which is secured by a deposit, of $3.0 million and is included in restricted cash on the condensed consolidated balance sheet based on the term of the underlying lease. In April 2022, pursuant to the Second Amendment</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company’s bank increased the letter of credit on its behalf</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by $0.5 million, totaling $3.5 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, none of the standby letter of credit amount has been used.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Torrey Pines Lease</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the Torrey Lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations. As part of the fifth amendment, the Company was entitled to a tenant improvement allowance for certain costs incurred while performing these improvements in the amount of $0.3 million, which amount may be increased by up to $0.1 million at the Company’s election and subject to a corresponding increase in rent. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all leased space has an expiration date of April 30, 2023, and an option to extend the lease term on all leased space for one additional three-year term, which the Company is not reasonably certain that it will exercise. As such, the Company did not include this option in the determination of the total lease term. On January 1, 2021, in conjunction with the adoption of the guidance in ASU 2016-02, the Company recognized a ROU asset and corresponding lease liability for its facility lease as the present value of lease payments not yet paid at January 1, 2021. The ROU asset and corresponding lease liability was estimated assuming the remaining lease term of 28 months at January 1, 2021, and an estimated discount rate of 4.04%, which was the Company’s incremental borrowing rate at the date of adopting ASC 842. The Company recorded a lease liability of $3.1 million and a ROU asset of $2.8 million, which is net of $0.3 million of the Company’s previously capitalized tenant improvement allowance and deferred rent, upon adoption.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three and nine months ended September 30, 2022 was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Variable lease costs are primarily related to common area maintenance charges and property taxes.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as shown in the table below. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining lease term in years:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.33</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future minimum lease payments under operating and financing leases at September 30, 2022 are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations, including interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,948 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,912 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations, including interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,081 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,793 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts presented in the table above exclude non-cancelable future minimum lease payments for operating leases that have not commenced as of September 30, 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div>From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows. 0.75 400000 400000 100000 100000 3000 5000 10000 13000 Long-term finance lease obligations are as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:69.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross finance lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of net minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term finance lease obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 215000 274000 14000 17000 201000 257000 124000 121000 77000 136000 95997 125.00 12000000 4 2 P5Y P5Y 5700000 5700000 15800000 15800000 25.00 2400000 14400000 14085 2100000 16500000 110082 0.0650 1200000 1200000 54000000 3000000 500000 3500000 0 300000 100000 1 P3Y P28M 0.0404 3100000 2800000 300000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three and nine months ended September 30, 2022 was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Variable lease costs are primarily related to common area maintenance charges and property taxes.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as shown in the table below. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining lease term in years:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.33</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 1056000 379000 2724000 1023000 188000 171000 680000 486000 1244000 550000 3404000 1509000 21000 17000 62000 53000 3000 5000 10000 13000 24000 22000 72000 66000 3621000 1516000 10000 13000 104000 80000 18688000 9071000 48000 105000 P10Y3D P9Y3M29D P2Y4M13D P2Y8M1D 0.0644 0.0578 0.0581 0.0576 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future minimum lease payments under operating and financing leases at September 30, 2022 are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations, including interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,948 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,912 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations, including interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,081 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,793 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 791000 2948000 2774000 2853000 2934000 20612000 32912000 25000 133000 19000 19000 15000 4000 215000 816000 3081000 2793000 2872000 2949000 20616000 33127000 Related Party Transactions <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, the Company engaged EVERSANA Life Science Services, LLC (“EVERSANA”) to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s Chief Commercial Offer, is an employee of EVERSANA. The Company incurred $1.1 million and $0.9 million in costs for the three months ended September 30, 2022 and 2021, respectively, and $2.8 million and $1.8 million for the nine months ended September 30, 2022 and 2021, respectively. Amount due to EVERSANA were $0.7 million and $0.6 million as of September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2019, the Company entered into a consulting agreement with Michael Dobak pursuant to which the Company will compensate Michael Dobak, in an amount not to exceed $100,000, for certain public relations and marketing services. On July 28, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to modify the terms of Michael Dobak’s compensation. The amended consulting agreement compensated Michael Dobak $15,000 per month from May 11, 2020 through September 30, 2021 and also granted him a restricted stock unit award that fully vested in a single installment on August 31, 2020 and represented the contingent right to receive 5,000 shares of common stock on January 2, 2021. On November 11, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to extend the term through December 31, 2021 with a continued monthly payment of $15,000. On February 26, 2021, the Company and Michael Dobak agreed to extend his agreement through April 30, 2021 with a revised monthly payment of $20,000. Michael Dobak is the brother of Dr. John Dobak, the Company’s Chief Executive Officer. The Company incurred zero costs for the three months ended September 30, 2022 and 2021, respectively, and zero and $0.1 million for the nine months ended September 30, 2022 and 2021.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other related party transactions identified during the nine months ended September 30, 2022 and 2021.</span></div> 1100000 900000 2800000 1800000 700000 600000 100000 15000 5000 15000 20000 0 0 0 100000 0 0 .    Subsequent EventsThe Company considered subsequent events through November 3, 2022, the date the condensed consolidated financial statements were available to be issued EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO=V]R:W-H965T&UL4$L! A0#% @ VH5C588=0"NU" /5( !D M ("!-^$ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ VH5C53:C6O%+! L10 !D ("!??( M 'AL+W=O&PO=V]R:W-H965T[Y !X;"]W;W)K&UL4$L! A0#% @ MVH5C5=V,)-(; P #0H !D ("!-/X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ VH5C50- RCUB! M%QD !D ("!*"T! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ VH5C5>)>O:N#!0 ^!L !D M ("!@D,! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ VH5C5<3V20%# P S!0 T ( !M%,! 'AL M+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0# M% @ VH5C59D^HH1\ 0 EA8 !H ( !=UL! 'AL+U]R M96QS+W=O XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 303 304 1 false 65 0 false 10 false false R1.htm 0000001 - Document - Cover Page Sheet http://dermtech.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://dermtech.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders??? Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical) Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - The Company and a Summary of its Significant Accounting Policies Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies The Company and a Summary of its Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Balance Sheet Details Sheet http://dermtech.com/role/BalanceSheetDetails Balance Sheet Details Notes 10 false false R11.htm 0000011 - Disclosure - Stockholders' Equity Sheet http://dermtech.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 0000012 - Disclosure - Leases, Commitments and Contingencies Sheet http://dermtech.com/role/LeasesCommitmentsandContingencies Leases, Commitments and Contingencies Notes 12 false false R13.htm 0000013 - Disclosure - Related Party Transactions Sheet http://dermtech.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 0000014 - Disclosure - Subsequent Events Sheet http://dermtech.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 0000015 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies The Company and a Summary of its Significant Accounting Policies (Policies) Policies http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies 15 false false R16.htm 0000016 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables The Company and a Summary of its Significant Accounting Policies (Tables) Tables http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies 16 false false R17.htm 0000017 - Disclosure - Balance Sheet Details (Tables) Sheet http://dermtech.com/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://dermtech.com/role/BalanceSheetDetails 17 false false R18.htm 0000018 - Disclosure - Stockholders' Equity (Tables) Sheet http://dermtech.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://dermtech.com/role/StockholdersEquity 18 false false R19.htm 0000019 - Disclosure - Leases, Commitments and Contingencies (Tables) Sheet http://dermtech.com/role/LeasesCommitmentsandContingenciesTables Leases, Commitments and Contingencies (Tables) Tables http://dermtech.com/role/LeasesCommitmentsandContingencies 19 false false R20.htm 0000020 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) Details 20 false false R21.htm 0000021 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Details 21 false false R22.htm 0000022 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) Details 22 false false R23.htm 0000023 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 23 false false R24.htm 0000024 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details) Details 24 false false R25.htm 0000025 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) Details 25 false false R26.htm 0000026 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) Details 26 false false R27.htm 0000027 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 27 false false R28.htm 0000028 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) Details 28 false false R29.htm 0000029 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) Details 29 false false R30.htm 0000030 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 30 false false R31.htm 0000031 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details) Sheet http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails Stockholders' Equity - Share-Based Compensation Expense (Details) Details 31 false false R32.htm 0000032 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) Sheet http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) Details 32 false false R33.htm 0000033 - Disclosure - Leases, Commitments and Contingencies - Additional Information (Details) Sheet http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails Leases, Commitments and Contingencies - Additional Information (Details) Details 33 false false R34.htm 0000034 - Disclosure - Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) Sheet http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) Details 34 false false R35.htm 0000035 - Disclosure - Leases, Commitments and Contingencies - Components of Lease Expense (Details) Sheet http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails Leases, Commitments and Contingencies - Components of Lease Expense (Details) Details 35 false false R36.htm 0000036 - Disclosure - Leases, Commitments and Contingencies - Future Minimum Payments (Details) Sheet http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails Leases, Commitments and Contingencies - Future Minimum Payments (Details) Details 36 false false R37.htm 0000037 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 37 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: dmtk:NumberOfWarrantsEntitleHolderToPurchaseOneShare, us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight, us-gaap:LesseeOperatingLeaseRemainingLeaseTerm, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - dmtk-20220930.htm 4 dmtk-20220930.htm dmtk-20220930.xsd dmtk-20220930_cal.xml dmtk-20220930_def.xml dmtk-20220930_lab.xml dmtk-20220930_pre.xml dmtk-20220930xex311.htm dmtk-20220930xex312.htm dmtk-20220930xex321.htm ex103dermtech-amendedandre.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dmtk-20220930.htm": { "axisCustom": 1, "axisStandard": 23, "contextCount": 303, "dts": { "calculationLink": { "local": [ "dmtk-20220930_cal.xml" ] }, "definitionLink": { "local": [ "dmtk-20220930_def.xml" ] }, "inline": { "local": [ "dmtk-20220930.htm" ] }, "labelLink": { "local": [ "dmtk-20220930_lab.xml" ] }, "presentationLink": { "local": [ "dmtk-20220930_pre.xml" ] }, "schema": { "local": [ "dmtk-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 482, "entityCount": 1, "hidden": { "http://dermtech.com/20220930": 1, "http://fasb.org/us-gaap/2022": 6, "http://xbrl.sec.gov/dei/2022": 5, "total": 12 }, "keyCustom": 61, "keyStandard": 243, "memberCustom": 37, "memberStandard": 28, "nsprefix": "dmtk", "nsuri": "http://dermtech.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://dermtech.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Balance Sheet Details", "role": "http://dermtech.com/role/BalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Stockholders' Equity", "role": "http://dermtech.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Leases, Commitments and Contingencies", "role": "http://dermtech.com/role/LeasesCommitmentsandContingencies", "shortName": "Leases, Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Related Party Transactions", "role": "http://dermtech.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Subsequent Events", "role": "http://dermtech.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables", "shortName": "The Company and a Summary of its Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Balance Sheet Details (Tables)", "role": "http://dermtech.com/role/BalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Stockholders' Equity (Tables)", "role": "http://dermtech.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:ScheduleOfLongTermFinanceLeaseObligationsTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Leases, Commitments and Contingencies (Tables)", "role": "http://dermtech.com/role/LeasesCommitmentsandContingenciesTables", "shortName": "Leases, Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:ScheduleOfLongTermFinanceLeaseObligationsTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i57a57c7174e447259a039ce49f168770_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i57a57c7174e447259a039ce49f168770_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2740864869b54064b8b7f88eca6da953_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i480feb8812c84d01821c627ce216dfdd_D20220701-20220930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i480feb8812c84d01821c627ce216dfdd_D20220701-20220930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ide55a8e70de840eb908709153ad3225c_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i59be81a6e7b141d18cfb417b8e6fabef_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "role": "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "shortName": "Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Balance Sheet Details - Additional Information (Details)", "role": "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails", "shortName": "Balance Sheet Details - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "role": "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails", "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "role": "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails", "shortName": "Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ia860df86d88c47b19d4f772ed990f5f9_D20210106-20210106", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)", "role": "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails", "shortName": "Stockholders' Equity - Share-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)", "role": "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail", "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i67d27e7f51e949edbd61874e10c81ce9_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "dmtk:PercentageOfUsefulLivesOfAssets", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Leases, Commitments and Contingencies - Additional Information (Details)", "role": "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "shortName": "Leases, Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "dmtk:PercentageOfUsefulLivesOfAssets", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "dmtk:ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details)", "role": "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails", "shortName": "Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Leases, Commitments and Contingencies - Components of Lease Expense (Details)", "role": "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails", "shortName": "Leases, Commitments and Contingencies - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "dmtk:ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Leases, Commitments and Contingencies - Future Minimum Payments (Details)", "role": "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails", "shortName": "Leases, Commitments and Contingencies - Future Minimum Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "dmtk:ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "ica3dadeae14748bba4cc8d621b82cad0_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i9aa5a9e6744748f2a9cc44ff2a785d8f_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i43a69fa76a6e4225a7af387a45ae752b_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i6f46ffa598ba49348e47df1ba7f9e275_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i5fb0d35e15b349388278e7af6ce1027e_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i5fb0d35e15b349388278e7af6ce1027e_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - The Company and a Summary of its Significant Accounting Policies", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20220930.htm", "contextRef": "i2fe0b7ebcc4d42f2835172e118186caa_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "verboseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "verboseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dmtk_A2022InducementEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Inducement Equity Incentive Plan", "label": "2022 Inducement Equity Incentive Plan [Member]", "terseLabel": "2022 Inducement Equity Incentive Plan" } } }, "localname": "A2022InducementEquityIncentivePlanMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_AccruedBonusAndDeferredCompensationCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued bonus and deferred compensation, current.", "label": "Accrued Bonus And Deferred Compensation Current", "terseLabel": "Accrued wages, bonus and other" } } }, "localname": "AccruedBonusAndDeferredCompensationCurrent", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AccruedConsultingServicesCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued consulting services, current.", "label": "Accrued Consulting Services Current", "terseLabel": "Accrued consulting services" } } }, "localname": "AccruedConsultingServicesCurrent", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Warrant Issued, Shares", "label": "Adjustments to Additional Paid in Capital, Warrant Issued, Shares", "terseLabel": "Issuance of common stock from warrant exercises (in shares)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "dmtk_AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization of laboratory equipment acquired under finance leases.", "label": "Amortization Of Laboratory Equipment Acquired Under Finance Leases [Member]", "terseLabel": "Amortization of Laboratory Equipment Acquired under Finance Leases" } } }, "localname": "AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_AreaOfBuilding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of building.", "label": "Area Of Building", "terseLabel": "Area of building (in square feet)" } } }, "localname": "AreaOfBuilding", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "dmtk_AssayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay.", "label": "Assay [Member]", "terseLabel": "Assay revenue", "verboseLabel": "DermTech Melanoma Test" } } }, "localname": "AssayMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_AssayRevenuePayorAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay Revenue Payor A.", "label": "Assay Revenue Payor A [Member]", "terseLabel": "Payor A" } } }, "localname": "AssayRevenuePayorAMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "dmtk_AssayRevenuePayorBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay Revenue Payor B.", "label": "Assay Revenue Payor B [Member]", "terseLabel": "Payor B" } } }, "localname": "AssayRevenuePayorBMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "dmtk_AssetsHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held under finance leases.", "label": "Assets Held Under Finance Leases [Member]", "terseLabel": "Assets Recorded under Finance Leases" } } }, "localname": "AssetsHeldUnderFinanceLeasesMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the market offering.", "label": "At The Market Offering [Member]", "terseLabel": "At-The Market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_AuthorizedForFutureESPPPurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized for future ESPP purchases.", "label": "Authorized For Future E S P P Purchases [Member]", "terseLabel": "Authorized for future ESPP purchases" } } }, "localname": "AuthorizedForFutureESPPPurchasesMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_AuthorizedForFutureEquityGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized for future equity grants.", "label": "Authorized For Future Equity Grants [Member]", "terseLabel": "Authorized for future equity grants" } } }, "localname": "AuthorizedForFutureEquityGrantsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_BrotherOfChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brother of chief executive officer.", "label": "Brother Of Chief Executive Officer [Member]", "terseLabel": "Michael Dobak" } } }, "localname": "BrotherOfChiefExecutiveOfficerMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_CashlessExerciseOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise of common stock warrants.", "label": "Cashless Exercise Of Common Stock Warrants", "terseLabel": "Cashless exercise of common stock warrants" } } }, "localname": "CashlessExerciseOfCommonStockWarrants", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in unrealized gain loss on available-for-sale marketable securities.", "label": "Change In Unrealized Gain (Loss) On Available For Sale Marketable Securities", "terseLabel": "Change in net unrealized losses on available-for-sale marketable securities" } } }, "localname": "ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ClassOfWarrantOrRightWarrantsOrRightsIssuedToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights issued to purchase common stock.", "label": "Class Of Warrant Or Right, Warrants Or Rights Issued To Purchase Common Stock", "terseLabel": "Warrants issued to purchase common stock (in shares)" } } }, "localname": "ClassOfWarrantOrRightWarrantsOrRightsIssuedToPurchaseCommonStock", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommonSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares issued upon exercise of warrants.", "label": "Common Shares Issued Upon Exercise Of Warrants", "verboseLabel": "Common shares issued upon exercise of warrants (in shares)" } } }, "localname": "CommonSharesIssuedUponExerciseOfWarrants", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_CommonStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock outstanding percentage.", "label": "Common Stock Outstanding Percentage", "terseLabel": "Common stock outstanding percentage" } } }, "localname": "CommonStockOutstandingPercentage", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_ComputerEquipmentGross": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Computer equipment gross.", "label": "Computer Equipment Gross", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentGross", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_ContractRevenueAdhesivePatchKitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue, adhesive patch kits.", "label": "Contract Revenue Adhesive Patch Kits [Member]", "terseLabel": "Adhesive patch kits" } } }, "localname": "ContractRevenueAdhesivePatchKitsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueProjectManagementFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue project management fees.", "label": "Contract Revenue Project Management Fees [Member]", "terseLabel": "Project management fees" } } }, "localname": "ContractRevenueProjectManagementFeesMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueRNAExtractionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue, RNA extractions.", "label": "Contract Revenue R N A Extractions [Member]", "terseLabel": "RNA extractions" } } }, "localname": "ContractRevenueRNAExtractionsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractualActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract activities.", "label": "Contractual Activities [Member]", "terseLabel": "Contract revenue" } } }, "localname": "ContractualActivitiesMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CowenLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen Limited Liability Company.", "label": "Cowen Limited Liability Company [Member]", "terseLabel": "Cowen and Company LLC" } } }, "localname": "CowenLimitedLiabilityCompanyMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CreditLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Credit Losses", "label": "Credit Losses", "terseLabel": "Credit losses" } } }, "localname": "CreditLosses", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DermTechOperationsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DermTech Operations, Inc.", "label": "Derm Tech Operations Inc [Member]", "terseLabel": "DermTech Operations" } } }, "localname": "DermTechOperationsIncMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_DurationOfOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duration Of Offering Period", "label": "Duration Of Offering Period", "terseLabel": "Duration of offering period (in months)" } } }, "localname": "DurationOfOfferingPeriod", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_EVERSANALifeScienceServicesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EVERSANA Life Science Services, LLC.", "label": "EVERSANA Life Science Services LLC [Member]", "terseLabel": "EVERSANA" } } }, "localname": "EVERSANALifeScienceServicesLLCMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_EquityIncentivePlanOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity incentive plan option term.", "label": "Equity Incentive Plan Option Term", "terseLabel": "Term of the option" } } }, "localname": "EquityIncentivePlanOptionTerm", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of debt securities with contractual maturities of less than 12 months.", "label": "Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months", "terseLabel": "Estimated market value of debt securities with contractual maturities of less than 12 months" } } }, "localname": "EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo21Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of remaining debt securities with contractual maturities of up to 21 months.", "label": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 21 Months", "terseLabel": "Estimated market value of remaining debt securities with contractual maturities of up to 23 months" } } }, "localname": "EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo21Months", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance lease cost.", "label": "Finance Lease Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FinanceLeaseCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance lease cost.", "label": "Finance Lease Costs [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "FinanceLeaseCostsAbstract", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_FinanceLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance lease liability payments due after year four.", "label": "Finance Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FirstAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Amendment", "label": "First Amendment [Member]", "terseLabel": "First Amendment" } } }, "localname": "FirstAmendmentMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of common stock.", "label": "Gross Proceeds From Issuance Of Common Stock", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses.", "label": "Gross Proceeds From Offering Before Deducting Underwriting Discounts And Commissions And Other Offering Expenses", "terseLabel": "Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses" } } }, "localname": "GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncentiveAndNonQualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive and non-qualified stock options.", "label": "Incentive And Non Qualified Stock Options [Member]", "terseLabel": "Incentive and Non-qualified Stock Options" } } }, "localname": "IncentiveAndNonQualifiedStockOptionsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use-Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use-Asset", "terseLabel": "Increase to operating right-of-use asset" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseDecreaseInStockIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in stock issuance costs.", "label": "Increase (Decrease) In Stock Issuance Costs", "negatedLabel": "Decrease in issuance costs" } } }, "localname": "IncreaseDecreaseInStockIssuanceCosts", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseInTenantImprovementAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in tenant improvement allowance.", "label": "Increase In Tenant Improvement Allowance", "terseLabel": "Increase in tenant improvement allowance" } } }, "localname": "IncreaseInTenantImprovementAllowance", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseInTenantImprovementAllowancePerRentableSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase In Tenant Improvement Allowance Per Rentable Square Foot", "label": "Increase In Tenant Improvement Allowance Per Rentable Square Foot", "terseLabel": "Increase in improvement allowance per rentable square foot (in usd per square foot)" } } }, "localname": "IncreaseInTenantImprovementAllowancePerRentableSquareFoot", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "perUnitItemType" }, "dmtk_KilroyRealtyLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kilroy Realty, L.P.", "label": "Kilroy Realty L P [Member]", "terseLabel": "Kilroy Realty, L.P" } } }, "localname": "KilroyRealtyLPMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_LeaseAmendmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Amendments", "label": "Lease Amendments [Axis]", "terseLabel": "Lease Amendments [Axis]" } } }, "localname": "LeaseAmendmentsAxis", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_LeaseAmendmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Amendments [Domain]", "label": "Lease Amendments [Domain]", "terseLabel": "Lease Amendments [Domain]" } } }, "localname": "LeaseAmendmentsDomain", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating and Finance Lease, Liability, To Be Paid", "label": "Lessee, Operating and Finance Lease, Liability, To Be Paid [Abstract]", "terseLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaidAbstract", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "dmtk_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_LesseeOperatingLeaseNumberOfRenewalTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Terms", "label": "Lessee, Operating Lease, Number Of Renewal Terms", "terseLabel": "Number of renewal terms" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalTerms", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_ManagementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management warrants.", "label": "Management Warrants [Member]", "terseLabel": "Management Warrants" } } }, "localname": "ManagementWarrantsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_NumberOfImprovementPhases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Improvement Phases", "label": "Number Of Improvement Phases", "terseLabel": "Number of improvement phases" } } }, "localname": "NumberOfImprovementPhases", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_NumberOfRevenueStreams": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of revenue streams.", "label": "Number Of Revenue Streams", "terseLabel": "Number of revenue streams (in number of streams)" } } }, "localname": "NumberOfRevenueStreams", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_NumberOfSixMonthPurchasePeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Six Month Purchase Periods", "label": "Number Of Six Month Purchase Periods", "terseLabel": "Number of six month purchase periods" } } }, "localname": "NumberOfSixMonthPurchasePeriods", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_NumberOfWarrantsEntitleHolderToPurchaseOneShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants entitle holder to purchase one share.", "label": "Number Of Warrants Entitle Holder To Purchase One Share", "terseLabel": "Number of warrants entitle holder to purchase one share" } } }, "localname": "NumberOfWarrantsEntitleHolderToPurchaseOneShare", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "integerItemType" }, "dmtk_OperatingAndFinanceLeaseLiabilityPaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due.", "label": "Operating And Finance Lease Liability Payments Due", "terseLabel": "Operating And Capital Lease Liability Payments Due" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due next twelve months.", "label": "Operating And Finance Lease Liability Payments Due Next Twelve Months", "terseLabel": "Total future minimum lease payments due in 2023" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndFinanceLeaseLiabilityPaymentsDueThereafter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due thereafter.", "label": "Operating And Finance Lease Liability Payments Due Thereafter", "terseLabel": "Total future minimum lease payments due thereafter" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueThereafter", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year four.", "label": "Operating And Finance Lease Liability Payments Due Year Four", "terseLabel": "Total future minimum lease payments due in 2026" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year three.", "label": "Operating And Finance Lease Liability Payments Due Year Three", "terseLabel": "Total future minimum lease payments due in 2025" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year two.", "label": "Operating And Finance Lease Liability Payments Due Year Two", "terseLabel": "Total future minimum lease payments due in 2024" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments remainder of fiscal year.", "label": "Operating And Finance Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Total future minimum lease payments due in 2022" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease cost.", "label": "Operating Lease Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCostAbstract", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_OperatingLeaseCosts": { "auth_ref": [], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease cost.", "label": "Operating Lease Costs", "totalLabel": "Total operating lease cost" } } }, "localname": "OperatingLeaseCosts", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingLeaseIncrementalBorrowingRateAtEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Incremental Borrowing Rate At Effective Date", "label": "Operating Lease, Incremental Borrowing Rate At Effective Date", "terseLabel": "Incremental borrowing rate" } } }, "localname": "OperatingLeaseIncrementalBorrowingRateAtEffectiveDate", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfPriceAtSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of price at shares purchased", "label": "Percentage Of Price At Shares Purchased", "terseLabel": "Percentage of price at shares purchased" } } }, "localname": "PercentageOfPriceAtSharesPurchased", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfUsefulLivesOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of useful lives of assets.", "label": "Percentage Of Useful Lives Of Assets", "terseLabel": "Percentage of useful lives of assets" } } }, "localname": "PercentageOfUsefulLivesOfAssets", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement agent warrants.", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "localname": "PlacementAgentWarrantsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PrepaidEmployeeCompensation": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid employee compensation.", "label": "Prepaid Employee Compensation", "terseLabel": "Prepaid employee compensation" } } }, "localname": "PrepaidEmployeeCompensation", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidSoftwareFees": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid software fees.", "label": "Prepaid Software Fees", "terseLabel": "Prepaid software fees" } } }, "localname": "PrepaidSoftwareFees", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidTradeShowsCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid trade shows, current.", "label": "Prepaid Trade Shows Current", "terseLabel": "Prepaid trade shows" } } }, "localname": "PrepaidTradeShowsCurrent", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private special purpose acquisition companies warrants.", "label": "Private Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Private SPAC Warrants" } } }, "localname": "PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ProceedsFromMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Maturity Of Marketable Securities", "label": "Proceeds From Maturity Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromMaturityOfMarketableSecurities", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ProceedsFromReleaseOfRSUsAndStockOptionsExercised": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Release Of RSUs And Stock Options Exercised", "label": "Proceeds From Release Of RSUs And Stock Options Exercised", "terseLabel": "Proceeds from RSU releases (par value only) and the exercise of stock options" } } }, "localname": "ProceedsFromReleaseOfRSUsAndStockOptionsExercised", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_PublicFollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public follow on offering.", "label": "Public Follow On Offering [Member]", "terseLabel": "Public Follow-on Offering" } } }, "localname": "PublicFollowOnOfferingMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "domainItemType" }, "dmtk_PublicSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public special purpose acquisition companies warrants.", "label": "Public Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Public SPAC Warrants" } } }, "localname": "PublicSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of warrant liability due to private SPAC warrants not held by original holder.", "label": "Reclassification Of Warrant Liability Due To Private SPAC Warrants Not Held By Original Holder", "terseLabel": "Reclassification of warrant liability due to Private SPAC Warrants not held by original holder", "verboseLabel": "Reclassification of warrant liability due to Private SPAC Warrants not held by original holder" } } }, "localname": "ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "dmtk_RentableAndUsableSquareFeet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rentable And Usable Square Feet", "label": "Rentable And Usable Square Feet", "terseLabel": "Expansion premise (in square feet)" } } }, "localname": "RentableAndUsableSquareFeet", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "dmtk_RestrictedCashAndCashEquivalentsIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Cash and Cash Equivalents, Increase (Decrease)", "label": "Restricted Cash and Cash Equivalents, Increase (Decrease)", "terseLabel": "Increase (decrease) to restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsIncreaseDecrease", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue", "label": "Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue", "terseLabel": "Increase (decrease) in revenue" } } }, "localname": "RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum rental payments for operating and capital leases.", "label": "Schedule Of Future Minimum Rental Payments For Operating And Capital Leases Table [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments Under Operating and Financing Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTableTextBlock", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "dmtk_ScheduleOfLongTermFinanceLeaseObligationsTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long term finance lease obligations.", "label": "Schedule Of Long Term Finance Lease Obligations Table [Table Text Block]", "terseLabel": "Schedule of Long Term Finance Lease Obligations" } } }, "localname": "ScheduleOfLongTermFinanceLeaseObligationsTableTableTextBlock", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "dmtk_ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and PP&E.", "label": "Schedule Of Prepaid Expenses And Property And Equipment Table [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and PP&E" } } }, "localname": "ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "dmtk_SecondAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amendment", "label": "Second Amendment [Member]", "terseLabel": "Second Amendment" } } }, "localname": "SecondAmendmentMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_SpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special purpose acquisition companies warrants.", "label": "Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "SPAC Warrants" } } }, "localname": "SpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPAC warrants to purchase common stock.", "label": "Special Purpose Acquisition Company Warrants To Purchase Common Stock [Member]", "terseLabel": "SPAC Warrants to purchase common stock*" } } }, "localname": "SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_SpouseOfChiefCommercialOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spouse of chief commercial officer.", "label": "Spouse Of Chief Commercial Officer [Member]", "terseLabel": "Leana Wood" } } }, "localname": "SpouseOfChiefCommercialOfficerMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and RSU release.", "label": "Stock Issued During Period, Shares, Stock Options Exercised And RSU Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "dmtk_StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and RSU release.", "label": "Stock Issued During Period, Value, Stock Options Exercised And RSU Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "dmtk_StockOptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options and restricted stock units.", "label": "Stock Options And Restricted Stock Units [Member]", "terseLabel": "Stock Options and RSUs" } } }, "localname": "StockOptionsAndRestrictedStockUnitsMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_StockPurchasedByUnderwritersPursuantToOptionGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchased by underwriters pursuant to option granted.", "label": "Stock Purchased By Underwriters Pursuant To Option Granted", "terseLabel": "Shares purchased by underwriters (in shares)" } } }, "localname": "StockPurchasedByUnderwritersPursuantToOptionGranted", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_TenantImprovementAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance.", "label": "Tenant Improvement Allowance", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovementAllowance", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_TenantImprovementAllowancePerRentableSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance per rentable square foot.", "label": "Tenant Improvement Allowance Per Rentable Square Foot", "terseLabel": "Tenant improvement allowance per rentable square foot (in usd per square foot)" } } }, "localname": "TenantImprovementAllowancePerRentableSquareFoot", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "perUnitItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Line Items]", "terseLabel": "The Company and Summary of its Significant Accounting Policies [Line Items]" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Table]", "terseLabel": "Accounting Policies" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_TwoThousandEighteenConvertibleBridgeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen convertible bridge notes.", "label": "Two Thousand Eighteen Convertible Bridge Notes [Member]", "terseLabel": "2018 Convertible Bridge Notes" } } }, "localname": "TwoThousandEighteenConvertibleBridgeNotesMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty employee stock purchase plan.", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_UnderwritersGrantPeriodOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters grant period option.", "label": "Underwriters Grant Period Option", "verboseLabel": "Number of days granted to underwriters option to purchase" } } }, "localname": "UnderwritersGrantPeriodOption", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_WarrantLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability fair value disclosure.", "label": "Warrant Liability Fair Value Disclosure", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityFairValueDisclosure", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability.", "label": "Warrant Liability [Member]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "dmtk_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase common stock.", "label": "Warrants To Purchase Common Stock [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_WarrantsVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants vesting period.", "label": "Warrants Vesting Period", "terseLabel": "Warrants vesting period" } } }, "localname": "WarrantsVestingPeriod", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_WeightedAveragePurchasePricePerShareInOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average purchase price per share in offering.", "label": "Weighted Average Purchase Price Per Share In Offering", "terseLabel": "Weighted average purchase price per share (in usd per share)" } } }, "localname": "WeightedAveragePurchasePricePerShareInOffering", "nsuri": "http://dermtech.com/20220930", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r39", "r41", "r89", "r90", "r215", "r241" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r214", "r240", "r291", "r292", "r413", "r414", "r415", "r416", "r417", "r418", "r437", "r480", "r482", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r214", "r240", "r291", "r292", "r413", "r414", "r415", "r416", "r417", "r418", "r437", "r480", "r482", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r146", "r192", "r193", "r271", "r273", "r439", "r479", "r481" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r146", "r192", "r193", "r271", "r273", "r439", "r479", "r481" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r188", "r191", "r192", "r193", "r194", "r214", "r240", "r281", "r291", "r292", "r321", "r322", "r323", "r413", "r414", "r415", "r416", "r417", "r418", "r437", "r480", "r482", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r188", "r191", "r192", "r193", "r194", "r214", "r240", "r281", "r291", "r292", "r321", "r322", "r323", "r413", "r414", "r415", "r416", "r417", "r418", "r437", "r480", "r482", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r40", "r41", "r89", "r90", "r215", "r241" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r32", "r404" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r5", "r21", "r149", "r150" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable gross" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r149", "r150" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r74" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums, net of accretion of discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued liabilities:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r34", "r280" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "terseLabel": "Accrued paid time off" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r11", "r185" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r43", "r44", "r45", "r48", "r54", "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Accumulated other comprehensive income/(loss)" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r46", "r47", "r48", "r470", "r487", "r488" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r22" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r93", "r94", "r95", "r328", "r329", "r330", "r351" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r294", "r331", "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r254", "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "verboseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r210", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of common stock from warrant exercises" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive equity instruments excluded from diluted net loss per share of common stock" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r87", "r135", "r138", "r144", "r168", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r338", "r342", "r366", "r402", "r404", "r453", "r468" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r30", "r87", "r168", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r338", "r342", "r366", "r402", "r404" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r354" ], "calculation": { "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value on a recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r160" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r161" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r158", "r175" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r156", "r159", "r175", "r457" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Total marketable securities, available for sale", "verboseLabel": "Estimated Market Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment recorded in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r9", "r75" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r76", "r452" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r75", "r81" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r69", "r75", "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r367" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease)/increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r9" ], "calculation": { "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Insured amount by FDIC" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash held in excess of FDIC limit" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r263", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant (in usd per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares issued for each warrant (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Total number exercised of public warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Leases, Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total common stock reserved for future issuance", "verboseLabel": "Common stock available for issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r93", "r94", "r351" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in usd per share)", "verboseLabel": "Common stock, par value per share (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r404" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of September\u00a030, 2022 and December\u00a031, 2021; 30,213,206 and 29,772,922 shares issued and outstanding at September\u00a030, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r52", "r53", "r58", "r461", "r477" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r127", "r128", "r148", "r364", "r365", "r497" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r127", "r128", "r148", "r364", "r365", "r490", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r127", "r128", "r148", "r364", "r365", "r490", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r123", "r466" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r127", "r128", "r148", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r127", "r128", "r148", "r364", "r365", "r497" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r184" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": { "auth_ref": [ "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract", "terseLabel": "Reclassification of deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r265", "r266", "r272" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Short term deferred revenue", "verboseLabel": "Short-term deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r282", "r290", "r489" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r62", "r87", "r168", "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r366" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Total cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenues:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r126", "r148" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Customer refund liability" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r86", "r91", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r374", "r454", "r455", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r36", "r86", "r91", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r374" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Short-Term Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DemandDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.", "label": "Demand Deposits [Member]", "terseLabel": "Demand Deposits" } } }, "localname": "DemandDepositsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DepositsMoneyMarketDeposits": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deposits in accounts that offer many of the same services as checking accounts although transactions may be somewhat more limited, share some of the characteristics of a money market fund and are insured by the Federal government, also known as money market accounts.", "label": "Deposits, Money Market Deposits", "terseLabel": "Sweep account" } } }, "localname": "DepositsMoneyMarketDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r73", "r183" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r73", "r183" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Accumulated amortization", "verboseLabel": "Accumulated amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Revenues Disaggregated by Revenue Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r297", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r88", "r200", "r202", "r203", "r207", "r208", "r209", "r397", "r459", "r475" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r59", "r98", "r99", "r100", "r101", "r102", "r106", "r108", "r110", "r111", "r112", "r115", "r116", "r352", "r353", "r462", "r478" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share of common stock outstanding, basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r59", "r98", "r99", "r100", "r101", "r102", "r108", "r110", "r111", "r112", "r115", "r116", "r352", "r353", "r462", "r478" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share of common stock outstanding, diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r113", "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "totalLabel": "Total accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current [Abstract]", "terseLabel": "Accrued compensation:" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Compensation cost related to non-vested awards not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average term expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options issued and outstanding" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r54", "r55", "r56", "r93", "r94", "r95", "r97", "r103", "r105", "r117", "r169", "r254", "r261", "r328", "r329", "r330", "r334", "r335", "r351", "r368", "r369", "r370", "r371", "r372", "r373", "r393", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r73", "r233" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r354", "r355", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r220", "r229", "r230", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r355", "r410", "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r354", "r355", "r356", "r357", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r220", "r282", "r283", "r288", "r290", "r355", "r410" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r220", "r229", "r230", "r282", "r283", "r288", "r290", "r355", "r411" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r220", "r229", "r230", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r355", "r412" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r358", "r361" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r358", "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of Level 3 Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r220", "r229", "r230", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r410", "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r360", "r362" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r377", "r383", "r392" ], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails": { "order": 2.0, "parentTag": "dmtk_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities", "verboseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid [Abstract]", "terseLabel": "Finance lease obligations, including interest" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r376", "r391" ], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Present value of net minimum lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r376" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "negatedLabel": "Less current portion of finance lease obligations", "terseLabel": "Current portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r376" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease obligations, less current portion", "verboseLabel": "Total long-term finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r391" ], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "terseLabel": "Gross finance lease obligations", "totalLabel": "Gross finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails", "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r391" ], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesScheduleofLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r378", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r377", "r383", "r392" ], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails": { "order": 1.0, "parentTag": "dmtk_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate for finance leases (in percent)" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r388", "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term of finance leases (in years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r162", "r163", "r165", "r166", "r167", "r170", "r171", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r228", "r252", "r349", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r508", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r184" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r73" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposal of equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "terseLabel": "Gain (loss) on disposition of property plant equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r61", "r87", "r135", "r137", "r140", "r143", "r145", "r168", "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r366" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross (loss) profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r73", "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment losses" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r187", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities and deferred revenue" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r72" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r72" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r72", "r386" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Increase to operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r72" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about interest income have been included.", "label": "Interest Income [Member]", "terseLabel": "Interest Income, Net" } } }, "localname": "InterestIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r67", "r70", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest on finance lease obligations" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r28", "r404" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investment Holdings [Line Items]", "terseLabel": "Investment Holdings [Line Items]" } } }, "localname": "InvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentHoldingsTable": { "auth_ref": [ "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.", "label": "Investment Holdings [Table]", "terseLabel": "Investment Holdings [Table]" } } }, "localname": "InvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure [Abstract]", "terseLabel": "Marketable securities, available for sale:" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r184" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Estimated discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r87", "r139", "r168", "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r339", "r342", "r343", "r366", "r402", "r403" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r87", "r168", "r366", "r404", "r456", "r472" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r35", "r87", "r168", "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r339", "r342", "r343", "r366", "r402", "r403", "r404" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r354" ], "calculation": { "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value on a recurring basis" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r184" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Laboratory equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MunicipalNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Notes [Member]", "terseLabel": "Municipal debt securities" } } }, "localname": "MunicipalNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r120", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r71", "r74" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r49", "r51", "r56", "r57", "r74", "r87", "r96", "r98", "r99", "r100", "r101", "r104", "r105", "r109", "r135", "r137", "r140", "r143", "r145", "r168", "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r353", "r366", "r460", "r476" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncements Issued But Not Yet Effective" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Property and equipment acquired under finance leases" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income/(expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income/(expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r135", "r137", "r140", "r143", "r145" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r384", "r392" ], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails": { "order": 1.0, "parentTag": "dmtk_OperatingLeaseCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Operating lease obligations, including interest" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r376" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r376" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r379", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r375" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r73" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate for operating leases (in percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r388", "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term of operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r2", "r92", "r132", "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "The Company and a Summary of its Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r29", "r404" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r43", "r46" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized net loss on available-for-sale marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r157" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r238" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value per share (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]", "terseLabel": "Prepaid expenses and other current assets:" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r6", "r180", "r181" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r66" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sales of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r66" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from contributions to the employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r66" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of common stock warrants", "verboseLabel": "Total proceeds from exercise of public warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r49", "r51", "r56", "r68", "r87", "r96", "r104", "r105", "r135", "r137", "r140", "r143", "r145", "r168", "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r337", "r340", "r341", "r344", "r345", "r353", "r366", "r463" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r10", "r184" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Gross assets", "totalLabel": "Total property and equipment, gross", "verboseLabel": "Gross assets" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails", "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross [Abstract]", "terseLabel": "Property and equipment, gross:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r186", "r404", "r465", "r473" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r186", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life of the assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r151", "r153", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r289", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r289", "r396", "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Related party transaction, other" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Related party certain marketing cost" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r289", "r396", "r399", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r394", "r395", "r397", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "Repayments of Debt and Lease Obligation", "negatedLabel": "Principal repayments of finance lease obligations" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r333", "r438", "r502" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r9", "r81", "r452", "r469" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r9", "r75", "r81", "r452", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash, end of period:" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r12", "r81", "r496" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs issued and outstanding" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r261", "r404", "r471", "r486", "r488" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r93", "r94", "r95", "r97", "r103", "r105", "r169", "r328", "r329", "r330", "r334", "r335", "r351", "r483", "r485" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r133", "r134", "r136", "r141", "r142", "r146", "r147", "r148", "r270", "r271", "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r133", "r134", "r136", "r141", "r142", "r146", "r147", "r148", "r270", "r271", "r439" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation, estimated revenue expected to be recognized" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r387", "r392" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for finance lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r387", "r392" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations", "verboseLabel": "Right-of-use assets obtained in exchange for operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Public offering price (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r127", "r148" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "verboseLabel": "Total Revenues" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Compensation and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]", "terseLabel": "Schedule Of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofPercentagesofTotalRevenueorAccountsReceivableforThirdPartyPayersandPharmaceuticalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.", "label": "Schedule of Product Information [Table Text Block]", "terseLabel": "Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers" } } }, "localname": "ScheduleOfProductInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r293", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Warrant Liability Valuation Method" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r17", "r19", "r20", "r84", "r118", "r119", "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r243", "r247", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r18", "r19", "r20", "r235", "r236", "r237", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Summary of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Assumed volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Assumed volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Assumed volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Assumed risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Assumed risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Assumed risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional common stock reserved (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock initially reserved for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Options remain available for issuance pursuant to future grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "http://dermtech.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual term of options granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Options granted, exercise price expressed as a percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "verboseLabel": "Shares, issued (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Issuance price per share (in usd per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r195", "r196", "r336", "r491" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letter of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r38", "r54", "r55", "r56", "r93", "r94", "r95", "r97", "r103", "r105", "r117", "r169", "r254", "r261", "r328", "r329", "r330", "r334", "r335", "r351", "r368", "r369", "r370", "r371", "r372", "r373", "r393", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r93", "r94", "r95", "r117", "r439" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r19", "r20", "r254", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r254", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of stock, net of issuance costs shares (in shares)", "verboseLabel": "Issuance of common stock, net of issuance costs shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r19", "r20", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of stock, net of issuance costs", "verboseLabel": "Issuance of preferred stock, total offering amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r25", "r26", "r87", "r152", "r168", "r366", "r404" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r85", "r239", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r261", "r264", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Conversion ratio of reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvements" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r162", "r163", "r165", "r166", "r167", "r228", "r252", "r349", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r508", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae).", "label": "US Government Agencies Short-Term Debt Securities [Member]", "terseLabel": "U.S. government debt securities" } } }, "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r121", "r122", "r124", "r125", "r129", "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r385", "r392" ], "calculation": { "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails": { "order": 2.0, "parentTag": "dmtk_OperatingLeaseCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/LeasesCommitmentsandContingenciesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Common Stock Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liability" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants expiration period" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantyRightsAndObligationsFairValueOptionMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "This element represents the rights and obligations under a warranty that is not a financial instrument (because it requires or permits the warrantor to provide goods or services rather than a cash settlement) but whose terms permit the warrantor to settle by paying a third party to provide those goods or services.", "label": "Warranty, Rights and Obligations, Fair Value Option [Member]", "terseLabel": "Warranty liability" } } }, "localname": "WarrantyRightsAndObligationsFairValueOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAssumptionsUsedtoDetermineFairValueofEachOptiononDateofGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r107", "r112" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding used in computing net loss per share, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r106", "r112" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding used in computing net loss per share, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123478648&loc=d3e12026-108606" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r401": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r406": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r42": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r503": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r504": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r505": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r506": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r507": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r508": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r509": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r510": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r511": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r512": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r513": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r514": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r515": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" } }, "version": "2.1" } ZIP 56 0001651944-22-000054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651944-22-000054-xbrl.zip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

EZ[=984GZ-:]*%2@2,46VDJ89Y0VT,!6+!4OXJK6YMUM7=#8 M7O>TV[V-_#BYH[1VJF /[P*W%6%HY2*2&&FK,B(>BWS+5<^2QBZH9;HO9\0"^9A8N*I#%CO:.GI?AC)V:K_Z M#>.]N;YH 2Q#&/O$OXW2CPDK@$&PMO"N/J9AV)]W ,0OG6L6O;9RUBL/H5^H M91-#_E4#@0LZOE%&+-MTL3KB8-" QNA>6NZKC\9%(@Y5U[.U'+.-)L;*V=YH7UKAK[1NJ3M\JR[^76OD MJ#O390>+RH1+6OEW&G*VO",XE,O^L+KSN]NZP,6A5B3_.YR*T*>4 M["#(RI##ZOL[RP%>_@!*<:>D+K+V9)(#KZ[BM-ID60;JQ#[+W9>!6]\!KH+N M\0Q'G6ZC2\?WH//2=DM_($AX,S+''W_X#U!+ P04 " #:A6-5,60T!X@; M O 0$ %0 &1M=&LM,C R,C Y,S!?8V%L+GAM;-U]67-;1Y+N>_\*7GGWYZ\O'/ES[_26\^ M+6.,SS:_/?OH:KKM@_18^>R_?_WE73G PP33^6J=YJ6_8#7]?K7YX2^+DM:; M.;\1UY,K/]&_@]./0?\12 5:?O=Y59_^XV]/GAQ/QW(QP[?8GO3___'VU=DK M*RX/UU@.OBN+PV?]E\]>+.85YRNL],5J,9O6+N(?TZRC?W> N%[1&#;/7'_Y M@#\\74T//\SP]&<'2VP_/*V'ZS^A"UM$+3J2_]CAJ<^^HBUI5HYFF\GYA;X_ M>7:'QP@J+0AZJ,@MJ: 2-TYZFO(&*HB$X;9;Z9I#Z0%8UD(\^65GDCU)/'/NNS]PQG MZ]7I3S;SN9G+BV\^GK=]\;\X6BYI24]4S%ZWZJ 56<"X6""4;*!@".A$3AC; M(,,X 7!Q-.=X\'Q9GBR6)'724$^??,*N3TZ4U3&:M"P7"')YJ9Q\XMGJZ/!P M\TR8KO'P].^[YMI;LNL%U^0>BX\@[RO?-\O%!URNO[RAA;!^/J\__<_1]$-7 MW[_A>J*#"':1OGH\TF>;>C8RO"8\ M-/CY^U^0S,7;/HVOVQ\KW QVXG65N20/+M P#1$48@D>@E9>"2EE3I&9#=<" MVH4.^O'0@6_RV?CP%E?KY;20H7R15@>_+>;E1%61G@K6)P.AU=S924"4M%!U MC%96G:OEIL)56'9A@7D\+&"99N)V9K4!V$;U]/*+??[+9Y/YNO2A_'BQF-(6K;I;67R8UR9"=\U!: MH_A*.P.Y!4EA6,Q.2Y6RK\Q"OXQBWW&]6!P>+N:;Y_XKS8YP0E*)1FH**4US M8*(-%%QZ"\)[$3S]3(?"/*IO,8S)I]U3[M\R>J_I9B/S\UJG?>QI]B9-ZZOY MB_1ANDZS<^ F&EMTN4D@$#3(F#6M+_2@FXLU!9NLYG9T;T8U)G>7F1C,(N&C M2BE'AWV6L6ZT,0'ZL,0#G*^F'_'5O"P.\9?%:D4.^NOV>_H\$9B-"\T#FAZR MM6C)*-<*/NKBC3/>&,'-F]M!').3S$VB 87%Z$*OTW2.]:>TG)-OOSH'^B6V M:9FN)QDS\3E&0)4#>78R078HZ1];JT>MC=/LSO1-J,;D5C/SAEDD?,KGPFY0 M5,VZ:$CK68KZC)4*NGJ^ M?I&6RR\T[<<.0 9X-N6GK@PD5E-<4^C9;(">5H+44HM.C!M?\<[IBBR-BYULL2$PE8&3(3Q%Y&QT&&4 &7<&40A&%U09D M4E4VJW2Q[.<0U^ 9DY/%1PDV";!QXM7\([U[L?S2=\@KF>7889#Z3P \6$/WW^T$]KR5J=VQ8[4TC> M^5:E Z]Z2H"I E+5!;2,6KA@6O.2_5SJ1ECCVX[D8 2W/-B(\LLTY>EL8Z@F M."> "UX*;2J:.N" 1GC:?E=I?TOG/>=ZH*/64U1?SFW\9_*^;:/ -DA2P4;8 M!%%%#=K*Z%1TFMST08];MX :D^_+Q0A>2; 1Y-\4DZ4>GM[=!&N4#,;D_W+1@FW^V1CQ\W3> MD]6NI*FK6E@M"F#I)\0VDX$/V4)VVCM;A&Z:6V'< &E,/C(7+SBE,(0O1'S= MLE^:2B(EEBLD6XFFR6L:,87PSOILK8U(/QG.G]B*B=/_JU6[H!*"V*3.62G) MF"--?W;159L4^:7WY?^-QD_:GPG7.$^WFO(A\Q)$2M6@JR"$)^/<"HTG46SC M8XMDEYN3C3L6O(G+H_&+^!FPIP"&4'BG;GS(7B:?/3@*1FE8FKRT&BM8K8Q+ MB/1;;O-W4\AT]UW/-^E+WW ["U&R+J[H!AA]HK&A@D1V!%+T.09,HDEN_;8= MR4A5W5TX<-5VYQY3ST;OGPX_S!9?$-_BYEARRT@]N:!H<@,I^B%-M!5RS)+QTYAR2DVZPGW.>CVB,9VQ,).$413#;CF=(BK>&;04.&"PW?%WF09; M,HU=5=1&BN"YOP[,+-=SCI :;&+XAQM^??3M7O]#W;&7![];T;R]H6RW: M";OIMQ>Q[%$??,7C!RD4WF4H3!7#_UPN5JLWRT6;4O A@V\I%HC"2I*M"OT, M0@(J'=$9':3/S$OLW.OWSWW]B/,C_)F6QS8+^&I>9D=].[T?)M-_M2?IZN9T M,R%!"XFLH$P:LJ=E(C 80PI/ZLP=U]P!YIC"X+ORY7):[+#28G1R5^O7[03N M1#MTT34!OA1S''>E& J4[&2)*<;DN8O1+@"X9= +CX(+=Y]B-BG_ANNO.?R3 M6DO21#) F\G[J63D@K<)0G%D4ULIR'[@>0$ FY]]?DQ%-:-, ZUS7SR&#'?2 M'D(5-%9A$"/WF+; &),JN[O,KW2F[SC??#1>S!<7L9QD4DT,9EV:"P1"]!(& M42$HT4 &]$*B4T%QV_8KP8QIYXZ/!#QS?P]42+7Y+%T$ZS& L00G%FM!EYR% MDBXI;QZ&"G?)T5WC$E?K"P\]_[:>61IB$5(Y!.$-612G"P2L% Q%8R59JH2: M.W3H="$+6R[G]S)+AV^K(4V7F_J3Y_7_D,)2E96BO(O9U]+:!1>7W#4(5/(/R[E><,!*8LO([=+/1],1TI M!"GT52$WUVJO0FWAOKVH_8)^U$&T*!%DMIF67VT0C!<0>BIU=C9Y9^\KZ']8 M';BOO+^E]%UGF9_ )PMT-9'>IY:] J'HY49A@QA,!6FUK9%B:UVYA7T)Q*B4 M&;?,]YOR 25OFD5$X\!GBD2,B)&\T> @^FI;-<7DQ.T#W2#Y.^1CX6S6MX3F M];A^\.NC)S'HHF,3H$,V/3&6G.U>H1U+L4J$)/A3E*]&,TJE=B7G!)PG+)XN$/%"QU?-F[X$&>+E]\R^!'C#0-C.FG< MTC#GK%F.:>0<54=B5WVSU!G1VR]9*-))W=N/6LE=77T-'-[#A$0L]D%GD(2A MEVB0813-@J\4!CAK='+XG"[JV;PDY[,C>PE6^=Z2 M,:A^LI9 &$&!8RR(@3UF&V@L8W* AJ+B*'CP@$8RK0Y^GBT^#60O+T0],(/SGUR$IRS2>@*S9E&"J[W6@C-@)(N!VEL;(;[ M,&\OP/?3W:LZ*;T1%1PYI#0KZ"!4L@+9:!\J>:_)<._-/KKN7O?'N[MU [N- M# =J/#XQ58D244,ICC#X1AB*-A!MTU6XG)+E3PH[CV!49O+!"+.'5#C3@OK+ MWRP7'Z>D]'_\\@=9C%?SXPS9OA%6*(P]KE#5,M!(6X*(ELQS\*;?&11!HTJ" M M@0V4^&=D?'<&\'^1=UU=/U7JU61ST_^'4[WT W6J]M\K+GMVQ\;@CH#CO?3F#=7*H^]-G7)9IWUE*IFGI=.RW MC=#*=I)&3F.$:'(V&$61:8![7Z[$,R;M^P"LV4L\@Q!FP]M^;XEYO7$L M-TW=-U4KK_-L^OZX:&*23<%"*@]$ZNU$;4H];.[GKPE;[[6L+;=AVAW=+:L0 M!T[LN1\>#22[O;G5MR,ND/PMSC: VMMW?YPUMWC]80/M5#W6B78A)=5Z44)O MWEUZQ%),+[\-R>JBG=#?G#Q?WO>XVZO'5)TX,'?N039#QPR]U^EJ?7$J5-"Z MI&*AH#!@,LU'ZJDB4:2@K6@.RP!' SNB8UM'OZ9UW][\\KIM:_L\4<+D:FH M%6-OZ%-[OSN'X&S,-0>?I9"W7D#7O_,1! ;[TN7*E<,HC6&\O33#37[)M3"% M)YS)!D#L]U3EYLC_J)&^C9I^;'NF_9".X"X@'T$@P<6R^Q$D']].')#?%\_+ M_QQ-EWCEY9B3FB@ZMJ'V7CP(IF'HT4\ K0IY)B9C%MQW[NR.[I91R(.XC^P4 M&T9VPW%K*^V=<4[E6B$(3U&3\@ER$PFD",%3(&6UX-YCW@G88PA(!F?4WA+C M*S[>9_?]^/SXU;PLNZO\$H__?U99_=/G M1,<>WI!D-(?Z'"#V];48W3=!$[C<\"R1=Z078I&.M MS153N'.C[QIZ/N(#T%'0LS' M7;D;TE$5K=X3S>Y!IIP[R&VZWF3_D^]BA1:!#!/V0)VL2+0R A97DM>JR,"^ M8W?V]C&Y!O=$DSM._8"JY_)5DA--BH]<"@-H^CTI_2:)X'4%Y4Q$5;V*BKMO MVRZX'L-VV_!J94]Y#=2>>',/T^M&D[!1;,\/%\OU]'\W$WE:MUA:JRI71Z;6 M:0JE*JDZ6PQX*Q0*%45B[TE[6XR/($F FV"#BI'O$BVQXG2%!NR,\$/'WM=C6\72H6_EOX93'P#$NR*>P0FU3R]"1VPM%JKYFZAMS.X7:@5_^K4XA <7[.6LUKHE]/5A\5J MVF?N=3O>49 3*UUS(M#(4Z]9D:5!CE*#1.]L5$YZ]HJ\ZQ'MM.DH_F(&CU%( M;,1YB1^66*;'CIH/V2J1+51A&SEJ2D.4LH"RY*]EGTM1W$F!Y]^_$RG^8EO1 M=Y[_>]C^.;E:KW<=NG1OU@1UP12+!.5M &.,AIRQJSFI:ZA22.0NU[P;TIU8 M]W1<0F4]9+\7 CCW,["Z\;J'J^.#^,/CRNCH,I84 M()6>L(:B=??-]BH(E:V0PC=NDW8WI#OQ[Z&33+D)> ]"':Q%R^\'V+J^3&MIJN7N$[3V9W:OCPPXGU;R8QIPIG:TYQ#>77=.$1-BB33 +9[V$R MN69RI'H9924RZZH*?Y?[Q]-"B8BW_N7J9Z*,0-#Z0O4NP<87<[^H+6"-2Z@W!<^3.$]P5VYB2=(;AS"!2&BQB M^3'->I^B=P>(ZQ.O]ETYP'HTPT5[=T 1V._T-]NJLO8(.O9_Z;YQ _.PF5S_ M;ZESD3 G\7 _(5^M-V'()-8H*,"E.#LGHE"MY /&E$$Y(8A0PM3$?=)S6XS< M2N^;]Y5R='BT.:#;7/GRM=-KWS'_$=MBB;V!:U;$O2HL&>U(6KJ[LKD5#=XY MM"V69AUWMA +\%LZ7\-N U*SYO4Z/!R'\Q.[PJ]'_!\A9YB90@K650-62$GKJ??I#C)# MD,+G@"$XP]TO\%%ZE@_).Q;A/8S#>5+D<'KQ29K7-V]^&LK1O/9E@SJ8NP^3 MR;&\^,*+12,O3D):95L5.2<0LO>:++9!U@(A%!\D2J4L>T+U#K#V+T[9O.+5 MG.*Z+I!)4=YDGS,X+1L8"M@A]NMOFHZV>*%D$?P=3R]B&-..&CH[#'_ M7'T%-Q!^7Z9*ZW'QZ6QKL.]AZ) M5X(9EU_+QI!++2!8A,%C#KM:/EKC\IOA55NT5\U#L86 2!]H>;<"S@270]/> MV=WZ^FY__KC\6G9!<\TLF[K[-96#Z1R77RZ/SVF4- 8'F+SO?38%XI$\:Z40E.9]$-A%! MN=YLS!<'FY:_19B6LD[:LE>K7@-G7-[S8 3A$@@;0S9U9@>+67UU^&&Y^'A\ MS^(Q'E]K=A4CY-K[AAB7"(_*$)-,T6A9K.3NE7DUFG'YTH/Q@TD+OD:/ .'#EI8,N56@%1DVHU5%,[4 MI$'%VHS";++F[@%QF]!AI$[U;7FRI8\1EU XBXM.#VS/5]K1U[/C\I1Y/5^A M6E;/=]09ZZW??^@Q[![30;3R>S5729.-]BRDSJ*@."])D>C6@^Q]]C7 MM5D;O#%5I.G7 M$3O1?63C0&8*NG-R"7<\Y]G]G6/:\1J&$$,*@;7@^VCKD)4J%#&IGN.9#9B8 M/"1LA82>!7U7<[3<^QQ7@N%8!WT+X6C6:U;?X?+CM'P=:2RN(%+,6524)-P< M^NT&FL:&5W*X>\Z4UC4H(\@M_&=9Z)YMO+.UJM%X>X)%_OZ&M5\I=3 M3$*Z+ )I8Z][HQ=!*SM;E@8!B6,$IDL,APL^VXZA?23X^; M9E"T0^JOZSZ<;]HBG(5&ORSF[WL%U/$%$?CM[>%J9 \?PK MSW6,DT4W%014*3,8XE'O]5X@:*&]]*K$Q!T<;@6R=X+#MH>>I9A(]-5J"R74 MKF*;@=B")16K6M R1(GHRS,/Z>&')'>0Q+DM/;)5\>X40%KXWR#H0O MGD:<$8*5#71V49;LL;(G2MR$:9 Q_S&O)YVR^B4A%,[T"N HU>K=V733NN'16S#KJ8)TBH.*5FPOA_# M)3(!2='"5A9;2BHBIGM1M*-7KX,RY59B>+A8HN\9+N;]-^0V]P^?)"4/&3K< M],[!(X5;#7K/P&"SB76QDW2O)UU-2$=4I5!!"$;VH] ,(4F*:M'EGH?F?% W M3?55#^>]YJ4_OV% M++>><#:+\J^TG/8:Y:\PG"(W44H#)5($89RP$'.6H J6?G6X286[WO02B#%8 MDD'$OM]T\YSHG;=>&PA%EH:VT(O1:C!:%(@1,V15BT2!I9G=3BZ^?3*GNW/- MG463IGL[1!M U"Z'7!N$32F]S<9;HY070SI UT ;C?[:2^C7^3]<OR(GYW6B,O:EK:NO45N6 M;)2B1DO7O4^P6#Q$=(* &HM2K%\_'@< %Q @#X X !>952G%13A?N'\GPMW# ME__X7S_.![]\A_&D/QK^_5?V-_KK+S",H]0??OW[KU\^OR'VU__UG__V;__Q M?Q'ROU]\?/?+JU&T+^L_E'+T??+L;]KV?37SCE?/6GXW\763( 1@EG61 II"8.F".>9LVS<\)! M_'^^_CMPI05UE'C.'9%1)>(CE\1#3-XGQDS(S8<.^L,__[W\$?P$?L'%#2?- MEW__]6PZ_?;OO_WVUU]__>U'& _^-AI__8U3*GY;_O:OBU__<>OW_Q+-;S/G MW&_-3R]_==)?]XOXL>RW__W'NT_Q#,X]Z0\G4S^,5P_ QZ?IY3^\CD;]-O\A M_NJD_^^3YM^_&T4_;=1S[Q)^V?@;Y2NR_#52OD48)X+][<?(.__SKIGW\; MP/)[9V/(&]$OEUQ J0+G_RZ?]MO>F,X0R#C. A#\+@P+P2MB7/?I^V.^_"R2 M(/O98%H1\>W/KHIW=.[[-05\ZZ,KH&T^B)S#>8!Q3:@W/O<:SB7(580)QN=3 MB&=_BZ/SWQIH+T?#A,N%A'^9C ;]5/;63U/\LVRVDU$^1;HUN\#D?N#I?/HG M*=LM=8(V"+?Y^&OXD2C]8;]\^QU^N7A&P=O%2N#'%/"?IE]_Z:>__]HW KA4 MBAL;HXS4AN1-=ER$*(7(EO6V>5!9TG)1@U&\\=Q!V5Y'EWP8^ "#YKN]V81\ M]?Y;[_)#40KP%O\ZZ24605B12; ^X[%E/;$T,"*3 $=I5BG8VVR:+-F9_20T M?%H\XK>BK=]@,)TLO]/HK]'=9A1S5>V^KH_P'88SF)R$R73LX[07E&;)14^ MX\8F0SE@*5=$1T=SH"DGDRNO:A7#S35=$?!DO%S=XFW>\74O-DI5[4Y'%84Z MUQPNX-=?1F-\M_[^*ZVDY#>X;GQ1&DC_1)/MY6PR'9W#^.TP#F;%VCN93 #_ MES[['SVIA&3.HHD@':Y?"4I"5((DZC4N17$58S<\V ;FX:FRGV[7$Z4SQ=SF M$MN72R]'D^EI7@"_%()1P@#3AL0<40C16;3-M2(&Q4&SMPZ"J,R6M4 >_=:Q MOWB[UGG/.@N6Y5C@VEVE>5NQ M?%_%+JS?X=?7/[X5,_GJT,J"IVB3(30#Q4,D>!(H1\:) #&%2)5.E=6\$&Q)H!8"C[*V)7 WI*="BYJ2OTT,4=UJZ''#'0=T M.3UC >W3A"YNE(%D$32R5$NT<;JV%IZ*\O>3[FUURVKJ?CN,HW-XA]9K3X.* M3L5,G VB7+4!"7Y.:A MA+/P'/(>H#BCBGB;!#'H"X4D/1/JBKV#7>#M< ICF$QO@+N. M^CT4MSADZ9DDT3KD+MHOQ&D?#";CN:4)9#1>9#DJ;0QXI&7.7,@Z M.F,A<4!TVOF#\\IYL B0D"K6?*(?Q,Z$JL,HU)IFUEUZ^(Z@,=O2>PL MSMNZ5?OJ]I]0TOH@G7Q'YGV%][,BBM/\Z\1E+C8E$ VE/"HV.YN$#,ZLJZWPK@H^=&=^JXS1W=$7=>]0>SDL2SBKF7 M53#<*T.XAD1D!HM.MXE$:&^=C1D=J]HVQ980GRI_JJCD-H/,O@QZ[<=#A#'Y M .,&VX+6#JQ2,A.T>_"X"V@=6W!H'GHMD$?/AOW%>UOGMK;. M%]SL*2VC%%D0+1TG$DHP72/ H'(($H+&W:QCK2^@/#F][R+BVYIW>U]F+E?Y MV8XAQG5A MA%_FB=#_'@>C":2__SH=S^#JFZ/A%'Y,7P^:!_[]UPE\+7_9E0F3\;3W83Q* MLS@]'7^"\?=^A),?_4E/&9TL^$ \NC-$.H<>C@^"4..B=CK2S-?D==_F C[@ M&@_PJRL.;'IV11;<4:QP!RMV4..HHC@KAI:NX9F<#-,"T>15LPFV M5;J9C8 M7]>W@=3ERINXZ.;BN\DH /IOWHN4O ;+EBPQT/K"$A%',S.IVC1*[[ M5KO]P]+ZC7J9HRA]&[E65':I3NF=3";^XH_&MNE%T 8R:,(B.J322H%K#)XH M%R("$5G;E0R4VP4NJQ]Z.$.LHHQ'%014L8*@P;%,39_YP4F<]K^C%&&RP&4U M\X&E3!PK!@@O(4LG!!J%/.1H!$1+6RGNCH<\>D76$N#&-_ _?EL1#=J*?W92 M@_9I.HI_GHT&^$\GK_]GUI]>W 17J19MS6.ZKDF[;V4KM6G92NLLS\ZB5Y0, ML\!"$,QG^O35OSP.HU:DQ'J6*,N&/0DF-6$I#1 MU:I1NQUX\CP8JG1Q>T1)DW) O,2#, CN?;0Q.M_*X-]F60\RVK>-?F]Y@GN) MM8,RM=LO1$\FB9MJ0F\F,]QRLXK$F>1)"D9$:Z+)ICY_UV\]CUG3^PFV@_2! M!M';R60&Z=5LC-S[ ./^:!%B?@]_-3^:]#SXK#7-!(2$DB*;B TH P/!9C"& M<5J[3*$=LJ=!B;H*Z** 83W*)O7A"F0HN3!,& * !K*$A":41@,Y)9]ED"5@ M7;V6H0VPITJ2/<1?,;^@L:SOI''SP]-O3?G_ZQ\PCGVTQM"L__CIRT<8@)\ MFO0:5"&TE6"(5.A;.^U283JS3"2F5C>8#>[+GD >+54.KH6*N8]W86\XW@8Z M6D8\&W3?8E!XCAI!+'X+CU7(R02N^:J!LAV!6N)XDOSI0@<5DV#F,9K+!+S) MY]%)2HW4_>"#[Z>WPY?^6W_J!XO$O/D"YR]%+P@0Z.MS8D*DZ/;G@!Z_U40$ MY6FV@H-AK7BS(X#'39A#2+V#E)>M8?<$S=%0YO!8%6BF:V:(-=*01"E//E)( MMG;&]=8@'RV5#J.6#A)?[CQO7Y]_&XPN8+YQ?IB-XQGND1\&?CCI2;"073+$ MF'*#;V7&/3(Q? =H5EH8ZZ!V6<^.4!\]IPZAH@[2:^XZB3>B[EG<2546G AC M4%J^> !!!J(I2S%IZX,YD)M^-]"GRJJ*ZND@<>=T>@;CEZ/S;V,X*S>?WV&> MP/QE. 8_Z/\+TC]&@Q)__!TE6K*:3X>?(.+RRBW)R;@_P1]=7^U[F)[FT@G) M@>'"*D=XC(+(4E@?;-+$,FX> M)4J\%#P V""JMV+I>DV/GLT/2NEK6+U?X@6B&?C)I)_[\Z;"EZ5C[_H^] ?] MZ<6K&7P>?1CWOZ-4/WTX>;DL+7L_FOX#!NG%Q>FX_[6/$OE'= Q@U&$OZJM<2[/,0 >12-;9$YE0Y"& )UD*([71^-/: MA:SW74OOG5 OA37.( .%UI9(7J*HU"LBI:'9)Y%DKK^F!Y)0OY]/MK,8CYU0 M?VL)V8T+,9/DW4JJ101F"3*Y8 6N$G$:^Y)S+B=6 Y2T,YRB-8!>B I M]ULI>A-G]A9X![D9*Y@6R8]M0&V3?[]-H=4Z0(?-P^] <:M55]6D?C!*<,XB M1#SV)"NE)LZB_X+F!T%#$N$I'WCU7K$'I,*&Y/QC,6$;87?2 OK\?#1LC)!% MXC)+'$"5!G6YE(\#!>(RNK#:2,OR\F7]BZD*+6($<\T75+V/,W$R4")$3H+ MYJC@O'8KJ*[JDN;7\1_&\\N>YGL][36-.2D"+)?\H(Q;K<2%6N/Q-8Z1<=E- MV',-F <1X]Y&W^OKE/85&E&B-:>#)F!TP5Y. M8Y.!:*T>Z1^*\6UBL_N(O6#4<(:Z;B/!H^N4 ;,Q8#G M%VU*]!2ZE?A=J%U&\%@B]?69L(VP#Q*I]TI:RW.IWRVH@@DDT C$"P7&Q9)N M5CO#\,%&ZK=2SKV1^FTDVT7#A%F8]%/?CR\^^0&R#>JHBB"W_R?J2*,6\=#<296(8&@"761DY :V\"U9+S MZDD_1V++?>;#LA4&H\\ MCE_R,@4]B9)GNF)*;BI#T5^33NY? MKCZ]ZYN6#>M8N5.1PBM%O0J>"1[F_N/@R*9?7ES/SKCHE M7HWEAI@B2Q'?.JF(I"83'TK3*JD21!:I<;7GU&Z/\D%$RK=AR)J:@BX5TX$? M-)^V/A^($YDP&A=N'60B'1KXWN*F:GT6627CO:D])>3JZ4>8*=6QKD95!-U% M5M+UZYQ27C>,_0'<*(?Y/-I6-,EZITUI= 8L$6DDOC 9!-'@@],0A%IM9EOW M3J[2.IX\#8^N_ X\^5?P;0RQWY3Y]8)@@B?+2/;9(!;P)#"$)APOHS8H"]7# M-]>??W@"'5^CHTKJ./BLS4!C3 52C"75G$I/K F&@! :&$O95<\U>6"S-A\< M>>HIK(.-YG+1[TKSM(]EXM=I1GF<3"8P/3D?C:?]?S6T7\Z/I)1+/-43"2(B M7FV0_4DRXJ10@4/&-Z&SZ>\M,?[D7+=J[6 LZ'*DV,WV"3V3/=.">>*%M 2] M<"@&IL.MUH=H4N1)U9[CM1[)3TK54%$'D\I/8AQ#HXEKI"Y#"B=Q-!LV:N=D![-Z0_B7<(%7

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

?CK.5!/QM6_%? _/=@QB#T3=CD\_Q1[C MM*F-^)_0Y0#9M;X^T(U,!B.%CQPXUON5P3LR&YPB214LH1:2?3\==CU]XGKI M!B*?MY17ZZWR'-.\CE"ZCRAZEGS1!D*(Y W4>R@>T=+K)N\MQHBV7V>5SL=_ MVRH<+K&=7\)FXS7?XV58U<'FB]67#XMPM0RI/J[Y5,V#UADX3'/XNSV8H6DX MO1!YI3([HQR1(A6?1(A*>&:"R1<'K3@TVNY<\NRV:#_1YAQYH9"OB!KRB00N MF0B<.1&,B#SEUB7HSV$:GF'H?/XY7M+_^.UO>(6+<%GGO>5/1!J*=4+MO;F9 M\;5\1U_ZN\KY]VSU\>X3+W*4,3-9K]6Y.D8J<0@F>"B&=.VL="JTGF(_[AL= M(\)LR,K'B8@7H_X1SA7>7..'^1U %*6]OEXL<%W"^M/\*MU\N,@4F]F,#(IB M!#-H#5X$#5*@<%(EVIU:7[7L">W$Z#:&0L:XC$=1/GT)5O/TG_./88'+'Y?+ M:\P7**,PY!@"=_36*J,$7R1]C$8J+XK4S0OU=D Y,5ZT$/@(];T[WKFW^0O: M>>ZE!$<>#9D_QB D;T'7?C\J.V8?#B8<:_?[KVAG_X!TY90U>;'C&*" MJ(,!X;V7BDL6;>L2F",0Y-E;"L?@QSZB;WW$\?9?;]^?O_KIU=FLX'F:X57" MR/ARA$D9HZ.>59D MOTZQ3RQR,IIN)SV%8(9Q=5O909E+-D)+'4&WP6#,]HO=3>IGXS'?NL=EQ?XQ"5S,>4 M9VM7\H?%?/5Q70->$;[]'Z;K>GYY'Z!FPB.+D=X\U FTO*9[(X=L/?WA)F)T MO13>9[5O6^'-Y3E:734J#"X8!4(49$B\<.-RK[S!2ZVKGMX1 M/%R^K=OIW2U_[ 'C].JM]Q+^KGK= R0W8KVUC:S0=N#7;=IJ@V\$9Y2$Z$S. M-@=%!N5;4&"O>NL6^MM'8*/66Z,.L5[B@^ -[>]>DJHHLE&:N;="%\ M(?76>XE]9[WU/C+;Z1/MN+BZ^7']*X8E_O4O_P=02P,$% @ VH5C5;'_ MO'8FZ0 C6L) !4 !D;71K+3(P,C(P.3,P7VQA8BYX;6S4O6F3XSB6)?I] M?@5>M=E,IIFCD@M $C7=/>:Q58=-9KA;+%73+^V9#&LX)^62%RE%IM>O?P 7 MB7))%$"!#/;T5$:$.PF<>T >7@ 7]_[K__KC<0F^R:+,UZM_^U/XY^!/0*[X M6N2KK__VIR^?W\'L3__KW__;?_O7_P?"__/JX\_@S9IO'^5J UX7DFZD +_G MFP?P=R'+WX JUH_@[^OBM_P;A?#?JYM>KY^>B_SKPP9$012]_&WQEUBA4,HP M@%&H8HABE$ B0P)IH))($1(3R6^^_D5&.(D#$D :100BC@6D/$*02BXH%6&8 M,E4UNLQ7O_W%_(?14@)MW*JL_OEO?WK8;)[^\M-/O__^^Y__8,7RS^OBZT]1 M$,0_M5?_J;G\CZ/K?X^KJT-"R$_5;W>7EOFI"W6SX4__YY>?/_$'^4AAOBHW M=,5-!V7^E[+ZX<]K3C<5YQ=Q@;-7F'_!]C)H?@3#",;AG_\HQ9_^_;\!4--1 MK)?RHU3 _/GEX_NS79*?S!4_K>17,[+WLLC7XM.&%IN?*9-+C;YJ;?/\)/_M M3V7^^+24[<\>"JE.-[LLBH-6#4IB4(:)0?DOYSK[Z0KXGO!NCK%Z %>9^\$7 MQCY./WB#^UGK@QP?<*>;JR'7#]3;E9CJV=UU=37T\1'[>BS6&[JG&--0CIE4_C71WH,H_-G(E9*V6!TV#7/S;G_3?%N)Q\]OB5;'> M/,CB3KU^R*5Z^X?DVTW^3=XIE7-9_"(?F2P609B0F 8!Y&$:0)0H! E-$\@R M$B1(2<+3:+'9/>0+N8)?/K5XJDX=>_R3@^V;,^]P(?]G;Y8'EJ MX(([!2K 8(<8-)#!KS7H_\\WF:)QXRH?9%I2#[H>G]RU KPB5^[(7=?0_WR6 MU#4_@+4TOMJZ>$G0FKL35(NAN0T:?S@@<5!)G7U#/QT-_VW1PJ4%OS "S14_ M\;7V1Y\V\. )-_[[0+LVZX%/3,VPAO4GL"Z$+/0^2JUB15)BI:L MLK)I\2R$-60;\ .-*A0WX =[ANP60,FP3W-A3\E MFZI\D!N@=;UT$Y8.57;2,8R D<7!V/Y^Q=>/$OQ@ MH/UX8_ZYW)H%?G"_+LPD#-QN-D7.MK6+J*7B@W[FUZN-QKM_;-#+%_S$%<->X8]R6:TZTF+S_+F@JU+[*7H0RYV_G3*6 M,Z$IT%P9893S)QL;M)Q28GV?F]!4:S@?M=X7.=?-OZ;E0[-J MF*0\XB')8,@BIJI'N8G)2U&8$ ZK,*>Y,]B M"?M:5D:7A0-"AJQ/GV3&83WZ6H8F6G]^P92OQ>8^ZWL7ET_>.-UBKC9Y W0JAQ[:\7Y<;NOQ_\Z?7:R$7"<[").,I#&@80,08@83' M"[HO^R]G O-3O/26YFV>_/MKA[@Q[Q>/SYM M]7OU]A_;_,G(_E\+,Z./<49%G.HW7L8*(DP%I(2F,**9I!DE*<^L%C]Z^IC; MB]^B!+*%Z?#1/D.CA4-S/3DCO^4[7G8(007Q>G8M#+V1;/-^I=VGZD&X_2,O%QD7 H60-?+LGT7#GLG7Z7KTSH^.%^T"(@213$5$*6 M8A,.'YN_\012166:\)C3D"XVN[C)BX_OR5ZQGP) "G M^YA4 WK-?"D#_1@O/0E@AI#^ MTE.%<2H0BI)D\4T6;.VPH=O3H]@@5H64I7 ;A ;10(1"GC4,A8 M4TL#IB>+.(*98%&L&PR)RES4UA^Q4\AN%9,#GAK,@*[$WO>_J9U_KVS')"59 M%L501CR 2,0!))A+F$:!"F,V9[ ?1WM(;;[G/DC:^3O6@OT!E10 MJ\?R[?ZQ[)_!#XE7L*#%7PQ#7V=3QS58&'XBUL'F+J_Q#V__>)*K4I;OM W= MS="_YYN'[BT+IJ)$\DQ!%G,!$48(9B2(8:+"- QPQK!PBGNZ$L_^0WH(KJ]Q(X83U8=JHUX1",+&MGPRYN0&M-?AG3=*! S2.*,!S2@ER&5?I;>WN4EG!R_0@,$!8O!KA=DE4N(B MVW;;+]XX''\C9EKZW/9GO-$XW4[-CD[C'?,N:(_;-5:\7-JXZ6]DTBT<*WM> M;N;8W31 <6\Y+[;2-%INEZ;=3[+XEG-9OMX6A>YQ$3$14YR%,,(\A8AKV:49 MII"F)$0JQ%&D['>R+_4V-\5M\)IGNP$,R@:Q@U! U[!]B:TM/;UB>[&1Z<36UIX#L;6^:>@JNWRB MN6B<:2WG=V;2>UNMQS4][(+^41I1'I(8HHQD$(7&V4U3!J,X# 7!)%0D=5NI MM.Y[;D+<0 >RG:0:CZ-.P-"\!,V:IN,1UC(\B: (4G,[B&=D1;^-<>J=S;!=SSZ1&#-XU3()/X-[\7XM[R/$1 MV\?9P>OTSNY4OJ?%\^K-]W0BJ=\#M6MJ0C_4R;9#;]3MUF$^:;6:J[0 ZF]$ M[>UJM_=.U4$F.5WN \[*S[J'\O2OWJP?:;Y:Q%D4$AF%4(2*0:3,]I>(B(E\ M3_50A4I)IU0C/L'-[8.P0]J)GG3[O<:D9&_*2<' _Q:X_3H[(Y! MGR=OV"NT2=WE,4A]Z4^/TH?'J-U.%I?_E+1XI]^,A50)Y@I+F"J3JP%C!$F" M4QB12.(L2141S$6-;3N>F]+J1SWQ$+1[BF([T1R#N$D$\3BTMYOMZ088X, @ M'SGBMX>K,8. 3W7[_>.">\BP"A7NN]]-D">H)O,CB$E,=6T94OVIV;GGPR<]2O( M%4R,+!!G2/#H,YVQO>^%U[=T7G;]K_V+_K*U2=[C,R:TK^FY7_M+"&FR3JZW MJ\U'NI$+G.IY6$ EI&%"((JK,,4@@9PD&37;#"IVRMUTJ<.YO;=O]>/Z6(6Q MB08ET,@MLQ)8LVSG$OCD;N0W_6P*R!8O^-C'HI?4CZ>H&3'EXT%WWSW5XRGC M;5(\GKQOZ.G?IT+JR4RUX)F2% E*& QCA2%2@8"9^2?"2$:(DC3!3JL\W<;G MIAE=;*['?3N4!9*QD$D!4YIPB)BI1&3TEPN.DR!&,8MBMP-40TF;YKA4%UV[ M;WL%?7::.I22D?73ZA$:<"[ZV%AO)Z([34]\%OK8J.-3T">N&;!U^6%K?*X[ M]2G_XY?U:O/0+JO7%7?*!9-,*!$0B'&H50Y)#C/%*22$LH!2RE5FGX_N0F=S M4[T:KCD&7>9_@$>#>+?K YYJS [;:I>HMMBE]$C@R*][P]V= AHKJ,#N-B7! MO7?N'/8B/7(XT2;D55RZ[4%:DM.[^7BIC>EV'2VM.=ANM+UGF =YZ)K^79JR MC5+<:G>$?CWP5'5WW(1V8L(32E,,<QU2;]>C=#JS)6E."'?&7DVICSHYO[Y3Q<=B[:F(,PLJX?37]; M]*"!?S@?O@&-"?Y7(+G;N?U'4<2LY+]W)P.T.BYZIPO/^02_%EI6_I MKM:WH4:212R*8@:3-$@@BD4,221-1=N,Z!'B+(@<3F!<[&]NHE)2BNJ0\R>Z-%'3 MO]"-*6GW?*?V=>X^[&]"E63=X/%46T#GGC.-PV/F@HY(\LIJWV.L\#09]=5JCQ6^8[Q1D_'29 M^2'9:H:QYR^!C6/_4^>T&4;/B30W QL:X(CNG%[=BW7L$T\QQ8Q%, L#D^:: MA3"36$%,TR#F21@E#H3+HT0:7O M5Z_K)\3WZQ18>3.L+V!+ST?!WN'-G5_?P@"TG5QJS#)C+!6$40,Z(5" 4!S-)( M0!2A6'"".:7VZ[##,,Q-DFS=W?9YAY$_/Z_W\X1#,)+C.VPH MYNOZ[M^*[^'['K/IS?OM-#U/__?8]L$>\(FFQCO3]UD/D5QP$<8QI0+B+#.N ML,A@A@(%L0QB%J1QK$(G5]BZY[E]?O13BOV?ZJM)MG.!1Z%NY(^'P[F^"OJT M!_L.V)KP9%_=[^R.]AW0,>1LWV$#PZ3I@]R\7_'UHS3EY1=$JPX20L @#D.( M0I/)1W\M8)1$ 6,\50G%+N4J#EIWDI@)JE-H<&#I7(+B!6%2"[.*S/EKED!$ MP@C2.)&0LC0+<, %YTYZ/9RP*>*&/1"6$H3#*,,P9%P3QE0""4D4Y#QB81 & M5$CE=E1B,&73G)7P09K=!VLP$2-_E P#-3#P@X'V([C=;(J<;>MM3/UENJ>] MF4.=/T8GF?#TP3EL>]*/RDFS7GXX3E\T[./PB3](L5W*._7I00_1*_TM$LTW MZ/9W6HBWCT_+];.4U;+-+J!8#_[?Z');3+&1AB25'NZ-$CT_Y,D0VGBHIPC8IV;#K>FFGB O].B,$5L M]DL#.WO +W+SL!9NPC/FD-O)V$P&L#&T7=D!EZ@UHC:T7L#NG M(W1C-YVA[ICTQP]$$@^-)I\=$.JGJ3T#YRV_(%%T.W$U<;7*1 M+[>;_%LG..;M'WRY%5*8:)JZ/'(%XDZ]I<4J7WTM[V5167+[:.*[%YG,<*KG M,S")A';=@XC 3(:J^B>73#*JJ-.&HP]4<_O*&*-@:U55MT]_7/)._C39V%=' MJU57ZG^L&G_7G$P!I3'/2!ROM^'*WFVX$4?<V.T8T\G7!"\/1BY MCDUFJ%JKS F7^M-T VK+/.Z?^B3:UQ:K%TS3[L+ZI/%HH]9KXR,LG'^4)A61 M,(<:W^4EITNS)K8(0AQ@A@14S,0MLC"!)F4%3!%)LX3)%!,G;7>',#2^(4:^ZG [N8F92U:4.S@@J^]19K15A MOJ:L_9U-.Q>U,OQHDFEWUU4%V=ZORFUAAG^A)*6@*642A8D41*00<\KUM$YVOIF?D=_HE,R/4=>FEP-,+ M?KJ/2=_R7C-?ONK]%P^<%E0Y0-[1O# ;B54^IN7:Y)Y?1 DB&481#+F9$:2$ MPBQ" 0PCEF4QC:0,D4M@XMF>G-[["8(4ZV,X=0%4\%AGXA> ;H#2V,$W QZL M5X":R8)VFLR,G-$R=YTKG"7>'+ M]S_;S[1N_R5SCSS^BS<,2;7VN"XV^3^;K2C]2JX+,TS/1J2>JK %KO^FWYRS M&:UPRI ,8NU/9-@A\L=N?I>[J7B9,8N>+D<,<=]Y:'>9??Y3M(=4[]4:RS>U*-,?O MJT[N]GMF"R0HQDHD,(GU3!O1+(0LH"$D$B="*!7J_RU6\JLIN&/GO([=/4NC[[O(?MSU=U9\N2[.W0\J3/O3LA+[WY "]='AGTT69SOU)=25I.+KLHN M0A11Q1(&0W..$8F001I1#,. 9 PE61IAIQ@)RW[G[L!7@B6:=87AP6%]S-LI MU0A\CBQ3+\+ *M!PK:"K<5;CL#ODX<5\65(T0[-77ZW>+\+*@HB^LR^;V MH=[6TK@F][38/#1 M_^';D(BPKQJG;]+3Q32>,.HIM M.G7-L/?R_>J;+#?FK?^/]=*<2RA_SE?R_48^E@LDB0J(BB%2U48D89"%3)CS M:P%C+)6*6A4FM>AK;F_M'BIHL8)?#5I0P;7[=]D3=R*_Z8-:<7WT+ M/CPI05]/DPJ#A#9T)=CSSW)CWL8[54>R-YNI-)0A58S"5"9: M-R*90))%%'*&@ACC+ EBITQD?9W-33@:K* &:]8W:[2.J6_ZZ+53#%^DC2P9 MAWR5>\(NQP&X9XRQH,17RI>^KJ;-V6)A]%'2%9M[!L95?J/YTARN>+!8Z';RR['AN@E)'79ZL M;(PE]MJG_J/,L[&Z!^EN&GOF?9 M/1+6D1]?@;&VW4X;)^M(QE'8K.O] UW,[=/3LEJ/HLO7M'QXMUS__GZEGXW' M.JU7>\@]8%$6$QK"."5:FI!V.0G*%$S"C,51E@FFK IF./8[M^]$%S;@&C=0 M&CC(]\C_XNB#6O)OZ8[Z9W5LS[1+J($,#&;0 3U*3@%'HGSYJY:]3NNZNE%Q MY,4ZWG[=PG:S+4SC.$AHDL)$$@Q1$FF7":,8RH"&"L,.9U:Y$)*,4X0#5%& M($\B<\Y7ZID/"P*8,AG@* Y$()R"989#F9L"N&=TNV(8[(1B&G)'%A6W[$93 MY'J[GE9/LG4%D$DE[GK"7LJAAQ8'G&C;WZ^ED6C]V@Q4X<=9U>^3#1 M.HEBSL-00)$&2,_.8@D9(1&4%%.9HB3$F95R7HUD;L+9S;INK '&G!=%]NY< M3W%M-]62P)UJEP3*_4IBB 07 M60!E9K:<>)I!*D,$$\5HQ (>,^SDY?=U-KO/48NUVH%M5[M*FR4N=Z(MEPP] MT3?V=V0X":>F1M9,483IB] V/)Q@FQ*"7_\]?UMY]T$[5. MZ+_LY>%BP]/X)9;F[=P.V^NO/(SS?O6TW90_RV]R&3;16@%+"0I"!7FJ] 18 M!@*25&D?0V@]()G$ 8T'';\Y[FMNPE!A ^' S8GN+3S&SPQ-+(([ _1W( : MZ UH"!LA],V"$]\'94[T]'V.QIPW^>QAF)Y;!LX[3!V:\GU9;J6X+W(NV]HT MBU"A1(8IT?H0F03C@D/",@0C$J2$*1X+YC;I.-?3W-3!0*PF\$\&9:=&UP_Y M"FQ+L?_)CXY3C[-<6\X[?# X]J2CP@AJD#>@@KFODN5QPG&)"U^SC;/]3#O5 MN&3NT3SCX@U#4@AN-P_K(O^G%._6Q;OM9EO(.L7I7TU]U39E&4T$2[* Z_E% MI!T+EB0P2[A6CT0EJ?Z+BB+[E76K+N>F('O05?BKJF"WY0&_5L!=DLA9L6ZQ M/NZ=RY&UI$.C!@QJQ*#)95QC'I24SXI/E\1[OGF=*KG>Y?M#VM#'H MI\PZ"C0_>=$ A^KUDI;EG6H*U-\55:*EYE]E\\_&B?N\;HM(OZ[J!%=UI1=) M%N$LD00FRJ1N4WI^1G"@)VDARCA)$AE(9.UK78MF;@K00@=YA=F$)3VUQ>&[ MQ9:KB5TUH2LM9W1^!L_"99MR2$;6HLH4$]/0P =W19T8[@;L!JK]43N!!)_7 MH+4*U&:!3_;UL?T,DX,G..5P3>0DUL.V5N#W9MBTIUC48W3AM?+E._HBM=>M MO+J3Z3Q.7WP<.*/>&AWFIWZ0&[,=6FU[""E>/7\II7B_VD44WO)-_JTY?QM) MGC(50<80@BC5_\G2A,%4$!G@+(U4D+B4.;'OVNG[-D'=$XV\/E"U-7E*]3=L MO8O)I3O0;LZOPSC8><;CL#ORI\H06P5,M+ !>P8_?*E9_K$3^GQ[F69GQ]J= M,4]>MT/'D[KD[H2\]-<'M## F?\L5UHLWS\^Z6ZJ$(]=34VSEX(9%ACR#'.( M>"PAH7$,TY@@:;*2\,QJK_5"/W-SP&ND(-]#!;3%ZN#!]1!KX4+[H6MDQ6F8 MZJ#<5V3UPY2#%^N'L8G\T[YGS)<'>IF07M^RY_;IO,;+-ASX@Q:7#_/TSAP2 M:4LN8RRY2*( !C2D$&$1P"S"$F8JP['DG*F4N"Q1]G/+EON:XFVMW@7@[=\X?G2,+:M_Q-.\%K>U8\>2F7>AL4M?,SO"7[ICE M7]I:Y*8_3D-CIT%A$CZQ*%KF%7 YR.0O5$-H\R993 MUY.*V!!27DK:H#:N+YGQN:"KTJSUK%=-RHJ (J9P@B"*D80(J022)(N@TJY3 MDA&FLLPI@W5O;W.3L,.Z$1VXPXMJ'#-L)U#>>!M9DL96(:AB)- MQ2Q3'$>#S@6\L36R;KP@RGMXB14/OD\&G.SK M^YP-Z#/[[.F WIL&YB;:+S= MMT[;<]M:JY/;#EYKZ;)F]]X/Y&*BM]SK!M<)4WTEX.FT/&U&G6.3CE+DG+C$ MQPKJWZ79FI?B]IO^Z5=9)]EI?VEF\.%"J93),*20A"J$)C#,U"EF$*44IYRF M06:7ZF8H@+E]Y%O$D-:00=%B;M98JS0>QVNO914H]BQI81LG-GC(AJS&^AV( MJ==G6_2@@0]V^)N4-\:"L99L[:D;91'7HOOON*QK3T[_0J]#.P-VW]M8I;_) MTO1X+XM\+18*8Q*K2,$T90%$#%&8)32$443#C&")$;-:X#W?Q>S$K8VE_%:C M-*<5-4R'3>333/8KDA]^1M:<'34-0'#OAQJ'K?6K*9IH5_W,4^1K0[V7AMZ] M]--W3K>-WHO\8 >]_\HK3FN_,F7)7Z\?G^2JK!-&FXZ^5KOTKY[WES1Y%ZO# M"C_ORGII?P_3**!0QJE61,)B2 GA4(4JH4&,,RKT+4) M=(P"KYY!][K&,% ?N!E>D,W# -NYCM,.V\C"7B&%%T:,-2,&!X_8L$/J7DCV M>9K].D#3'WOW0N#)\_%^6O8:\5Y7QCN(2=UEI\N"$*4!BJ"0YOAF1 FD+,(P MC!@+,Q%Q)9Q6YMTAS$VJ7[?E1$I@'AZ0M] [ ?".U44&C(N=XH[+]L@*>R$B M?F=$)R)^E#R#PTD<-TB^#\ <@N4M"+(,FK=I:6@*U#7_K3YB]&9;[%SF:F?C M@_R]^DVY2'&<25.XA"6I@"@S:8FH""&)4JY2(6D:,[=]D2<7C$ :<;-:<]/FIM.PZPL\;DTYT>0MGZU-GQ,GMG6@X3C#KU]W<)+M)P-V5 ME1O0I-3LP';-6][+^ 6M]L[CR#I]+84#,IG;,'-%/O/>YB?.:FYCZG%N%/#A]F\# Y^M!L%NQCH:M2/K3Q^K(YRI&$23 M[[AIJ[Z_3QRU"RUGXZJ=&AF8J)-K/WM;G?GX(#=?5H6D2Y,:M%YN-3W_57?R M\[IL\].B) L3'F@!BPC54H8RF'&M9T)[29'B61()IW505P!S4[,.?K#>/,C" M3!^>"OD@5V7^38)\I?\M?_IAJ2UPC-YT'AL[A1N3\9%%[O;N]?L;T*7<0 4_ M&+ _W@"+8ZXWYL29V7_W7U)B**^^DI>Z=C]M?M.!Y!RE0!W:CONL\4VS!&$2 MKBZ4XE$8D01*IA*(,I5J#RX,(0DR'$4\98Q;SP^[#<]-SEIL#@F,C[BZ/+,; MRL#(\F)GO--,[92E@^9D!PU--OLZ!;\[SSKY^P%KZW\M]!M[7ZRYE*)\IR&T MFUP'2T$+17B01'$*J7X?(4HB"DDB0X@%23(<$QF&5D&$#GW.[06M4(.G!G83 M?M+9$>PN7CJL"%L.@,4"NW]:1W[K:T9;Q,! !KL]UA>+[?X9=5AD]\_L1*OL M+L^LKW5V-[)Z%]HMFYINI=W-MH.E=L=;ATTJ=?M/LM@\W^NG8'.[$J:\Q)-Y MSKZ44FV7/^=*.U1)FFCICF D3#Q-(CADB50P$Q*G$BL5*:=YI$6?@LW.WQSO**09K=GPM25_L;]HU:%OSCQ:=K6\>R M; Y\EF\Z#R]"$:,1C2#/E DHSP)((D&@RA(ITX!285?6V+WKN6E#@[Q)EK1F MR_QKY>;I;VB^XLNM">O2?]-09.EXYL5A/.S$9!R61U:8EN#CU/6;-6 2W--< MC"([[FSY"B6R[WC:.")G0HZ"B-Q;<).RLMB8!1VQY9OR=B4^R>);SF793/XQ MXTEJM$JRT$0\!@(R' <02Q&1+,XR'E@5".WM96X"U0"M5B(;I'8RU,]EO^)X M8VC\Y=J7Y'A<-+%BH4\T= ,=P=#_VHM%?]N3Z(*5>:T$V%T\]!C%IP>Y7)KD M%73UO$BBF,1)B&!HSD(C'BM(:1##E.,PC&5&$U,4T>781+?YN;W?38Q_!1$T M&%W/1!S0U_]F7T_*R*^T$Q\##CB<,ON* PT'S4U\@.&4*<<'%DY>-2"NY MO>"?'_3<@1J$#H$>;F1?>.5'I7#*Z<-^]M"FO"J!Q@XJ\,"@!P;^:#P[Q-6, MQO=$X36'\^+ECO>GEG>A>:^>ZBJ),%"Z9U]A-H.XZXVV<6MQNJ";098>Q-X, M:V& _+]?\<)T\D;6?[Y?[9(C& !F0:M<<)S)-(PHC&BJ9VB,93 +*(4"893* M*(TYHHN5_&I"K2UTWZ9/JW>'U.].M^?Q7IT6K:EB/22%C3W=%KKOC<)IY+Z% M"WYH 9N$7&"?0J4B\_489#J(NV]2)]+T';FB\X36&0D.GU-?0N["4Z]^6S4T MG6R[V'6@UDXW#BQR(LM2RC-E*3L?A@_RC\WGW^7RF_QEO=H\E NLO?5$)#%D M9E<0J1B9/&0!#&,6WJF9&&.8)35*H8K/@F!(&64P$#(4,,Y2D&;9;<+S0S]R$;0<3['$.V>$\ M)M1E._,JFB99?#ADR']UN'X:O&Y*'O?R'78@SYIZ>KOQ_.6##Y+L#JHT>:#: M'%'E(HD$1?J]AXPCIIV@0$!*I1$%3/1=01 @JTQ[-IW-30_N#\Y2>4JT9\6Z M#/6O6(*@0JG47";X^\&=PAL@.YR''I,K6K#A[^C.N>[FOJ,SD6C3QS.N7S/,!G_\NFO M:_UVKJJOPE>IOQ.R_/2P+C:FX-UA"?,FDPF.PT#*+(:!T@*#(BTPF< 2IHHF MF*49H=PI]M49P=P$_\N?/_T9?-W9 (1)=5+N0+O)C/MXV&G/J"R/+$A?/H$] M>-"B!Q5\:*K$O1(P]_XG5;7!]+R4NN$-#=B,N:\<@D]/TGC' M]]OB2?LHM_P?V[S,S1)RO=NO>VKSG#9O7!HJ&64B@%&<)!!)+"!C5"L@(W&2 M,1QFB578[Q48YJ:!M17@T_WMZR%)CP<.A,7&S?CTCNV--R, MV%%_60"]C8'#?L_X8S'1#E S)F4S)D_-F-#.F/#=F/C.4GT=B[W[0P.;GF[' MZ#K;#_:0KFQJ8#T;NI1ED;6_/886><(NW>'MI<#7W5,3O8Q;=V2 M/C./ZI3T7CP\36%=[N3M2KRA&[E@%$ND?4B8!H&>0(Y7^8OY55VJX%#Z*4"$XA2Y&>$RJ, M898F&&*NTI2A*,DBIU6QLSW-;>:W UJ='E(-5,<-T+.T6FZ!^B!K[$W0 YY: ME#>@PNEQ&_02%;XV0L_V,^U6Z"5SCS9#+]XP,/N,^+_;.LEQ^7E]*T0UB= 3 M"YJ+]ZO7]"G7GFZG#-IAS&024)QBDL$L-N?(DXQ#(O1\@"AD8._F9BNR1%:ICAHD:VQM2'R[/5Z"QY:832"S%C6U L7M. M' ^\^DJ7"#M*,F.CS:OR>JU,#$C2$4A%&D:F!*_":214% F0M"( M(LHQ750%5BWUL6K6R9?:-3[V>LB01*,-399ZY6S\V,K3;_' 9%J^):!N]#ND MQ3K[6A[^=M@+]KXJ@O)IHR='Y@7_V9"KW^XJ )$J&2'.4\A%G$*44@II0AB, M99S&25D^YRG!1^> M7OB^GB95 0N37TJ#S2T#/\BK32[RY7:3?Y/[O?BW?Y@D3U*8""6S=;*MM^#N MU%NJYUNKK^6]+*HZ?Z^>3S=0O1$A$DIE&,,84?V5QRB%6:C_@T5,$,(\B873 MV9D1L9294!AGB<< 45Y@[1J=WFY_? MHE6-[J8Z$RP%^,$<$JY^Y%AJ\(!$R_WM@<2,+'LM(S4PCUO9)\SUM8/=;7K: MC>L31AWM5Y^Z9N"KRA^DV"[EG;KE?+U=;4PZ0E.>\78E]$\*W4,G5>%G\YO/ M\H_-JZ4IE(33-$XS%<*,8'/FF:20!J& ,DR2-%0X3B/LXK== V9NCEEKBSF MTF"O O;DJJPG2&8[J/U%QRI'D;AF^"Q%9:)!&5N$#L>C,@0TEIP;"_!K90XP M]H#*()^!.!YX]:5VUT"95AT]D':DIC[:'%SJ^47SK[>%J86[D"265&IIC1"* M()*40X*R!,HD9)@E+-'_<*SI?+JGN>EF^QHNATKB>4Z#,$-9',80\Y1"A!#5 M'RX6P#CC82KT-XR*U&DSP0NGT^TOC,>LY23?!U]C3]&/OP(WH('IM2YU/Q/^ M"E"?Z6?J2M/]YIXH*7WAAF%Z^T%N7M/RX;Y8?\OU'/G5\Y?2U*EN3LJOOMYR M/1>N^ELDF:*$FVJV$3-KDJ&>MLI,PC2EB$0<2QPC%[&P[WINZJ&1 ZZAFQ/6 M%7; GH%J<6M9:8&[J8G#6-C)RS@,CZPWAER#&MQWR/W!( ?YZD>P P]N+]/L M+$/NC'G2)8>.)Q4J=T)>*M> %@:[CL97U4W>KY>Y.2ZY*X?!4NTA"K=T=#[2-[^\,86R( MQW.!#'\NS[F.IO9Y+AA\PNFY=,? -3X3HO6P7NH[2E/?=?/\8;WI%#7#),4! MB_2T*$LA"E(%62 )Q(H$"6.(AW'JM(K7V]W<)*.+]G^ &B\P@ <+QP6Z+5?= MO)$X]KK:-?RY+YI9T>)K6:R_LVD7OJP,/UK:LKMKF*R\?7Q:KI^E_"B755KH MXV6!,.$Q"T*M)RJ,M2-""&08!Y '5(E,I1&CTD59+O8X-W%I5Q-X9^'?34PN MDQPCDB1*STR9"C3)+ U@%N$4"L0REG&BD I<)JI^29Y\=6M,JNVDVRN!(ZMW MBQ46-=B1U[VLJ?&DX)?[FU3$K/V-PZ3\K_1(C?[&E4J61.^O]"ZH?4Y M$9 $#$&4! IF@L:0\)A$01@'&(4NTGW4P]RDN@78E.P8<.+HF$0[O;B*FI'U M8<=*DV#:P/,G!VM^UKR7K_?Y"WU-^/9K0R02<:0=L9":]QIS MUK4.9VGF.E--LN;RPS/?7;G:69W7\@GFHNW?QA/VH1!W&T> M9%$?.VI]X8BG8:8B#EF:,8BX3*$)3("<2Z&BD"0XI&ZIGB_V.3=%:2 #66,N MJS"BM8$->(UXT)D^&_;#- X%3CBD/.1FTF="&7 &@Y0HDC'%(Q6[3/I\LS_9 MM._I^XV!G=A[9G9DU6\?Z09NQ68%&-2(1Y@3.A#D+2GTY1XGS@UM3<%QBFC[ M6X=D2NUDH-:33^.?WJF/G[Y418S-Y^?NR2RTE&U::K$(%$MPG"4PBLUW(<,2 M9DC[FX1CG!%*14"MO@O#NI_?)Z*;4UTC!T5M1@E^>*(%^$:76PG6J^7SC]6[ MI@?O('5]73-@75OIDM33>=SZU6S\T1A=V)J!>%<-1(T>W"DS)B6X-070*ZH; M$W9I[\\?5_!!NDL2U3')GRI_JO=!<$RA.I3#_NRISJU.F#AUJ,6'.5,'MS)L M_O$F+_ER76X+W4U]5DWW*+JG)VY-_/,)Z@"#ROTAP=8NC:: MJ+7NA8V=H#+4S?7V/?AV;OIW'-*1OWR^1W/40S$C#8.GB8-O=)-.,D:B]N6$ M9*QNKJE9^**^]P=-6#.'IRPA%&$")2$"(A$@R*(0P5 )D]4SC0+AM!Q^H;^Y M*?W/Z]57:"IL-/'<[>[7FBWSK]5@Z1G_4I;E;C'E:5VX[ZQ?&@45*!QHIJ%, M4J*_SS&!- GTWR0/:,)PA#EQ.R+N<1RF3(F^O#P>?IFW^SAZ9'/DCUV#]$0] MW#U/DBXWSS_?-W4! M"$JE0$$ :9PIDYZ90\:S#*(PB# -@B *K3S_LSW,3=%KC* &J5^ /]\[+&"< MI-!B8>A:8D86A0-.P,_@?DB9G)/<.*S?7,O11$LTQ\^/K_HU?03TKJ^K)+T7CA1BNXL\"%&64<8R&-$@U4+'*:2*UK'N> MFP">"KEU#/"P9]W.?1J%RY$UTRHP=)3 #V>VIHH5_3YA(.^CIEM'UZ M6E:S>KI\19?&S?OT(.5FOR!0[A?ETC!40:0(C 1A$,5$S[M#0B$3"M$T9)HH MIR.*+IW/3;$:O* "#-[(#NIXUK&T#*4:3;D#8&Y\4NS.STC:S_?+^Z>Y(%-<M>F[)"!." MPC2D)DNVHI!(E4!*D2)((882I^QGUCW/311)B$BB MN<>I@%1Q!,-(Q"C1L_M8";<5PU'8GZA,2@/=1.2NSXS%\U@C8?O;)S?3SYWPEWV_D8[E0*HU9D*4F;%=!Q&,)210&D'/,(QQBP1*G M1.>7.IS;EZ+!"RK H(,8_&HP@PJTXW'[BZ3;*91/*D<6IBM9=)8C6VH\J=#% M[B85'UOC7VJ.]7U7I-@>M+5>[Z_K7F]7XEX_5Q_TD_9F_4CSU2+C(I"<81AB MJ6?E$160J#B"491D+ HD0:&3/(T!X;XO0YT$T+._4WZD!L;DK/N9? M'S8?MF8_Z4[M"S6\ILNER3#77%?_5Y*"NQZ?[>I'?XL-[\I]Q\E'S] M=97_4W]5JE+U[]9%\R-S7;A@-$BRF%!(48HA8C2"&2$A5"A.DS@,4QSQ(5OZ MT\"?F^K_79I'0(L&_28+^E6"*LS2'!OFYJ>;-6 2%#N;AD4,3/1DN(4=S&^\ MQ]X#/'5T8>_05;&@M='UB88ZK8U)6@B>Y0;L#;T!M:E F:_+WEC_P0[3CI'G MB(F)P'^7L(MI!^9<[,;$*(:N?G.9?S-G@\HJ@>WS/N2 *:1H'*20!\P[VINGYU=J:$]9-?E[;.LVBYL^^!J]"7M%B3XM48Y MSOFRRV1X6\0^V]'$R]>7##Y>N+YXQ]"L0OM3Q-6I8;-H4BY(BE$4AQ)&F)E$ M0H& 6:I5(DIHR(@*L9*!6R*A4]W,31<.$T/HP:P3:U7'WK4O6N6!:,2_20+Q MI+M^,!O.3[HAUVPV)YFWTX_K^1Q9.PZIK#,(5!A]YJCIX\!;6IJ3G4RZWF:Z#Q/R]X[I?0T;/6UGHPM9!K%:2HP MC,,LA"BE :0L8# @DJ8H"Y- V&?..M?+W&2NQ6D6^-<-4O!4K[J8[9='[1D] MV&Z_]/-K(7\^6!M9 '>$W2G0@FR6J7R0Y*"!/LB:2 6'D.8FAY?(Z!7$LS=/ M)XF7\!^(XL6+ATT0_UJLRU+[E"K?+%B8*4)%"I/85+7 D?;X]#P1\E@Q%8=)9V@F37D[-3ETR=%GWFUQMI9GCO3;+%)1O_IYO'EYOR\WZ M41;O5WRY%::R85E*_?_%9_K'(DF3!#,50IPEVI7)0@5)5@<2IDF<)C*4RFV] MUQG#W!R=.NJDJ UQ/!KT\.;Y# H+2<;)PC M\<)DS ,U(VN/(ROVLXD+II_0C%+R/W]=?_M)WUK+A?[+7B7.-CC-Y.*".;MY MQ:7KKJB$\[XLMU+H2@&575>ODT\?@-6_J;R'6B$$-N5DLNJG3XI8W0..NK_"XR^A&E,_R1Y<[G;X4DC41)\LBV=\] MI"J&U$_::D._RCOUI91JN_PY_R;+.U77W5BD*,.8)AF,,AI )-(49BH04 J> M(,T!L M;PM)[]2K;;XT\_I%)&G,0J4@3S/M%*:8::>=Q3 E0J4!C422"6MM/6Q[;E)J MT)F'E37X:G_N'UO]'0-*RHW+KN@+%BUDVG3:\5\I>W#*=B!49RX9H$NOJWE8[576WN:7I_6J+8&S.Z2F M/[/:$T01UY/7C"*(%,60*A% &0=,\D FBJ5VTUBG?NSZ^V M&OQ!R;/AIV_=AL5" L>@>F1Q;#BN,;=S6(-Z5TS+2&<+? Q>'41U#'XGDENW M9]F7&+L2UBO3UHU-)^"N]AU(N_/-0_/4*9HB%,*))$BJ"]"_=5I'/]30W1W4/%-1(7;/7GF/4]!]_G"TU;TZC-[9V6M0L["U9> .,U: R&W3LO@&[9Z(U M'1C;)TP7YFN8ILH==C7>>242\T6_[XO/Z]]5" MX4 ID0;&?440"2(@E4)"FHDXBZF2%%OEF^GI8W:?A#J(I\%Y PQ2DTG*8'4- M<#HF],(*@Q^:1M;>00P-"'8ZR\$5\4[';4X<\G36J..HI_.7#EB:O)3ONLJ& M56W45-LS"Q1S%0>9@!G#@78ML8(L1%3_#>D_XC1$S"IAX)#.YR8)IY/I%P8T M7"NXU;^I-@\=ELY<'C+N;V':@1@KP#T6VEX 2+ M=E/[Z[@96;X;6M[;T.(\6SYON:?I[8D.)IV/GC?PY02RY\H!#F&=G*5)("1> M/7]9Z1M_+W+S(ND?F]CAS>?U737=_*O9))%B$>-(1!&*H';_,NT*!A0R;I8? M$YH&44JB++!ZY8<"F)L@-%NJ;1JF*OOPMF/&P/WJ(4-CX2".3/C8*WYU$J<= MU:^>0=< T%J@IZ&@M@$T1HS,O(.C./((3.0L?CK(/7;\T#^U(U%-EZJ1^%H; MXVO/^PH>>SW&(>U.YS5>8?6!YWA-.\.\QS?R:5WFF_*7]4H^_T*+W^2F_=$" MX4QB[4E"'E !48@4)&$804$X#T@2<,:M@C>!I9]5M(-Z#""6J@H/VQ/S_3@@Y/#F=?3Y-ZGA8FOW1!;6X9)A&[R:O9 MV5B5LMP55$^YBC!B*219$$"42@IIB#.S&Y$AF:*0A%8YL"[V-#=YV*^^R :I M8]'Z\YS:2807ID86B#U)+#(\M&&Q-=D=6#_2-4::8N,GS_K@WS9P9.*S;GEL[@IY&U$;ZIQRGL;\- M9HB,,4!; QIS0&N/V1?M6&2.SAP6?<_M7- Q!LKE,S/E@$WU'?+R;GG[5/EB MN/];=G4O$W[L?#%R^#7TUNK ,'_^(,5V*>_4?;$66[YYO]*/WV/UK'\V-5/V M9U>4"%&*20)Q&'"(,LD@D0C#2$4R(D&,>.Q4U\2^Z[E]!C]M'Q]I\6Q>P+W? M4J5AJ)-BMFDUK>?Z"H8DMZ:9Q==[E*[KB.5W>F[T9<\RDG2)@%DE.>0(1DD3/SA,& M,\$)C&(2A#PCE##'M):7.YW;N[K#;+YK.]2@A>T\>W,: $MWP3.M8SL*US,Z M(#6B/47>$B-:=#EQ6D1[$HZ3(CK<._1,V5OM>W_-5U__6JQ_WSR8DV]T];Q( M,I)R&@D8(BPADHQ"2N,4"A4K)&6*$VQ7UZB_G[D)3W-RJL4*:K"@0>MZNNPT MM1<6Z_P1-K*D#.1JP#FS7B:N.&MVNMV)SYOU&G=\YJS_\F%^26>[0L_6[XI* M=T1UHE7/_:L8VD42Z?F 3!'4+HCV39)8NR4$FZQ848#2B&K!L$J/ZM#GW,3A M]4$2YR=:@&_5X?0G6=0QQ%4T\;84^Y\XIG"V&0@N!%,A%S -F9ZP)5$(LSB+ M8* D"@3),A0)MP3;GH=BVKQDWWIS44W2@X*6CZ'+K\$]$OJG.M-RNA*GBHK]!4GNDLGR3EWRY M-JOXNRE40#.12<&AP*$Y>88CF'$L(,ZB($[CB(1)[/JQL.Y]CI^-!GRU_GT M'^SQ#Y[5NHV-O62-PO@$XN6+[$$BYDR:1SFS[WMR87.FY93$N3?B/BG^7% 3 MJ_/I^9&MEXN49 1E"=9"QA1$0@:0(FX6RUF*19J2@%O5Q#MJ>6XBU8 #-3K[ MB>XA79>GMH-)&%DW+.UWFKR>M'70=/6PIC8C.-%HA/7#'/[F_2[SU6N"O/A MO6/+_&NU'UWNLI[5!Q&;?=( )QG.,NWU$Y9"Q*B"&949E(IR%AK?7SDEG7!& M,+?7NS5@%\%FN8P\? CL//Q1B1U9*%KL3;Z;VM7OX#_('=F<-?>W_7TU@YY< M?O?^)W7[!]/STO4?WM"P-&QZCI%_DW7T?IW,L7FQ6)2R1*$(*A1@LZS!(8V" M##*!&(\0SZ2RB@Z\U-'<)&P'M3V.4X-UR^UUEM4++HM'KD96I3,T758>-[[< M\I[YX&VZ'&<-?\U!I1JOKW!O"S(N92L[>_^DFKRXO?V-C<%:,%6\Q"QA^LF /T$VRF!-]I&EH0#QCI(VR01_J3!BA%/ M&M'?UZ1B867V2]6PNVF8?%2'NQ[62]'-C_C78EV6"Q(H%;(DA"C$VFD0*H&$ M5T>O>!QAR2*421?M.-_5W(1CA_2*G*4]Q-IIAA^Z1A:,/5-=E#>@PNE/+2YS MX4DJ>CJ:5" II MJA"4DF$412E+J9/0C(YX;GK5659ES[L#]<^@@NPF6^./MIWZS6H,1Q;1WN$# MO]9X/4[+)N/6DRB/CW=2;9^,_I>?B.DZ'I2T;%4%"34GV.^+]?^5?/,+7=&Z MRM,[N5M]D0CIF:L44& 3AA!+ BDC*52"8R90G/#(+OS'K=^YJ7X#%3SNL)I2 M]FZ%B*TYM]@.&(?)D;6W!;W+G-"RNL<-#/ AVP4.]#HE.AN#YLE2GC5T%PW= M3Z;M)2URW[*K9$:R5&))$JM5!\=^YR8Z#=J\SB+UN$/LO&'JRK^%1SD.JR,K M4 L:&-2@A6WR'>Z!@T\CD^O@3XY#\D3^I"^RW;Q*=\IZO4J'YJ;S*MUM// J M!]Q^K5=9A=)\6>6;\N.G+\V\*E6_7\2J[X@_&(;O_( MRX5,D<)$1#!(C9Z$2$"&,RTJ$8_,J0I"8J==JDL=SDU-#O " QCL\+J>C+Y MM9VB^"1P_%7&L]R!7PU8K^>=[7CQ=L3Y0G<3GVJV,_[X(+/E?4-*AN[RA[[; M:D](-LD+/QKW>'E/GZNM^G?K8E<,IIH3/^7ZM]6N?EDG&3U,GRM(2@,6:B6B MF4D%9DX]X"""">=)FH8XE)']]'4,A'/3KVY2WMI*T.;@K!/1MW;6]3$[1;R- M[]1D>FM+>KM,VT89?HO9\_<>U)$U=3>>=T?C69NX'U!3CV _G+?5DF!E9S.8 MH,['[)"6>:J7W*%&ZG<>[:F*J';>8E6/^F,SZD4]ZD_MJ)MDY^N#EY@WHU[5 M+O"VQS0F\_UE5\?H>,*ZK"/R=EBX=-#ZI^W_:L)?._IFK!BX<-)4R/DJU M78E]6-2V,!^DA4H0BEF"81"B3/OI2L(L1(E^M3G5/Z&I<(NB[^]N;J]ZBU9_ MG WK35,&R!0Z-!^47'LSN^E%')O8^C2$/&-F(2$,8:94""5+11BC(&3( M*2O,U ;,3>T^/\@VT78UWZ"@4Z_)[")TS )[NT!KF&.9ZJD?%SN9G?-#,+)P M=TV_ 0?&US6V.N8?5GS8,]#-AFGNN?#(@%]'<1"_UR#Z*@<^-?QIJXQ_I\$Y M*E[^O7!<>9"M4]WP[_GFX>BH0WEXUJ$\/!FQ^^A7;2WB+ P1#S#$2%&(, D@ M23B&:<(2FDD:1V&Z>))%OA;:^&)C]R4=!:N+4KY$/)YHOI)?\]7*:!JC^A?< MLH#XN*,:416AD#$8$$H@2C"!&=4^4D!E0CB7::K"9E3?:C_PO]*8MGC'&]&W M=17S&0VGG>?RW0=H9/=D?\[PYJ 4\^_:1M U$M16@D,S;\#.3E 9>M,YJU@U M.\(1Q3&&PO>Q1*\8O\]1Q#%H/GO\<)3.!NS+=]?[:P]%'M0Z?F[W!MYLY7]* M6GS6#XYOC%;EQ= M'WRW&2>VTA02UR\1=MA4'39"%GOCH_,^]DSS8#>[L:")8]B+\FX#7%L!C!F@ MLF/T 7#8MAY](";:E[X[O]&\7_0^?!V>S8!LC#V^=J*O(K-WJWE8R]/M)5]E M^<%F\74M>8H]W==V#Q=)%O"89PH2QCA$*,U@1C($$RP9%H0&!+&KXDX[GF<%@#]\JHTR[)ECM(GJ@;>__H*-KT!MQ?9NWZ0-,3=(P59-KM MZOL&F)XP^F)PZ:E[!A:OWFK?^1];W=C;;T:5=@6EF*(X2A&&*DP"(QL",I)( MF*64*!I(*B.GO9US'%GJ<]3:B84/PD86BD%S>WO MM!!U?9([=2M$5=":+JOKRMOMYF%=Y/^48F$.1J>22Z2 =RJE K-94GR3HJJ.6E5%+1W+HHXYX)9Z-X]A'%LR M#318V0"Z=H*.H2:+6_>ZQEA067O3U% R^[^=QZ$V&>QM]JB_XP^,+PD?$>FT M7X'Q*3_ZD$S0Y<3?HMV"\6U9;A_K&@DFZ[$Y /JW]5(W8^;C'^E&_D+_,(N. M"X$)Y4)B&*09@]KG-2F+HPPF,:9!%G%$8C3)I\D9^NR^5 :WUJYO.[ WX+&& M.M&'R7WT1_Y.C3JF\_]L=;*4=@BX 2T%8,\!,"3<@%\N/"_3?/GO#$0S["KY?\<*L([^1]9_O5TVD4ZE1F:W/VY70/RFVBPF-K,M^*%D4^A=-PDFWC]? 0;/[$(T_%"-_5%H#P ^M"3^:/=[=X#1F M5./0& (ZEOC[+ES'I">-'PAB4KV^CJB7VGME:P,B-JJ=N%NMX:(N.6^2A>" MT3#C"-(D#;7/CV.8(HSOC2LX==]T40,]J ]B OJN&^8-OMG* MS^N/4KN9QBLMC"XV9\BT9G[0T)N3C;%,!%*1A"1."$0R)) %*86$T90D*&5A M[)2_SK+?N6F>B5_:K+4/5P'77E_A>H+4EG [UVT$&D>6QX;!!C-H0/MSP1P9 M\>1SV?8ZJ9/E2,5+K\KU]H$A1WI.E&_>45Y-6"P#"+$CW9% Q2 MA3%,*(I1IN>A,G4+-3K1R=RDI<8(6I".,46G6+23D&NY&5DO7M R0A6B/@)\ M10V=ZF+::*$>(X^BA/JN'?B6F]H\=^KOU*R';>Z*C_G7A\W;/V3!\U+>%SF7 MNU^6S6_+<)&&**HJ/8K(I*P(2:B=#A%!E9(TC7 L$N'D= Q",3>=:/&")P/8 M[-[^7D.N]NRWI3"!B?7>O>/6_;!!LE29L:D?6X:J$FB:[ :D?OI!A=+L.S0# MYJ+#W*SB$00 M(:)22&-FBN#&F=9"%D&1DE QGJ4XX BEP),JG.YC M4FWH-?.E0O1?/&!/JHV?Z]3=OG\P64,7 9$BCE *LY JB))$0,8D@H*C1&&% M5!999?7L[V9V2K$+;\WW4,'3@V/6[/.T6FQ5>2%KY/>_X>E.@0Y*<.^/)X>] M*R]\3;2#-8@WM]VLBW3T[FF=OWNZG:V+%ASL;UV^>H N5EGT?R]RHSE_-7.T M^RK]S%T5:K5@$==N$@I@&E.DM1$I[3]A @5+$198A5&*%]]DP=96ZMC;FF&4ZZWW>AJX)_TTUBK;]G3#8+9A99:9RGO8/Y\S0E M=N]_TNGR8'I>3J6'-S2DB-:3- E$[[?%D_;/;OD_MGF9UYE'3<+E7);M5D!; M^C.D49#@%&(2A>:8<@BI2F(H!,%1FM!(IE;'E ?U/C=Q^W1_^WJW/^92U+!#O]^'O%@MU /A+B6B1B1^JO)/S0 \-0- .P/ M=P/0[,S[J_ TD+C^ZDVNC4Y8F6F@O8=5EX8V,CB'5KDIMMST\'YU7ZR_ZN=. M^]GKLEP@D>(D3# D2:!]71)$D"9$PB 3L>!!%.A/A&,*K7-]S4WXNU!AOH)/ M#5CGW%EGR;7S:3U1-K*^=U&:HTPMSAM0(?6:.NL2'?XR9YWM:>K$69=,/I$W MZ^(MGC+N?=;M-/&;68H(82J$"<8((H8QS&@S[)VXQ4TM MRF*S^"C;M?=;K3[5WLAK<\91%M4IE _Z 6F>[9!B+'F2PC TB:%5*&'&%==_ MPQ%1*4526$TXG7J=GX+L40(#TTX[W)CN5Y'1^!M=3UY0YU%)!G'2IRFZP8Z> MZ'_MM<2MKTE499#YK;X,NWE@KB2Y7-:YAW^AQ6_2+*N9I!2K4BY$2 FEG,,D MDZ;0C$HA08I R4(4810QEF5.N8W.=C4W3?E$ETTVA\<6J6,.HO.LVCDD?K@: M>W&J!ED1M8,)&IP>D_!Z4DJ8F1K,,J)#0NL!3B*3)?!:B$+*0QR95N,I0G& 16*G#Q9[F)@XU M5E"#A=H1;^$Z++KV,FNQHNV+KY$%XH J<+>G:LA"=2]G#HO2OKB;: &ZX5#5 M'%9E'&O$OM::;?CH75?N;6"Z-60;.P[6BZUN&.A5F?CTA_52WU&^_<;\RX@>()( M2Q__*FK&]NT[X/X'J.&!V\VFR-EV4R59VZQ-4@_ILS;\>49\>?C''4SKV9\U M\,BC/W_EP T(6CZ8_YG&ONGY[)K\D^87>O)P^(/.E>]7S2G#-WGY MM"[I\J_%>OND[S!%==>F>.Y6BB8N9[TJ%UELHOD4AA%/.$0LD'I>P#,8!DA0 M052J<.*NS%.:,$_--S;= &[.S,J]:=4$O-@97OW^!K#=]V&MFMA:QVV5*9^8 M6- L#>,8IAG&$"F508)8Y1Y))6B$ RYT&_&LKJ2'W''E-&=S?:]27F$7CQP\,[=AR E@10L5#=V>4![(GPN/WX M'8;/UW[FE-"GW2#]#H-RM./Z/3 ,\[>J["!WZDMI\GW+S1W;T'PEQ?O5VS_X M@\D5_FY=G"SWN)"Q8$FJ/X4BS"1$5,_ * HR_;>,""8$CYA3.,A@)'-;>:T, M@6L%MR80T]A2@G5CC0F>DHT]52H13^E#A@^CW9=JDL$9^;.S&YB*$75Y $MC])-OM>17';6EM M]4Y,](<*7*TZ4ZK2U$5NS:\_ "]5K!L+8 $4S_NAW;)%,C,?D(D$D/ED0@LA M%>1YFNBU*.:0Q5FN5Q8$9PA)I->H5@=5%P2-S5M6NH*6LL!H"VIU+4]>+J%[ MX;#*(V:!G5A?N.P/6RRQ..%_5I+_^X_%ZW_H1U2N1_^P\S@7'SS,&8RE>=LC M&-OK>QQ<__H_OW[[?OOU]LM4R>]\*K7BW^7R=9S1L+Y4[1[O5JN-B0L?EW2^HKPB:1$QCZ,L@ZE,E?;)>0QI MI*.V)!>1CN$D+[!P2CET$#XV]VQT-UNRY0'Z#9AO&5RJ=KU@6II@%ECKG1%7 M]/-U&2?+ \Y Z(<^^JR!_UX!OZ/.J5OFWFV!;^GO\1"T!VJ^CD==1 ][<-H# ME*,CU3[/Z!%][O,3?%RLUDV/]4F"(Y:A/(*)U"M0%&$,61*GD"+*8H0ET;&G M=-:5X= J0-0BUC3#TR!?PDP:H(_&D5=HLH.L!QB M23^@#11!GGJ]?(6,EX'H#!0[;A\N/+QLPUY0:'%Y#Z]XNUK1MV]53\P'^K98 M?FA6.+&07"BN/2%*("I8!@DN/Y8G12NSQEIL)_?ZQ-=DH+2:+O_GM0V6SPZ'W2(W#,B!O>V91LJ[0*I6 MW28$]= \^1)BP1HFGQ7\SDV2+P%RN3'RQ2?T\V;;)O:M_LJ_:8F;I13W\V_2 M] K40@W'_>KW^8*MY/+59(O?S5\V:_UK#8B^JYP3'^6?ZP\:AG],##,SR1F% M&4J0]GL\ACB-*:0\SCDI1$&2U,7OA5!R;![R^^;YF2[?S+94RUD:RT%INOG% M%SV9S4!JU0)]N-&V"D" ?3AI!9?4A7#6/%-NNU_6RC44I M16DF89)F'"(=($/&(PPC422F;#+74X0]J^HI$:-S[:62NY;I+F2>)R&TV"&X M&IC09S('F/1B.CT)C@N=Z;4@#<59:OL".9*2=IG?S3QZ\LX!Z46[--_G$.V\ MLF7U& 7VL(E'3J-G8*0XMXYDID G_E#2B->N#S]:"X M,.!GWAQOI#?G(>CFNCEQWX 4-^>UWF>VZ;BN/WO YT]W'^_FY?+P M]MEP$4YBCD61913RA!.(=,P"&8D5Q*3(9)9B5BBGECXGI8S-H]7* 5IJ!]@; M,"J[ETP?PVD7PUP-4F#G5E48&PU! U6EH]_ZX+,0>"SD/98Q>,7M63-/E<:> MO[@O:;GIMEQFS-5A-LZ(2J-,QRM8+U40EQQ2SC",<)8RG$6R0-2NB^)9&2ZO M\C#-$S^VFDZ[,I,? AAE45)($ID.E!I%BB1D2$6044[BG"0JH8,9T;$-6N,)'4Z>3RC)P1?M,OBWE))E,>,YI, M@DNTOTZXVGWH'M *_+G7K0BK;-Z 9W,7D/#69O"TE(&;"7::>MPRL/ORGD5- MIF[@@WZR,)^"?N_+M?"MZ2[UH^1J__"VNZ1N3'BKEV)BO_#@]I5.9T:OSXME MV:!UDO)(1I(CR"DWG.M)#C%*,91)*F,<(:IRIQ2P4(J.S2-5/6U78"D-)SZ@ MC;XEYX2IE"I))UXV2_/3VG 7JLU:Q\E5Z^'5%653H=X$.QJ*$ZW;O_2@M]EC %7A,?!5[A5)SV,*PP& ?%9&% MEM?WC+',6S99&3_F9=/#A\5LRM]V(17/>*X4*J!>9&*(]'H3TDP4,$M$5- D M3B+IU,WCHL2Q31%-CGQ+8]>3QTL8V_ELK\@%=KX-:']4*H:)7JT!\78V>4G> MP,>4EN8?GUC:WMB7Q9ZN2Y]6QLX3O;I-J%34T*3$$*5*F=@T@BE7/$4%E1ES MVNW??_S8W,56NWKA9IEI= 8[RVBN-R*A8S!K,'IP?I^RV1O?]][#!^;Z/F78 M,<_WR:OZ;E.M5E+NUV]^DW/YD\X>Y?)Y@@3.8T(1%)&2$*%8KRZC*(8R1VF6 M$IZ3G+EM5W7*&]LG7:L&M*QGUWVJ;F!M]ZN\P15\W\IH>@,.RM(-DW %X6,7 MA#VVKZR \;:-U2UMX.TL*]./M[7L;G/G4OQ49W?\]X8N]8_LF7Q;+]81D M69I+GD(6":77#TD$22YU,%"((J9SSF+!86=58= D9V\==Z5C6SY5:N@8$)V"T MC0*N R?XU+^/2X!3ZBX$O,WQ)T0,/+&?-_)X-N^XMM]W7I(OKVHNU6U)N\(1 MEU%ALH\9@RAA>@$@XPS23+*"XY0+H5P^])-2QO:EU^K5_ &.? &G<;3[TJ]& M)_"G7NEWTU ?>_?%_;[W_:7 EE3]JU:_9NIF MI(@52@J8\"+5DWR108QP:D+Y#!+8_, A35B+1.0&S!;S']!] M8^ R[':NPBN8@=W&T:; 5MT;L%/8GPNQQL:3.[DL;U#78FW^H9NQO]'-Y:ST M^O6;.>Z\_7.ZFG DI8Q5!B6C5(<4L80L-5N,"9(\52I).+)Q*WM/'9OK,+NT MT]5ZRNFLH6BPK\S>QZO;'_1&88 #@!, Z)!!Z^DA7#AI=]?WK&]H?/]9@WRK)]5OOL?3O^Q13_CX)$W2 9V_W*__NK+LT ]MU4'4"DO1*X*!+F0&"*$$61%7, HED*A",F<6VW]7ZO(V+[L MG9J@T=.A$.^:$;FP!3@@SH%]A[8"U&8 ;0=HJ(ON%="F@)8MX,1HN!V_7CTJ M#F64 XW.0.669I1X/4J&8F^U(YB:ZE%:M4:)[D;II;;*5UVF!TP[ZS>O>?YP M=9X>4-BK!_7QO+YY:275PP-=KM]:].IE)(1D*D21%U 2IB"*"80L7-[B3P<\O"6AG98#R;!_]&E_^0ZY*;[%Y]*U/Z3=M6R=;?#2M9N67SM^GZ MZ>-B7NZ=;>CL-[JN?W&O?G]Y7"3Q;_J73ZM)FL9Q$9ENJI)H+R--FR^42^UT MBH+3+(T3:;7E'4S#L?FFK8W@N302O#9\DLO&3B"TH6"UM13\U*8"OK-5W]H8 M:V[P]T8(>Z&^/*OIHS5$?D6Q.!L1'LC 3& M2M R$^SL-#?^_@(>]1C'X+=1C+%+W[1W'NNA^JP%^Z[C^KOVUJ8MX(!TMW4+ M(7C -G !<=MO&Q=2D!^2O1;/W*>*9FZ2DQRC7.10B51 ) 2"V%!9Y"GA$4D8 M%NPJPKUCD6.;VKV3[YU V7;=X1.[X,N/0U*^7]I(U@J?+QR]FJ'O/#J!V/I. M"'Q7YK[S %QB\>NXLS\3UJ__W$SU[&D($&[7'^ER^:9%E5YP$@LBR^2:-$US MB%1,(<8%@BE))4X94Y@[.9EN<6-S,$9;('?JNK-B=4!KYUG\ 1;8JY18M32] M 70-&F6K@-PO8]9E5#Q29W4(&YQ#Z[+AI\BT+.[JF9I7[;2NODDNIR6C^E>Y MKK.!)A@IE$J502X1A6ZAV>FK_H4SF[NULMOA9TET8;H,ZB??+8K5+]/.8W6>!EJ\D MORY1P^;Z61A]E/)G%[== />J*K:@/C M>:MR:]?#S>?8P6_G?/Q!.A"/<:VOV06J-08[E5N;A_X\CA-$GER/GTL84YE8Y@IV1/9H&3R-HY&F]XA3ZG.(3*^X&O%1*^V0A.RGH?=&5CP59VZ6K;@ZHNL,L4S>*<<<@5BB#*)(:4%0G,(JPB6?"8%%:YQBY" MQ^8]VIWCMJKV;.O7A;6=(_&-8&!_ME9@'"V-YW- MO3U23;:U$;=S\7DZ-\OE_2J))D:J#K6$J<[\/%UQ.ON[I,L)(CR*98HADDD* M490+2(G^B6=<18J)N$B%=5+)=;J,S3\]+DS?X)I=\WDZGSYOGNN"JY=FN2 V MTG0K->^P0Y[ E6/6[= &'HG ?FY7HF42KFM3:J+FK3%@NWS;FF,2.2J#@+%H MN,%Q2-<8;I &2LS8#9;)N^9UY^W]&L6WW<>SW [60@%5#=:;MLQ7]H4??#OS M+*X4,5Q&A1\L]G(G/#W2:SKVZI,6,%N8B79'9HD+DLE$K]%%E&:F7IA!1J(" M"D4CI@C%26Q%^--#]MCFM+/YQXY+=Q?X[>+O0* &GI[.XPEVBH,_ I&-.B,6 M-N/[I.0Q9(!W06*9$=[YB'XN[&ZNOWBY6M_-^>)9UETGOB[FB\:O?I7K"4D0 MSQ*:P;Q0)M6+*,A$06#.:18AG N<.FT4V @=F]-J=-:1ME'Z!LRE8[:7%=1V M?LHW@($=U!:[2E_P2ZWQ7TJ&@ZW2^F\=F#J[)A>0//DD*Y&#.B,7$ Z]D-.] M_:D1=^'89_TOJXE^G2@1)(%Y9/A4:)I#A@F!:1'E1*JD8(4S->*!C+$YERWW M7VNU"$I-W;D1#^&\L%#W U)@!](#GU[DB&<0N(H<\?"9@Y,CGC'J%#GBN4O[ MQ18F)X.NGAZ6B]>ID.+#V^\K*>[FNR6;#FI>R]/1+1.82*B2' M(960HE5$. M,4DD5"PM1%3P3"5.I.CN*HS--91YC6JV^+D"9GC!8K>]L=7=D82MQ[C8A25A MT0[L8[3RH 2[4=]TP?G%6*!#OK^TN)MW5@2A>.L/HJ<@IH<"@X8T_0$Z#'"N M>-*5:1Q?IG-YIW_4T4X1%7F:)E IT[>>" SU@DK 5*5YG@G)F73J8'HL8FP> MK=7]P.@(2B7[]H/8 6GGHJZ#)[ +??)YY2B,Z]Q3&P.,-: RQ[UT_:IA"7'F>>7PC//$ MTWPR93&G,*(1'K^RA&'A,8*%GI>B_0Z/F(Y=4HC[)(VMCFJ4M9\>_Q@H:YJ M=UE^AXXGF]V VT6ZWF ,/,GL32LW8*OJ=E[QF$=H XFO!,).6<-F#MJ8?90R M:'53/W_R-[HL^T1K3_9M^N-IO;K?K%=K/7GI[ZAL $;B(BOBF$#"%()(F@U! M)%)88-,7*1*4Q)F+2[DD<&Q>I=$7R#]?ILNJ/[-V_].%*_%O3OE:"K.S MIR4POBW@_QQJ5J MS<6 #SWGG&5,=>5*-C: RTA=5:O\A MO9HE=9"A?7>"U.L_V[#4J%>/0@]6U/XRWYL0]6JT++A0KY?1,X.ME>RZEP4[ M2602Q2B+H4BIA$AE*:0Q$Y!E2F1<1!BGT61M#C#M=JC.2G*:C;?R0A_*+M9/ MI MP"C&>6Z5TM4I96Q1>JTG6!M%P(KN88^O&U_ M_-]3[6V7_.GMBWS5UALJ+1G)S+ *:5\8(X@XXQ#'DD&-:8&2/,H(([W8ACK% MCLU-[BASP%;9GG'"D@459#*)(U8E),"8S=^5R]Z67V @_*_ MEMJ"G;HE-;)KNI.?,;/S=,.-PT"ED?O[I3=@:R#4RD)CX@UH]]YO:6F:;E3DA]^KWE;S5KD0O MIU-,$HP()"G&$&$D(/9P/6#:.?)!AV:P-ZNM,4,2JVA_FHJAW<#=@/6.EFO MC#)5[L:LH[L\=DOR!;*OADI7ZS-LSR5?\!VU9?+VX)ZM5I8+L>'KN[GV&\_E M9O*7;34WDI*(M$B@)(8$2&@?C)'*H.192AB+4I$[50!TR!J;=ZU5!2U=KZB4 M[P+9SD=Z@B[X$4M/U-Q[IES&PU>GE Y)P_9'N6SR45<4BUOZ99$A&8Q2J'*$48LEAP*"B+29[D,1%V?>D[A(S-46Q9L7:*@DI3 M=]:P(T O'+QZ@BGTYI@[0KUXP\Y!JPL]>Z?^1?-.:S MAZ?%7%;!R(3A6 A35TQE4N@%66SX1WD$:9(F613C.%%61X>G'CZVC[K4#Y0* MUF&[_<=\!-SEC_@:. )_O Y(.'VTYTSN];$>/6RPC_2<&>V/\^PU/=*=/BY^ M2CV'/T_-H5+#.6":%M'Y6]WD)HWC),X9@31C&"(N8HB%8#"-(Q*I6$EIUVW5 M4M[8/MU2XZIVJ%(3?/GRT2&_QP+A"Q^T?]Q"[UF4D-7:MCAE&@ O]A+JA:)# MOI1?- ?*G+J JJ_D*7ML.M.H+!XS7$*5O4U[J54.MUUY1%:EKYK3MXDH(IQ+ M)6 1%1E$"8D@BY(<"I+$+%<19S)VR4$_(8[_M4JR7A?X)UXM*^G1CVRU7OYG?S5SU7 M+):FXS'.*4MSFD.5&)*EM,@AXTELCJB$0BE*E$K<$I(ZY8TOT:A1[LVUZ4(7 MJG8?_O5(#=5FX:@^W7 CMI3UV5S! A-O716Z9 W<3L'"[.,^"C8W]>58_WG+ M^6(S-[[H8;F8ZQ]YU=_Q83&;\K?JSUTCI"B6"O.$0LX*H==HL828$ &%E(SS M1&$6.1VLN"HPMD7;3GFPKSVXJPZU/VS6X.MB#?XNU^!7I:3AA):NA.N.@V3G MET)"']A5:=7!6>1O0*4X^*/^?Y#.57W1\\:R[BA^8([U?N <,ZSW?(ZO&*JN M>?DDE5PNI:C+_F[GXMY4L);Y1JM)@I-8BHQ"R5+M$RF+(,8)@6FD5($X2VGB MF.W=3Y'Q15U-#59=X5O1JE7%OW4E5J\DQ)[CU#=<\X;]N\9QS5C4ZI=#41I0 M93(&#>Y<$ P6]5DI\<[AH M0E^-$IZ?U3)= MYX/:&]&W;U(O;#?R@;XMEK?-:0L75,8BA5F<,^U$4@QQE&60Q4J1/,N8CK*L M3P7/21F;]RAU [<.YU9G\;,X\_.!2F!74*H(:AU!#4^?\[WS[YG]J9X/O 8Z MRSN)FZ\3O$LX=)[;G;UYN-.Z2_KOG=%=O+A? -4<]TWE:EO5O.O3/$$B8C1" M!,I(2(@(4Y"J2(=0.259Q#F1.7$YI.L6-[;SNHHM:K;3&3SKR%8K*@!= V6* M^&M:N#F@8&ERSIY'+]]J#?AK5>"!J^VQ]1/+"D_*"$D M2A6#C"0)1)EA,T=3_/F6S M2_6>O=&V,0SM7<[!YYU:Q0$7?T45%R4.75QA"\&)(@OK6_OYFV^R+/Y_ MH%I*F>)MN@[KY:.O) M#V8Y^?M\P59R^6K(;N[F+YNU_K4&7M]U4!:KAR9F*N(PRF(,$=+Q,Y$TAEBO MY.,X15&1]&,J]*CDV*:BUA*T925HS 3WIO"N6=V7EH*VJ:"T%>P;>T75N_1#CQG[0;ZYO1(+XY&^L;74/EQT8B07^5ZEQG^N#"MB?1B[74J#)/&[RLI[N:[AKXFI;"B M6V.KLJO!I$!8B217,(LC"E$<4XA5DL TIPH54F0DLJJD"ZGDV*:@EHU5T[K: M2C"7:S SA2/Z7\W/9>NZC3;/9-7LZ/GIUL+_=*2O#/$&V$TV[SVNH0\-]X=T M:R#0%N[7N9A?EQW;&D,-K]$OOU>#_!?0ZF2_M1?\T5CL<<8).2"^&#!#J#@L M(69 D(_X,4/*\GP&<)A&3A%.LUR8Y'X5091C 4E")509S6/)DBS!3IW9;06/ M;69H]"XW4;9*WQ@OXND\H%\"?P@\ WOD1N4;4"I]B.@0B?NNJ(4^-WC71'U7 M,*Q/$/PFYC\LZQ36,N_L@2[OE]_79A.H#.8?Y+),19L4E F24@)3P]V$4))# MDB(.99$RFA18,)9-7N62+>Q=EHU@EP^L+3[D=U;KW22@OM F54*/5Y5W6F:@ M;E9B]R^.B:B6HV+KS'PC'=R5-1#7^:E:9\-^66E=;V9IO:N\59_^RP4H;][+ M2NC OLL%B&//Y71WS^0NN5I)N4]7O.5W>*!O95SX:2/_+NGRLWXS)VG*HRBC M"F*LW1A*1 YQHA(8,:%DRBGG<>X2ERODEIE= 8$,G8U1 MJG[36L36=.9;_6_,\I>9]-"IN '&!&!L\)@"UA,]7TEAKN*'31/K"%JYZ<\H!78'?4!JD\)8A<,_FH,3TH9NHBPR]0358*=E_<] MQ1 E>2>=F3GD;OZ1ODS7=%:75J@B3G,B!$Q37.AU&=+Q3:S792HJ4I1'#"OJ M1!K1*6ULCF&G+##%F% ONGBEK^LQ01?$MOO]GH +OG&_Q>RAQJQ6]7+)3X\] M=PM0O&V>=\D:>!?)/YG4;B*Q?_XJ8/3^)\U[!2/__F+^Q:0Z/7) ME*^E,(?D7[76==/Z!!$I"IG#7.#8D/HSR,Q.*9.,1#F)(DR=N$7."1K;9[_3 MLTQ$@)V6/HM"NG'P5LYQ1LS A1C=QAZ74%RXOI]K_9LT3=BD MN-6?&?TAF\YMGZ:SC?[78VHAB506LT+!N#"-=(G0SC9C$N*$)T7!,%74:1'F M*']LCKA1']!*_U,<3TV6*%\\OVS*HY=M,NGVT/T&B,KB_HQ0KB-IYYL"CD]@ ME[4=FEKU=@/+:I!:>M^ VB)_WJPG9-#^8\K7GQ7(]_5?Y[V>3HB:49P1'@L*41#IH941 7- "2H8Y MP;'*4!J[,87Z4LWJZQV4.]0<9P*Z,P^(EGV.6^>^QL]REWW(,1EH0[XU#FV; M;L#6JJK$N&77#3C(]KS93_?TN(/O&7!?F_V^U!KV7, SF$='"+Z?W\^GEW/$ M!ZH#---G1\Y7I;1;TY_XAZPX,':7U-D3MS_I4FQKR&Y7J\WS2UF6;,J537S^ M/PMM5YEO\4W;]]MT/GW>/$\B&HLXISIP-DSY2,8*THPP*) L6!I%E#,G0IWA M5!];S%WJK5W0ZU;9&_!HV(PPX^G9SQCC'-/"L4EH$2Y- VVS0LML48K6O MJVT'I?%[W&4M &Y P'880 ,"#?@MPOOB_/L,_S0>9J?!E1\T!EL^ $YG./> M08,>E+L'"8-ZBP M^%PEA5%T^%514,!/KH+"2NRQZMDOD/JX6*U7DT+(2- "0Y[H90TB#$%<1#DL M(L+UBH9+D1BZF[KNM]-FWZ8ZZ^22ZG M)5E=71&4Q062-,]UM(LY1)G $.-<0I467.:4)#+C3D579P2-+59M] 0[19U/ MBT\C:GWZ>S5.X4]S#R$*45=U 0A_IZRGQ0Q]:MII[(E3T.[KKV['6 90$R)1 MHIA>[F*>2HBB1$*"20*)8#)+(Q07TJGT\E# V+[^_;:+_U?T[U$4Q:?8;_X+ M9-&-_J7YKTG=HYOUTV(Y_9=)ZEN5V6)ZY,MA^;?_%>?1?Z71#3#O7[FG]4F/ M7.M7XB[ ?J) M+U53\=EYDG:[=\7.OUWS!@3V:_O](FN6X:H/>Y!.D7OV^^\.63W^O3I"[AG7 MT05R_[I^;NN39.N[^6J]+*/7KWJ(Z_I$$A69XA&%:1$7$"F90,RR"&82*10S MR8K8:@.,JFZ?]UE,[3YS'T@%_MQ/@A2@X/,2%)Z^_+-B M!O4 EXP]] 07K^]Y#,"?I-C,Y+UJ;P;)]>IV+BS(NQ]-1+7CT^28)TD>$8BH M]B HIM3DW7)(HEAAAK4KH4Y]@KQJ-S;?\WWS_$R7;R;^J8PJXX^39/TZ9FEM M&Q]3]SL>%7@=<\O3@?<:R= ' K5=9A3;/1CQ&((_2B/#D+$&@=_7QK]7 MW8;=ZP\!Z]'V?A A/7;T_T;-D<)Z>R)]JG^KD K'1@_;79S%5G-?IPD.('6>+M@\9[C3!@>K]DX?7.[S0=1=U>'=;G?5 M)I%D/(LY@L34/Z 8F:["5$&1R%AQI5?[L;J&H/M0H,L'\$[$W,=;C[W+@"^ M;Q<0^P,TL(,^XM^N2WMWRH;BW#X'2A"N[2-A[\BQ?<[P;F[MLW>]>\_&,@2= MJ(0F-"X*J))8AX9<,DB+.(6$2Y6F^CS]-](.OK\/TJ788]J?'7I.4?:[*Z*!_Q>// MQ21-HQPSGFH72Q*(I*$BRQ)# LM)'&4)EIG]EFX/!<86EUN4H *A@_;IW*0. MH3Y)S0ZC8[$A'!CSP)ZTU1/VL,*QM6G^0]J[N]6GT^)[/,=#V_4S M70WJ[?(J@7"29"12B""88&2:F(@"LJ*(8)JR3*$B$CEAO7NJVV@PMOG&:%7Z MO(4R!)?;M%M@7A+PLS[HD7_*)9^NI&,NB/OXV,7Q05$//., M?-RKSZF4#%J@U+>JUSGE*D=53LG+P^\<3?!E.(,RQ2RN,!Z"95F MD.180!YS(G*1D$A:M89UECPV[[&_=]2T-NS:.PJT9>1[FVY$SL9]?RX4QH'V MX_Z/V(A[C_TW[QMO(]UQNWJK[>J0<5Y&GG^;KI\^ZN7LXEDNMV+JZ'1B"$,% MSA)((VK(1",)L>E!Q3*5,IEF**6I6TJHC5B7;V>8Q-#O3XOE&AI^-2":Q,:E M?)5S6[_DA'JJD@210D&>)#IJ9[R U/Q$XQCC2 B:Y$Z+>M^8#U+G9A '0R%N M&\/[Q3%X0%^I"WYJ?4&C\![!YT??K<)<(/(6ZUN('#CPMP?A>!7@<&_/'-W6 MQ'(WUY^87*T-@=M\)2=(\BQF>0)Q3B*(*%80%RJ%0A9$I"S+(N+$2]0A:VP> MIU'/9%'N!T53U_.1+H2+2 DL1093GG.(2"8@3HF$64QRPE@J4D3=IE1/& \S MD^Z"T#+53,T6/U?5F92J%P$E]AX!M_/MGD ,[-(/J)JWKVRMJ<<4WLMP^,K& M[9 T;&+M99./Y-N=-DTC0 M/!$H@:1 J2G:XI"R@D.&,2]PD:F(N^WP6@H>F_=^T ]Z,H[#''B_U&V)RH6N M;'H2Z?B1FS$H#V-IP[*FU[ON+'36PV,96 8 /71P66\?M'4&C=* ;=9 JPW> MY-H3?7Q?J+SEGEJ*'3C-U V,XXQ2Q_M[]K*MSL(-]< WTQEROW%MG"99E!$8 M,VD2\A,&"4,$1JA *(XC19 3B527L+$YK9YU_U:XVGD>7V@%]C:-FE7B>ZEH MNTNLQ^:P%GCXZ@3;)6K8MJ\61A_U>+6YIY^[T"Y(KWJ_K^FZY"'_8@;-]""L M"-(2CFF$BP0R%@F(4!%#0B,)$Z0B+#*2\42Z^(M.:6-S&)6R8*LM:-1U3S)L$ FP!?:^)QQX2JF*FLL"I)#*+=V&:*_893AI7R]APK MY1ZEB+FJ;65#4VD,!:6E?6E$O+P#EM[PO48VM/OLRS5*KQC5_O0A/M'WS1WB M1;?W(0[Q">M9UA"O0AQ37^5TMVGY?VC(J_";-FK[Y MF^D1.$F(.:4DR'2^81 )'$,2Y3F,HR*144Z1_ER=ZM:LQ([M<]UJ6*\ W1NX M6L)M%_;X!S'PYW[&.Z K5+*_79'=(DH)8TI3B')% M32VMCA<4X]I?H323PH4DS%ZTDU\:@!%,:UZE9VU65;;$M-$9T*W2;H[*81SL MG%48= ,[+ -L2=;5J&W:/O_R>X7R7\!6>7![&69GM^6.F"?7Y2!X4/?E#LBA M"^OQA'YN[+@UZ42R3$F5*KV4R1.SG84@%5D,DX0G%.4XR2*G5-UC$6,+ETYU MMG7S0B=@M/,VUX$3V*L>[# MI6MX5,'VX\-P8Y+:_"^8W%AKV0@ MA ,[F"VXE0F@M@&TC !;*[;H7^Y:[&\8'*IX!QB.@0IZFV%9UR6.G?6]?9\]7*GOE=;O5?U>^ZR^:78F2#6OZ?]>S$S:7M7T M:R)YBE."4AA'L9Y=N%*FXX*>8DC!LS0N8JRL-LLOR!G;!+)3$S1Z]NM[< Y7 MNT#3 UJ!)X,^0/7(I.N$P5L.W6DI V?/=9IZG#?7?7G/CJZ&=J8BG/FT,2=Q M#W(Y78CR*._7YY?9XDW*\IJFSN9!OQ,3D7*B\H3#A)A:QAC%D"H>0[T,S;), MH#@IG/K7]])B=(ZDDWFS,:/B60*-(0V7FAX ,1V$=5X%8&@,H" M4)FP[3S?:R#<6ZA> Z2O5JF]=!BV)>HU,!VU/KWJ8;T)^%Z6\DG.5]-76:4V M?Y7K>_5(_YRH)$_3+!8PSXA).)89I$3JY;H.I>)"YE&&,Z?F(^=EC>T@84]5 M,%NL'$\-NF"U\V2>P KLK_9QJDL6?OFB\?K+#3"'!GHNT1K?@-OU>CEEFW79 MS6F] _4-W_'1;C\4?2=E30T3=\EDT]0]5V\I2?S^2N=SLS@?EXLO].9_"39 M^KO)CBH/$6XYWSQO9B9C_:]+_7+\/E]*.C-M^_Y*I_,/4BV6TGP:$1*%=C$I M+)!V-JC %-*HR& LXBB)%$X+MTQ7+UJ-+4XK=04[98'1UI4(WF12]XFU+W9U+SH-R[CN M$\8C%G:O#^^YA_;\0J=+LQB_5U\6\Q]?]'P@JM37Q\4'T[G9;.6)>S5!$2QN=V=XF4\Z)I'8H^XY7Y;"!Q# M[\#M(-1QH=$:EFHW.?TZ+F02-*KK:SSNR[G"Y6NGSEKNL'MWKG <[>8Y/\ ] M%_[7^7I7D?5-EO6'\Q^F\G:SFDA.HA01#&,E&$29B"$NLMQXJ"S"E'-16'%- M7A(T-C=4Z;IMB+#5%E3JVJ?.=Z)[X738(V:!74Y?N)PR[6VPZ)5XW_G@P?+P M;5F_FZF/.F3#N*=81")$Q1E$"$#)=8'B KL>RD MC&%SR[K,/$HOZ[RX-YO.TB2K?9+5_^_FS1[X-UDNCUH%>I-(?^-1Q#F,P97*]^N1/;*RN.,F3^2'GO10W/V.(-R@L+'_1D>&7U: MS1"^RC_7CS_E[%7^MIBOGU:3G"$>*^VZHMS0"HJT@%B:BAXD%$&8"IKT)K*V M46!LWDR_FJD'5IDNR.T\6$@@ WNQ\^PSU8Z+HMKF$/4K_G>@5"(\H(,4$NE#+G*,UW^ M0Z[!J\DU<4SG"O="V#GF<0QS8!=>6@ _&!- VTS0LM/49+:OJVT%I;$WK4RQ M\IW0([_?.;$VVF,.6?"!\95H%D[18;/1@@-^E+(67F*_:>K3=$5__%C*BI?P M7GVK6C!5&>U%@@611$!*DTC'V.8G215,E**(HD)$;DR:7<+&-E7LZPKN%:BU M[5.&?':8.()]?7*6I0YV5C]*'[L;K':V%!U>'V M;#:N7K^GB$1;"%X(E6*"/-06G!)C[&YG?[%!?T;7_<= M0LNP,_S A(XI.XH-FC;:72/C<:OS2C##%AQV4%D6'5@_SLV[KI;K MR4?3OT@N7^AR_?95OYZW?TY7DTBQ%#')8(P2[3;S6$(JL(*(9TF>*QJEPBHD M.R=@;/ZPK2,P2MJYMK/X=?LL'Z@$=D9'@( _C(8>HJI+QG7ZFR[=[=;=>?9_^F$_5E%.] MR*O:E!E_LIA-^52V^:RS&(M(?^%I7"00I2J'6'($%9=(F!W F%EQ*/I09FQ^ M09M3,U)43>!JBTS8-%VO0,LHL+,*-&;UH*OV,J+=WF?H<0KLJ=I#=-L:(KV4 MOAOO$#D0C0PX5 ,1CI@AXZVO:K7_5:U:0T9W0_926^:+>,03KIT$)-?*&(Z( MQ!,:>X0DOI[9<\N /TFQFGG>X+9H M<&.VN+FOOR\CXFN-W2%IV'7T99./ULH6M_0M*"HGNYP]<*&%E['&]A-UM M8;(03>K7X\_%1'()MYY;\HQC8*VT!W*E\4VW$O8$_ZO\;O4&IN,?E ME!M2GKR2I=!!G9(;$(<^R?'N?B[I8;EXD4OMZV9F2X-BJRMQ&V-C<3Z-KN6,J&T5OP%PZ-B_H M1#B2L4 $82A2@2"*"=,(HP*JE.81CS.61ZD+R9PWA =@F7LT,L#+(#C;N7A? MZ 5V[(V:-V4>RKI$[M<=/+@G:(&]=LV1A]Z:ZM[>APWER'I MMM7?ZM/"=-J:%!BK'!X MG9;@CTI/EU/$TUA:'-]>C5!@CQ .'(>#TZM!&N@XU!TLMX/.3APZCR]/WSG< MH62GYGM'C=U7^FB6U2R^)SQ&>:2!@E)$AA53$DBY#D=3D@B:((%S1WJ3DV+& MYNYVS:'*CGYJMOBYJK*%%_OMM%S93TZ#;!&=K?8.KJZ1^!S:U"YFXL-+TNI3#Q5'A/HGZ>O91INW40H4H*+ MB%&(E8PA4E1!DDD,4R8PPP()Y9!09RMU;/["J UV>H-*<;#5W*%3@1OZ%M%3 M"$P#.Q(K./MTRK+&U2'P"H'O0+'8=:^M6USF"E-GJ&;]L.&B-U?[]@(ZYYM[ M'L72Z;+LZ/";GB8VRU+6WZ;KI]_G"[:2RU>33'(W?]FL5]^DL7DZFY9OX#?# M$&SJ,\I-T>T)C2$%-G3[6M'91I@>KK_2I>E#O9J(.,4D8P06D9D5.%80%SB& M:9H62J$T$VY5KH-I/K:9Y>.3J68VO$\E54+)D6!.%>K&=F.1X9CS8FV!Y MZCS&\0U];FT&M&ZLTS(;_-1V@[;AH+(<[)M^ [;&@]+ZO:-O@T#=# ,T*)3L M834.'H_!AQXZ7P?I@^D][%'\T,-Q=)@_N +])L.]^L**Q*99TB1YH3*4Z#6, M$A"AB$+"20SCB"A&,>=%H5PFK[.2QC;95)F^BYK09UH5YYKSC84>K;7^0*BPL"1^=(Z$RN2L_QW.CK6&=Q"6$[]^$3M]!>I%*U!&VK+*BU#> [ M;*'Q57IQ2=RP]1>6QA\58=C>=P6_X8?+C%8?#AFMMC'7K9ZSGZOYVRC&UU+\ MSV*F'V-"J6]T+2=)&F.)L@)2@1!$.(T@C97^HV"%0!+Q)'5S3>%U'IMW*Q76 MD_WK5LL>K(6!A]G2/XYK\ 8,U'KR&.[6[*!E^0UH; <[XX&QWC.AX3!#Y9/9 M,+#&PU,<#C,$)[D.!Q+=X[2P[!;WL%QP*<7JLP;N7BE9KN7+GG&?I-AP,UG^ M/M;EN5 M-*:7X2G?&5_M#I1]3YIG&<+?$@"'<[DAWA^+H]*1O16!I\/JA6C,!<9>T*@+ M*HO!UF30MAELC2Y)2%IFEW^O^N!L'_7K.-\'AR/>D;T7 YT.#^XP?'&=##A< MG:?40^@QW 'W@*CNG8T/*;=O8>',E"]^?Y)R_<6\FB8T,\1X"6=$)C2"!.>F MI#GFD#&LH!"I(J@HDCQR.D@X)VALH4:M)R@5!8VFKM6#9T"U6]GZ@"KP_'L: M)6_4@[9(>*L /"-FX)J_;F./J_PN7-]S(X]NB5I*DOD'N2R79Y.XR'F1R1P6 MC#&(4AEICY!I!Q%EG.0)CRER*BX^)VAL'N%APV93OIORJ]8@AEUYLQ*F)TC% MLNQ*LGP.9LO=+P_@A=ZRHBT.IINZ>X;6L]JC\KB[= $*7UM"Y\0,NX]SP=BC MS9=+U_=S$JV^$Q7C\>UF_;183O\EQ804C!/#N90R(2&*$8:$)C&DBL2%#B10 M+)S\1(>LL;F*CRV&]IN:?!W0K;K]*=F[\+9S&)Y0#.PS]COK5(J"G:;^G(8% M')[\1I>D05V'A[\I:0HSFL8R MP0ABI%7X@;LPQG=M(7$%+V0-)[X25+CJ\$Y5E#YC.DUSV M>5C?9COZ<68[]5X9&KQG6>T9O2SEDYROIJ^R_E>V6B^U$M8=6IR>.J8OL-&\ M[M*W4QE4.H,_&JU]?FW]\/+6?,5-^L!-5WI!<]QLI=]C>BYN##OMO?I;5:9R MO_PV_?&T+O?O4!H54L48QI'B>FG#,602<4AE(4F:,!Q)I_CCK*2QQ1@5?;+^ MJ&I5#>EIJ:SC,N8LLI:+&!]XA5["G(/*^^[H131\K6#.RAEV_7+)W*/5R\4; MKJ2;V)['2#MW,!5\ 3^_'=$$A=S!_HS2)P^RO5''C'L$>U%\\Y21EQY"&J://U& M_YP^;Y[KU'S%F>2("LB(8<=*388Q4LB0["G)%24)*VS;J>T]>6P3>JVT M?9RZO].KK _\?=9Z>:Q*.&OM%0W2]I\W6&>TDV:T6Z*=OJ#?-'K+^>9Y4RZ( MR\R&$P&]*9[\*G74_TC_G&2%C*,BR6"22],AMD@ARU(.$R*SB!18*4E<@F]' M^6/[@EOJUTE)?&_!.].ZNTW'K@-B-UD'A#FPJV@C7.4%GMQ2J"K52_9,$_9K M&_S-^#W!\Q0/N$H?-%KH"[Y-=DT=4EU2&P2V%I69V&: M:J.&&Q^'Q.KAQFF@G.EJ,&KF!%&-UTMI4TW=L]JC6)#;T3KXG'RE0OL!N#/+ M^4H1PR4P^\%B+S?9TR-[S(,?EU),UV96E:M)Q)(HISF%*$'Z#XP))$3/;U$1 M9:E"<:9D9#VKM9\\MCFJTJT,RYUFG#VT+.:/OAB$WA:OS/]RE?D.[KDO# ,Y M6SLXW!SF*9,[W=_>#<,YLU-Z[KFFDQ?T/,NCJR=S6*C_9Y@)]41FV&6_R=5Z M.35UI*=_7W5*F7"N.-:@Z8@[TA&W$!'$'* M /,G:.E:Q0);@\K?.QX17C-@EJ>( PU#:(]JL#=X'P["S>$(G+EJB(Y./K#V M=8QYC2K#GG1Z .WH,-3',WWZX-OU1[I4P8QBI9TM+R F M!8,XYIE((ZZ*'%_O; ^DCM&K5F6GY@>YT]N'$SU$_!IO>06.[^<6Z1HT6E<[ M$*']W!F4@CJT0YDC\%QG8+!S4>=N[K'P?)C1BJ3Z]HZ*&EL/F>K*RB5;?*67!9IG\.'7XQ+83;M!8N\-N@T_$=VM)/_W'XO7_]!W5H&=_F$7SYU[ MWC ?>[V MU6L"25&$4IY 244.$141)+&.@A@M8E2(A/#,?AEL+W=L@=&N<:I9+FC=X3\; MY??3=!V69PZC8+$0#H-M8->Q@_6V@A7\]VE8^RQ_'?!U6/F&P7F@1>_^:SS? M>XWW\I=]K7?=T>IPO<'K?[ZQ'\>2G_N9%S_O9I\4RG\TFJ M"IG@(H%)02A$@N@ +X\3&"=IH1(]&12(7]O=]T#FV%Q]NV'K5M7K>_ >(FT7 M]WG&+[ [/PD=^*/2TV/:G ,J 5O*'DI\]V:P9R"P:>-Z[M:^Q%O:=3TM9OJ. M5=7QW.S0&>KVV<)(-+F492KE!$4ZA,R+& HF,42%V6G+!8&2Q3@A,9$D6UJ!;+CE#0!EZ*7H"Q?+\!.ST!G\$2>5UALL;P9FM MW(&IS1SA."8U;%<3_]51N4UF\J$U8E$K=;RH&-8.QUA^4!MR O7&I;0A MN2(GF\N M)EOQ[T/5Y C.628GU^?T%COVGE$,[!*V #XN M0*,O:#>DZ+-%;X.DP]Z\9T0'VI2_^&KZVHQW@*=S%][F.<-MOSM8M;?O[G)? MWWBJ73XZ(0D2B2HX3),TUBX8YY#%.J2*:9;S)->_$YE;--5^_-@<;JO(FCN7 MN1\@9QM/]<4C>#1E5_'?(Y(Z9;&W.&KOX0-'4:<,.XZA3EYUU>+GFS3[WQ7? MCUHLGTVZSSV;37]LUUE&WN/T65]RK[[K?UVIJH%%11 43WBL"E:@7,=75$=: M4E'(S XW$K(0*"E(P9U8\'TI-CX'4=IU Y:-989/JS$-++:VW93\V>7GLR[- M,[M,JY:!-S415Z]5V_4#[K3:&W08AUDE&D*-9@1;5H'[U@@VAH''[0A^WQO! MA^X1[+O(] :WW\7I]6J]QZ+6&YAG%L/^GM]O"OCU^66V>)/RNUR^3DWK6+J4 M'W1<6#93D?-5J<974WRPTGK<_J1+L2I+(-N__[A8K;\NUG^7ZV^2+W[,RR:$ M1 M+)G\I)/FHL8@MSDAW!M@-TF,8EQ#G]$:HV!I%7B@;Q5A@%F* M_2@S$6[ UCY0&G@#C$'F%+<A;7#X/ M8+^)YVZN?:F661%J-YG7J,@X41QF5&00,51 $I,84D2(*F+!$Z5S8.?A-+.^5X+4&"_>8"-QQ8=-@!X\EPG10SJ=+J,//07G=?V M^]0?EB8_8OWVH,=V?3L7)K7EQZ?A%3E_+ M%M14%07-,=%K4X$ARKF"^LUBD- HPH0)41 ZF95+MK!AU#A\O,O7T!82[J,HU3*[W7'R"_L+:!2VI]0X M0K#;=UR+2F ?X0J'$YW&.;M[<6DTR-[[)O)<-&?N0X^ M?E^9'[[_\\M2/D]7->-#J2]06F%+VH>+ %_XFCW"%OPLL-*R+.2N] 25 MHL!HZ@DNAUPP3[ -E /6%SZW!# +3#H3O[KN'R[AR\**O40OF^M[4O=7+=3+ MC+$OT[F\6\OGU02K6-M4Z&448]IIJC37,8[*82XCE61I%*LX=:+J/R5E;!ZS M5+(\UJ]R08VBH-34,A^T&U.[%=/52 5VDGU 0)HI5208H1P[M44Z(V=L M#F!7DS:K:M)FC:;75/OM8+7S ![ "NP#CFKWOES$ZT']_ILM_R"J67E6KY*DM1_65PVGGH0(.T6!]WVOH?VF;\!"O .I$2_AKGM:3NVHZ-]F@^UZ[SAY;?=K( MB<(YY1CE4.5*+[H*0]>?X1QB)'E6D)P3%;OTW;@DT"G\&J 5QU^7"[VT4)76 M-?/"+H7>T0%>1)O3+",1PS"G$84HPPJ2+,YA5,@BBA%%469531H$[0&"W6'1 MMIM8?&(8> JI53V*@&],5B^3X(%./98"V +CBRKLDKAA><(LC3\B";.]KT^' M\\6\K'FOT_YOQ9-<35_E UWSI_]GNFWSI91B*)'&BPVUI(FW),NV@!55,D0@73LQ )V2, MS1>7#7.?Y$R8K";Y)Y?55O[G3W)OB,B:>: I^[M-_7W@1[4VE6\LE(0$@#>RNC*MCI>@.VMD"U6$)CS9:4 M]1+D[FX!R=?/1]SI7].JH>R-J5MAQKS=TO[N??C ;+ MZ?Q'U3]DV?RU5.&QK#=)8Y))I%=K2"_7#!$1AA@I"J4.VI#(&.;$JHF3=\W& M%LL9PT!I654NMRKS,=MQ2&,=N)^#K7U-]Z*MA: T$?Q1&NF8 .=OV"W/#=YC M,$,?,&S'\:8U2O1PE"Z-3__&)+ZP]-V^Y&J]WJ?)B2\XS[9"\2:@QW%(^ZC% MS!T['ND"4XQDSB%-,PJ1*B1D)I4PHRA5$I,$$2O:H&XQHW/">\>JW#HTO0"F MQ3&'%XB&/#LMHT@KEFX7I!Q.+[P@-M"!Q?%[Y>MTXB(*G0<2Y^\>[@SBH@5[ MQPZ7K^Y;JOZJ7X/%\NVK7$\(CS/%9 )3&G.(4HPAY5C!7'$DXX31.!%N_#>[ MAX_-Y6UU) M:WIG-Y>)?0_TS80Z'W7LHQ\]01DM>W P-_.;VGA R= ML]MAZ(F'^V"_;5/N=[MA MDU0O61*4$5AD>@Y'*<&0Y5D"!54D3[)"1-C*/7C19FQ>I++')!*8>H;-UBHP MTR;)LHZ![NT>K[1AUY0V^!E3BR74D",5V)W5@W0W!SMC@+$&_&+L^8O9 MR: M!+1-P!@%=E:U3@.&'"67Y+,!1VNHM+3MI]7ZK'Z843/?ELN7Y2UWS1/(W5EM MUPH9,-_-$Q[[F7"^'MICKOPBM=.69TH+'Q:2D$)0Z]G17?[8YL/')ZF'S6CHX"A[P&XQ@84% M,_"452E_ \X7&;=++&Y "3DPA@!C25CP'>:EL(,PT$P4:C#<9I_^4';.-ST> M.]P,T]_FO3GEBL?TVVGYSI^DV,SDO7I8+L2&K^_F91\,\YY61[H)2606F^:- MB.EY@TH&&1,4QBHN8BH+1HD3N<1%B6.;*1J%P;T"M)R*BW1'"#//$.I;U MH-!H75;YI95&-?W8:YZ$AW^CSR__]:M#^.5CW"R"X8%'8RB7=W]B(&Y+PHK* MI/(O6Z- :5#M$($Q#)26N1RV^Q@OA_AYX'$;**!N?T@O]?C)4Q^2KYT;CS!V M!M,^Y P777M$92_<]OG++7\.N1?S%>3B)*"1C2#M(@51'E!((MR M"47.3=U3)DG*70+N8Q%CFZXJ#NO(CM^.A//M_E]1V&D+[J<5X3D#8MT-T^[WT$[;[LWJ@$_JAKO0(T MTSIIL:?/=__9@WZY)\TZ_&A/7^3>/N+7^7JZ?OL\GJXO$J><-UDBBPYAV+XFNRWKWN.-2BM5GK<[=:K4I^SBK M:N8I)YY)AK-$4:+#:!8A_1$G!=0+(@DCE C*&"Y"1];*ZH41[02GNP*M4&BYW>8&.: M=4]-!_;GETUYE&WR%LN$*KTNJ^ZX CVDGU?\)E?K MY91K:88GZG9>_L_LG[[2F>'Q//VOMW].5Y-,93Q-1033A&L7J7 !<5&V[,,) M(Q&GV*[SU_6JC,U?[BP!)26<.7@H?VCI#?XPFCMF(5PQ6G;.<)@Q".P9?<#O M[!"O1\Z3=[Q"D4%=Y?6 '?I-#T_LD1_Q&YUK)VU.FYJ]TGK;LY")(FFN($US M 9% !-)(%9#F2!&1QH7,K'JT=TH9F^O;Z>FX==R-Y84-*5\(!79,)\#IPS!\ M%B6'XW\?: UTIM]"[6>MJZ_3^TLH=![)G[UYN'/V2_KO'9Y?O+B'\WN4<_V@ MN^>7Y>*U?/3M;+;X:9;N#W+9=%6LFRDN%NM)SH5@BF10%@6%*$TY)*8'A\18 MYCBEF9169^5]A(_-55;J@^E.?T ; \HU\[+I^-ETE=5&E&OGS4I4B^K=O[MT MFW4=- OG&W H OOD>A1:JH.M[D K#[9]5YMFJUK_@& [^/" H _DVGM] KZ< M?T_X.N<$UV<.-U7TM'9O!NG[C#X3R\_%X]-BL])KM\>?^LEO%2_LG98U7QO^ M>OT>U5$/R57!$$,P53K$1A)E$ N$85ZD,BHRPC([ZD)'N6.;3O3+\QUMU M@='7Q5O9PVXS*P0!,_2$\',!&JU!I?9I6/N$[@[XNDP$07 >:@[0>*\;O-<5 MWK+">[K%^T7?XLWO.Z/5[?+M'S>@MW>V<=_1N]_NJ2BZV>S6LXG\26>/65! M[DF\+5Q["!0#._:SQ;8ULO<*U)J#QU#(7EG@?"W"[UW6[(KT]77,78@Y5R^? M?-C[UBQWV7>Q4KGSYOY]KC>RS9%;,TUMJ4-I$64XSS*8)E2:^N0<4JZ=.6-1 M3F*!I<16SMQ:XM@<>:TPF.TT_D_W[M/=(-N=]GF%+K#W;E!K*;LECPO2[\4: M'(]MHKOE#=X1VLK\4\V?[6Z\NOO4EIO;=):>+0P5]_8+B".51LIL+<UC+&&VR **CNY3-W3TCG5DYGE*4>5D?=#@E/BZ>33EJ&5W7E:D3 MFBLF,^UX6!%QB(3AJ,XQ@R23>EF;IA0K-PY<*[%C\T./IE=5E;$.F=&YS!-M ME':,?NR MPR!O,,9V#.5>L)245 WVP:WYCBW.MJ]:>@*/ 9"3A#YBH;LA X; M$CD!<107N=W=LSQ=6T)73X;:>[6NNI%43/SZY[NU?&XU#N%Y3@H50Y2:!'>1 M2XB)X65!!4Y5EN*4*:>J=5O)8W--WS2NSF]X4"\\HF,&V,*E,) M56,6T-9,7_L$5_;#9.?%@H ?V)'5.H.[/7"W:H-2[R!1EC-:ODKJK>4.6VGO M"L=1 ;[S ]SK?&L:UK=?_^0EC>M7_69-1*%7<88QG"$D(#++.R9)!.,(YQE3 M,D'4JDCGG(#1N:I:1] H"8R6]J6^)T&\L-GO 9K0$9$;*D[5OEVF]RKW/?G MP>I]N\QI%_QV7M(X M@IE*.&*,)R2Q[\706XVQQ2Z-(:;L?_@JAOZC>6'%,]@8!?9RV^&YFX/050[] M!\,A(VJ001DH12KVE6US^M9U:$7!N7?Z\^ M+J68KELL$;?/IN_?1"B4X"B)8:0#9#V%)06DO$B@4D@DBJHBX5;5R+8"QS99 MU?J6_%FEQH[I$)?PM0N1?:(6>/IH 58IN\\G4^GK,?7!$AE?20^7Q V;[F!I M_%&B@^U]??H^F,/Z^Y>24/=V+G;D"N4O?I]/MV7G/"*8Q[R O-R^PSF%I-!_ MS66,N4*Q_E>KCC-N8L?F8"J^W%KS\BSKV_??79+([0&W"&"#P!AZ(W\/0=-@ MH<7D4OVR5+Q/X94]N"X]%$* /%2GA!+/1>MU7>[ +A-UP,88X*U1@BM6W>T0 MK)\V8-,#5POW6QLXW]US5U7.Y9+.M(A;\3R=3\W)K"GIJO-/FH^ I1E&A821 MB J3M48@(408,E;)!,HQ44[<7E92Q^;1:Z7+CX/NJ>VXN6H%N>4>JV\@0V^U MMC#JY-IE98ACIX8^0V#GJ0(#&]AOU=I7I-&-_N"G-@ T M%IA4V]H&T!@!M!4^.05[0^B-3-!=@X%9!'M#=$P?V/]1/7-B=N36'^G+5'_% M%<>K#O[D\E6*SXOEYXUI;M/P84]841"6Z[5US))8+[5%!HG*E [3"*621PBG MR*T9C;,.+A_IH UKJD4+;3JY [58[FCS>U-.NX\10K$@D#I$KMMV,5>GSLIJ^@J >>O-J- M#6Y K7[#"OZM#7UEPK8K@L?DJ;[P^4JI/S7V5RMD4(EP [,*N M[34P!/U-#?72NMWC]*_+ MQ:I5UH5RD:"4PI12I(./2'^5F8X28X9$$N=)Q"+AV#;)0NS8/MEMEV:S[;1- MB;P!/XS2CK5:EL#_?]U];6_CN);F]_D5!!;8Z5Z8&+U0$K4+#)"J5,\-MKI2 MJ$K/Q:(_&'Q-/.U8@>545>;7+TE)MOPFDS*ETKUHH#IQ+)US'DH/RJ M\ _GP*]^H_#,E+S;&$ _[ U:@^2I.6&E+]>2C9"QVZHY #$B:Y*+E?WXZ9M MDOW=ZN5U4WY4&^EE7+NU4QI%81Y02),40Y3C$.8ACF @$5&[I)BSP"GNI$/6 MU%C(Z 9B-[KIPM*.8SPA-#"Q[(IJS$"EZ S4@ UP(F"!B2<*Z9(T*F]8F'Q( M%C:7]&.(6_&R%FQASK3UD<)SL=XL_KLZ8D="AGE$]1Y""(@HBF#.$8.YB# E M <4Q3]Q\6AW2IN>]NF'L]?EU24Q_M9:F;K31!7"8(Q9'C$),@@@BSH5.KZ-0 MADDD!,6YD$X4[ G>D6JM#0RN'2=[@FQ@3FYK.0/JMZ4P23'F\+:E\@Q\*E8O MZX*_LDXPG6G: B9/--TE:52:MC#YD*9M+NE[('%\[M$44WI[7[U)BV_B/=FP MIS]>;OA_J>_HQ>1#41^>_%[PA5PP4N7L-+>;G/>Z>LN'&6!;G_I/'[;! M/66G3XJW5NJ:E8V=P!@*7U_ SE2P*4!M[ RTS:T:%E=W]^FF'W1$O#GSA]%R M9)?_H% ?'PP,*ZZGI\#4A1&F^O!!FU-=H$_'K']1B[7/8JTKS<^#! 4RXA)* MK&8+E) (TB@@,"42"2;R*!.1D_/ 2?S4IH-&8]BT8>:USF"ME*Z.4BL#P5); M6)I3[Y?*&,=C;\>!LO1,# ;_T,Z*&M:ZC/E1Z^5&>Z#5GX': (_NBU[ ^?)H MN D?U\G1"Y@COT>_N_2CP-/E_UHE'-^][;Y25WB\^4[6?.N=N2G+U^P:TY4";#AK;#>G[X_K1QLG3]#"\OJ/.**/!?S@)C2?XZKK[-ZLJ M*^FI6*KKRZHYU#P)DEQ2@B&*D8 H)R',42@A3R+*$T1Q*M+Y1L<"VDT[EP0Z MS1I;L4.'.;:Z>AB_:=G2^W_^#QR%V?^IVYOUKL=_&GZ[6< GJ .3^,<#)#]T MHW9-L?U.*/R7V3\M[F<5V.\TOJ.T?O=U/3+.:\>#6F:KK>RS7I'?T^7BT?#@ M5_5O*1>"_R=9+W1X]WO%<@MNNAD5JS]>N"*XIO;&K6AJ<-1WG..8AQB%B>(B M?<28ZR/&S)!4FN5!+%B"[&(5!U5S:LO@;8V:7WBMZJ^ZU).3XWG@@>TFO>D, MU\!4N?48MZP$.S/!ULX9:"P%>Z:"RE8=BM&,^>UVS.]6C4MZ$F/ND* _B;$? M*:'_IS\#;O4 !A^:SOH!PTD?K][ X CNU2<87EK?'&(3W?&9K#=O#VJO5!(3 MDU"^>VO_Y>;'HIS'."8\"%,H!8DA8GD(J0@(Q$$0\!1QD<>Q6^JPK>BIS>RU M?L HZ)HP;(VWW8YD&!0'GW!; ((_M78>HQ7=(?&6[FLM>.0L7U= CI-[G>]P M50/4_R35R6G=^W >,203&2FR(4D.49:H'0AE B9$!%F>D2!-G/(R3HN9&L\T M33M?R(*#S>)9=]61O7J='N)IQRW7HS0PCS0 -1IN6YIZ[V-Z!@._S4L/A?R, MCJ5G##W3IO3P M;9B.G=J:!G:V.2=U^AUG.PX;??0&IKRQ!LZ9*+T"[8E7_>@T*@U[A?&0M?W> MO(>/^N%[\?!4O);J27WXKF[Z]N'Y95F\"6%*"$P9I)'5^;L+#F#/)[>HN]Y(^-=)6SW< &IWKDIZ-UB;!U,'!Z#P2 M%K[B(?$=F%:5ZJ#1'53*=R+=IXBJ,^0.KMHAH1_) ZN'8-,,P:8: M$,057W MYJ49@A=UI:_2JGVAZ_20.M]T/,=G7WOW_)F];^(O13K:%EM- H9H#G.:A1"Q M3!>,"F.("0K25 242;0J;WEM9Z@4A1H3<$'_7Q;!]AW0GIAL^<)J(%?^5X8 MN=5@NP!"OW)LYVXZ7F6V"V;M%6F[]-U^T_GO9/V7J'I\5MUJ#!;#?I>X)N8"+8:0EV:@YP5FB!AJ>%0)>D4=<#%B8?+@ML+ND;S-1T?7E/ MRJ>;E?F?#JS^1I9[1T>D6=3Z'S8XJKXEU(?JDA>Q7A3WX_9/I#U:K%Z M+#^+M0!W8$YJ-#1M MDXV.,U!KZ8]_+L#@B6[.21F572Z8>D@FE[[>LV*"8J)[:M ,[; MXIDL5O,HCSB120[3,,;:3QI#G*413)A:&L613O)RZKEQ6>34&$5KK#G$Z.Q8 MH> ROG;\X!>U@:EB#S#P9Z6?QU6*/1B^$O$O"QPWD]X:@*-4>/LK>S+*4=[J MIV)3G?Q^?5DN-N^+U3?U)R7NB]Y8A',:YX@(06! B(0H#3.(8TX@Q4$NPC3D M*'3RV+@J,#6VV>D'3)*/?I%T7JB27"]?2FV&(P^YCHHE*PV(]= *"UG]6T90PP493->B M$>>MMK##BNA/E<3+G@0 MI269'P%WX23N"C &)M_JJ>D1)MFVWB$"LB<*(P4W&NU\12R>,+4S&+']_?'B M#$]HN1=">.KO/9NRJR7MQZ(L[U?5TG>O:\NV9[7W[V]UR7K'\2/S3MER5_S)(@"F8L()D$H())Z MC2FC#/(LS&1.6,;<'/P7Y$V-K+Z^/C^3]5M5O7W7E;5?%]9> V"Y2?8'Z]![ MXEK3G>^.O@&C+?CSP81(:*V!4=NG.\\.(%_[W@O2QMWFVIE^M*NUO*QGG85M MQ?KRH;CAW$Q/9/F9+/C=JMT*EQZ6U/RBUP1J.A-?U1NX8+JDS:+@.I+@<67N M8N*[YS&G*,E)#E,>IFK#)[G>',=0+;6$(%&JJ,NIBO+0"D^.^?2@0V.,/MC< M6N-8_F'H8;:CQRD-WM#;WL]W[V>G*R/O:M&VBH3I">Q]H1 R$K!0YM+JE.B2H*E1_;;KD;N+M0M."\^A)Y &IM26EF"G9A_7 M8A=<#JY&3["-Y'KF]VBNE.>U:.< M5X]R6^J 3_*37D#I(LI2Y_9^,^TEU#[V>Z7QMGB\8TW&;M1ED%)): )YCC%$ M@A%(LARKJ2GC6"912I%3K/CUF(\Y-?T,Q.WV%-YP''CV:G="V?4I5!@VN@Z0 M@]X%B>\L]).R?DX>>I?99S/1.R_JW0=6=[JJZO?J7B+OWA[4G4Q55T%P$J0X MAC+-&41$'T(EH8 8"Y[)+,LP$HZ]7,_)FAR9M%6M.@%I59U;L)[%UHXX/"$V M_*+W%%C>B^5:H.&O#>E926.W$KUD\HEVH!1@'D,I8I34D4BJQG)Z ^::VC]?YA=;YVJP=0[R8_;FFLUR$T,!.TE!L@ M9_6\Z?X;]_R4#-7S!G8TY_&3CSIX3[+?%ZO%\^NS+LU/XX@BB$*],\RXA#E+ M$B@8YPEC61X(IT7%6(I/;85RH7/E##Q7>D^LA67S&%B>54]P<(<^]!Z]H>4, M_'[A49E>9\N#?R8#!&;W=Y*+_'6<]OBW6YN5&2N99>N]FE MP!+K6@L8DT@7;Z&0IH+#'%/,='! ;-?)X:R$JP5=+AM.(D?A:G.M>B M,K1#;!^0/N.-XQ39?>>^VKT 6P'KX7\S"(U.8=9S 660R1$ (2 MA&+(TD &*9()B9W"-AWE3XT#U;.$'+?RCH!;[O.'@W%H)X#1? :VN@.C_ QL MU9^!30&H #K,8U85NU,F>'04],/.EQ?!4?JX+H9^T!SY'WK>IF>SG/K^6F M>!;KHR.+)A,WR!#640QI'$F(PA!!&B<"XERD1.!(9A0Y'4!VRYO:&]^H"XX/ MV!P/(B_@;'D8Z0^]H0\DSP,W0#%M2UQ\'4U>D#;N\:2=Z4='E):7]2VM:4)3 MOPA=/D8M3DXV,IX'(I0LY#$,A-3;/6= 5%N%L^F 6X=\0O$CQ=A2D%6:_AU%7']WQUEUZX8)3MF\H[] MP/RT;>"^P_]T*_<9N'DN7GTN9YR@\E9.TT;FR+4T'6 X+J3IH 'G6LG2O%^1M#A]/2L4=F^L>A.^M 99[GTX@ M)3R%61Z0. Q"$B>)6]QMA[3IL7"M+.!*V][](KH1MMSP^L)MZ.WN%C*M:*MO MQ!";71M,O$7A=LD:.0[7PNSC2%R;B_HQR*=B533>][L54[MI15&*T,2NMWP: MY(@H HDPRR"*&(.Y0 *&>2@IDVF$,Z="IA9IQ%)$&08J:#>5.I%BD,0Y0%@4Q%G")DW^V\ M4]34>.6AWALJ>JGWAP[A0-V@=G.)7Z@&)I&ZA/%6T:H5>:4JT+IZ \TAF,H; M>"-%5=4@+K8@ZE*']4-G?!2^LN.M@.F,N.J^PWBA5U:6[,5@V5TQU;0*\L/$ MTP=)E#(:9S .]&I/]PHC@UK%A4=E@FD5^^/V#Y-64:O]3Y96L3\8XZ=5',AW;X/]04VH MF[<;SM4MR_I_'QLS3B:4ZLNCAU2IG: MW%(I"FH59\T/0"O;&0#K .R%'80ON(;>//1%RJDE]D4D>O7$/G_7T9IB7S2L MW17[\I?]O?CA7 :,!$CF4 0R42\^R6 N40BSA.0Q321!F=4ZM5/*/]2+?[^R MK:+7"6S_%W]*;9!Z(^7EQ>_J:=3_Q1^I59&5838O?M^F0[MCCW)S+^L@F;G( MLCB@.(%I0%.(J,@AE1)#%L0(,QZPF#@6$6K=?6HO>ET<1-?(K=ND*26=3R[; M\-F>5/8$9?"3R0J)+Q>JA?8XACQAL+=CQ_:]1SYF/&'6\;'BJ2_U:1#&V/I5 M\'?%ZK6\6?%;(<5ZO;^=:/)$,J[+-U(U;0L:ZJZ(ZBUF60"Q6KZ'$8OS&*?V M_<.LY4[M_:XU!]_)HZYP0[4%IAMZH<\:71I'V4-O<28P#* #^@^921L]5X+HT[1H$Y+%Z>M5@[YY8WH#=KM@_:_++O+7_<@:MNSN8_>U& M;![F;.-^;S'WR]VXOEQOYI_7!7]EF_MU72W=U"#,0HQXB@)(4H0A0ED,:20C MF%/.22HI3Y!54\AS J;&WK6.YO&OU;1CE;,(=G.S#UP&)N$3D'@KVWC)_*[E MFKJVM513O^V6:6=O.\H;?\FHYM6^^+V>5;<7*YUF8/*M_RX6CT\;P6^^B;5: MCVS3$5F=6G)?AEL0)O@JS+7QU+1[L-EMU6;[@A&)AJ M:L6;8A"-[J!6OI4+9;[1'2/B7F^Z%VR^"E"["1^W(G4O8(Y*5/>[2X]-Z]<7 MP19D^?EU_5*4XH9576#T(DDMF,CJK:F+_5"HK[ G);+JQF>:5#7EE]3*AH0B MA#+.%2TFI@8ECF$:TRQ7JZ(L2:T:?OE2:&I$^?7SS?MMS7>=Y_E2:ZXW"[JS M8:EU_U\.6S(?HV:Q$1YY+ 9FS-H:4)L#6O: VJ#=*#T4H+%IO_]DCYIE7MXQ M^YWUR*,VTI;;O$3?+[U$OC;:'C'LW('[D#/>UMPC*GM[=I_W[3$'?EZ+%[+@ M'YY?EL6;$&U7P3P). N$P)#&@D)$$5%S&Z50?8@)#1))[)I97A(TM3FK5A6( M6M<>G2@O8FLQ WE";/!M?P56H^:>Q]436 X3@"?01B+VSB?-%Y];0-+)TUW7 MC\>_%E;L\:K-]WL>2J\%7VQ^(\Q4J#/.NY3R,,R2#$IA>CA*!/, Y3 4""KQ/\AB];$H MR_O5+@OW9JV6;*O'6_6KJ>"R*/@GL;F7#^3'/.4!CV,I8$2R "(<1#!/10 3 MEB/.(AQR[I1,,92B4^.7G3U@)39@J2P!:J-#OI&%@F,IH"S6L"1+ 9[)^B^Q MT9_USO ?;/3M6&T*8SHP-]Z_OYL=EA28@9N]T?RJ1G,&6@-?6PVTV> 7;?BO M,T"%^JYH-16< 2+5$PF4P9Y+=0XX)#X+?@ZAYOAE0P<$^V3QT2'E]2TV6&[6 M"UT/[STIGVY6YG\ZH_";>C%6F_+TITV#B3S+"-)I#X'D$"5Q!K%Z*6&*"$=, MH#S*M..:AA[NV3=11-'P'=?9UW+!S&;_TZMY[>(<(1ZJ M=7@L-3_2F.CNDA'D$4%9@D0N$JM^UA2"@<=)))OFZ=B MK5>(V=6!1EJ\FLD?'297&(,= *?\#;;=@^ZG#-W3PP/4%#RHK M=4!<92?8&3J!F@:7QN!G%R\XJ]\_1I6"2_!Z*T=P45"/ _*#$+3F$/ZS6N$* MM?TWHNY6]U(*[1"8YTR*($U3&..(0"22 !*61FJ"B#(1212+W"XIV5WVU A_ M&Y;9Q,ANHU9>M &Z3T#%\8;M7TN^^\22]/L,D,7!^W"P#TS41X&PVS NH[NN M65WQ+[A;@4;_X:!V.+8?#O*13O+M'W;UK!>U';Y.^/NAUWGH[WC+\>( ^MFZ M%QK0\Q:]>@'O8IEUKNT\H$&0"I3 /$PRB/*80IS+!(:,!#+E:9*18+[1J=\6 MT\/AW9TF@*V,X=Z)*H5]+P/")+0[M;P] -""OJ^!96""WDM< .^OQ,*I]6]_ M3$9K^WOXG/BBQW/&7VC[>W#1F"U_3^M[T.[WS)=ZT-07P9:D++OHJ'0A'D-[(1.AJYB4K]5&S^)I;\W=O]>O&H-%KJDS.QGHDQA2%E$8,2IXG 1AGL1S1;^TL%H(>U?0Y?EOJSG0 M8B(@RQAF<4!0&-A5:/OIC\(XC=3^:1\$B\G[IP[OP+/_TRV;,=@VM@;+/ M9."<'%EE)-!6@G=OH+$3_.WGCZS#4N2GCO!(:QFG=_BE/=+?+=YA7^NBP4:B M$FK]0-R=3'NEC!$3:?V@L9]$Z^F>_8)+;A7Q< MB\=ZMJ[K*3[HR/8'\6/S3MG^USQ0SRUC,H!9(!*(HE3 /&,4LHA& :%Y(*G5 M1.@D=6HSWE?V)/CK4K0J>9:@98DPZ]WZ+^"KD>L6 &(W&'9!'=XA'GBRVM>W MA3'XT^@,M-+ :.TQ\-8))4^A%'8R1PV/<(+A,.3![>(>R_@F-**^\=?-6I#G MQ#AK5@_/PCV=%\UNU1KPKL5JW-S4I'D$46NEZ MC@<8Z8Z4?6IB=0'F0(:>@!N)$4\\8S,-H"]"M$"CDQ6[KA^/&BVLV.-'F^_W MJHQ8O);B7KY_6@BI _?UKIDL[Z5<,+&N'U62499')(:"98HMD>20))+ $/,L MI4&0H]2JYK.UQ*G1YD=!5@3\O2C.Q[#WA-;&Q>H9L*']J$9=O7XT"H.=QJ!6 MN5]U00LPGE^?%+L5S^5JQUVL0\SU/.)16ZA6(*41KD$.&HSP:Z?ZPRT; :-T;ITS=9L8.S6E4YVE@-C.MBW?09: MUH,_M?V@!L"Q8L'PCY"=0W52#\; ,]Z$G@GW$N=CC9.OJNB#ZSMN(?6QX#^J MO3Z:X)ZE%TGY=% WXJC:Q/X'K6]69X)J?[369WZWHOJ_^GWYJHO]?/C!GG2" MH>Y7_$%*P39S$L<110&"$<]#B+"0$&..(,=I3A *TD#G>%_.UO@YZCM-DB.D M@WP2&_ +K_7^]=\6M24Z(8HI4V?F7R!:16+T>?QZBX?YNV.AR7&?%[M)<+I/ MP< SXGLSRH>E@&9@9RRHOF+B,/8_W+^B0@$T,(!?&B!^-3ZE"@O0@ $T&J"" MPV,YSI\RC+Y*?8ZK_+AE1'_*P!R5*/TY6O0I :^VK-I'\:BVL28'\F93!U@GI-YNF'LCG84!TJ1SO%B.V/0<0FZ -4&77%AI/^]2+XD;=6=H:?[@7M+ZN'\-\4MJK M_>/]^C-9;^I?6HW$?EO\$/RF+,6F-)^N!0_GB<1IF"0(LH#'$"69SD8(0Y@F M,2(TY2AF5O5PK]!A:CST>5V\B+6:5K7[2;LA7TP%0U+K"U[5?+ ^:.CK1D]] M!LJ.L0:&?V 2JQ56#SW0^H/F]Y8%,V!L )41H+'"'[%=@: GKNNCP:CT=P5$ MAXQXS:VNC*)X]U:?:.FW^[>U>M'%BE5-J (D"$*,0\Q8K!.6&20B1Y!2'E": MZ?*-3DT4+&1.C01;>H*MHCV##3J0=@P7\(/?P"QV$CKO7< <,/%]N-XA\><< MCU^&X.P!M\6E/5SI.@!L8;H2E;K#0:'6?:M'=6.UVONX6(F[C7@NYSEE'&UN!/K3J/PU+!]>Z;TQ'ETIO*O4>'FNUKA)S9V+(,BB0#%X2'$($1<"XIA@F'-)DCS" M42I3IRX0OC2;&N=O$__OZQ8 H+N?0*DKG+6_N-=0H,YG=XR"]3?L=LO7GS*8 M \\W[0(.-GTARL[&$!?'T;T'A&_,??5^\*;7N#T??,-YU.O!NX">D:4:#WWL M8P)6%^5?58MA_=,\9B(2$:,0ITD 4:I6[3G/!4RS+$$YPPQ%@5-W[_.RID;; M>ZKJ=[YN2C$#V+2ZYH)W[#V/I5\%8H_?O7]5H)G,>2!@$-0L@H4X3" M<09ID(8P3IC(*.$L3)SRK;K%38U3C+: 5.H"\4-S?:^.W>K42*'F (*(Y5JL6QB".$I1F M@L5Q8A5,TE^%J=%-2VU &[V!LLNE(&>_P;!P-PX.\=#4U.A?]329@3;<6QNJ M#(R;#=B: 6['& ''^7@ S&2TW*8 7'S:5Z%9:>3L]^=Q_-Z7F7YGAOTNCNY MQQR_7VS>;M:"O"^XFD4DY8$DB8Y&5 O4G)@NAAQRS G&J4SBQ#K4N'WCJ@E0-:._NXXCVP+K#\%1 ,O56UL]XI=OB4J;U"AO=N-%JD\"GUVP'")__> M;X_X'V*EWO#ES8K?\.?%:E&:C>@W\:':$,UYCD*2"@)#R3%$*$\@#BB':<9$ MG(42YVX1>A?D3>W5K-4U!V]D3V&WG>(EF.VVBA[!&_BE;N.VKRNHE?6W5[1$ MQ=-F\9*T47>+EJ8?;A=M+^N9:E!%S%%]5[:9"YDA0E 8QHK!B%<0!J("&(L M:$IY0JA=<=_3MY\:853:.>8+[ -FQP7]81CXU:]C8_]L5/,9]G_29E]!_OLW M'S>D_Z1A1P'\I[_5]ZAI&^!PNRC9LM!A:+O2]#21,D@$@Y'I&YX&(<0932$A M,J5,L$BM!]Q.F[K$3>TM-KL=[=<\B+W9BP-Q/7GJQ-OV\,D7BH.?/^V VVD* M_ASHG,D&%6]'39W"1CYMLC'\^,#)ZJJ>04T;LC$N@GMI.IY4O>)*755"[5F: M*0[C)"29S&"8QTRM":0B%JI^RA(>Q3F*A41.NPHKJ5,CF:W2)HJEI?:_@DIQ MFSGTBD&PHQSOT [,/%Y0=0_X<4')5S"/E*NX)"4Q3M3E!,4T@P22!/ A"A*5@<> 47G-6TN1HB-1Q M=%I!1YXYBZ8EM_C :&@^:RR_$P62N9[\K+8D&7=W;GJ;UE5F5*+IHC2"#/( MTSR&2!\,$8$5)\98=-QT+@3"0Y MQ$D6JGDI#B%-20 3)I,XSD@>ADZG%Q?D36T*TNO%CT59Z@K5U8OCM@J_!*_= MDMLC: //%XVF.[S&29"Q1,C3XOF2M%%7RI:F'RZ+;2_KZ1T\F?PW3VDFL%K, M0I3E"41Q&B@V$1)*Q"5#*18\MXI#[!8S-1(QKA9(3;HL:^GIZ"(\#:FE?_!J MH(9V#IY**=[EBLZV-<2\!SUU0^/+:WA:R+@NPTY#C_R%W=^^HF5YO8@I37'6 MI?B;.9QX*)I"R_R]S2^%3 MHY!=_^EZVUL"45D JL,=O0EHRH.#8B6JC7"/9MZVHV.Q_1T0\Z'=A-ONZ(WN MH%8>5-J#AV);XAXH US6AKW@[M%4?0#81^^V[O2T^^[%[@B@59-VVWN.W[W= MT=J3;=U=[]&K)-O*.&GK#O)?/MU\^&$^T,V2ZPZQ8@8-GTU_9-6MX+E1=NWR?,8NN65MU M4'/-_KJ>Y7>KLMDFO+?)DW_[8\47)2M>5QO!/_Q@HBQOGO5O<[7;YT2J+7^0 MRP@B)'3MG9! @4G*HB@-49K.5^*1J OM=OY.\JU>C+QZ,=I:#/=>?%2Z@<7S MR^O&G#RK24&4YXL^>!@!.S>!?U1'ZLU;%W&O4Z2WJNL&O#OE0:4]J-3W6,*W M#VJ^BODZR1ZWK&\?6(X*_/:Z2<]$CB4IR^TB]G[]9?'XM+E_W90;LM)M^N88 MUS9%LL09&W1EH*>PQG<,2&E\)'9?$C9O286G\45*'[74]-J]- M!]"[U8-8Z8/208AQ %(L84JG^"01G.8F# M1&UBK7>O-A*G1C-WK4[2&Z.U7BHU:@/2Z.VP&;,"WF)CZQO.@0EGB^3="E0* M@Y;&X&8H)!WVM;X1'6EC:_N,^MK?NL#4N<&UNM%X.UP7N_:VN$X7]EL/UN>0 M.ARG:EK3=)3ZK!Z%S,X2R4,6*!6AHB$D&11!G.><DCLNUTB;@KU(;-'K/@-%\ M9E#^%I4.@D==7KH#0YBQ *D@BK&SHPA87,J5%& MH[)Y$_A.:3?:L ';CC\\0S@PD>RAU]*WB>B[?,;JS"D. 'DB%QN)H[*, P2' M=.-R:3_>N5V4Y/%QK?#4&&=?7QV/UH0HN'>"LP;=CGQ\0CDP\QR@6#BBZ$P[MM!X MXIR+XD8E'%OC#]G&^KH^2;F;AR?Q.UG_)3;W4HKU8O583[293"E)HQARI+@% MR3R"F.,$BB309?9ED@N'M-MS8J9&*S<;J#0%E:J@T=4E5?,LH!8^="\P#4P9 M-QMP J$^86#GH7+)6_4!V5B9J1NP4= ]5] 5M;J^_. 7D>C.*#U[]8@YHYM!E:LQJ3(&%A*]J0T.J^JU%;8\^ M*A*U14 6:[ T!T@%72ZJ2<^Q#N8U0Q@CC&*4,"@CF:N!"Q',*0E@&B,I&<<1 M3_+Y-[&FQ<0&L:W31(:QV';H^(D#:NDQ&&>0AO8D-*.C[ #&$'#?&IP/[<$Y M:)^R"PWTZ&6X'E1?WH"@^W[%O_N=2%%LE2-&']<<:B'*$4 M4J[3G*7B68(# @,1)B@.)$895E#OJ^LH?]=ZSH?XV9'95:@, M3%$-($:[ 3R;9VWW5IOY\/XCEV,^8]YQ!>9S7SSW+K?'X*/ZZ=__I?E$_:-S M]/_]7_X_4$L#!!0 ( -J%8U535C\I980 -?-!0 5 9&UT:RTR,#(R M,#DS,%]P&UL[+U9EQLYDB[XWK\B)^=U4(E]J=/=]VBMTKE*A49+U[WS MPH/%H& G@U21#*6B?_T8G(Q]GL!\_4+^O?NC%XNO M9\OIE^/U+YQR?O.WR[^*+!D HX2S+(@44A,'S!%/L^;9.>$@_C]?_@I<:4$= M)9YS1V14B?C()?$0D_>),1-R]]#9=/['7\M_@E_!+\CPOB^67WSBEXK?S3_^Z_?CW6Y__4W2?9LZYW[K?7GQT-;WK M@_A8]MO_^OWMQW@,)YY,YZNUG\?R@M7TKZONAV\7T:\[F3]*UR_W?J)\1\X_ M1LJ/".-$L+]\7Z5?__U??OEE(X[E8@8?(/]2_OW\X_ ME5_^]F*!4'COOQ12NS]=GWV%?_MU-3WY.KOXV?$2\K_]FD[6?Y"B4^H$+2_\ MOR__^+?+=W]=P@KATO'Z%G^P?49YV^YTP/#M_PVP1KWUH5B2[6)[_ MYEIL!$8'$3VU;==I_JJ/I\MXR^+)6H/-X[SU_EEO*;;VZ#= M?N*WKWZ)#R+Q>#I+YW]==I :NEHO*DANHQ8D]]=?D.L,RR6DMQNMW,M!*9!"^$)1*%P*\P6-TOKB>0JYR 52UQ5 M4?Z-%_?" 6\?!X?(LQ%(O(?E=)%>S=-+/((G-@N=,XO$X,!R0^+BG#XM/3SU;2(?@MIS7ARE ;B;+1$ MTH!<)+2;$.K>:\ZT";[.^7#CS;U (=L'Q4$2'7F3>#5?3]=GKZ'=Z$F Y MB3E;Q5,DCMJRP:5$K,(-SFNTK[UA@7-^$!INOK$7"E2[*#A(@DUH_P-\F18A MS-?O_ E,A(X9!+(O(_B"7DF"%)1HJATH+AF+I@("KK^U%PITZR@X0))-(.$- M.O-+W,(ZP7]$^<.+Q>E\O3Q[L4@P49)GE8,B2MB(/$D$=D!32,F4=*)>*5H# M& \2T0LGIG6XR;H%0DZ *+; 0DB 4G& M4JT54S'908#!^P6PZ(^'C-V$VA(R7N"71\M/BS_GDQ 51P@S8CQN>+C)H5D= M)+(@(T\Y*1?48;[J/2_NAXJ&XYHU!-H2)CJCZ6CY?KGX-IU'F'@5J$_>$VY3 M(-*@O6VE1[9$,M(RD_"TK >,&V_OAXZ&HYW51-L21-XO5FL_^_^F7SNCFE)F MFLR7XCFX) MZ$LYC2>@],4U1P/)"E^L) $Q"H,FM#X(#E??U@\ #4+ M^7EL3O$LD,1,(@U(>T+>G6*):.=T!MSH!(\'J?WF&_NION'PYD$B'%G]'R&> M+A&ZC(=/T_4,)A:\".@'$9]3)C(:09SWF0!8%WRT3L;# A(WW]A/_0W'-0\2 MX>AW7I^6ON0F?3P["8O9A%H.VD5.&$A=-JY +-A(5 X,%/+S^"M, QWK%RL6(9?>66!H/ZXE=:HP&F5I7_U MK?TPT' ,\F!1-N$0O#A=%G%M;F<+I%$'IZN)D8D*")EX+4LV85#$)K $O,X2 MC 65:OB,=[^]'S2:CT!6$&T3$'DSQZ>A.*;?X*5?^RU;$P 3(:*9Z[-#X62& MNYYEBN2DF,G:4%X%(G>_O5\.5?.AR JB;0(BY8I_^<*OX39)2+UBS!#G M+&Z"*6?\*EDBE.(TAYP,U,J3N'AI/T T'X7<7Y!-X.#CB9_-GI^NIG-8K29H M]\24$+? 8LDU3V@/"R>)-Y$QYF1(J08.KKVT'PZ:CS?N+\@F+DJY^?3;A(S(:(;$#@1#HC$.9B=$]*E&DL2=+^^'B^8# MC8<+M@E\?#R&V>R<>HFVX[ZGT)HG-%)-K+AD:6!#TL#_OV._NAH>&H MXX%B; ($2/A)2?%9Q#\^'J/<5D>GZU+?4SSK2=2,V@B:F"B 2!\1S<'A2:A* M+-5(D86H (J':.@'DH;CDY7%W 9H4')+/WLS3_#]?\+91'.7\ 1,A"5ID &3 MB15 "6B-9V/)*955'-7KK^T'C89CEX<+<^P;JXVK]'JZBG[VO\$OSPL/*&5 MF> D1%YN[=&S=EHXXJ0!<,X(&@Z[S+SOS?TPT7!0LXI(&RGLN63B-?YD-1%, M6X'>$LDB(0O*1>)I-"0'FB.E6GE[F"MRSXO[@:+A*&<-@3:%B4V9TH8)AE81 MA<2(]P78UGGTJ[(D@C*O#/,^RCKE/;=>W0\7#8O_^MLMX;W% M'^Q7L(]&T'P%";]8+6;35'HR//>STFX W2Q8KZY3W[>2_]&G5BCQWXWR VO_ M3U?DB_=?)UTJ7%'_47X]G>/+IK@-+#:U?A?8RCYG<(SC#E "5\$:X@U$PGG0 MWLE@'C;&LE^%#@+;EV[6%C:=\\X?\>SU0K%>L$E ,\!;2-T MM8N_[9DBH03NM='1@@C2N(?N3_?A\CH%XW06& P)Y[M,!7&/>,!( M@.L"67H'ZW->F(B4"V0C>\O+48_BH2(1S;)GVK$0:75SZ %ZQNFO,AR,JLF^ M 1R]F7]#JA?+,V1A@M:AUB)9PI0H)J+RQ'O!B#&: ^ZD)ON' 8?K8]A>4U&$PD*D@QXT-+,B#0*B /) MB:5,.#"9F@>OC?>!2P^RQFG9,AR*:FNB 7!=)]ZZD 1X05(N7:AZJ=#G;$QNGN,N#QM+=T]X?&8NUGE?:=Q5=8KL_>SSR*8YZ*V?^U MA#;*'AH,4]'G0*Q6>+9R9DFPM)1YT6!YD%I [?/I(7I:,(^K>.[5A-[ WG*$ MG/B2[/T6_ H^E'Z]1_DS;IQ%7!,TYIU0@,>N,H%(4;H,1(I2$CDY+RF/YJ$2 MNWT0]"!!+9C&52!43^P-8.@#H$2F<0U=Y.'=8AZWFZG@4MC@(W$FN-)349-0 M/$5T#CTUW OM'[JNW <^]]'2@K%8R+$8_I(2B;X?D;E$ MW0%Y2I3Y:'0.*=>.,M])2 M6<9V-YF Q-X"5#?T3G[44!==>E"H3KQ1QW">2 M!)4,T/1+^:&*W_TMWQ9,WHIW#CL)L@$C]^W4A^FL"S^BM=4EAAXO9BCT5;&\ MUF<7HO%1)EYDX3*5R!>/>&[B%I@\1* 29'ZPV^4^ .E+V[C&[^ WGH.HJ(&= MYPI?-WW.F(3S5F4BM (4%U7$>O048];,*N-%4@_UNSL0;$W=B@ZC_?LA=H@J M&@#5>4#\O3\KT?#ST$,$&RS03+)*Z"^*)(B-QI0K%4V#*DV]PD#7$- '1>G7R=+B.&@(;;G"J(O@$,O5C,.VG\8[H^?G&Z6B].8'G.U=G%GALU M3XH!8;)$ZSD:FC88BQNO2RYE'I5_:/;27NE />@:-T0T$+*J*V34/E!WAT]O M\9,DIY"T)ER5RE+(@02+NR]C3M-DG!:L-L >IFC<<-) T*JHA 9VKHU?#'?S M(GBT*6ATC5D9#F2,)C:CP'!SEE9%#]K6-JH>HF?<>-1 <*JF@ ; =,=!SCCZ M$@$"\0'="PDHE1!QCS49F%$H+Z%K[TE[&D_5*SX'!LZ!PFX@P/D/ORQS9DKP MI+L*O%;Q[@3/M.O1J:@I ?M(/( F$)W)7BIE1>U;_(?H:<:7&R[25$T=#>Q$ M=^ZJ5V^"9,S4A$2HUF7A661'ECP[2V/FW!D9'ZHAK':R[7CU]A0.WG JZF4 M!C!VCR%XA2$NE/(B4R*L0X82J-)FVN+QK:6@-!BO:^?I/TI4,^[><#BKJY@& MD'9%:I/HH[,0RV0MBE2'E#WA469++3+D:J?37GE],Q[=DURX["3L!@RJ M!R22=01G0N)!S9QT@9<%=)E2+XX(-5CF-=I&+N(NHYN;\4K#Q!T M T!YEE*W?G E^6EZ,W_AOTYQ5[O"UH1EQW''] 0TE*[[DI,@K2 A\*R 4Z7D M0ZU]]KI->92JL?-3!@%3966T *\83T].NPO'+K.O]%) .J MJ0$4?H"UG\XAO?++.7H7JROLOH0\C=/U! U+*Y/K(K2*2,T5\0)Y*_9BI$QR M;>JG?C]&U;@NWT!8JZR,!N!U6U 3[2E36G#"M->X0#0EGI7J4&JRE)F#K%[H M?YN*<7V^@>!SH+ ;PGD8_N\Y*K59LUU_Q!'W9'N#I29NT,1VS M3H((YW(I7W#$L6Q(X.!\'M8=JVP)TF! M8)9K8D'E,A \$5LBG MZ^/%)'+4A$/)'(/BE'&^8/C>:O@:4/*V+&&I\;2'@IH M$4=7TR\H2(F^:R(\,4.DLFF372_ >J]R-/4[OAT\_W/'X8V[T/+Y7L]DU,\^*%%^"3QFFT?2(QGG(BK?+HYVE& M+$4<4M!:VMKU_/>0!'/SEX!NC*FB1I8BJQ M^@&IJQ2,:W/7T/?M2-3>$A[QU%HMUZ4A4#J-:_0,8/EM&N'9]^EJHHQ.%GP@ M/I;V/\Y)XCS:<=2XJ)V.-/->7BJ^X HZ\+M+9-SW[D;\L3WTN*@HU#9 T07 M-ARL7BY._'0^B9Z[!,R2*$(NG5KP, Y@28A.YRA1.K[7WM$/&;<)& <>=71Z M&R '"GC,B1YH,Y26'/[L=S@)L)Q$T 9)T(1%QG#WE )E$CQ1+D0D7&1M\V-F MQ\V'CJ[L0_6SJ""LL95\7H5WZF?/RO#D+C*^Y<-J5J+=&:WR@'QPIXAW0I"@ M>$ C6D"TM)?2'WC).$&4@4!02Y@-N+H71R5:^O &OUQ-$HL@K,CHHGL42TE- ML;3PD@0X2C-Z\K4MYMM4-!)TV]^ J"3@!B#R ;[!_!0N^S\%I5DJ+4F!AU(< MP"6ZW5P1'1W-@::<3.T1-3=I:,2^W%.GM_(G#A!P.P!YC7*ZJ]@;/;79:8G7 ME-Y?^+]4\HVD$I(Y*PB3)2:D!,5M5PF2J-?(NN(JUN[KN0>9X\+L,%S<#;+! ME-0 #E\L5NNCO&7T0FA&"0-,&Q)S1*%%9]%*TXH8%!_-WCH8(%Y[!R&-G&AU MMJS#1=T:7B;66; L1\)93@1QGXG/.I(875#,EIK+07$R[EY30:$/060GZ38 MC;\M%ZL5>@YYNIXXE7+&CQ C2\]+0QVN&!?0:TC>))^B][6;?EYY_;C;1GU8 M["O9!M+\+HH9MZ,=+@_F+'B*-AE",U \*(,G@?)8'$N(*42J=.W\OGN):>2* MN[)LT4W].&PB.*T4RJCT M.]*J=))DG$3.1!8:=!3U_?('"!KWZ!H&2_4TT "<_@9SE-$,>7F63J;S:9'/ M>OH-SMGQE@*8TO7/B]+$QE%B=:0$CV8)U$+@L7:)Z2,DC7NX#0.IFEIH %2W MA#3AACL.5A#/6$#;/TDT%V4@602-*T)+M &'MH[&39,:!CB'2;HE@_JR('&B M046G2HVU+2FG40$)S"FBLF3&6]"T^IYS!QF-9-55-J+W%',#2'FWF"^NQ]MG5AZYQW;3* M4+@UA;6R7AK VFL_77;E.L_2?YZNUIN,Z?,N?Y,83,:S61/(:-S)8@[8&/#8 MSIRYD'5TKG9W\P<)&M=Q&Q9=]32Q.ZS@[ M<+0%G<-OP2;&(O5>V-I%5/<2,Z[;-BR@ZFB@!1L+UE<,1)Y3S(%%)!E]$LDC M?B5T)%891J72-K/J]M15 L;M,%W;=MI;M W@XA]06M!">O8-4?X%WIV6/+>C M?*L,$1109XIOX4O&#PD&!:5^:9[G2Z0@LL[5K[78B<-P&U)5Q-9QJ M&K"9[F'NY71V6DJ+;E6#914,]\H0KB$1F4LF)S61".VMLS&CRUO;BMJ1Q%[8 MLS\V]JJHIP'TG3%AR4KEDB^6PBA]I)(G<2 MT@M)[@=!TN&B;A OVW4P45I&*;(@6KHRA*1<"6ED**@<@H2@<=<=&#%;4OK% M#.@/"II]Y/U#U@1?Z^376HI5/=70\[!7N(O<&SKO[NHI^GB_!STKWF+\O9L7P M^YN?S@N#1_./$$^7FY9LR^D*?_42OYU_P1U\ND@7G4B3LM(PYPAWP94";DWP M=!#X;;;&)6,,U.ZM-10OC:1\/P&4FT!# ZOB#A%1--$GP&8MG?PP72"OVE1W-/X:4Y NIA5M,#Y@&9BWP$?!W"_*85%)\TX0SD1 M6EM<,$9TG56(E(9FGT22N?8FUE+7F?I8>*0'S2[R;N#\NZ!^(Y&R]2[F9;5V M?38DE2("DT2Y',H,392+YF7&HN+2V=+2W">B+ :V5 ^\.I56'<2T@AF#E?TS7C:P5)O #I7 MN@5NVW&PQ %4R9O.Y*:6T2,"YD*BKV_)^,>4FYB M?/L]P MYUR9=H)NY67 X\W\&VSRR\YC'N?\6:=,S(Z8TJU;!D [T5-%DD*;48&UN%YJ MHVM'&L<-#@P N"%UU &;T[@.>]%Y:G(3#D2H$0W7-3$&A-)5,Y[H15R4MO> MOIN2<^51/67W MKYVT>A,D!XEX;XQ\[>Y9D)?ENM)F9$X"9EE= U4),XD3U(P(EH3 M33:-C$Q[RK9+!V'E,"&W!9;-;(BKMWZ;I? ._NQ^M9IX\%EKF@D(":6/!G^$!@3D9 +7_*99MAOX>M+17(%7 M;>P-H8^QH7=9-+OZM+@GC+LMIMT(9+, )T& X$YQ8D*)Z?(<2%!6$Q&4I]D* M#C=SG^Z;*[ ? T-MJ?00 /FV\YL3@3-T5!69OD*=(1T2;\PTI!$*4\^ M4DBV=J>&G8ELK@#L$+-N6!4U@,$';8I7)U]GBS/8;/#O3Y?Q&/?R]S,_7TTD M6,@N&6),*4&Q,I=D18;KC6:EA;$.:E\?[DEJ+B<6 M=WR5!2>B7$A(7[RK( /1E*68M/7!/%$HY6%"VRM2&\KSK:.K!@ Y6.Z_ \.% M58[P&$L:I<(U:9,FEG'C4/R,Z]KQXU$K0=B/3P >+BR[Q[2K=%3!A31B/S1)7A8E(G3SQ+E'@I M> "P053O*SXT3_U6PH]R(=,4 L8.#B#Q,[]:3?,T=BQ>]-5Z._5A.INNSUZ> MPJ?%^^7T&RKAX_MG+\[[;KU;K/\.L_3\[&@Y_3)% ?Z]N^.:>$IS2C:3&'2I M_M*:!!H,<5X)JXL$;C:3N2=L4)VT?C!N_0JH ;4UD0YZO1)76#3_>1+$)UL: M+OL2%9::"$]M5$_QOOTY;Z&^Q2CDH3B M=DPD.ALE%1$(3Y(%$P6/KG8WQQ^OW'<7+#Q2[KN+O!L(@#Q'*?7=2=*]RWUVDW@!T;A>B>B6MY;GDIQ8N@@DD ME,XN7B@P+I: 6>V Z0]1[KN38A\M]]U%R@W Y.-I6$W3U"_//OH9;(_R;@7Q MS"&50YLZ6SIQ"TE\DH[DA.>WS*84^=0^H>XCII%"A0JG4Q5QMX";2_+?^1/\ M\M/2SU=H\:%.MNM*,>:MHX$X$TN+?[#$VL@):.U-H%IR7KW$Y5&J1CZSZJC_ M)JCJZF+LJY)GZT_'L)E&>I3Q]=/YE^W>ZI@0/HI F"J1+Z5Q;^7X+=6!TCXW*8^XD[B&G$?=I3RW=>4QPJ\@:PTRMKX3)UK?S7SR.\6*S* MB"QI(]5!$S"Z\%I:8QCT!;3&K55%KV.H?:EQ"+V-F-5U$/ADBJMX]?JDO?'] MZOCU;/'G0#WQ+Y[^!+WP[^:D_AW'Q8LNPMD^(D"]R81[6T;#!DF"Q_]X+K20 M@0GFJSO%#]!3^4:#QT"34)9(RD59?I:X7,Q!P:E)(CGN!PM*MW6C<9CF'[G( MV$7,#9R(]SNM)BK046M4ZZ9FI0P:14:TBMPH;;BTU?OZ'A0B>JH+C)TTW#M$ MM(NX6\#-X]ZL\5'Q3!7)1J";$C(NJ@B!J*1RU J\KMZX],<-$>VD_MU#1+OH M8NP0T?O3,)O&UXL9;M%'\QOQ#%-:TK'$B&-)(B.E<#U)3:SSRB7I)4O]&@@\ M]);F T4[J7,QA&S'!LG]$2]@ 22:_(0J[G"/CI9XKSA101@! 82]V?AVD#CB M<)[5@/"H(]46CJ?;[J=1G$IT TF*E!*98B:6;GH? K4,D2ZK'T=M=_@[R) Y M3, -0.0=K(LC\'ZY^#9%Q_+YV>=5Z8MZ=#[2^AFNJ&^;PJUS-\% 3)&E2$"7 M2544'08?2LLQJ1)$%JEQN7Y^_(Y4-F(K[XF+VSGT0RJI 1@B:WFZWHS'CDR8 M8O19!V@#N@ $W='0S7W**AGO36V/Z_+MX\)F:#TOJ@B] ;A<"X26HKEYG,[@ M6JG)I\6NHDS6.VU*".EM:9CW8?KE&)E!^3U;K6#][&2Q7$__JU/UJ^^EOAXFE'*) MEDM"'RXB?]K@2DN2$2>%"APRKKK:V>.[TCAN*DUS>!U4Q0U N,L3>7ZS"<3$ M9,^T8)YX(2V1PD,QP!T>"3Y$DR)/RE8&ZMV4C-MPN#DX5E!7 Z![%N,2.AU> M64!'^>5T%1>GI8IDGMXOX61Z>K*ZG(13:O1YI%'AT@JEI;Q K]#1) C3Y<>9 M:>YJ)S7O1^FX[8N; ^T3J'MW4+L-J.?PI:2X5('U95/]4X[(8+2]A M\^\5R6U3\BX3;(!IET(B$ /*SEA#RK0IP@7C*DAKO*I=GM:?NG%[)#<'TX'4 MVH!9<)LS/#FZ$P+E#M-OW:U84(!<146HDIS(J"F:ULB3SL@>G@L^TMHN5!^Z MQHTO#86)1Z%WH((:W2>+%3+'/\(E.P%%LW0F$)^H(%(Q0QQ7F;#H-/4*N.2U MT\H?)&C<>-)H0-M7)8TB#.W=KWZ:7FXIV@8/T!#N6IAN3(Z)U#HR&;J0;(F& M\4QL8I)HIJTW:!EKR0>'7A]*QXT9C8;)ZDIL%*S78V 7W10/\# M=(.]K_(6J4O).DN$*/L&5E MMN"2)"(P2:0H 2V-:]$;QB-S)J=\PX>YK\2S]SN;- =K VU(/;1X"".K:.&N MS\IHN36NIM(@]&OYR"1PX82*E(#D:,UX[Y S]/."##Y1FKS,M>NX^E,W;F!Q M[..XCM*:.)/[BW*BI03J!2><<8L[N5/$^9R)8L)(EI/PJG;M0G_JQHTE/C$@ M!U):N[[RZ^GE9[''I<) M:M)'KH:*!SR1PU74&.:VI4"OOL,R3E8E6N?H_SAX^>2>MXMF:.O186K<^[21$@G M+->60.R,E"R(M3Z3F*)/.5C%^(UH8 \OM]>KFW1V:R/L";32V,:V&:>.;M-J M$E74/.2$:$F.2,5XE_%S%&;3+YT&5Q,9@@DZ&4*E*.EGRJ*-"XIDS15$S9S1M2NA M^U/7I-G7_$ONBK?^7HZ/X6T36DJYUQR M/FG@I8TN2)1-5,0;'M#L$ADLY<[8VIF03\G?N.9-2\MF2& <.#4;Q;1<_WA+ M1U.CP'@@1CE6$J0M"1X\\8[F"-(+)VI?CS:W=)YR+/P/LW1V 4;5@?.'N+,W MA'%#!)<5TP:%G6,DF3*+9JC,Q0RU!&U=:R4:OE[7SL[K2]NX]>F5 3N(0AJ( MF]S##;I!R^49+K&N)]F$60[*&DJHQA-(9F^)S8P1Y9G03%KK=>TFU+T(&_=^ M:QA,W+%3UE50 ZB[+KE)4I)G@=YZ*2O!#5JC?%QTQ C#)6,<+9[Z$;FK%(Q[ M>_4D.#I Y T YB![81(\U\(BBY$!1V:Y0;DE-*6##IZ"8;GZ"+R#"![WJNO) MMK6G46@#$82/IU^_SCICQ,_.IWB]F>?%\F2CU'.!2BZ=Y5X3P04N2A[0-O%! M$>HY+DO%.;?59YWU(ZT7(NT/8LL-H8X&]L@W"N\3 1B*H M$D1"Z1BG="2>RZ2"8=3[VJ[!#1+&GEHU@)IO%P6/D^&A1>VOJ35POF+D?9',:1B4- M8&U[L]MU@TG3]6D9S3R/IX62YZ?K=XOU_X9N&4TH2$TS#;A\?,;_&$ELPA.> MRUN%7UI&SF?-G)LY/.3J"[V!$_E&U_ZC ML/9HPJ0W\_,[^]>+Y7V-LV(PV80VOFC3&TL)B]*-U 4LT^^\B%] +DC M)W0^R;G]5-IL +A;@1XMW_OE>OM-5XBYZ4W]>OH=TJ;-X+8\,[&)#-PQ[2AA MQJ0R7+0TQZ2)4*.2=U$Q:6$8!V87,D=._WP2H ZMO=$/Z&ZUO9E_GB_!SZ;_ M!>FR@_JS;WXZ*P7KN!A+MX0[*]AE4!KM:B B==-^,B'/Q?-37 MR1KB\5_BXF3SZ$_'4 :F^/F9GR?_\?3DQ"_/RI#)U^K?KODZR;'VS=>0]U /,+W-;K#D'X]>,++C==< M@%@D)Z*3CKB8T)UF+!,K$B4. OHC#GRH/EKH?FH.G@"V_.+GVXDF+Q;S%3X^ M;3:.;J;)A1:/\G9)^]E%'&U5TGAFB]7ILC23>5!'GU MSV>EM!/07[.0,\DI M=/6=GMA]ZS,$[[:.T5=I%#P+-!6R98=DI'TDRGB)LI2%614U8RL8H+C28 MVE<:50BO>1M]36,7J^G*5PD"I>+*RWEM")>N:Y9%_-*:::A]KZZ"WWC M[HE/C\.'KK*KZK+%K:\+MAUW$=M5R099G^VS\]WQE(,WOLX\7;AT54+^T\W( M,_0D7W25!E]@OJ]#_/A##]Z7=J2[TC9UY7W/;KSOBL5^CD#G C7&.1+QN"-2 M*DN<1QAF/)LHS4JC!U'[NG\7 @_.>[A\V5U+(T3#8LB:4*8VQ4]W[ MK(,WJ'Y45MJ7[GO9)9RH!:X8$"$M$$E%)"Y93U#Y@$8]XI6O]/M3][8M3X5L7.[-F,8);6X M+WT\#2OXYRD^YM6WKM9A'Q?NYC,.=^ >I*J6^W;C)9=&>#8R>8Z(4;K,OL6S M+ "@$8Y6LP2=)36U%]Y]M!P>7+K^W"N!5R63"5D0XZTETE-)0L&Q930@AT$: M6KN&\%YBQDY,KX"#VY&@&H)O<\LQ[J[1#@Y1@TC.4E)9-". M>-"*@)#!:*F5X[7#+\/=7;XK\P7@*%_I(&",S#$(($8K/'0C2R1D6UISYT@% M>&U$]0Y=MZAH]OYO%^W?2@8Z3-@-)*,]]ZOIZBC?D,_9YK^7N[ O_P2>/QJM9Z>H+NPFN20 M$^,Q$D65PH7B@'CF E%>J^!PH>A4^V[N.@7CIGT/!)T#A-P 1.XNV7ZLI'NS M+B:, XBN^"%:5PJZ#?$A,,*DB$XIFYBH'?\XA-YQL[H'@M^3*; !L-X[->?F M/FVY%;:TMN:E9844RA$+DA,E3%;">AE#[9VN+VWC9FP/!,)!%-, X%XLYA&Y MV%B:'Z:K/UX@#=-U^6HBN*'4EL[I$;=W:5E)(G8>)<<8MU(*7%C5+V+N)6?< MU.NA]K9*XF\ 21_@&\Q/X0/$!?KCA9_;2R,8GE@D $!Q:?A T*"D)'-G@]-) M6ZA=QOPH4>.V9!L(5755T02V(N#!'F;;@,Y53L!H+[4H=8662*4$\9YU66-6 M1DLS=?4[9=U'S;A-809#4Q7A-P"C5WXY1^F4!LT?CU&D-]F!&$5,%)>!9=V@ M&HV,E:[,49JD0&@?:@?M'B%IW$8> P&JIAH:0-5K/UUV/0=_!U]N)B^MPIN, M!9=1,A)/=&=SV74I"=$:(E(*,7$0F=5.[.E-7+]8*OW!H#:,;AH W3OX\XK( MEHLY?ADW:=3W!/8T1\]$E:F_/!&92LM?F3(:EY3KY+B&F\.8*XS4V(W&?A#\ MX>+Y0VKJ)[J=_-19&$]X-[E]X5@WDW?Q._R]9/820$5+8@8\6X.,)#!AB-=! M,2U#9+)V8L5P]Y(OIRO_Y=RI8&FJ;:66.\% M4=Y9]'.8I::V5=>+L&9O+W?!R,W=KKY*&CAL/\9C2*RB-W7-7FP>@KB!E-,4["[,V&T7 MD'DZ[U2#4MR:MNEH_J&T85BB@+O+WAO,2YID0B8)ZZ: &1.0>31IC(8D0!I! M0^WFIU49:/9JM0YXGUK%3>&["P,@1R7CMQM_^.Q/OTROT/A;G %L9G">+N,Q M?J);$:_WA2%#U)[6OJ.E+8G$N7AF'/HW7%@DL9L1/4JW>'8 M:?9>MP[VQU5_ ROA8O'W6/.?YXNP@F47D'TS_WJZ+F'^><2_VAQY%S(0C@I6 M!M32,OU8RJQ)B#F0S&+F' "WBMH;_A!\-'N=? CV1U=XBX&#.YIE[!\4N/]A M0S3U&-"9K]-2(09*N?6KC1YMH[5&&*%]V)[O9 MP>S&J:%KCN")U2A+2.=4S'5S@HZA-YQPQ#C;\)/INL6+=3;_5WV M-U#O?=8 O9<&-$\?Z:83(3"G/1#M7"92.4JLX.B(AR0"ZCY07[N9Q[ =F"XK MT*_&+EX(8J1UR6G&1)<1E2 M!=S5-LPKL]!T-Z==\'?'7=9HJF[J5.]D_/SL19DQ; M.>[N!*UN:JE4657OT_,(2>/:G0,BL:8J6CQ7'^W*M?\QV_?1PW<6&_ 0WJU' M%+/:1M",E+Z_:(K94A,E#-$J2"^$<8C3ZG4=3]!?[(;[]78Q__()U;2QA*'3 MSU&833>I":N[_*Y@>&#H7Z%A;' =%1/9Z9*A@):J2"+2Q/..3O3N5/Q([<9V M@=(]7O+ :FK@(.U8>K%8K6^P(2P#&M$ H*%X0X(A&XE:PHK@0*E(>>UJZN3C;K:V&Z"X>:(NFM% M>0B09.GH5RK^96:E_2E88CQ0DSR5V?0;CC8$=>.&7)Y\0QQ)K2W:A7NFUCY+ MJ:MZ\[,KN6 'C 88@HRQTH[[RV;X9.0@( HI?&D.6.9,RTR"$:$$(X//5$EC MVV^2U*W>2V64N1L;71SE-WU2P"?&>J&BID1HW"VD0A^LW M-_4 (IK-1=X%(M?VTZ?22 /VY;V]"9Z??<)'//L^74TTMTH%E0C/,966=VCA MY)#*!9,+4L?@JW[1=XT;R!D65G4%/2)N5LOUY$.Y-^QV>)L RK1>DJE!4KF*Q HT M)GR,GCN!&SWOE::-3[UR*N)WER?BM1>. Y%1;*[]!=T".K:@IL$FP94F8,HL MR2!<81R(8B7-7!AM^E44]L''F&?3 X])#>RPK?1OBWAB44=@$JB%"#6 M,^ ^QH(FV2?$O=:.]VL>_8C*K[UT9*7OH[)%#?F-K7C__0KA&;E4V23B7.DS MP<"6YF]H[6<+>&I*![J7E_28XJ^^=)SSH)KB]Y;?R(K?%BL?+3_"\MLT;G8] MH[T%R2@QKE3P>&>(,SD0)26:1A0/.=TK2O.(_N]Z]SB7+*.9!0>+OPWXE"NI M+0>KK8&=4U8R1D%4$"7/B%)B]6HRU0]#MPD8[R Y7*>W 7*@ M@!OP3OW9^>9H(EVDZ.T4NX+)N[M7W.#M-D%ZC),NQ>WI>,7*S+>/S ML[L?T&VK(J95P?N%Q*J"41DU(*RAH#LG8.X8#LC--?8=1[J%; T>PZ M>>=/SF.6U&D;8]E"O.WJI6CIEBR) 3Y=G]LO+DKG#!.$FBB1+Z:)UUX0 MPR%D:E.BH=]%5.]7CMQQ;@C(#"CS!G:HDQK;[.U/2*F_+F$3OB/1>X(H]PFX4'6[AGT #F-X*P^".Z#VX$: M:0!<5[N)O2V?+LHJRS%&::',#Z,RE=8O3A!/A2'E8EQD])!"]?KJ^V@99_;6 MJ*=J%;4T"J_M DPF&.59(CP*3B1+C%@%N!ZEM8()&97,3P"P%D[(.MKN :$] M1#_V]<+U29OG*1;*.YU9)(%[9 #_A'@;2Y=5R9SQ,GAQ(Q9QCRMYU]/;P\(^ M:EO4E.'8(-AO&WX[G<.;-9S@.C*44HD>,#@T*R7$DM)K!,DT&./!7&\-G'9W]V#I?OKQZVRZ?K&8?\-?E6&;1>ELHD(&GB,EVH,E MDMM,7,"O@F8R4JV,!EGY#-R5QA^N2&I/]-SL>3.D*AN ZKW)\I]7D$]G;Z<9 M)LQ&G612)7.Q%$)8((Z"(J ]S2(RY47MYF ]R/KA,LCK +*VPAK X$O -\=- M'_%)0',F92J(-AK]<8L,!,B:)%PWPDO#Z,TZY K=CR_?_\,E(-9!U=XJ&/7B MZ=$U\;?E8K6:4&\CJ ^3\U0Q34!-K^AJ[_6UPG1_/29[Z;,W:YFBZ6TH09"%3AOJUL0G?>/H MTP?E')1*[MKAM'Z4_7#1VSH8'$!M#9AL;U":TV6A?-,Z[^WT&Z1-;>RGQ7-X M.5U]1=RGHSQAN91+.TD< TFD%IPXIP/QBJ%(%2[#["KCL3=Q/UP8I@XDAU%> M ZC$_7ZQ*DDOBSF<_>Z7?Y3).)L?39+5P<> UH73"@4F&7&XN(A/ C0H;06M M?3?_ #F]D&=_.N354E #6"L1]-@DD1C19Y680 M>[!$!REY3 :4J^W"WD%&OQ@P_2EA=8A&QKXV>W=:;OHNQF!_7"_!HTBD$B$Y M*HF6TA,9'!"7$RZ3*&QV-+-;!07WW(;=_?Q^:/EYK@QJB7ILM&Q)?P_+KC/G M/%YIA/T1_[O*4TC_X9?33= M5EW^8[H^?G&Z6B].8'D^1NKLQ>FRJ' "$IQE$GTB*S.*V>!2UMR3R#+G'(U7 MDVO?U?:AJQ]R?[Z;B^HZ:Q^')Z(D+^7(VA,O0)&0E*!%/DQ5MR*'8:4?VG^^*Y06D-' M MDR\P%*/EP1\EU'UR1(:YWB0$1"RTMZ;X@-1I62^630(XRL>F9I+\+Z@??G MNXZIK[4?!8IE^&I)N_PT/<&/'.6-584+#W^'?S!=)%;.*%Q[D1&92J\/A0>5 MTU(398710B278^W$AUJT]P/TSW>W,XKN&\#\^6%) M\\!X)#I!*A.J+;%,"**B*[TZIA@XA MOGNZ/CI=K]9^GLI\KPT_P4%@TF?"H9CB$25J;4"F=*00!_?%D"VN&0PMGYE>P[4??6 /: M*DCS"2:W*68"F$A\0*M")ENJ%A,EX-UFSC55[4]NN\B-N91O=[)L!;RIO L0 MG/2TE!'A42(Y,NFI-P27N<2]!$)*U=.)'Z"GW4%M.R#B5G)2+06TT93Y>@-B MW/2C]8$2IBTG4DM#K$^)6&ZB$LB:9K0/@(;JZ3T86.II];&^W;N(N V(W-&Q M5@2? TA<-N!+]#4"6B8J%1\M^R2!.27JX:3YOMT[Z;17W^Y=!#QV)LC55M36 M1\VD<80QRU 20956U(S0Q(2/3!L7^6.6TX_0MWLG_=S7MWL788W?NO'\%G"[ M-3Y+Q[!"[_=]N43\GY<]!(5C,GH12! !UT(PG#B:T*_(QF0CA69.]$) O_>U MV,][;W ,(.*Q-X<;+'UX]^S5]^X'I1OEEA\CF:-1&2(".J!2L$"-EXU3N/@U>#A9N8V!!B?TGQ/7O?NZ_=/W97L-%>WNPP27F/7*4 M$Y'2:N+1;B\M4;V&;%5._0Z:_N\4OPVI):J:DMX1J M4&C.!S34!+-$Q)!*HQJ;1"\GYW O^>U.G7X&:SU\]<7)W^L5@2ON9@N/G'WP/RUAH^ *K1?ZT6/O95HJ+Y>V[V[Q8?CJ>+M-[ M7PJ6_1FRA6]]?^R7)W@>G:[Q9;-S::]&B*@_'5.CA>%'TMOPL7M-8Z)9V=(0 M-Q/IT'!UBF=BC?#>1?Q'U^[=/ESL_ORVI"OO+P;=FWF7"%8PLCULN>-*64F\ M](%(9@PI74UPWZ$\F83FEJC-[J-$-1O%WP4;MQJV555% Z8)'FUEY6\*;CY, M5W\\/WL.\WB,^\(?78S2F\B#D)QH)1F:\EJ2 $*3*%761@B7JJ?;/4;3N,BJ M#(';*?CU]-$DOLZYV7JBCD;(1F62)2MW:D&6(BY!=+11:LDRBG)P?%VG:5Q\ MU47 H_ Z0!T-P*MTO5EM;95W<#[;2*!T0AET8WS)48'L29 "=W@)%)W0J"VM M79IQ)R&M >D07=\\" \6?!-MKVY;M^>S42-$].4, 8$;N42!$)><)=P[%R)E MU$'M5AOWT3)ND&=0%%41?QNWW==O=H-*RG(4A0@"30"*:\ 9XTOOR=$# :78:RC*G)N R=W!.,U2REY[HG012(N PD^FX4ZSTFBW3-R7S ME#AI#>&!&^,0\+9?9MUA89IS4^6/06E/^;< I>V%SRV6SN= 1:6T8HXH M@_NM# H=.DB>:&T4'K\)#*M=8O (28U!:E_5WX1413TT *O;&_CEY3[5B>+" M,X3Q7.9%T8@",Y90KH/SCGO.:D>.'R!GG"ROISGR:FFA 4#=6A>75]]L@CY M0N_ $Y"VI(MD2T*2C!BA4]*<2<]KE_D_1,^X.U0UI3]VZ.VK@9\Q@6;3)QW_ M]KSMUK2D4W:#AI-?7TP$1L&5XO$E/N*Y7TW'S(XYD.+14U]J2GSXO!;OA++! M2,)SSFAR&H&[>(PD>:>E !]3JIT5.%Q>RX5P-SIX=J<.CBX%CQ]XMY@OK^EA M<[AY3P.:+IRH+'$_8C:0H''O<)DQZY0")4QEL50COMD\F5VP=N_L\B=5;0/V MQ>OIW,_CU,_>S%&,IR4EOG,3+Y=<%N@CP$L+ZLE'2 M-HB!3H?SR0$16B1D)@;B&,LD"\H5S]X:6=L*>I"@<;$W'DYN>7:UE-8 G\_ MG:,@O_I9FEH*2[G,J(^:;'BV7IPG5R]SHR,NJ$9X@* AG4*9>I:8H MRDU:91FMWO)O9R+'O?]K!J##*K(K=G&Q/(TL1L MQ'T_*DLD&CS$\^@(S2G0%))&$VDHW_Q^LL;=0AOQ@BIKKR5 WL70=D6KJ#(S ME)+D3.ELX#6Q'-=V5LGF*%6BLO;-=@^R&G'+:T'A/JA5TDNC4%M=K-CM?NZ2 MX49$0= $441F38FUWB-C&7\2 @A;N^U^'[H: 5LM,/0 VT&::0EMS\\NOOS[ M%)9(U/'96_@&LVZ-*B-]B,D183A:*]$Z$L"7<7 0DW(>6:X=Q.E'V;@687/G M;2T=MH3,JZOM-G_;=8W'1E!6TI)^6UI7:Y0?C8%$DYW0WE&CXE-LB/<1V,C. M6!$A?3;'*NIJ"8MOYE]/UZM.8NR\H96/S%'."!.E>6LN^54>(K&):H[BRTG6 M'D_V #F-X*P^".Z#VX$::11;0T:",LNE%9^QT3@I;O:L&P1< MHH78WKC@VD3?1)^<-_-OL)GU_:"P %>$LIX22(81Z;4ISKPCFD<#2N*"D;5QU8^R M<9V685$V@&X:V+N>??/36;%S7R^6I=G49:K$]<2)B4Y*R>0,X5)1(JD'XEFD MQ)9.YM92IW+M*[:^M(U[4@Z!BYNVV!!*:@%\]RW8B8%$@TI %#6)2!"*^#)E MD9O #8^"9_5DGL&XCNRPFUH=#>P/I=(#N0J4KKA)#\F**R\C*$#UIS*HW3(2 MHC$DIZA""B$96[L^I!]EC<221W<[!]#CV.V%_H&^C9^OSSD[NVNUR91,!#!$ MQ'(Z)&3%4YY($#&!T\:!N='^]YY.0SU>-NYQ.82"%P-*NX%C\F&137+V(1;9 M>,:!R& %<9X%E!SED2EIC*Q=E?DP1>/N90,"; "%5#LZQZ^NQ[/C].1K-]SJ M\PK2>O$22@(V'@N7Y=WYE8_'1]V'%O.7?HT_^5M9KF_P;R$]?7U]/9K'JK ? M2.K#U]BC 2F2EXP 1=M 2HJ^"@^VC,IRPAAFC?MQYCY?-H;Y>(R[%!I$D(HV M8;[:;GPH[\WHKM7SL\O/O/=G7=7"GWZ9-M=-UANOHPPDLVYL@HW$TH@6N I< M!6:XK9[*6HWX9FOL=\':_;,HGE*U(W?1_5!8ZI+@A+(>7*0$&!YA*#H\S*2V M1(-@F5'&<^R5))E;TX5/(MP&6;M!&9!'#.D5#2@B25G(32 M]]/&1#U0[H3L53C7!S!C=]3=4UDWU;V'Y$96^._3^?3D].2<<$^EX/9.K*'YO^340B+BO_8808)*4D@2NJBII0; 5K>\/-"42J_#;$N#F%+G MYEE)Y^/>2!:3SZSVC?G/WW5G)T -VG5G!^TV@.QMB/KLP_3+<7?9V*4UEHD@T#FO\,:VD93)AI\=-Q%HJ2WI?F^ZJ:9 M$:'6TI;WD9V;'_R%;4/@/Y;+*Q-M&J2C#2,44J\SXI(XPT)I8Y< M)@F>6FE9]3&M3\7;R&;=S[ZP]@#0S[:P7GW_"J4XY3\6,WQ,R4GK#G&7G8A0 MKHB\\^AD2D8\L$2HU*V5,(TZVW(F^T>=8[B_-X2MJK'-4..=)#DZ5 M@=:*^,09$9SYZ(PTKKH#_ 13*Q^N1.Y*CS_/%V$%RV_E?KMK(XB_7LPC_M65 MRA>KRM-@_-UM?L@KQ[>^2-H>@&C*:> MS:@%THYG5ZDMD X])Y2NEU&3X*CACC(IXV!]E0]O.3]\P[Q1T+-?Y_E=5-D2 M0/OU@G5>X7X7$.S0OWD7C;0$ MKN=G%^U#7LS\:M6M2>N3DCHIHKB/1*8 ) ">#IE10#LG"Z4&G/ERFZ!&.@8U M=NX>J+B64'BX9&^*8[O%LJUDJ7N("G2Y".$L=4S,!\"OW*-)M0G-HX8ICF.3"AG!EL^F5% M/AJ90M*4D3$63'ZNI?+"S^+IK/ORPV(V>[U8EEN=B4U.2RG**!F/CD+IHN:2 MU\1Q_(=&H([7[@HU.%,_S?FQ)VZ'6T@50-32JKKBK/]CNCZ^Q?SJ.O>K#S<: ML&Z/X<0:U)U74.#8$ NG/X"RI-S)EPE7) MQ ["$IN+?QHC3\&D9$VOWE(_Q/GU([A0#2VI>L@Y\/QZ-4_#9'T]]S,_C_#Q M&&"]32:[4M+5T?*+ MGT__:[,,$'Z+V31MEO \O;_"YY6N,FC9K#?7;A=9,KBE:TB)$6I8)C*Y@"N% M:9*4BL"E5B;6C@E5(;S>5*N_+V:IG'#;3B3.BQ1S+/) )Y*C$^E5Y*1TT&/) MLRQ5[52!>T@9U\=X>G3=/]MJ?PVU8(C8%8F[N"S 80.6EKS%VV6.[NG%_$;E$VL252 ])N2HC9*H@[)/#J'A6DT7)(E,V/Y,C(B,C+")V]"ZPD)Q_0G?(%154>HN6.W MP7UD/@+H-.T?5C!Q$64BER@JXR.81->H\';T2H: R4&B7,(!SM"63CCI'DJ%EK2_%=Y SK,GL(X9I)?L1P&A[5/#] MK7%V03MF^E_UL>URM4Z=3DI)SCJG(<58G\<:#M&@!^ZYU5(:ED7K-/N^-(XM M:#X0',\,=6ZJJ1%,Y'V&OY0N+^IM N9_+.;+Y1^S!8;SRG"]%_L-RWR!7\-? M$U161Y4CL%2?)B1NP"-+8&U)M3L/RMS\36L+PL=F)%\$LSWH=/PF]4FFZ^7N M+=-6ZRSI' +$^D0VF4*[-R9 [K26 HUOWO.\">'#^I]C _+A.MT?R/X*R#/\ M5@GI!TH=E::%_ R>O#19:.9$;:T=K@&O:1>/V1YLUQ-+ZJ5O2HLN)K14N[O MO%J70M2M%[L,YQ_":O.#C^4]+I=?OX<9%Q_H%[XO)SYRCD(*B&CJBR^M(#*7 M($86N."2!6:>PW ?A/T=[KGW >B]UTI#*GGHAW./\_X9:UZ.#K'.0OCCQ]>Y MX!L!1"UB1)U &!= !1_!\20@92<=>?&6N7@$RH^C;M@ ;)10?T%U#XWW5[3> M=%6]=7*9,+B0E?;D(X5ZFNWTZ1,XO?NIP\9% ^/K8/&. ML<'>SI)#$N:/,,VUL^",F TDWD]O^BJQW+E8OZ65W?DQ-IA MQ!8(MF1"L,X4(,74/GL]BI+*^^JJ4P97WW%Q1OMQM7QUN:@FY$9&L@B*/+V& M7(*JS[MI@S/):-/GK#5F75SK]RI[D/=W<$GW0>%VX-^7)D>0.-VP]FZVO%Q4 MRS/14@@GL@8BNGK,.4%M#PM6"R&#\=&;UG68VS0,"[?>E/TXJ Z3_-"^VX;X MKXN0Z;":_WDMF0DS+I-/H<%E3TQP)^I7!:R3R3FI4I*IDQ_WU K#Q@Q]@Z.= M<$>"D"_SLOJ31/L6R0O5Q>3,'4+(08*2,D!4(A(G(1OO@M/>[P..NQ\^K*__ MDK@X6*0C@<0;\L'GOQ#O-A.?"*=X]JP LS:#*C4O7Z]I7&9,BSIS(G1K#[1C MD6%O)5X2(D>+> 2>R4/Q3%A1$3D/(%6=J1H,@9T;!Y9QF:2M<6SK]GX/J1AV MRM-+>2='2G\$^.D@J4E(RNKL,C@M BA3MT3@$HQU.A4OM->M*^L[D#7LH*,7 M]G^;Z6<$Y52?%O,?N%C]^G1>!Q3,\IO_>SG]4*=J/L[Y"//R[.;ZZ_$1C"#X$$/\/%KP<<34P2M(F$ M A\$"GJ1DZ[&^O^^T''&T4,;0;7YW*2_JL+1:T MB1JYKQ>LA5APY&/ZH@I$3=9:Z,A"[GB#\^CG#QWW]X:.5C(=@:5Y>[F835>7 MBWJ:OYW^5;]:7C'"HJ%SVV1(-IGJ*&B((@0H@@*/K-#&W/HEV9/$#)TIZ-W. MM%'#"/#T'L,2O\_/\[N+'XOYSZN3_HH3KHPMNKJ:TDKB1'F(M;J#<\<8MR(H M; VHIZD9.K'0.Z(:*6($D*J.Y6IQF:IRWLU(=-](6QM6BK%68B9K&^M5.T8+ MH7@'Q; 0C$PEAM;>T YRALXS] ZJ5JH8 :IV2VL2&7-<*PZ>EYIYBP)B<@$2 MU[)8'11K7JF]FZ*A,PR]8ZNA0D:05[CSUN$U$A%INBE4_G&.FP!Y\Q9M_?=/ M,C]ASFCF,($5S-8WX@6\*05,LL5IYQB9[M9/!AK1_G>HY3HF-S$(!D;Q(.9) M5G['U21$J20K$F0*M),="G!)!@A"&D$^2!"E=1N?7?0,ZPD.C])FNFIF=5^J M")'VY^+R_H3D0%ORZF_;3/%MNGZ_I8I'26-4U8ODAVK/I )KR$M07EKPS">0 M+"O:%IPK)1L;F%%4+UY?(7_&]9ES1V?;ET">I>!,"< BIP.%67*K)'ELF6F/ M.J2HFU^B=2;N[U"YN \"M^UQ/UH<0<2U,27_#.E*NIL+0\N,SDYY*)D"AWI? M3:>800HAG&>6Y6Q8#^.U'Z%D6.#UI/:'+NFQ.ACZ+F/#PF_SV65MG_1Z0\+= M<^N:+:DP69DT6*SS7@57%#-Z!I9+;AS66;#LN1-\SS6'O?/H%T1]BG\$]NE9 MX4V2T$E['L!E4VHY%H,@(P.'$;413,K4VE0]2]2P0?;+6*VVFAE'=FC+JWY0 MIL-B'6+)H-1 7RG+@#CQ8#!(03Z$5K'U7/IGB?H[U)HV>(CFEQ!."59*8$9X#Q?L11# B\N!3X,_&OYU6&M;Q:JS51\[* M-B(>P0GYZG*YFE_@XC.6R]F-Q'[=<"."$MD8R"*'R@W97UL8R!B"*E:JXEJ_ M0]I-T; &JQ]@]:"+$2#KJI#T*8%-ZM-X&Y@"EK0F07%-\4FV8%-4J*TQOOG0 MHMT4#>MU]8NLAKH8 ;*>9D2&X+CT&817Y K4B9LDF B,7(#(D0G3O@?B47CJ M[1*B7SRUT< 8;Q>^K.;I/VN-#:&U7INL?K7NN+7G"D??$!S#4:,[@(0*K$VT[2X&*,]K4WMLD:-HA2;6. G>0,ZR?WA 7VQ:JE0H&/.Z6 MB]7D P:1Y,,.@:J/S> MH@,K_1"5S5O(;VC%A[_N$!X**E>?(IG$&'GG+@(YD!:TYV3KA,NZVTSZYQ1_ M=]%AVT90!XTUNO; I[$ M$HM768C6[W4>)63HL*.9HK=O-8^6^@B@0^1?S&?KO74]($J2FQ51051A'8AI M"%XDT#(;%YSUI?GTKP=$#%S*<[QB'[R[.4;*(X#)YN;^4UBL?JV'GX7U&Z+E M;[_N_F2]I:1T1I";7@<_$&=2&7"8/40KN1*&&5M:UR9VIV[8O']?AUE/VAD9 M[C;[4&B3@C8(R=HZ+H^\?-I'!9RF32AH*U*@V".^QG"F]:7O'; Z0/A#%TB\ MFO^)L_?3B^F=DJ.U50^S7QLKK!SZ3*$"!$V67$GIZ_U] A\%=RYE)U*W@03/ MKS4>Q!RBRGE_TP H9- M#_2#MA=0Q>!P.P]IG>,]^T9_;#&B68G.)E[OA4)]N)+!)Q; <2><]M8ZQ[MA M:L', O?UIQL,:&,#S;6E@B98E,EB(G@8@%=,.'5Y^#Q>XV4G2,^.,B9!C'7:M.4(HY*49 MRU+Q% V0U]8K:FYI&38B.U;'.R%SH,"'/GJ^_CG_^GU^6>?&O:G6%[$^??R) MB]64MM1OBVG^AK4*]L;IRJA,2@QD(@95+*$6+WG0PBH1(D_:=3N1]EQX3,@Y M5-7S%Y+["(Q1;?54Q715PD!&V2LC(&0AR15C]!77 7Q@F653;,+F[;CNK#]L M7\.^#JR#)3PB=&PVD<.45)8>$GEUY.IYBN&$SE"4$,%G;RG.ZPD?8SB6#M?D M$Y X0*PC.H:^_DDR^W55X?)NENB;Z4^LK&TL(8O"B5*?,)<@2$*.D83HV^)D M4BHHJT79]P1Z9LUQX.,0M3YQY+24\?B@L^GEL;:WGRX7Z7M8WF5.I5B/4HH# M.=;T0%;@G<^ 2GG+<\H\=\L7[[ORP-,*>H-10WD/#::SJN5WLWR9[E1D/K9# M1*(-H:PC\27RQW0F?RR1^%BT@MO@9-?1Y%U7''A 02/P]"+?$7@T9W^&1?Y* MO[P^Q*W-R@D2#YI(AS@&E0%%E"%S)*$1J[=#<(Z 35NRI>;R'RW@$ /GR MG63W&QG&>WW,SFJ"\BI9N?SMU^WO? J_UBF*RO$MV[.\M0V3-9;8M>"E+$D%S4B"UR#*2K4HP(IPHF&/&$74'I14+3V\AXE MI!,&W:EY>\?+? S N7U5M=Z'R[/+U??Y8OI?F"=2^1B841!M[1-9G8R0+0-/ M-EE&9353S0NWGR9G%+62QRC[Z?=L1TE^!"#Z=+WNX]P@*QA9DN"30++724$0 M3$+*FHRK$$JX]H.#=U$TBH+(AE!J*/^#T?03%W'>WBA]"HN/B_7[X_S/<'Z) MGW"QYF\242E6LH64E*(#6AD(TE0>N43OBHJA1^/T%%FC*'[LQT@UT<0HX'5_ MNSS)5^8&;;W&)G>3 FU98Q ?%-2"=6;02=Y\0$@WRD91*-F;^6JBCU'@;,W. MN^7R$O/KR\5T]HU8F0D@@?C4QV6K+'.268@2I'62XX5T(FP411>-D19>VV,&6173L M7\$+S,IY8#8E4$&0T)PN8"47,2B4(K1^ M/=>-LF%K7UX,9L?H8U"W\9#$K44+-%.HD"&OO446RN7D<+K3FFN_=8=]E*I'93Z%OG0"=/U,-M/ MBWE"S,NW),BZ)^I0OH_ECK\YD5KKDHL!9(Y89,]!%=JJP[# MZ[T!!\N%C\JY(+<+.9].L#^[6B?$^!-!3'/QCF4([S-;(";K4DX%0LP4O=;' MH='F"(8[&0O6=HJM.[RU,46Y1ZP>#0LQ9DF@]-2 M0*FC12P3#K>[@G5#"O#?EC.":[PYO]\+027+,6.7J$*3Z;CD5 M"2&0>=7&!*&8RU8TK_)[@I9N@#JAY'@3H0]]ICT(1Z_S%K]AF2\HYLB7JU/H>^6P_GNOZ$-W_5LJ*:41.2HE8=P4K) M0'DF(7IO :45)EET;KNDN6NZH#VQW5!Z LGU46IW:+0_VC3BNM7#YMO->?!U M?NW)W@V&L@IU$!AYJH61)K)TM+6= XF&&9E2(:^U$Y2/I:0;3D\@.__R>AG! M>7W-&FVJ*]X^7JZ6JS#+M+&^XN*"-I5V;-V:2,;:0+L4BA*$MV[5+>\W4F]EJNCK'?U]/)+O=,Q]G>.6C.)>S-XI# M\>36JES?*M0G4UPHQ4)A'+?'2SYAR/9\M HR_:N ML6+R)J#'=+FX&N(:SL]K#G*;WTE)%-@K)R%I[U^G"03E>82 ;FN&211)Y;OA^X:+:[:6$R.061,U)%NO3[1 M\"'1'T58KV1BR;8>I[:+GFZ8.H';B>;"'P64'C6\=Z*>B?1!!B\]Y)Q\G=LD M(49->R5[KE0NQ>76TV>>HZD;I$[H'J*I$D[/(7L3TO?[OSLI]?UF*)(8KK4K MC.RR*Q1Q<^X+%QX^_ MB?^]]M9M"]FN@'W!.X:QJ7VOS/^K\S!V_EB\U?U]_BD MT"E@R+F!8C5)!XL#5WV=FY%[Y;8DE]H)9>*T93Z1JHR2%%O&D" (+D!([1,Y&T;SUHW7 M^^.FV[8X@4N?D2E^:"_ZD1:,5Z6;Z^O3PA(SE@FH71=!6>+)1^^!92[H'"S: MZVY=NW8NTPU;)W"+TUBB8S&/FVSLQ!ION*T36'WAH+2OQ;S2@\W%..Z\,+%U M:NGN^MW:/YS0)H=JWU7+QJ8Z+]]\KW.D?I40= M/D:A$CHAR"'(=8*A#>0L9I,=67ZY_1"[_R:^^S+1#=\G=,$SK)K_#C@_RWF= M$ CG#SNF*1V$(B<'G:K=%#(=84$'P(P^D[*4E;W$Q?VPTPW[)W2+-!;5_QUV MP48 /\/TO'9$?3M?K)](3@0QZQ17P&JO<95ENHH"T%';1#R('5D70N0+04M0J?B!=E M@PG8*<)[?JUN&#N!VZL^9#LT5%Y?7CGT'\OUN[*-:Y\Q"&9+!I<8^?<\!?!, M9Q!H;2@"9O!I=75X"/!Q*;1_>O<47QP?(^1\OIQ8_S9YWF U?ZMUNN MMOG=+'@/.?UPB'^M<)8)U@WZ\MXCI0[+/HO+U2*D%7E,+G'O#7!9^PPC+W6* MEX;HK%2,,,NW/<\V_7B?I.CH1,3ME)6#9_Y>[]4.X+L961=<]Z.OC+RO_Z#R6T?Q M!>=L;0@./F'M2"\,>,4#,!-UJH\K/&M=;;"#G(&Q-PQ YOUH:[S V\Q 4U:% M$IP$+@Q%W*YFZA0FBJ>4I.V=M4FMBUQW$C0L^)JIO1N<#M#!" !5"V1I=X9S M7-X,4?C;V2Q_"(O_Q-5M-ZX-/SXY'KC1((1U=48G X?6 G+T-<%C8RZM_;1G:!IV ML%=_8&JJBQ%@J^9GB(#OQ-!K_(GG\Q_K6>OW6.*)VYPS@QSK?'6FZT0I8\&; M7$+FTJO8>FI\SA4P: M;H2%7&_YE9$2G$(-TB1F@F8E:]D89IT(&W;(5W] :Z^5$4#MX OYVX1E88[B MN_).Y*[C\N(B M+'[-[SZ'N[XG+-OWA%4$.3] 8R9LRV],\6EYU;),S MZLN+?7"QX_+B*!6,X>Q=.RWTR^O<9I$N1W*'(0EI*>ROXM%Z/9G+Z#K:6^?6 M12?W"!C-E<-Q:MT^(@^6\0@ _4:2]%4$[5M 5CD'-4Q*TN07?K2=1MO4Z8Z^W1ZO@Q=Z2& M1G#@/MIP>YV 8,J+%)P%7"<@BG?@Z\5GS$I@M('SU#JG\R0QH[E';II';"/[ ML8)HL]]$*%&HZ$$H2\>^,V2$2QW,21+*+N5@2^NZA1WD#)N(::3P+C Z0/I# M'X'/!-M37%Z'VQM3JW1AVI$I-RQE.M^5A9!4J&../?=*>Z&[30_<=^41HN@0 M?>^1Z3A.^.,Q45NO0#%(HQ76UA2UY)K1!@RYZ-JDHE@*G+5GK4N4'R5DX'1& MO^?;$3(? W#V?D*>DG?H@@;#>2$&.0>OHP,ILF N,!:;5^KU\]+_A3N.[@6, MHQ_Z[Z.EH4_&?0>\ACK(A[CS6*K1MINEH'UV%&LOB7!62('X+8IWKM9F2\NKBJ^#V\" M<-R"1U? ->2W4>7;'5K.MFAY/5VF\_F2#-A-P1/#9%.=&:FE(&![K"\8UT,K M)+-"2(/&@9WI7S?VMB*.:'/YQ53M]4V"CE>!* MU3=*:AUREWH5X1,4X[/EV5:#W7C_="!K&+CU (*'(TR;:F3,(*L,7 M_R G8_%V.JL!S)7[LDG&T*&6C$@9DJP3JX(0X-$B@0F:E??"YUR4E$)4/(J $8(+ L( @VWR(,OK=LH'=NS6JT,6&$ 2XH#DH@P6"5PER*58$B9IV7',8ZNB2[ MU072 G?P0M_=8N6IM8>YN>GOW&HBXX$Q\AE_;)*S9]\6N-Y!VRS=-*I E,HZ M(,8HS,AU"Q21P.28D.>@LA4-@-.9H&&L3AN=S_M6P-!QV/^>GB_FOSYC.%_] M>O_INL:P*.V""D2Q)=/)D$-4%'%DZU@,Q6>,6^UAGHB\'OOTX>#0DP;G+<4Y M @_F%2TY7;T-:7H^7?U:[QG!#6JC'$1I:@[61G":#N<4L5" :+D4K?V7AU0, M4YC>?S1UI+Q'AYC-'LH>A?..@99D8DDLF>RLEL0(&BFX#,FU[C'U&!T#7W4< MJ=N=4#E T", RWMH5]!4OUR92%)Y1,) QL$WXZ*,'EJQS3C+:09U\ECW M\A@=8P++(=J=-Q;U".#RI<[:C;^N6%EN\9*9\M%I"YPS.J<39HC9,""165T? MU(* M._79>2XTNEYPF.=-_0;2ATES#!"X;K/HF#2.D?^-AMQQD0($:1$$!LR:EV2[ MW9%W <'@(<]ARMI6]P&2&UCA'\)?TXO+BPWA02NI!=DIBMX,83T9B#QXB-$P M@Y)K85KL^WN+#JST0U0V;R&_$?@,MV]V7X5E[>Y;_U-O57^&\VH0'__;]38A MUJQ54@'WL?7D14'PVM/>-IJIP+CVDHT"JV,(KEX*4TV@?(""1P#FUW@1:B?U'_/E M](8'YS07V3C@NCX=+IF!LV']C$O:G)0G9AJ#]#$Z3A%\AZ!@WE@E0]]/K N5 MSNBXLQHNW6I.C1 MCQ^P;+.Q^H^7WM#ZWW$HOK]Y#JF#"]G( +:XVH6+7'4?5 ;CF5&:G"617"OY_^Q.7'Q+P"&+7)]]@_&,Q7RXG M64FIG7. S@E0*!R)J4Y6)Q:-=[69;^L"F-T4C?-IP7&XZD$7(T 6!=^+VH9F MK9MZ&,\7J^E_K;^=6%V2Y\&"M]&25\_I3$:A:J.;5-#Z*+>?.#5(CCQ)SCC+ M?MM@JI461@"HNT^XKBO?KR<868H1O97$@/,!E*BN/?T/Z.P7W$GR[%AK.[6# MG'%6[+4!5"LM#.THG2TP?"R_79(H24(3%BR:1U]H!B^M(44:]*T;&,)4L M1>[8_O7>YXZS$**!&W2$^(;6_%7?Q8S'^NBZ'KE+0_*ZC)M_M<]4,A MQ9?_>TDB?CN?KR:N./3:""![F>O\ HI"35;KP:B)*PI"?3>7><^%QWG+V0 [ M?2I@!.?4 _;(=2-9R6P2R88C**,$;0\RD4C'.%'^;4^E( MF0]MDJ[;4]UAX-.Z#_%$.^X$SPR(%5Y[)P3P+-6'ZI'''+R,VT._GNG^]6") M<>9U&IB9-D(=&AKO<;E$_$B!8:C26?M=UYR1K<0_P_E77)"<(K.,X,Z!!ZQC M=CCA/3 #R>H8M(M1NFYM([JNV DX_@2!TXO(1W P/<;7'7XFQ7-A N>0@J)X M,"0/+CD'V:!7UHG$1.M7_\^0U"V+R$X+8WVH8P3HVF*D]C%>9TC7>=%)L5E$ MDP,4+6P=WZ# E6( C8\N&&\S:SW\="=!W9!U8@GJ]JH8^O1[-TN+JTS#OD&# M]R:76BZ0,0102D7P5G HTC%C1?1TSGR$9]BMH_..1;I!Y<1RT$TE.SJ7Z?TTQ/43 MQHEU/OA0:D :"BBC [C,/5AD$KDITC1O._ $*=U@=&()[);B']K.W.=A;4:K MQ,+Y;_/%8OXG_>!S6.'9ZDTIF%;3G_B:OIUX%I2(%*GR[!U94EYHGT0)VN6D MG+,VJFX6Z*#ENX'J%#/;_6MC!%;K^JQ^C==G]E,;2493G%<<6'"E,F; 1XG M:A^(%(50HH>NE-V(ZP;"$TV']Z.B@['W$Q=QWM(E?XJO[5 W>Q&X)IY2INVE M0I(02*Y@(BM"RZRE37MYYQT7[@:N4TRJ]ZF!$=BVQW)R-YME,Y1R^?H2)\Z: MD'0JY"/4MHVLU$?!Z\;6H@3-I1*VT\OJ(W.EC]'6#7PGEICO54$C -YS+^4F M,D=IZCM,A[KV'>'KVAH!F+VTSCC&<^N6+\_1U*T6\T2S\TT5,G24\!PSVU9] M$L@E+:;40R\Y3$+YW6WO@Z$!MBMKYVL+ M26&!)99 <9XA,ND!F9,^\F",[98A/3(O*DXQT]Y(KB,XX!Z_[:S/O*Z_6U]Z M1IX2S](!MTG4"P+R%YDBSU%AC@6MMJEU;X=NE'7#V(GEWGM4SD@A5P=MU=ZW MG]>)EV"M#2:"YIFXD&L?4=0(1?ID>$ 96C>]>8ZF;C [L;Q]+PHYR;&+U]-Y MY^7]?/:M;JJ[]?0?X_GTVYJ 99^C&/!%:&4SN;^\=2W97@0.W YW6!0VT=K^D/17D)PA MG1.;W^T%E).27(B".*C%2A1V15T;"VLPJ%&3=YQ4MRDCQX)OF$>K(P'97EH8 MJWU[=;FHHIX$I47FY/1Z7\N:9+*USC>#)9EA8-8DU[KL>A<]PSQ>'0FP#M') M>(W5[_-9VC D/--<(X? G:WRD1!1*= 4TQL#X,R0-\S1V)#@[4#,- M;^!?,NJE'_V8S^I/*+ZKO[QY,-YGD/OW>DAX!5OX9%M-:=W[+@%#,^9@=)$NB4,I*"%9D2(E' M-()E65IGPAX0,6!CK)Z0('8F1:6%- MU*8<>.X,.;NVL?Z;B&_ H'_3@/;6ZU]3?QM+6*>23PQ"E,2%\PE\C@ER"LX; MA9;=7N\]T\'WB25.*?]XL._11L C.$[N,K)5/7NO6ULLJ'/M9^)UH*-2< NQ M/MLUQB7K$Y=9I\:'3$?2!G12&J%@1\C>2B4C0]J#UFU"EAPU RS1DVW%VFHY M(^3LB16N/>K6](FA=R'=WPH#+=;ZK M25Y%[UF0W:K[MC]Y0'^F+02.E]O0ODPM5/T4IOGM?'%UEU=K5<\O,^9WLP_$ MT>75*[>/Y5Z.D\[[&[EIZZOOQD%Z4XOQ44$,H0Y3LR6PQ%#(;EVLCB;EE*[- M#O:-7E9A(SC9[D<+UX40DQ"RMW7B/"NY#K!R")$X *9#UISQD%UN?*@]3LF0 MW=!?%@L[LST'*68$\-IU>FN2A4PN@BNVSJB@P\&QD,$SE+)8II,96^?AG@KA M!P5:*Q4-^L;U,68^+:9T/OP(YS>;1TAM32H.K*T3;761Q$G.D(K15CLG4^RS M7N !04.V3Q\-YHY3TPALW%:<^S&NPG16Y?CFK_2]#M8E&3_UB-Q;D5-M)F:] M)G-N>(9@"CDJCG-$5]O+-Q\>>SBYIU3@J+-E6JVD$H4H/W,@J=$F;7VM3N2^,P?>M?'J2]ZFX$ MV+R[P3IP9US0J3 #F;PH4$H*B+5DLBBGDPI1:MEGA6$C7#9O^//RN.Q1;R- MY7'SK+#'8NV="_9?J=V=WT'*M%VTGKNLP85<9Z ' M1U_)!-G8B)G7-PFM[<2+OC1^/ E!2]UYT7HC#$2IUL)@UM>G&%Z YT@^"Z^] MY$@8K/E$TGWH.Z6Z[WUPU:UW;@.=C> 8[]1C[LJ5SG4FS%L2;3C_#PR+"2,_ M)2NM04>'M42Q/A32'GQ)*MH8BMYN=O0R;0$?I798K/:'H$-:!AZOSE,!+HGU M=SK&OOZ)YS_Q YF([\L)<][J@!FRUZX.K0[@%'K(3F0OO$[I=JK "W>SW*9U MV.+6<8'V6%6>$&3K=OSZYWQ2BK6*3BT0D4=05B@(@4OP644C9& 16V>9]B1Q MV JCT0'T$,6=&BX):#@)*(J*K,Z\M;4?'[/TE0H@O%3&91]4\W8X>Q,Y[-7G M.+&YM_).#)UOYY>+21 FEFP1;8X2 MFWNK;NCR\)W,?9W_AK58YZS0:C?L<>F9L"5#L+:ZV ;!AVB(1V>%2-FDU.TY MU/YK#WM1V3OB7D(C)V0+)]QGFZU3%,+5&?59T49BB&!H \D0K12A=:%'TY;] MO5U-CL[V[:6J$4#PL5*4)\27@TVAT)8JF3Q@)4V&B#&"%)I)5ULW*]\8A-VI M.Z6'H\Q' ;!:XLVI4B0*EMR?!0G/TA+%*B%]KKU_4Y'TH9-.XX$AH>H MZ530M\Y3:1,P!$VQ6<$ BCQA\(HQB-DQ$8566KVT/1Q)"P75Z M0"KGO @,>!T;J5*U[";;VI1'.F%D=NI%VM6.+H4X(@3NK:BA$X?/,74_0^6% M#]9(#Z9@;<+J#$21/3#N-1J%#TXEGEQTV7=@SNGK6P@D8N$GV)KN" M#&RIO0BM);$EH\ G5BC*BCR+ES9LP^8%1V+0]E+,T(9L*\5Y-LN/LG>3>;]) MJQ8?LE8.1-;DIXK$(5KGP@VD?U DZI+\HAJ;\74\[0 'R6N]T) M)9YDP42^:G%DRE4BSR%&)-DR3;NZA"ADMZ/U.#H&;)CR(B!YM-5E_QH[&7 ^ MEE+"$!4F\C E=FM\=\#B W9<&34(#]'-R6%OG5R2G!>5 M(H)CV8$*N28X=0 KA%;%T-9SO!_T#9?I.Q'\[:V?4T/@.OA'%@NWM,4H-*M- M2X.OP;\&IGF.5I3H3;>RK4-6'R;/=QKXVUL[IP2_K]]Q@:%FH2;%9E6;"$+B M)8%RS$ 0D@'&G*3Q*LHBFP/P=OUADH'CA^"!&CHE$$Z^@-DPH_O3^>NT9/[I\DY!JMR6-414DP-I&Y\O1'-$J# M5];+Z(MQO/7[G>=H.O;*XWJJ^L?RU$J__;KWDSIN9V(]DSFZ<-4+B+Q6 2$Q M!>B")AD8QK9=NZ,%<1"AP]8$-L73]I5(_XH;P87<$ZR=_35=3GSB 3VGN-T8 M3?RH5 =N(E@F44^D3G3ACF"Q1 M7U3M_LL@ZF! >.^EXI)%V_K=^TZ"1FG2]E=[-S@=H(.APX0W_WSS^1XAY)>TOSX"#):,CP1TMNKQ%0O$$,,:)6 MW<*#+JN-$C&':';>IYB'QLUK\HN_DE^\"6S(9+^;I0T?%@-RAP:BKX::[#+Q MD2-(S!P=\ZS(W DN.Q89MD:])Y2T$NIX3ZFM@WUMB)VR6 HAWI/9!15\;2+K M-*0BK?%U+A%KW?^J.W7#XFPTCM*Q>AL9(C<;U43ABLJEEOHA[:EU43W)S6M9 MN! RI^8-+AY2,IVR'!LMO MB_GJ>RUI6G/TYB],EZOI3[S/D&;"(XN1)!5R?4TFP87((5M/_^"I;EL!P3+4,XZA SD0K!&SKQO"2_2W(& M/$072S)66]% Y?<6'5CIAZALWD)^(XM.[IC!]],9OEOAQ7*2L- 95A2A7]0! MDR*!2R8"9TX$(R)/N76;E>=H&O9Y[&ABX\-T-%[,?<%S^A??_H$S7(3SLUD^ MRQ?3V;1> E9?:S.#B!NSH%)B,YP472M]%(Y461FO&5X,S$Q+FAT;>U::V\;-Q;]OK^"E;&I#>@M M^24[!A1)V:C(VJDL(^VG!6=X1T.8,YR2',G:7]]++=BYK_OFRYCJY#"2;7UTR/B69]_\4VQ$\A44\C:8-8O 0\X ;TFI4&X\CV,WW$$<>U'=ROC<8C8?O MA[WN>'ASC<@=W=YUK\=D?/-L)/OB^>CNX^"6-%JTTF@?TB/2O>Z3QC$KGNZN M^X,1&7\8D-M![VXT' _1>/!+[T/W^E\#TNV-REN99]=@.PY#$= I$P93##).'B;DF/^=4(=3%G(P@D\H0 MF9+W4B6D4:_\3"*IT S(;TNK#/V1C .,".WD!E( E!O#AHG]8M6O>Q3CHQ( M'U0RAC NDV$:5G%2SU_#I#;W;E+?48T3@9.6S,E]*F<"V 3*?FZ5GU$FT854 MHFK 'BA/"4WG)$^-R@$C0!WA) 7.&24)/BE.!8EHB*\4D0DF.B.]W89!"B%H M3=7Q2.#V"?5B#D"O4'VB68G7TA($BLYB',=&Y_5C5 MGX&"HA$;0,*U0*%B-<^,FQ@#U!F$SD';;H'-4$ZQ&B/!?'T87@L$6W\?" *) M>(J3;/&RFM0RX@_-L5BME?,4N0;1A3(9OX/M:\-;>.[R-'TW.FX.S9N/T0A>(*J2$I0@911P?#_61 MF[DAH0H<1G#.>2# 93= 8 :"Z]C6L&8),J1E2?O,N Z%U#G6L]RII/!@R90, M@>%K30X1&PP0;!X @XHHPHX667P=T6AAU< +U-9IL /1 M!XU["9PNE]6^C*6R3;@AS?7N56SF"P!Q4?3D6D'JVK$* M>T68ZZ2K0% 'M"*9KL!2+@C9%G(D3_1%2\&9.X'0>: YXU1Q&P#W*=^E@=2V ME&N;AMW2U"YG.Y*4&M A@Z1L*V6H+7F8"VJY'<-R3JS2.=;PXF!=T^"W *PA MTB_6!_8"NMTO( ?[!.16>Q/(.U/6!IYW)[N=88U+870YX#E5\7CTS7I*E+'@]%0%FN,@2U=I(D M#*5BS@$G4B>0HM(0B&TLL1LFYDQ0@'O\XN+B&?+WJT%PN$\(]E0\F%*1.[ZR MTPM1A#*13W%B]!:YMU04._"O?]RN !U@L2)RI_8Z,Y"Y>=Z#73($75J#%='1 ME_<])%C(<[<&P8\$^N/P9CMX#9AC^X2Y@C7]=&["PFZ_"_'F2K9B[RNXTJ9T M&8:YLI._EC^WM)I(;?"]/=[$MG2(#15'.^3PF2H1HAA9[(EUX3CNFL"='-A# MA31?^G7DO8JI7HH-RW\.]A.W X^O^NZ\]+ M]5V!,@UE(T>TV9VNW3.''! ;1;I>[GYF0.]M_O6RS65@)SC=N>?B=.BK$%=L M5/PYPQ9NHPPK:EA2V[/H+&0J5D&(H9HL>Q&@40'H/$& X"BY8(J4LO4<[54E M^#W<%G4QCT<*B:.,\PZ.[A Y[IRZ@%C9IT&>3J68@LV%*9T4Q^VJ8$A(,B'G M@*6S6'I.I(\ C(#[)D*A^A6_"1JWDRJ* P0@J J.M:"9AL[BRP5R=R;HO,-3 M-V*NTD716""-D4G'7@"8VAR XJ'X;=5!RA>O[@94Z_Y^@%'XGRUZ+HJKKJAF MV&99^Z1ZWGJ^N%YM/%OV1\TVJ^?GW[Y5=/;T;+=F:VX@_&#@>.N,IF]+K=*B M0@'(3C-[((W'MPLL1I\.N1_M]>L7?^$"_Y^B\C<1]BJN-P=M)![WN?8K_J,P=X1OG;B4OS;M9I>S"$B@P<(3FDO&6Z):OYF727\OL>//_J>P<5=OM;1<-J^O MJM UU=N-JM\X7I?\>EO&KH[CU>_ U!+ P04 " #:A6-5/]AW'7\( "_ M*0 %P &1M=&LM,C R,C Y,S!X97@S,3(N:'1M[5IMD#EF=&LI %SO_ZZI>'%!F_()I7?+GZJ5%A7A7D"J66A!FY!L-S(=,P^"3#WK%(II*Y4-M=R M/+&L46\TV">E[^64^W8K;0R7"ST7-?]\47.#7(R4F%]>"#EE4KPIR=:HQ7D0 MUJ,1\-9IT#H[;O)FJW[V.C@6)V'C^-\!&EE#<=_'V'D,;TJ)3"L3H/';K>/, MGL^DL)-V4*__O>3D+B\BE5H<3&-G_]7KV-3$]1B5696U@P9JLO!@*SR6X[3M M_"MY50OQ$0_OQUKEJ:B$*E:Z?1"YO_/BJ>[^SJE+)>*)C.?MGXA]\^JJ-QCVW_6O.L/^S35B?7![U[D>LN'-LR[NO4N#NP^]6Q8T M>25H'?(CUKGN,L1T\71WW>T-V/!]C]WVKNX&_6$?A7N_7KWO7/^CQSI70W;S MC@5GS5;YQYV!SBWK=&\^#GO=]8B2PR[*S7J#G'1ST!F\[5SW;BLWOW[H_;9P MOU&O[PSQ)[Y_>Q=;6UWLE]D_82I3=ING91:"MC*:,SOA]M7!\>GYS@LTXT(@ MRU9BB&R[^7JQ9&4J,++M"OWR%WD85!=.?/_1'T]+X[1Z3-/09Q,^!:9QWF&& M^!(+!(IAADPLLJJ&7$'XICLUYKERER#:(+*W'\'L8Y M\0L"9RV"902==!R$<2?($I3C>(7) @[FR= (>^%*_#))Y#$*(! 5HL4-9YP] M(3<3%L5J9A8HU3"6QN+^P#)./WJ[T))8@0Q)+ MTK.0)HR5R;$?<:=6L0=+IE4( G\V[!"Q(0#!Y@'0>P@G/!T#ZR M#?(8)5PE M>WP(W@I7R=*3?Y14?Z8>I*2?$7>M8==CB6S9>:#HT4 1#K3(XNN(1@FJ!KZB MVCII[!%*<6NP-S!M5<\"FH@N&-QC8+A<5OL\ELJ4<$.>F]V[4.8; >*B&,GG M4I5K5( $-97&T1Y*0>KT4(6](LQUTM40

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